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Abstract 
Early age at hepatitis B virus (HBV) infection is known to increase the risk of chronic HBV 
(CHB) infection. This thesis investigated whether, in addition to increasing the risk of 
chronicity, early age at HBV infection further increases the risk of hepatocellular carcinoma 
(HCC) by maintaining high viral replication. A systematic review of observational studies 
suggested that early age at HBV infection might increase the risk of sequelae of CHB infection. 
However, there was no data from Africa. A project was therefore designed to explore the effect 
of age at HBV infection on HCC and its predictors in The Gambia, West Africa, using two 
proxy variables for the age at infection: birth order and maternal HBV sero-status. 
 
A historical cross-sectional study of children born to HBeAg-positive mothers and 
HBeAg-negative mothers found that having an HBeAg-positive mother is associated with 
higher risk of positive HBeAg in children. The distribution of birth order was compared 
between HBV-related HCC cases and HBsAg-positive controls using a historical case-control 
study and data from the PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) 
project. The former study did not find statistically significant association whilst the latter found 
an inverse association between birth order and HCC, suggesting that chronic carriers with low 
birth order might have an increased risk of HCC. Finally, an open community cohort study of 
HBsAg-positive people in three Gambian villages found that having an HBsAg-positive mother 
is associated with a number of factors predictive of disease (delayed HBeAg seroclearance, high 
HBV DNA and alanine transaminase levels over time, active CHB disease, significant liver 
fibrosis and condition requiring antiviral treatment). These findings suggest that interrupting 
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perinatal mother-to-infant transmission might significantly reduce the burden of liver disease 
associated with CHB infection in The Gambia. 
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Chapter 1. Background: epidemiology of chronic 
hepatitis B virus infection 
 
 
1.1. Global burden of hepatitis B virus infection, liver 
cirrhosis and liver cancer 
Globally, hepatitis B virus (HBV) infection is one of the most prevalent viral infections. More 
than two billion people who are currently alive have been infected,
1
 of whom 240 million are 
chronically infected.
2
 The global prevalence of chronic HBV infection is estimated to be 3.9% 
in males and 3.5% in females in 2005.
2
  
 
The Global Burden of Disease, Injuries, and Risk Factors Study estimated that 1,030,800 and 
752,100 people died of liver cirrhosis and liver cancer in 2010, respectively.
3
 The 
age-standardised death rate of liver cirrhosis was 15.6 per 100,000 and liver cancer was 11.5 per 
100,000. Liver cirrhosis ranks 12
th
 and liver cancer 16
th
 amongst 235 causes of death, and the 
latter is the 3
rd
 commonest cause of cancer death, after lung and stomach.
3
  
 
HBV infection accounts for 30.3% of liver cirrhosis deaths and 45.4% of liver cancer deaths. 
Overall, 786,000 people were estimated to have died in 2010 from HBV-related liver diseases 
including acute/fulminant hepatitis, liver cirrhosis and liver cancer, which makes HBV infection 
as a 15
th
 ranked cause of death.
3
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The prevalence of chronic hepatitis B (CHB) infection in adults in 2005 varies considerably 
between countries (figure 1.1); low prevalence (<2%) is seen in North America and Western 
Europe, low intermediate (2-4%) in the Middle East, the Indian subcontinent and Japan, high 
intermediate (5-7%) in China, Southeast Asia, Eastern and Southern Africa and high (≥8%) in 
Middle and Western Africa.
2
 Because CHB infection is responsible for about half of liver 
cancer worldwide, the prevalence of CHB infection and incidence of liver cancer are positively 
correlated (figure 1.1 and 1.2).
2,4
 Low incidence is seen in the USA and Western Europe while 
the incidence is high in Eastern and Southeast Asia, and Middle and Western Africa. In Africa, 
liver cancer is the leading cause of cancer death in men and the third most frequent cause in 
women.
5
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Figure 1.1 Prevalence of hepatitis B infection, adults 19-49 years, 2005
2
 
 
 
Figure 1.2 Age-standardised incidence rates of liver cancer, 2008
4
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1.2. Serological markers of HBV infection 
There are six important serological markers of HBV infection: hepatitis B surface antigen 
(HBsAg) and its antibody (anti-HBs), hepatitis B e antigen (HBeAg) and its antibody 
(anti-HBe), and two classes of antibody against hepatitis B core antigen (anti-HBc IgG and 
anti-HBc IgM).
6
 A positive serum HBsAg indicates an active HBV infection. The infection is 
chronic if HBsAg persists for longer than six months, otherwise the infection is acute. HBsAg is 
the first serological marker that appears during acute HBV infection and it is followed by 
anti-HBc IgM, which usually disappears several months after the acute infection and therefore 
indicates recent infection. After the clearance of HBsAg, anti-HBs appears, which usually 
confers a good prognosis with lifelong immunity. HBeAg is present early during acute infection, 
and disappears before the HBsAg seroclearance. It is associated with high viral replication (i.e., 
high HBV DNA levels). HBeAg loss is often followed by the appearance of anti-HBe. As 
anti-HBc IgG persists from the acute infection throughout one’s life, this is a marker of past or 
present infection.  
 
Chronic infection with HBV (CHB infection) differs from CHB disease. The latter is defined as 
“chronic necroinflammatory disease of the liver caused by persistent infection with HBV”.7 The 
terms: CHB, chronic HBV infection, hepatitis B carrier, and chronic carrier of HBsAg are used 
interchangeably in the literatures. 
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1.3. Modes of transmission 
HBV is highly infectious and can be transmitted through skin or mucous membrane by exposure 
to infected blood or other body fluids (wound secretions, semen, vaginal fluid, or saliva).
8
 Major 
modes of transmission include mother-to-infant, child-to-child, sexual, and contaminated 
needles, syringe or blood products.
8
  
 
1.3.1. Mother-to-infant/child transmission 
There are three mechanisms of transmission from infectious mothers to infants and children, 
two in the perinatal period and one in postnatal period: i) transplacental intrauterine 
transmission; ii) transmission during delivery through contact with infectious maternal fluids in 
the birth canal; and iii) postnatal transmission through a close contact between mothers and 
children.
9,10
 Perinatal transmission usually occurs at the time of delivery and intrauterine 
transmission is relatively infrequent.
8,10
 The term “vertical transmission” is defined as a 
transmission through germ cell lines, although it has sometimes been incorrectly used to 
indicate perinatal mother-to-infant transmission of HBV.
10
   
 
1.3.1.1. Intrauterine transmission 
An indicator of intrauterine transmission has not yet been established. Theoretically, the 
presence of HBV DNA in the liver tissues of newborns should accurately reflect 
intrauterine transmission. Indeed, a Chinese study reported that 8.3% (4/48) of foetuses 
from terminated pregnancies in HBsAg-positive mothers had evidence of intrauterine 
HBV infection (two with positive HBV DNA in liver tissue, one with HBsAg-positive 
liver tissue and one with HBsAg-positive cardiac blood).
11
 However, liver tissue is 
 17 
 
rarely obtained from newborns.
12
 Studies often examine HBsAg or HBV DNA in either 
umbilical cord blood at delivery or peripheral blood of neonate at birth as an indicator 
of intrauterine transmission. These proxy measures are not perfect; the former has a risk 
of being contaminated by maternal blood,
12–14
 and the latter may give a false-positive 
because the HBsAg particle can cross the placenta.
15
 The risk of intrauterine 
transmission, indicated by positive-HBsAg in peripheral blood of newborns at birth, is 
0-6% in neonates born to HBsAg-positive HBeAg-negative mothers and 7-15% in those 
born to HBeAg-positive mothers, after excluding extreme values reported in early 
studies
16–19
 (table 1.1-a). Table 1.1-b also shows that higher levels of maternal HBV 
DNA are associated with higher chance of intrauterine transmission. 
 
Positive HBeAg without HBsAg in cord blood or peripheral blood at birth is common in 
neonates born to HBeAg-positive mothers (90% in cord blood studies
20,21
 and 40-60% 
in neonatal peripheral blood studies
22,23
). This condition usually represents 
transplacental passage of HBeAg. A spontaneous clearance of HBeAg usually occurs 
within 6 months after birth without resulting in infection, if the risk of postpartum 
transmission is eliminated by passive and active immunoprophylaxis (i.e., HBV vaccine 
and immunoglobulin).
23,12
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Table 1.1 Frequency of intrauterine transmission by maternal HBeAg status and maternal HBV DNA levels in infants born to HBsAg-positive mothers (case-control 
study was not included) 
 
Table 1.1-a According to maternal HBeAg 
Author, year Country Study 
design 
Type of 
sample  
Type of outcome Type of exposure Prevalence of 
intrauterine 
transmission in 
exposed 
Prevalence of 
intrauterine 
transmission in 
unexposed 
Other factors associated 
with intrauterine 
infection 
Wong VCW, 
1980
16
 
Hong 
Kong 
Co Cord blood HBsAg HBeAg 46.8% (22/47) 24.0% (12/50) Longer 1
st
 stage of 
labour associated, 
HBsAg in amniotic fluid 
not associated 
Barin F, 1981
17
 Senegal CS Peripheral HBsAg HBeAg 66.7% (4/6) 7.1% (1/14) N/R 
Goudeau A, 
1983
19
 
Senegal CS Peripheral 
within 6 
days 
HBsAg HBeAg 30.7% (4/13) 5.3% (2/38) N/R 
Marinier E, 
1985
13
 
Senegal Co Cord blood HBsAg HBeAg 0% (0/26)
a
 0% (0/106)
a 
N/R 
Roingeard P, Senegal CS Peripheral HBsAg HBeAg 100% (2/2) 10.5% (2/19)
b
 N/R 
 19 
 
1993
18
 
Wang JS, 2000
22
 China CS Peripheral  HBsAg HBeAg 6.7% (1/15) 0% (0/18) N/R 
Xu DZ, 2002
24
 China CS Peripheral HBsAg HBeAg 9.8% (13/133) 0.7% (2/269) Maternal age not 
associated, threatened 
preterm labour 
associated 
Wang Z, 2003
23
 China Co Peripheral HBsAg HBeAg 9.1% (3/33) 0% (0/21) N/R 
Shao ZJ, 2007,
25
 
2011
26
 
China CS Peripheral HBsAg HBeAg 14.6% (6/41) 2.5% (4/163) Maternal age not 
associated, sexual 
intercourse in the 2
nd
 
trimester associated 
Guo Z, 2013
27
 China CS Peripheral HBsAg and/or 
HBV DNA 
HBeAg 13.9% (57/410) 5.7% (36/633) Maternal age not 
associated, menstrual 
irregularity, severe 
nausea in the 1
st
 
trimester and vaginal 
delivery associated 
 
Table 1.1-b According to maternal HBV DNA levels 
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Author, year Country Study 
design 
Type of 
sample  
Type of outcome Type of exposure 
(log10 copies/ml) 
Prevalence of 
intrauterine 
transmission in 
exposed 
Prevalence of 
intrauterine 
transmission in 
unexposed 
Other factors associated 
with intrauterine 
infection 
Xu DZ, 2002
24
 China CS Peripheral HBsAg ≤5.8 0% (0/39) N/A Maternal age not 
associated, threatened 
preterm labour 
associated 
5.8 – 6.8 1.4% (1/72) 
6.8 – 7.5 3.5% (1/29) 
7.5 – 8.5 0% (0/18) 
≥8.5 22.2% (6/27) 
Candotti D, 
2007
28
 
Ghana CS Cord blood HBV DNA Detection (≥5 log10 
copies/ml) 
10.8% (13/120) 0% (0/7) Pre-core wild-type at 
position 1896 associated 
Shao ZJ, 2007,
25
 
2011
26
 
China Co Peripheral HBsAg Detection 12.2% (7/57) 2.1% (3/145) Maternal age not 
associated, sexual 
intercourse in the 2
nd
 
trimester associated 
3-5 5.0% (1/20) N/A 
5-8 18.5% (5/27) 
>8 10.0% (1/10) 
Xu WM, 2009
29
 China RCT Peripheral HBsAg ≥9 25.5% (14/55) N/A N/R 
Guo Z, 2013
27
 China CS Peripheral HBsAg and/or 
HBV DNA 
3-5 12.3% (64/518) 6.1% (32/528) Maternal age not 
associated, menstrual 
irregularity, severe 
≤6 8.5% (15/177) N/A 
6-8 13.9% (41/296) 
 21 
 
>8 17.8% (8/45) nausea in the 1
st
 
trimester and vaginal 
delivery associated 
a
 Number of children exposed (having HBeAg-positive mothers) and unexposed (having HBeAg-negative HBsAg-positive mothers) was extrapolated from the 
prevalence of HBeAg reported in the same study. 
b
 Excluding four subjects with suspected contamination at birth.  
Abbreviations: CS, cross-sectional study; Co, cohort study; RCT, randomised-controlled trial; RIA, radioimmunoassays; RPHA, reverse passive haemagglutination; 
qPCR, real-time quantitative polymerase chain reaction; N/R, not reported.  
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1.3.1.2. Transmission during delivery  
The risk of perinatal mother-to-infant transmission (including intrauterine infection) is largely 
determined by the maternal HBeAg status. The risk of infection (indicated by a positive-HBsAg 
at 3-12 months after the birth) ranges from 15-35% in children born to HBsAg-positive 
HBeAg-negative mothers to 80-100% in children born to HBeAg-positive mothers in East 
Asia.
16,30–33
 Subsequent studies have confirmed that maternal HBV DNA levels are a more 
important risk factor for perinatal transmission than maternal HBeAg.
34,35
  
 
In some countries, an elective caesarean section has been performed before the onset of labour 
or the rupture of membranes to prevent the mother-to-infant transmission. A recent 
meta-analysis of four randomised controlled trials of elective caesarean section versus vaginal 
delivery in HBsAg-positive pregnant women with positive HBV DNA (>10
3
 copies/ml) 
confirmed that the risk of infection in their babies (indicated by a positive HBV-DNA in cord 
blood or neonatal peripheral blood at birth) was significantly lower in children born with 
caesarean section (10.5%) than in those born with vaginal delivery (28.0%).
36
  
 
1.3.1.3. Postnatal transmission from infectious mothers 
Beasley and Hwang prospectively followed up a cohort of Taiwanese children born to 
HBsAg-positive mothers. The children were given hepatitis B immunoglobulin at birth (which 
reduced the risk of perinatal transmission) but not hepatitis B vaccine (which made them 
susceptible to subsequent infection), and were not yet infected at 12 months of age. After an 
average of 17.5 months of additional follow-up, 67.6% (25/37) of children born to 
HBeAg-positive mothers became infected while 22.1% (15/68) of children born to 
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HBeAg-negative HBsAg-positive mothers infected. The association remained statistically 
significant after adjusting for the presence of an HBsAg-positive older sibling (a potential 
source of infection), whilst the association between having HBV infected older siblings and 
postnatal infection disappeared after controlling for the presence of an HBeAg-positive mother.
9
 
The study illustrated high postnatal infectivity of HBeAg-positive mothers in Taiwan. 
Nevertheless, in the absence of immunoprophylaxis, most of the children (>70-90%) born to 
HBeAg-positive mothers become HBsAg-positive by 3 months old.
16,37–39
 Therefore, the role of 
postnatal transmission through HBeAg-positive mother is not large in East Asia. 
 
Although the exact mechanism of postnatal maternal transmission is not known, the authors 
suggested that maternal saliva was a source of infection because the infant’s food is often 
premasticated by the mother in Taiwan.
9
 Breastfeeding was shown not to be a route of HBV 
transmission in a recent systematic review of intervention studies.
40
 
 
1.3.2. Horizontal transmission during childhood 
HBV can be horizontally transmitted during childhood in the absence of perinatal, sexual or 
parenteral transmission.
41
 Horizontal transmission mainly occurs within the household from 
infectious mothers
9
 or siblings,
42
 however, it can also occur in preschool day-care facilities and 
schools.
41,43–45
 For example, in Okinawa, Japan, 10 of 15 children identified to carry HBsAg by 
a sero-survey in nursery schools did not have any family member who carried HBsAg, but all 
10 children had HBeAg-positive playmates in the classroom, suggesting that they might have 
acquired the infection at the nurseries.
43
 Another study found HBV transmission between 
children attending the same day-care centre based on molecular evidence.
46
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The exact mechanism of horizontal transmission during childhood is not completely 
understood.
8,47
 The most probable route includes exposure to blood or wound secretions through 
cutaneous sores, abrasions or mucous membranes.
8,47
 Transmission can also occur following the 
contact with contaminated saliva through bites,
48,49
 skin cuts
50
 or skin that is not intact (e.g., 
chapped hands).
51
 It is also possible that the transmission occurs through sharing objects such as 
towels, chewing gum, or toothbrushes,
52
 because the virus can be found on objects without 
visible blood,
53
 and can survive outside the body for at least one week.
54
 It has also been 
proposed that blood-feeding arthropods might act as vectors for HBV transmission.
55
 However, 
a randomised controlled trial of an intervention aimed at bedbug elimination in rural villages in 
The Gambia failed to reduce the incidence of HBV infection.
56
 
 
1.3.3. Major mode of transmission and its geographical distribution 
The prevalence of HBV infection is correlated with the major mode of HBV transmission in an 
area and therefore with the predominant age at which infection occurs.
8
 In areas with the low 
prevalence, most HBV infections occur in young adults as a result of intravenous drug use or 
unprotected sex. In high-endemic areas such as sub-Saharan Africa (sSA) or Asia, transmission 
is predominantly in the perinatal period from infectious mother or during early childhood from 
one child to another. 
 
1.3.3.1. HBV transmission in East Asia 
In East Asia, perinatal maternal transmission is relatively common compared to other regions. 
In the pre-vaccine era 15% of pregnant women in Taiwan had HBsAg,
31,57
 and 40% of children 
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born to these mothers became HBsAg-positive by the age of 3 months (table 1.2).
57
 The risk of 
transmission was especially high when the mothers also carried HBeAg; in this case >70-90% 
of their children became sero-positive for HBsAg by 3 months in Taiwan
37,38
 and in Hong 
Kong.
16,39
  
 
1.3.3.2. HBV transmission in sub-Saharan Africa 
Perinatal transmission plays less of a role in sSA than in East Asia, and most HBV infections 
occur during early childhood. In Senegal, Marinier et al. tested mothers for HBV sero-markers 
and followed their newborn infants unvaccinated for HBV and examined the risk of infection 
(positive HBsAg) at birth (cord blood), 1 week to 5 months, 5-12 months, 12-24 months and 
24-38 months.
13
 In mothers, the prevalence of HBsAg was 9.8% (141/1442), and 19.8% (23/116) 
of HBsAg-positive mothers also carried HBeAg. At birth, none of 132 children born to 
HBsAg-positive mother had HBsAg in their cord blood. The subsequent risks of the infection in 
those born to HBsAg-positive mothers were 0% (0/88), 3.8% (3/78), 10.9% (6/55), and 35.3% 
(6/17), in 1 week to 5 months, 5-12 months, 12-24 months and 24-38 months, respectively 
(table 1.2). In those born to HBsAg-negative mothers, the risks were 0% (0/374), 2.2% (4/186), 
6.2% (6/97) and 14.3% (5/35), respectively. These imply that in Senegal most transmission 
occurs after 5 months of age, and the risk of postnatal transmission is higher in children born to 
HBsAg-positive mothers. 
 
Likewise, a cohort study in Kenya followed 51 unvaccinated infants born to HBsAg-positive 
mothers (of whom 8% were also HBeAg-positive and 26% were HBV DNA positive);
58
 by the 
age of 3 months, no infants were infected. By the age of 9 months, 25.0% (1/4) and 4.3% (2/47) 
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were infected in those born to HBeAg-positive and HBeAg-negative mothers, respectively. 
When stratified by maternal HBV DNA detection, 7.7% (1/13) born to mothers with positive 
HBV DNA and 5.3% (2/38) born to mothers with negative HBV DNA were infected by the age 
of 9 months. A cohort study in Tanzania also found that the infection by the age of 8 months 
was infrequent: 20.0% (3/15) in children born to HBeAg-positive mothers and 2.6% (1/38) in 
children born to HBsAg-positive HBeAg-negative mothers.
59
 
 
The findings from these cohort studies are supported by a number of cross-sectional 
sero-surveys in sSA conducted before the introduction of hepatitis B vaccine. In West Africa 
(The Gambia, Senegal and Liberia), the HBsAg seroprevalence during the first 6 months of life 
was only 0-3%, but this sharply increased by the age of 5 years when the prevalence reached 
14-35%, indicating the predominance of postnatal transmission during early childhood.
17,42,60,61
 
In rural Senegal, the second peak in HBsAg prevalence was noted in the age of 6-7 years 
(32.0%), suggesting that in addition to the transmission during early childhood, entry to the 
primary school might also increase the risk of infection.
17
 By the age of 12-13 years, almost all 
children (91.2%) had been exposed to HBV (indicated by presence of any HBV sero-marker), 
implying that transmission during puberty and adulthood is uncommon. Similar patterns of 
age-specific HBsAg prevalence were found in Keneba and Manduar, two rural villages in The 
Gambia; a steep increase in HBsAg from 0% in infants aged less than 6 months
42
 to 10-30% in 
children aged 2-4 years was followed by a second peak at the school entry (7-8 years old), and 
by the age of 13 years >90% showed the past exposure to HBV.
60
 In Namibia, Southern Africa, 
where 11% of mothers carry HBsAg (of whom 15% also carry HBeAg), the prevalence of 
HBsAg in infants aged <6 months was only 1% (4/314) whilst the prevalence in children ≥1 
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year old was 13% (81/604),
14
 confirming the predominance of postnatal transmission. Based on 
these data the proportion of HBsAg-positive individuals who acquired the infection perinatally 
in the pre-vaccine era was estimated at 40% in East Asia
62
 and <10% in sSA.
63
 
 
A different pattern of age-specific prevalence was observed in one cohort study in Senegal. In 
this study, two neonates born to HBeAg-positive mothers were both tested positive for HBsAg 
at birth (peripheral blood) and one remained positive at 6 months (another lost HBsAg). Two of 
19 infants (10.5%) born to HBsAg-positive HBeAg-negative mothers were HBsAg-positive at 
birth and remained positive at 6 months old.
18
 A study in Ghana found that 10.8% of cord blood 
from 120 neonates born to mothers with positive HBsAg and positive HBV DNA were positive 
for HBV DNA.
28
 The study found that maternal HBeAg positivity, high viral load, and a 
wild-type HBV genome were associated with higher risk of intrauterine transmission. A recent 
study in Malawi which assessed the risk of intrauterine transmission in neonates of mothers 
co-infected with HIV and HBV found that 3% (1/34) of children were HBV DNA positive two 
weeks after the birth.
64
 These studies confirm that maternal-foetal transmission occurs in sSA 
although it is less frequent than in East Asia. 
 
1.3.3.3. The reason for the difference between Asia and sub-Saharan Africa 
The main reason for the lower frequency of perinatal mother-to-infant transmission in sSA than 
in Asia is the difference in prevalence of maternal HBeAg. Although the prevalence of HBsAg 
in pregnant women is similar between sSA and Asia (10-15%), the prevalence of HBeAg 
among HBsAg-positive mothers is 10% in sSA and 40% in Asia.
63
 Moreover, the risk of 
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perinatal transmission from HBeAg-positive mother to infant is also lower in sSA;
10
 positive 
HBsAg by the age of 3 months is 0% in Senegal
13
 and Kenya
58
 whilst it is >90% in Taiwan.
37,38
 
 
1.3.3.4. Sibling-to-sibling transmission in sub-Saharan Africa 
The HBV infection in sSA occurs mainly within the household and most often between siblings 
during early childhood. In Ghana, HBsAg-positive individuals in the household, rather than 
within the larger domestic compound, were the main source of HBV infection for children.
52
 A 
phylogenetic analysis in The Gambia support this hypothesis.
65
  
 
As discussed above, the risk of postnatal transmission is generally higher in children born to 
HBsAg-positive (or HBeAg-positive) mothers than in those born to negative mothers.
13,42,61
 But 
infectious mothers are not the main source of postnatal transmission in Africa. HBV infection 
tends to cluster within families,
66
 and other family members act as a source of infection.
41
 In 
The Gambia, the risk of the youngest child in each household being sero-positive for HBsAg 
was strongly associated with the number of HBsAg-positive older siblings after adjusting for 
age, sex, family size and maternal HBsAg status; the relative risks were 1.0 (reference), 3.3 (95% 
CI: 1.2-9.2) and 9.3 (2.6-33.0) in children with no, one and more than one older sibling with 
positive HBsAg, respectively.
60
  
 
Child-to-child transmission is frequent in sSA because infected children are highly infectious to 
others. The prevalence of HBeAg in HBsAg-positive mothers and HBsAg-positive children 
aged less than 5 years are 13% and 86% (children aged <5 years) in The Gambia,
60
 and 10% 
and 57% (children aged <5 years) in South Africa,
67
 respectively.  
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Table 1.2 Risk of HBV infection (positive HBsAg) in unvaccinated infants and children according to age and maternal HBV status in longitudinal cohort studies in 
East Asia and sub-Saharan Africa 
Author, country, 
year 
Maternal serostatus At birth 3 months 6 months 9 months 12 months 24 months  >24 months 
Asian studies         
Stevens, Taiwan, 
1975
57,a 
HBsAg(+) 20% (21/103)
c 
41% (30/74) 34% (18/53) 37% (26/71) 36% (25/69)   
Okada, Japan, 1976
30
 HBsAg(+), HBeAg(+)     100% (10/10)   
HBsAg(+), HBeAg(-)     15% (2/13)   
Beasley, Taiwan, 
1977
31
 
HBsAg(+), HBeAg(+)     85% (17/20)   
HBsAg(+), HBeAg(-)     31% (13/42)   
Beasley, Taiwan, 
1979
32
 
HBsAg(+), HBeAg(+)     96% (45/47)   
HBsAg(+), HBeAg(-)     17% (3/18)   
Wong, Hong Kong, 
1980
16,33,a 
HBsAg(+), HBeAg(+) 47% (22/47)
c 
81% (39/48) 79% (37/47)
d 
    
HBsAg(+), HBeAg(-) 24% (12/50)
c 
17% (7/42) 3% (1/30)
d 
    
Beasley, Taiwan, 
1983
37,38,a 
HBsAg(+), HBeAg(+) 20% (N/R) 93% (57/61) 95% (58/61) 95% (58/61) 95% (58/61)   
Wong/Ip, Hong 
Kong, 1984/89
39,35,a 
HBsAg(+), HBeAg(+) 3% (1/34)
e 
74% (25/34) 79% (27/34)    64% (30/47) 
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African studies         
Marinier, Senegal, 
1985
13,b 
HBsAg(+), HBeAg(+) 0% (0/26)
c,f
 0% (0/16)  20% (3/15)  0% (0/8) 33% (1/3) 
HBsAg(+), HBeAg(-) 0% (0/106)
c,f
 0% (0/71)  0% (0/62)  13% (6/46) 31% (4/13) 
HBsAg(+) 0% (0/132)
c 
0% (0/88)  4% (3/78)  11% (6/55) 35% (6/17) 
HBsAg(-) 0% (0/1221)
c 
0% (0/374)  2% (4/186)  6% (6/97) 14% (5/35) 
Greenfield, Kenya, 
1986
58 
HBsAg(+), HBeAg(+)  0% (0/4)  25% (1/4)    
HBsAg(+), HBeAg(-)  0% (0/47)  4% (2/47)    
Menendez, 
Tanzania, 1999
59,a 
HBsAg(+), HBeAg(+)    20% (3/15)
g 
 40% (6/15)
h
  
HBsAg(+), HBeAg(-)    3% (1/38)
g
  16% (6/38)
h 
 
HBsAg(-)    2% (1/42)
g
  21% (9/42)
h
  
Candotti, Ghana, 
2007
28
 
HBsAg(+), DNA(+) 11% (13/120)
c 
      
HBsAg(+), DNA(-) 0% (0/7)
c 
      
HBsAg(-), DNA(+) 0% (0/20)
c; 
      
Chasela, Malawi, 
2014
64,a,i 
HBsAg(+), DNA(+) 3% (1/34)
j 
   17% (5/30)   
HBsAg(+), DNA(-) 0% (0/21)
j 
   0% (0/12)   
HBsAg(-), DNA(+) 0% (0/2)
j 
   0% (0/9)   
a
 Number of children with positive HBsAg includes those who already tested positive in previous tests. 
b
 Number of children with positive HBsAg excludes those who already tested positive in previous tests. 
c
 Test using cord blood 
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d
 Bleeding by 5 months. 
e 
Definition of intrauterine transmission is positive anti-HBc IgM in cord blood or in the 3
rd
-day sample or increment of HBsAg level from sample in cord blood to 
the 3
rd
-day sample. 
f
 Number of children having HBeAg-positive mothers and having HBeAg-negative HBsAg-positive mothers was extrapolated from the prevalence of HBeAg 
reported in the same study. 
g
 Bleeding at 8 months. 
h
 Bleeding at 18 months. 
i
 Study included children born to HIV-positive mothers and excluded children who are infected with HIV during the follow-up. Hepatitis B vaccine was started from 
6 weeks of age and hepatitis B immunoglobuling was not given. All mothers received antiviral regimen including lamivudine for 7 days from the onset of labour, 
and similarly all children received regiment including lamivuding for 7 days after birth as a prophylaxis against HIV.  
j
 Bleeding at 2 weeks. 
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1.4. Natural history of chronic hepatitis B infection 
1.4.1. Establishment of chronic hepatitis B infection following an acute infection 
After exposure to HBV, a person can develop a symptomatic illness called acute hepatitis B or 
remain asymptomatic. Except in those rare individuals (<1%) who develop fulminant hepatitis, 
the acute phase does not result in severe morbidity.
6
 After acute infection, some individuals 
acquire lifelong immunity,
8
 while others develop a chronic infection which may eventually lead 
to liver cirrhosis or HCC. 
 
The major determinant of an individual’s risk of developing chronic infection is the age at HBV 
infection.
68
 Infection persists in 80-90%, 20-30%, <10%, and <5% of people infected perinatally, 
in early childhood, adolescence, and adulthood, respectively.
68,69
 
 
1.4.2. Natural history after establishing the chronic hepatitis B infection 
According to the international guidelines, the natural course of chronic infection consists of five 
phases of variable duration, which are not necessarily sequential: the immune tolerant phase, the 
HBeAg-positive CHB disease, the HBeAg-negative CHB disease, the inactive HBsAg carrier 
phase and resolved hepatitis B (figure 1.3).
7,70,71
 It should be emphasised that this is based on 
observations from Asia, Europe and North America, and to date there has not been any study of 
the natural history of CHB infection in sSA.
72,73
  
 
1.4.2.1. Immune tolerant phase 
Persons infected via the perinatal route frequently experience a period of immune tolerance for 
10-30 years, during which there is no or minimal disease progression despite high viral 
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replication.
74,72
 This is thought to be related to the transplacental passage of HBeAg or 
HBeAg-derived peptides from mother to foetus, which induces a tolerance in newborns against 
the virus.
75
 The observed association between perinatal transmission and higher risk of chronic 
infection may also be explained by this mechanism.
6
 This phase is usually short-lived or even 
absent in people who acquired the infection during childhood or adulthood.
72
 
 
1.4.2.2. HBeAg-positive chronic hepatitis B disease 
Individuals infected through perinatal transmission may advance to HBeAg-positive CHB 
disease (also called as the immune active phase or HBeAg clearance phase) years after the start 
of the immune tolerant period. In contrast, those infected later in adulthood who could not clear 
the infection may transition into this phase shortly after the acute infection without experiencing 
the immune tolerant phase.
74
 In this phase, HBV is recognised as being foreign by the immune 
system of the host, which tries to clear infected hepatocytes. This is characterised by an active 
hepatic inflammation associated with elevated serum alanine aminotranspherase (ALT) and 
reduced HBV DNA levels. This acute exacerbation is often followed by seroconversion from 
HBeAg-positive to anti-HBe-positive status. For example, a cohort study of 58 Taiwanese 
children who had HBeAg seroconversion (78% of them have HBsAg-positive mothers and 
therefore considered as having been perinatally infected) found that the mean ages at peak HBV 
DNA levels, peak ALT and HBeAg seroconversion were 13.4 ± 5.8, 16.3 ± 6.0, and 17.2 ± 5.8 
years, respectively.
76
 
 
Table 1.3-a presents the rates of spontaneous HBeAg loss reported from cohort studies of 
chronic HBV carriers. The annual rates ranged from 3.2% to 9.6% in studies including subjects 
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in the immune tolerant phase and those with HBeAg-positive CHB disease. The annual loss was 
13.9% in studies restricted to those with HBeAg-positive CHB disease.
77–84
 HBeAg 
seroclearance is slower in men, younger age groups, and in individuals without symptoms, who 
have an HBV-infected mother (as a proxy for mother-to-infant transmission), and who are 
infected with HBV genotype C (rather than B).
77–84
 
 
1.4.2.3. Inactive HBsAg carrier and HBeAg-negative chronic hepatitis B disease 
There are three possible scenarios after HBeAg seroconversion.
85
 First, many people will be in 
an inactive HBsAg carrier state in which there is usually no progress to liver injury with normal 
serum ALT and low HBV DNA levels. HBsAg clearance can be expected (2%/year), but some 
may experience reactivation of hepatitis B.
71
 Second, a few seroconverted persons will 
experience HBeAg reversion and develop HBeAg-positive CHB disease again. Third, some 
patients develop HBeAg-negative CHB disease. This is associated with the precore or basal 
core promoter mutations of the virus, which prevents HBeAg formation without compromising 
replication of the virus.
71
 Similar to HBeAg-positive CHB, serum ALT levels in this immune 
active phase can be increased because of active hepatic inflammation. Serum HBV DNA levels 
are usually lower in this phase than in the HBeAg-positive CHB disease (2 x 10
3
-10
7
 versus. 2 x 
10
5
-10
9
 IU/ml).
8
 A longitudinal study in Taiwan showed that during a median follow-up of 9 
years following spontaneous HBeAg seroconversion, 67% remained in inactive HBsAg carrier, 
4% experienced HBeAg reversion and 24% developed HBeAg-negative CHB disease; cirrhosis 
developed in 0.5%, 55% and 23% of subjects in each category, respectively.
85
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Table 1.3-b presents the rate of HBsAg loss reported in cohort studies of chronic HBV carriers. 
The annual rate of HBsAg loss ranged from 0.4% to 1.0% in carriers in immune tolerant phase 
or HBeAg-positive CHB disease and from 1.0% to 1.7% in inactive HBsAg carriers. Male sex, 
younger age, delayed HBeAg seroconversion, low viral load and low HBsAg levels over time 
and having an HBV-positive mothers were associated with a delay in HBsAg loss.
77,80–82,86–90
 
The rate of progression from inactive HBsAg carriers to HBeAg-negative CHB disease is 
between 1.4-4.4% per annum in Taiwan.
91,92
 
 
1.4.2.4. Resolved hepatitis B and occult hepatitis B 
The inactive HBsAg carrier state followed by a resolution of infection through HBsAg 
seroclearance usually confers a favourable prognosis in the absence of pre-existing cirrhosis 
(“resolved hepatitis B”).93 This condition is characterised by undetectable HBV DNA in serum 
while anti-HBc and anti-HBs are often detectable.
70
 In contrast, an increase in duration and 
frequency of the CHB disease episodes leads to repetitive liver injury and regeneration, 
resulting in hepatic necroinflammation/fibrosis and an increased risk of cirrhosis and HCC.
8
 
Occult HBV infection, defined as negative-HBsAg with detectable HBV DNA in serum or liver 
tissue, was associated with chronic liver disease including HCC in two recent meta-analyses.
94,95
 
Of note, neither review included any African studies. 
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Figure 1.3 Natural history of CHB infection (adapted from Chen et al., 2007)
93
 
 
Immune Tolerant Phase 
HBsAg + 
HBeAg + 
anti-HBe - 
HBV-DNA ↑↑↑ 
ALT normal 
HBeAg-positive CHB Disease 
HBsAg + 
HBeAg + 
anti-HBe - 
HBV-DNA ↑↑ 
ALT ↑ 
HBeAg-negative CHB Disease 
HBsAg + 
HBeAg - 
anti-HBe + 
HBV-DNA ↑ 
ALT ↑ 
Inactive HBsAg Carrier 
HBsAg + 
HBeAg - 
anti-HBe + 
HBV-DNA ↓ 
ALT normal 
Perinatal/ 
horizontal 
Transmission 
Adulthood 
Transmission 
HBeAg 
Seroconversion 
Progressive Liver 
Damage 
Resolved Hepatitis B 
HBsAg -, anti-HBs + 
HBeAg - 
anti-HBe + 
HBV-DNA undetectable 
ALT normal 
 37 
 
Table 1.3 Annual rate of HBeAg seroclearance, HBsAg seroclearance and HCC in cohort studies of treatment naïve individuals with CHB infection 
 
Table 1.3-a Annual rate of HBeAg seroclearance 
Author, 
year 
Country, 
settings 
Baseline 
stage of 
cohort 
Mean 
age at 
baseline 
(years, 
range) 
Recrui
tment 
period 
Frequen
cy of 
F/U 
N Mean 
length 
of F/U 
(years, 
range) 
No. with 
outcome 
Annual 
rate (%) 
Factors associated 
with outcome 
Other risk factors 
examined in the 
study 
Alward 
WLM, 
1985
77
 
Alaska, 
population-
based 
IT & EPCHB 20.5 
(0-68) 
1971-7
3 
≥6 mo 102 6.1 ± 
2.3 
Overall:60 
(loss) 
9.6* Female, older age N/R 
64 6.1 Men: 30 7.7* 
38 6.1 Women: 30 12.9* 
Chang 
MH, 
1989
78
 
Taiwan, 
hospital/sch
ool-based 
IT & EPCHB 4.8 
(0-15) 
N/R 6 mo 228 3.4 48 (loss) 6.2* Older age at baseline, 
presence of 
symptom, maternal 
HBsAg(-), origin of 
participants 
(univariable) 
Sex 
Bortolotti Italy EPCHB 7.2 ± 1976-8 N/R 76 5.0 ± 53 13.9* Male sex, previous Age, ALT, liver 
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F, 1990
79
 (Padova), 
hospital-bas
ed 
4.2 7 2.6 (seroconver
sion) 
acute hepatitis 
(univariable) 
histology 
Bortolotti 
F, 1998
80
 
Italy 
(Padya) & 
Spain 
(Madrid), 
hospital-bas
ed 
IT & EPCHB 5.5 ± 
3.4 
1975-8
5 
≤12 mo 112 12.8 ± 
3.2 
108 
(seroconver
sion) 
7.5* N/R N/R 
McMaho
n BJ, 
2001
81
 
Alaska, 
population-
based 
IT & EPCHB Median 
19.9 
(1-87) 
N/R 6 mo 532 5 218 8.2* Older age Sex, ethnicity 
Iorio R, 
2007
82
 
Italy 
(Naples), 
hospital-bas
ed 
IT & EPCHB Median 
6.7 
(1-13) 
1981-2
005 
≤6 mo 62 Median 
10.0 
(5-23) 
46 (loss) 7.4* None Age, sex, ALT 
Tseng 
YR, 
2011
83
 
Taiwan, 
hospital/sch
ool-based 
IT & EPCHB Median 
5.7 
(0-16) 
1984-2
004 
6 mo 185 19.7 121 
(seroconver
sion) 
3.3 Maternal HBeAg(-), 
early maternal 
HBeAg 
Age, sex, maternal 
HBsAg, ALT 
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seroconversion, 
genotype B (vs. C) 
Roushan 
MRH, 
2012
84
 
Iran, 
hospital-bas
ed 
IT & 
EPCHB, all 
born to 
HBsAg(+) 
mothers 
<10 N.R 6 mo 139 18.2 
(2-29) 
82 
(seroconver
sion) 
3.2 Longer length of 
F/U, having HB 
vaccine and HBIG 
Sex, maternal 
HBeAg 
 
Table 1.3-b Annual rate of HBsAg seroclearance 
Author, 
year 
Country, 
settings 
Baseline 
stage of 
cohort 
Mean 
age at 
baseline 
(years, 
range) 
Recrui
tment 
period 
Frequen
cy of 
F/U 
N Mean 
length 
of F/U 
(years, 
range) 
No. with 
outcome 
Annual 
rate (%) 
Factors associated 
with outcome 
Other risk factors 
examined in the 
study 
Alward 
WLM, 
1985
77
 
Alaska, 
population-
based 
Mixed 
(HBeAg(+) 
69%) 
20.5 
(0-68) 
1971-7
3 
≥6 mo 150 6.1 ± 
2.3 
Overall:9 
(loss) 
0.98* Female Age 
90 6.1 Men: 2  0.36* 
60 6.1 Women: 7 1.9* 
Hsu HY, Taiwan, IT & EPCHB 5.5 ± N/R ≤6 mo 375 4.3 ± 10 (loss) 0.43* Older age, Sex, origin of 
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1992
86
 hospital/sch
ool-based 
4.2 2.5 anti-HBe(+), chronic 
active hepatitis, 
maternal HBsAg(-) 
(univariable) 
participants, ALT 
IC & 
ENCHB 
9.2 ± 
4.4 
N/R ≤6 mo 45 4.0 ± 
1.9 
3 (loss) 1.7* 
Bortolotti 
F, 1998
80
 
Italy 
(Padya) & 
Spain 
(Madrid), 
hospital-bas
ed 
IT & EPCHB 5.5 ± 
3.4 
1975-8
5 
≤12 mo 112 12.8 ± 
3.2 
7 (loss) 0.49* N/R N/R 
McMaho
n BJ, 
2001
81
 
Alaska, 
population-
based 
Mixed 
(HBeAg(+) 
42%) 
Median 
19.9 
(1-87) 
N/R 6 mo 1536 12.6 106 0.54 Older age, ethnicity, 
HBeAg(-) 
Sex 
Manno 
M, 
2004
87
 
Italy 
(Modena), 
blood 
donors 
IC 36 ± 11 1972-7
7 
12-24 
mo 
183 N/R 59 (loss) 1.0
 
Older age N/R 
Bortolotti 
F, 2006
88
 
Italy 
(Padova), 
IC (except 
one with 
11.4 ± 
5.1 
1975-8
5 
≤12 mo 64 14.8 ± 
5.7 
9 (loss) 0.95* None Sex, source of 
infection, peak 
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hospital-bas
ed 
ENCHB) ALT before 
seroconversion, 
duration of 
HBeAg(+) phase 
Iorio R, 
2007
82
 
Italy 
(Naples), 
Hospital-ba
sed 
IT & EPCHB Median 
6.7 
(1-13) 
1981-2
005 
≤6 mo 62 Median 
10.0 
(5-23) 
6 
(seroconver
sion) 
0.97* N/R N/R 
Liu J, 
2010
89
 
Taiwan 
(REVEAL), 
population-
based 
Mixed 
(HBeAg(+) 
16%, 
ALT>ULN 
6%) 
30-65 1991-1
992 
6-12 mo 3087 8.0 Overall: 
562 (loss) 
2.3 Older age, low VL at 
baseline, reduction in 
VL over time, high 
ALT when VL 
became undetectable, 
obesity, ethnicity 
Sex, ALT at 
baseline, cigarettes 
1994 9.2 Men: 399 2.2 
1093 5.9 Women: 
163 
2.5 
Tseng 
TC, 
2012
90
 
Taiwan 
(NTUH), 
hospital-bas
ed 
IC (includes 
some with 
VL <2000 
IU/ml with 
ALT >ULN) 
≥28 1985-1
995 
≤6 mo 688 11.6 130 (loss) 1.6 Female, low serum 
HBsAg levels 
Age, ALT, VL 
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Table 1.3-c Annual rate of HBV-related HCC 
Author, 
year 
Country, 
settings 
Baseline 
stage of 
cohort 
Mean 
age at 
baseline 
(years, 
range) 
Recrui
tment 
period 
Frequen
cy of 
F/U 
N Mean 
length 
of F/U 
(years, 
range) 
No. with 
outcome 
Annual 
rate (%) 
Factors associated 
with outcome 
Other risk factors 
examined in the 
study 
Alward 
WLM, 
1985
77
 
Alaska, 
population-
based 
Mixed 
(HBeAg(+) 
69%) 
20.5 
(0-68) 
1971-7
3 
≥6 mo 150 6.1 ± 
2.3 
Overall:3 327.9 N/R N/R 
90 6.1 Men: 2 364.3* 
60 6.1 Women:1 273.2* 
McMaho
n BJ, 
1990
96
 
Alaska, 
population-
based 
Mixed 0-70+ 1971-8
7 
≥6 mo 1400 5.6 Overall: 20 255.9 Male, older age N/R 
824 N/R Men: 18 386.8 
576 N/R Women: 2 63.3 
Evans 
AA, 
1998
97
 
Senegal, 
male 
soldiers 
N/R 29.9 
(range 
20-55) 
1992-9
3 
N/R 2611 N/R N/R 68.3 N/R N/R 
McMaho
n BJ, 
Alaska, 
population-
Mixed 
(HBeAg(+) 
Median 
19.9 
N/R 6 mo 1536 12.6 Overall: 36 185.3 Older age, ethnicity, 
reversion to 
Sex 
908 13.9 Men: 29 229.8 
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2001
81
 based 42%) (1-87) 628 9.3 Women: 7 119.9 HBeAg(+), multiple 
switches in HBeAg 
status 
Evans 
AA, 
2002
98
 
China, 
population-
based 
Mixed Range: 
25-64 
1992-3 Link 
with 
death 
registry 
1150
6 
7.1 Overall:704  863.8 N/R N/R 
8795 7.1 Men: 643 1029.7 
2711 7.0 Women: 61 320.2 
Crook 
PD, 
2003
99
 
England & 
Wales, 
blood 
donors 
N/R 
(HBsAg(+) 
once) 
Median 
29 
(17-64) 
1970-8
2 
Link 
with 
death 
registry 
3658 22.4 Overall: 21 25.5 Male, older age, 
older calendar time 
N/R 
2681 N/R Men: 20 33.5 
977 N/R Women: 1 4.4 
Manno 
M, 
2004
87
 
Italy 
(Modena), 
blood 
donors 
IC 36 ± 11 1972-7
7 
12-24 
mo 
263 29.3 ± 
2.1 
2 (HCC 
death) 
26.0 N/R N/R 
Ribes J, 
2006
100
 
Spain, 
blood 
donors 
N/R 
(HBsAg(+) 
once) 
33 ± 11 
(men), 
34 ± 12 
(women
1972-8
5 
Link 
with 
death 
registry 
2352 N/R Oerall:12 26.5 N/R N/R 
1575 20.5 ± 
4.6 
Men: 11 34.1 HCV, HDV, alcohol, 
diabetes, HBeAg(+), 
anti-HBc IgM 
Cigarettes, HBV 
DNA 
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) 631 20.7 ± 
3.6 
Women: 1 7.6 N/R N/R 
Chen CJ, 
2006
101
 
Taiwan 
(REVEAL), 
population-
based 
Mixed 
(HBeAg(+) 
15%, 
ALT>ULN 
6%) 
30-65 1991-9
2 
N/R 3653 11.4 Overall: 
164 
393 Male, older age, 
alcohol, HBeAg, LC, 
VL at baseline, 
persistence of high 
VL 
Cigarettes, ALT  
2260 11.3 Men: 135 530 
1393 11.7 Women: 29 178 
Tseng 
TC, 
2012
91
 
Taiwan 
(NTUH), 
hospital-bas
ed 
IC (includes 
some with 
VL >2000 
IU/ml with 
ALT <2 
ULN) 
>16 1985-2
004 
≤6 mo 390 8.5 28 240.8 Older age Sex, VL, genotype, 
ALT (lack of 
power) 
Tseng 
TC, 
2012
102
 
Taiwan 
(NTUH), 
hospital-bas
ed 
Mixed 
(HBeAg(+) 
19%, 
ALT>ULN 
29%) 
>28 1985-2
000 
<6 mo 2688 14.7 ± 
4.3 
191 484.4 Male, older age, 
HBeAg, VL, HBsAg 
levels, genotype C 
(>B) (univariable 
analysis) 
None (univariable 
anlalysis) 
1634 14.7 Men: 154 642.0 
1054 14.6 Women: 37 239.6 
IC (includes >28 1985-2 <6 mo 1068 14.9 29 181.9 Male, older age, VL, persistence of 
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some with 
VL <2000 
IU/ml with 
ALT >ULN) 
000 600 15.0 Men: 23 255.9 ALT, HBsAg levels, 
persistence of high 
ALT or high HBsAg 
levels 
high VL 
468 14.9 Women: 6 86.3 
Unless noted, variables in the last two columns are those measured at the enrolment in the cohort. 
* Denominator of the rate is duration of follow-up rather than person-years at risk. 
** Rate was taken from the paper 
*** Incidence of HCC and mortality were assumed to be equivalent in some studies because most of HCC patients die within one year after the diagnosis.
103
  
 
Abbreviations: IT, immune toleratnt phase; EPCHB, HBeAg-positive chronic hepatitis B disease; ENCHB, HBeAg-negative chronic hepatitis B disease; IC, inactive 
HBsAg carrier; LC, liver cirrhosis; ALT, alanine aminotransferase; VL, viral load.
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1.4.3. Role of transient elastography (Fibroscan) in the natural history of chronic HBV infection 
Transient elastography (TE) is a non-invasive method developed in 2003 to assess the degree of 
liver fibrosis by measuring the stiffness of the liver.
104
 The probe of TE is applied to the right 
intercostal spaces of patients, and a vibration from the probe towards the liver tissue induces an 
elastic shear wave. TE estimates the stiffness of liver tissue by measuring the speed of the shear 
wave propagation. The technique has been validated against liver histopathology as a gold 
standard in patients with CHB infection.
105–108
 Meta-analysis of the validity of TE in chronic 
HBV carriers showed that for the diagnosis of significant liver fibrosis or above (≥F2 in Metavir 
scores), the sensitivity was 74.3% and the specificity was 78.3% based on a cut-off of 7.9 kPa. 
For the diagnosis of liver cirrhosis (≥F4 in Metavir scores), the sensitivity was 84.6% and the 
specificity was 81.5% using a cut-off of 11.7 kPa.
109
 
 
To date, few studies have used the degree of liver fibrosis determined by TE (Fibroscan, 
Echosens, France) as an outcome of CHB infection. A hospital-based cross-sectional study in 
Hong Kong examined 453 treatment-naïve HBeAg-positive chronic HBV carriers (median age 
37, IQR; 30-48, male 60%) using TE. Severe fibrosis (>9.0 kPa in patients with normal ALT 
and >12.0 kPa in those with increased ALT levels) was observed in 22%. Older age and higher 
ALT levels were associated with severe fibrosis whilst sex, obesity and HBV DNA were not. A 
subset of the patients (n=28) were followed for a median of 102 months (range 95-110) and 
longitudinal change in ALT levels were associated with the severe fibrosis determined at the 
end of the follow-up.
110
 The same authors studied 1,197 treatment-naïve HBeAg-negative 
chronic HBV carriers (mean age 48.0 ± 11.4 years, male 65%).
111
 Eleven percent of the patients 
were categorised as probable cirrhosis (>13.4 kPa) and older age, abnormal ALT and high HBV 
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DNA levels were associated with this condition. A subset of patients (n=72) were followed for a 
mean duration of 91.2 (± 14.6) months, and were assessed for possible cirrhosis (> 8.4 kPa) at 
the end of the follow-up. The study identified ALT levels and the number of reactivation 
episodes (defined as ALT >58 IU/L) as risk factors for cirrhosis. 
 
 
1.5. Hepatitis B vaccines 
1.5.1. History and current situation 
In 1982 a plasma-derived hepatitis B vaccine was introduced. This vaccine has been gradually 
replaced by a recombinant hepatitis B vaccine (introduced in 1986) because of concerns that the 
plasma-derived vaccine might be contaminated with HIV and other infections.
112
 During the 
1980’s several hepatitis B vaccine trials started in Asia and Africa including two Gambian 
studies (a pilot study in Keneba and Manduar, and the nationwide Gambia Hepatitis 
Intervention Study). These studies demonstrated that the vaccine had good immunogenicity and 
the efficacy against HBsAg carriage was >95%.
113,114,115
 Consequently, in 1992 the World 
Health Organisation (WHO) urged member states to include hepatitis B vaccine in national 
vaccination programmes.
116
  
 
By the end of 2013, 181/193 (94%) countries have adopted this recommendation,
117
 and the 
vaccine has been introduced in all African countries (with the exception of Western Sahara). 
Coverage with 3 doses of the vaccine is 79% worldwide, 72% in Africa,
117
 and 95% in The 
Gambia. 
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1.5.2. Birth dose of hepatitis B vaccine 
1.5.2.1. WHO recommendation 
Currently, the WHO recommends that all neonates receive the first dose of hepatitis B vaccine 
as soon as possible after birth (i.e., a birth dose), ideally within 24 hours (i.e., timely birth 
dose).
116
 WHO emphasises the importance of the birth dose not only in countries high endemic 
for HBV infection where mother-to-infant transmission is common, but also in countries with 
low to intermediate endemicity because many people acquire the infection through 
child-to-child transmission during early childhood. There are different formulations for hepatitis 
B vaccine: monovalent or a fixed combination with other vaccines including 
diphtheria-tetanus-pertussis (DTP), Haemophilus influenza type b, hepatitis A and inactivated 
polio.
116
 Only monovalent hepatitis B vaccine can be used when immunising a neonate at 
birth.
116
 
 
1.5.2.2. Delivery of the timely birth dose 
Despite moderate coverage of hepatitis B vaccine worldwide, the birth dose has not yet been 
successfully implemented. By the end of 2012, out of 181 countries implementing national 
hepatitis B vaccine programme, only half (52%, 94/181) recommended the first dose within 24 
hours.
117
 In sSA, only 6 countries are undertaking the birth dose and its coverage varies: 
Botswana (99%), Cape Verde (99%), Djibouti (87%), The Gambia (95%), Nigeria (12%) and 
Sao Tome and Principe (2%). However, these figures are highly questionable. In a recent study 
in urban Nigeria, the median age at which the first dose of hepatitis B vaccine was given was 14 
days, and none received the vaccine within 24 hours.
118
 In The Gambia, only 3% of children 
were given the first dose within 24 hours according to the dataset from Keneba and Manduar, 
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two rural Gambian villages where the vaccine efficacy has been studied (see Chapter 6). Most 
of African countries adopted a vaccine schedule using the fixed combination starting from 6 
weeks after the birth, because of low HBeAg prevalence in African mothers and relatively 
infrequent perinatal transmission.
119
  
 
1.5.2.3. Rationale for the timely birth dose 
Although WHO strongly recommends the timely birth dose within 24 hours of birth, there is a 
paucity of evidence to support this. A systematic review with meta-analysis assessed the 
preventive effect of hepatitis B vaccines when given within one month of birth in infants with 
HBsAg-positive mothers.
112
 The review included randomised studies where hepatitis B vaccines 
were given alone or together with hepatitis B immunoglobulin (HBIG). The outcome was HBV 
infection, which was defined as positive anti-HBc, positive HBsAg or positive HBeAg. The 
findings are summarised as below. 
 
i) The efficacy of hepatitis B vaccine preventing HBV infection compared to placebo or no 
intervention in children born to HBsAg-positive mothers 
- Overall, hepatitis B vaccine alone reduced HBV infection (RR 0.28, 95% CI; 0.20-0.40). 
- There was a marginal evidence of heterogeneity (p=0.11) in vaccine efficacy according to 
maternal HBeAg status; risk ratio (RR) for HBV infection in vaccinees varied from 0.27 (95% 
CI; 0.18-0.40) in those born to HBeAg-positive mothers to 1.12 (95% CI; 0.31-3.97) in those 
born to HBeAg-negative mothers. The latter was examined in only one trial. 
- There was also a marginal evidence of heterogeneity (p=0.07) in vaccine efficacy according to 
the timing of the first dose; RR for HBV infection in vaccinees differed between the first dose 
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within 12 hours (RR 0.23, 95% CI; 0.12-0.42, two studies), within 24 hours (0.44, 95% CI; 
0.27-0.72, two studies) and 48 hours (0.14, 95% CI; 0.05-0.41, one study). 
- One trial
38
 compared first dose at birth (4-7 days after the birth) and at one month, and not find 
the difference (RR 0.70, 95% CI; 0.18-2.77). In this trial all received HBIG at birth. 
 
ii) The preventive efficacy of hepatitis B vaccine plus HBIG on HBV infection compared to 
vaccine alone in children born to HBsAg-positive mothers 
- Overall, a combination of vaccine and HBIG further reduced HBV infection compared to 
vaccine alone (RR 0.54, 95% CI; 0.41-0.73). 
- There was no evidence of heterogeneity (p=0.47) in efficacy of vaccine plus HBIG versus 
vaccine alone according to maternal HBeAg status; RR for HBV infection in vaccinees was 
0.51 (95% CI; 0.42-0.61) in those born to HBeAg-positive mothers and 0.24 (95% CI; 
0.01-4.06) in those born to HBeAg-negative mothers. The latter was examined only in one trial. 
- There was no evidence of heterogeneity (p=0.38) in efficacy of vaccine plus HBIG versus 
vaccine alone according to the timing of the first dose of HBIG; RR for HBV infection in 
vaccinees was 0.52 (95% CI; 0.43-0.62) for the first dose within 12 hours of birth, 0.60 (95% 
CI; 0.35-1.05) for the first dose within 24 hours, and 0.14 (95% CI; 0.01-2.64) for the first dose 
within 48 hours. 
 
In this systematic review, 18 studies recruited neonates of HBsAg-positive HBeAg-positive 
mothers, while only three studies recruited both neonates of HBeAg-positive mothers and 
HBeAg-negative mothers. The number of neonates in the subgroup analysis of the timing of the 
first dose was also small. Consequently, the authors noted that the meta-analysis was not 
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powered to answer whether the effect of vaccine differed according to maternal HBeAg status 
or the timing of the vaccine.
112
 To date, no randomised vaccine trials have explored the timing 
of the birth dose.
120
 
 
In contrast, a few observational studies have examined the timing of the first dose. A Canadian 
cohort study suggested the importance of birth dose in children born to HBsAg-positive mothers. 
A cohort of children who had been born to HBsAg-positive mothers and vaccinated against 
HBV between 1984 and 1989 were followed up in 1992 for the assessment of HBV 
sero-markers. HBIG was given to some but not all children. The study divided children into four 
groups according to their age (days) at first dose of hepatitis B vaccine: 1-3, 4-7, 8-61 and ≥62. 
The study reported that the risk of breakthrough infection (positive anti-HBc) increased with 
increasing delay in the first dose (OR 4.3, 95% CI; 2.2-8.4, for each unit increase in the age 
group of the first dose). Similarly, the risk of HBsAg carriage (positive HBsAg) increased with 
increasing delay in the first dose (OR 3.3, 95% CI; 1.3-8.2, for each unit increase in the age 
group of the first dose).
121
 A study in China assessed the prevalence of HBsAg amongst children 
born between 1992 and 2005 and who were vaccinated with three doses of hepatitis B vaccine 
without HBIG. After adjusting for confounding factors, the ORs of HBsAg positivity in relation 
to those who received first dose of hepatitis B vaccine within 24 hours were; 0.54 (95% CI; 
0.27-1.11), 1.53 (0.80-2.92), 1.26 (0.69-2.30), 1.31 (0.95-1.81) and 1.54 (1.10-2.20) for those 
received the first dose at 2-7, 8-14, 15-27, 28-180, and >180 days, respectively.
122
 The study 
showed that a timely birth dose (<24 hours) was associated with lower HBsAg when compared 
to a dose given >24 hours, but the study did not find a difference between a dose given <24 
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hours and at 2-7 days of birth. The study was limited as maternal HBV sero-status was not taken 
account. 
 
In a non-randomised controlled trial in Côte d’Ivoire, West Africa, two health centres provided 
HBV vaccines with routine schedules (starting at 6 weeks followed by 10 and 14 weeks) whilst 
two other centres provided the timely birth dose regimen (<24 hours, 6 weeks and 14 weeks). 
HBIG was not available in the study. The prevalence of maternal HBsAg was similar in both 
groups (7.7%) and 14.5% of such mothers also carried HBeAg. At 9 months of age, 0.5% 
(9/1896) of children in birth dose group and 0.5% (10/1900) of those in 6 weeks group were 
tested positive for HBsAg, and all of these children were born to HBeAg-positive mothers. Risk 
of HBsAg positivity at 9 months in children born to HBeAg-positive mothers was lower in birth 
dose group than the 6 weeks group (37.5% versus 58.8%) although the difference was not 
statistically significant (p=0.16).
119
  
 
1.5.2.4. Frequency of immunoprophylaxis failure 
Table 1.4 presents the risk of immunoprophylaxis failure (positive HBsAg and/or HBV DNA) 
by maternal HBV status in individuals who were vaccinated against HBV and received HBIG. 
The risk is almost 0% when the mother is negative for HBeAg or maternal HBV DNA is 
undetectable, and 2-14% when the mother is HBeAg-positive or viraemic.
23,29,35,38,123–127
 The risk 
may be even higher when both positive-HBeAg and high HBV DNA levels are observed than 
when only either of these is present.
29,35,123,127
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This might be because mother-to-foetus intrauterine transmission is the major cause of 
immunoprophylaxis failure, and the risk of intrauterine transmission is determined by maternal 
HBeAg and HBV DNA levels. In infants born to HBsAg-positive mothers, the frequency of 
immunoprophylaxis failure despite passive and active immunisation is between 0-0.6% in 
children without evidence of intrauterine transmission (i.e., negative HBsAg and undetectable 
HBV DNA at birth) and 15-32% in children positive for HBsAg or HBV DNA at birth.
12,26,125
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Table 1.4 Frequency of HBsAg positivity after the age of 3 months in children who were born to HBV-infected mothers and who received immunoprophylaxis, by 
maternal HBeAg status or maternal HBV DNA levels (case-control study and study providing anti-viral treatment to mothers were excluded) 
 
Table 1.4-a According to maternal HBeAg 
Author, year Country Study 
design 
HBIG First 
HBV 
vaccine 
Type of 
outcome 
Timing 
of 
sample 
Type of 
exposure 
(log10 
copies/ml) 
HBsAg 
prevalence in 
children born to 
HBeAg(+) 
mothers 
HBsAg 
prevalence in 
children born 
to HBeAg(-) 
mothers 
Other factors associated 
with vaccine failure 
Beasley RP, 
1983
38
 
Taiwan RCT <7 h 4-7 d HBsAg 9 mo HBeAg 6.0% (3/50) N/A N/R 
1 mo HBsAg 9 mo HBeAg 8.6% (5/58) N/A N/R 
<7 h + 
3mo 
3 mo HBsAg 9 mo HBeAg 2.0% (1/51) N/A N/R 
Stevens CE, 
1985
128
 
Asian in 
USA 
Co <24 h <24h HBsAg 9 mo HBeAg 20.0% (5/25) N/A N/R 
1 mo HBsAg 9 mo HBeAg 12.5% (11/88) N/A N/R 
Ip HMH, 
1989
35
 
Hong Kong RCT <1 h <1 h HBsAg 3 yo HBeAg 14.1% (9/64) N/A N/R 
<1 h + 
monthly 
for 6mo 
<1 h HBsAg 3 yo HBeAg 8.3% (5/60) N/A N/R 
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del Canho R, 
1997
123
 
Netherlands RCT <2 h 0-3 mo HBsAg 12 mo HBeAg 7.0% (8/114) 0% (0/??) N/R 
Wang Z, 
2003
23
 
China Co <24 h + 
1mo 
1 mo HBsAg 12 mo HBeAg 12.1% (4/33) N/A N/R 
Wiseman E, 
2009
124
 
Australia Co <12 h <12 h HBsAg 9 mo HBeAg 6.6% (4/61) 0% (0/77) N/R 
Chakvetadze 
C, 2011
129
 
Mayotte Co <12 h 
in 83% 
<12 h 
in 83% 
HBsAg 
or DNA 
5 yo 
(2-8) 
HBeAg 1.8% (1/56) 5.4% (2/37) Lower maternal age 
associated with the risk of 
failure (p=0.09) 
Zou H, 2012
125
 Taiwan Co <12 h <12 h HBsAg 7-12 mo HBeAg 5.6% (27/484) 0% (0/385) Lower maternal age 
associated with risk of 
failure (p=0.06), HBV DNA 
in cord blood associated 
with failure 
Chen HL, 
2012
126
 
Taiwan Co <24 h < 7 d HBsAg 6 mo – 
10 yo 
HBeAg 9.3% (54/583) 0.1% (1/723), 
(0.3% (3/1050) 
for those 
without HBIG) 
N/R 
Wen WH, Taiwan Co <24 h <7 d HBsAg 4 mo – HBeAg 12.3% (10/81) 0% (0/189), Higher maternal age 
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2013
127
 3 yo (0% (0/33) for 
those without 
HBIG) 
associated with risk of 
failure (p=0.07) 
 
Table 1.4-b According to maternal HBV DNA levels 
Author, year Country Study 
design 
HBIG First 
HBV 
vaccine 
Type of 
outcome 
Timing 
of 
sample 
Type of 
exposure 
(log10 
copies/ml) 
HBsAg 
prevalence in 
children born 
to HBV 
DNA(+) 
mothers 
HBsAg 
prevalence in 
children born 
to HBV 
DNA(-) 
mothers 
Other factors associated 
with vaccine failure 
Wiseman E, 
2009
124
 
Australia Co <12 h <12 h HBsAg 9 mo Detection 2.9% (4/138) 0% (0/??) N/R 
≥8 8.5% (4/47) 0% (0/91) 
Chakvetadze 
C, 2011
129
 
Mayotte Co <12 h 
in 83% 
<12 h 
in 83% 
HBsAg 
or DNA 
5 yo 
(2-8) 
<5 
(IU/ml) 
0% (0/23) N/A Lower maternal age 
associated with the risk of 
failure (p=0.09) 5-7 16.7% (2/12) 
≥7 0% (0/22) 
Zou H, 2012
125
 Taiwan Co <12 h <12 h HBsAg 7-12 mo Detection 4.8% 
(27/562) 
0% (0/307) Lower maternal age 
associated with risk of 
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<6 0% (0/426) N/A failure (p=0.06), HBV 
DNA in cord blood 
associated with failure 
6-7 3.2% (3/95) 
7-8 6.7% 
(19/282) 
≥8 7.6% (5/66) 
6-8 0% (0/1) 
 
Table 1.4-c According to maternal HBV DNA levels in children born to HBeAg-positive mothers 
Author, year Country Study 
design 
HBIG First 
HBV 
vaccine 
Type of 
outcome 
Timing 
of 
sample 
Type of 
exposure 
(log10 
copies/ml) 
HBsAg 
prevalence in 
children born 
to HBV 
DNA(+) 
mothers 
HBsAg 
prevalence in 
children born 
to HBV 
DNA(-) 
mothers 
Other factors associated 
with vaccine failure 
Ip HMH, 
1989
35
 
Hong Kong RCT <1 h <1 h HBsAg 3 yo >5 pg/ml 17.6% (9/51) 0% (0/13) N/R 
<1 h + 
monthly 
for 6mo 
<1 h HBsAg 3 yo >5 pg/ml 9.1% (4/44) 6.3% (1/16) N/R 
del Canho R, Netherlands RCT <2 h 0-3 mo HBsAg 12 mo ≥7.5 29.2% (7/24) 0% (0/48) N/R 
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1997
123
 
Xu WM, 
2009
29
 
China RCT <24 h <24 h HBsAg 12 mo ≥9 12.2% (5/41) N/A N/R 
Wen WH, 
2013
127
 
Taiwan Co <24 h <7 d HBsAg 4 mo – 
3 yo 
<6 0% (0/16) N/A Higher maternal age 
associated with risk of 
failure (p=0.07) 
6-8 5.6% (1/18) 
8-9 17.1% (6/35) 
≥9 25.0% (3/12) 
 
Table 1.4-d According to maternal HBV DNA levels in children born to HBeAg-negative HBsAg-positive mothers 
Author, year Country Study 
design 
HBIG First 
HBV 
vaccine 
Type of 
outcome 
Timing 
of 
sample 
Type of 
exposure 
(log10 
copies/ml) 
HBsAg 
prevalence in 
children born 
to HBV 
DNA(+) 
mothers 
HBsAg 
prevalence in 
children born 
to HBV 
DNA(-) 
mothers 
Other factors associated 
with vaccine failure 
Wen WH, 
2013
127
 
Taiwan Co Some 
not 
given 
<7 d HBsAg 4 mo – 
3 yo 
<6 0% (0/221) N/A Higher maternal age 
associated with risk of 
failure (p=0.07) 
Abbreviations: RCT, randomised-controlled trial; Co, cohort study; N/A, not applicable; N/R, not reported.
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1.5.2.5. Logistical challenges for implementation of birth dose vaccination 
The WHO summarised evidence on facilitators and barriers to improve coverage of the hepatitis 
B timely birth dose through a systematic review.
130
 The review found that births at health 
facilities were associated with higher coverage of the birth dose than home births. For children 
born at health facilities, the integration of birth dose with maternal and newborn care is a key to 
improve its coverage, and this can be achieved through a local health policy specifying birth 
dose vaccination, ensuring the availability of the vaccine in the delivery room, giving a 
responsibility for vaccination to birth attendants, and coordination between immunisation staff 
and maternal health staff.  
 
In contrast, for children born at home, there is some evidence mainly from China that home 
visits to provide timely birth dose by village health workers are more effective in increasing 
birth dose uptake than asking families to bring neonates to health facilities. Factors associated 
with higher birth dose coverage at home delivery include vaccine storage out of the cold chain, 
birth notification and pregnancy tracking, and the use of Uniject
TM
 (a compact pre-filled 
auto-disable injection device) instead of standard needles and syringes.
130
 Of note, storing 
hepatitis B vaccine outside the cold chain was shown to have similar immunogenicity and 
protective efficacy when compared to storage at a temperature of 2-8 
o
C as recommended by 
manufacturers.
131
 
 
In SSA including The Gambia, there has been no study investigating practices to improve the 
coverage of hepatitis B vaccine birth dose.
130
 According to the statistics of UNICEF 
(2008-2012), although 98.1% of pregnant women visit antenatal care at least once in The 
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Gambia, only 55.7% women deliver their child at health facilities.
132
 These imply that in order 
to improve the access to the birth dose in The Gambia, home delivery of timely birth dose needs 
to be considered together with the integration of birth dose with maternity care at health 
facilities. Otherwise, universal screening of maternal HBV infection at antenatal care and 
subsequent provision of selective birth dose to neonates born to infected mother can be an 
alternative strategy. However, no study has examined its efficacy and feasibility in SSA. 
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1.6. Factors modifying the progression of liver disease in 
individuals with chronic hepatitis B infection 
1.6.1. Viral replication 
HBe antigenaemia (as a proxy for high viral replication) and a high HBV DNA levels are 
associated with an increased risk of cirrhosis and HCC. Several population-based longitudinal 
cohort studies in Taiwan and China have examined the risk of cirrhosis and HCC in relation to 
HBV DNA levels at baseline. These studies consistently revealed that the risk of cirrhosis
133
 or 
HCC
134,101,135
 starts to increase when HBV DNA levels exceed 2,000 IU/mL. Similar findings 
were reported in case-control studies in Senegal,
136
 South Africa,
137
 and The Gambia.
138
 
Furthermore, several studies have investigated the trajectory of HBV DNA levels over time and 
its effect on HCC.
101,139,102
 These studies found that the maintenance of high viral DNA levels 
plays a crucial role in determining the risk of HCC. 
 
A number of studies have examined the association between viral replication and predictors of 
HCC. Tseng et al. prospectively followed a hospital-based cohort of people with CHB infection 
in Taiwan who experienced spontaneous HBeAg serovconversion and found that viral load after 
the HBeAg seroconversion was positively associated with the risk of HBeAg-negative CHB 
disease (ALT ≥80 IU/L and viral load ≥2,000 IU/ml) and hepatitis flare (ALT ≥200 IU/L and 
viral load ≥2,000 IU/ml).91 They also demonstrated that the occurrence of HBeAg-negative 
CHB disease was associated with cirrhosis and HCC.  
 
1.6.2. Serum HBsAg levels 
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The risk of HCC among chronic HBV carriers is positively associated with HBV DNA levels. 
However, the rates of HCC remain reasonably high even among carriers with low HBV DNA 
levels.
101,102
 Several studies have therefore identified predictors of HCC in people with low viral 
replication. Tseng et al. prospectively assessed the effect of HBsAg levels on HCC incidence in 
a hospital-based cohort of people with CHB infection. Overall analysis showed that viral load at 
baseline predicts HCC risk better than HBsAg levels. However in a subgroup of people with 
negative-HBeAg and low viral load (<2,000 IU/ml), the positive association between HBsAg 
levels (≥1,000 vs. <1,000 IU/ml) and HCC risk was observed while viral load (<200 vs. 
200-2,000 IU/ml) was not associated with HCC, suggesting that the measurement of HBsAg 
levels may complement viral load in predicting the HCC risk in people with low HBV DNA 
levels.
102
 
 
Higher serum HBsAg levels were associated with other outcomes such as lower rate of 
spontaneous HBsAg loss
90
 and a higher risk of HBeAg-negative CHB disease in a cohort with 
negative HBeAg and low viral load (<2,000 IU/ml) in Taiwan.
92
  
 
1.6.3. Viral genotype 
There are at least eight genotypes (A-H) of HBV, based on a nucleotide diversity of more than 
8% in the complete genome sequence.
6
 The viral genotype appears to modify the natural history 
of infection and risk of HCC. In Taiwan where genotype B (80%) and C (20%) predominate, 
genotype C was associated with delayed HBeAg seroconversion
83,140
 and increased HCC 
incidence.
134
 Furthermore, a Taiwanese study comparing 107 paediatric cases who became 
chronic carriers despite HBV vaccine and HBIG with 214 age-matched controls who became 
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carriers without being given the vaccine found that genotype C was associated with vaccine 
failure.
141
 A subsequent study of children with CHB infection by the same authors showed that 
children with HBeAg-positive mothers have higher prevalence of genotype C than those with 
HBsAg-negative mothers, suggesting a link between genotype C and mother-to-infant 
transmission.
83
 A similar finding has been reported in a study conducted in Japan.
142
 
 
Although most HBV endemic areas have only two HBV genotypes, five genotypes (A, B, C, D 
and F) are found in Alaska. Livingston et al. found an association between genotype C and the 
persistence of HBeAg,
143
 and between genotype F and HCC.
144
 
 
In Africa, genotype A, D and E are common, and the predominant genotype varies with the 
geographical area: genotype A in South, East and Central Africa; genotype D in North Africa; 
and genotype E in West Africa.
145
 Few African studies have related viral genotypes to clinical 
outcomes.
145
 In Bantu-speaking South Africans, a case-control study of HBV-related HCC with 
asymptomatic HBV-positive controls matched for age and sex found that the prevalence of 
genotype A was significantly higher in cases (86.5%, 96/111) than in controls (68.5%, 
76/111).
146
 The majority of non-A genotypes in this study was D. In The Gambia, the vast 
majority is genotype E (75-95%) followed by genotype A.
147,148149
 The Gambia Liver Cancer 
Study (GLCS) did not find an association between HBV genotype and HCC or cirrhosis, but the 
sample size was small. The prevalence of genotype E was 77% (33/43) in HBV-related HCC, 
79% (15/19) in HBV-related cirrhosis and 50% (2/4) in HBsAg-positive controls.
149
 Preliminary 
data from other West African countries showed that HBeAg prevalence was higher in subjects 
infected with genotype E (89.8%, 35/39) than in those with genotype A (33.3%, 2/6).
150
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1.6.4. Aflatoxin 
Aflatoxin is a mycotoxin produced by fungal species of the genus Aspergillus. The 
contamination of agricultural products such as groundnuts and maize with aflatoxin is facilitated 
by hot and humid climates.
151
 Aflatoxin exposure alone is associated with an increased risk of 
HCC, and the combined effect of aflatoxin and CHB infection is greater than multiplicative.
152
 
 
In The Gambia, where groundnuts are dietary staples, people are highly exposed to this 
toxin.
153,154
 Studies have demonstrated seasonal variation in the serum aflatoxin-albumin adduct 
levels, with a peak in the dry season, related to the availability of groundnuts. Cross-sectional 
studies have examined the association between aflatoxin-albumin adduct levels and HBV 
seromarkers in adults and children. In adults, aflatoxin-albumin adduct levels were not 
associated with HBsAg, HBeAg, or HBV-DNA positivity
153
 whilst in children acute hepatitis B 
was associated with higher levels of aflatoxin-albumin adduct.
154
  
 
Aflatoxin-albumin adducts only reflect recent exposure (over the past 2-3 months).
155
 Recent 
studies have used biomarkers of historic aflatoxin exposure. Kirk et al. examined the prevalence 
of a specific mutation at codon 249 of TP53 tumor suppression gene (249
ser
; AGG to AGT, Arg 
to Ser), a mutation induced by aflatoxin exposure, in a case-control study of HCC in The 
Gambia. The HCC risk was increased in HBsAg-positive subjects without the 249
ser
 mutation 
(OR, 10.0; 95% CI: 5.2-19.6), in those with positive 249
ser
 mutation without HBsAg (OR, 13.2; 
95% CI: 5.0-35.0) and in those with both positive HBsAg and the mutation (OR, 399; 95% CI: 
48.6-3270), suggesting that the combined effect is greater than multiplicative.
156
 However the 
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association was not found between the 249
ser
 mutation and hepatitis B e antigenaemia
156
 or 
serum HBV viral load in The Gambia.
148
  
 
1.6.5. Alcohol 
Alcohol is known to cause liver disease including HCC.
155
 However, the interaction between 
alcohol and CHB infection is controversial. Case-control studies mainly from Europe suggest 
that the combined effect of CHB infection and alcohol intake on HCC is more than additive 
(and sometimes even more than multiplicative).
157
 In contrast, many Asian cohort studies found 
the effects of CHB infection and alcohol combine additively.
98,158,159
 Because alcohol 
consumption is usually influenced by disease status, case-control studies are less informative 
than cohort studies.
8
 In The Gambia, more than 95% of the population are Muslim
160
 and 
regular alcohol use was observed only in 8% of controls in a case-control study of HCC.
161
  
 
1.6.6. Metabolic factors 
Three systematic reviews of cohort studies examining the effect of diabetes mellitus on HCC 
support a positive association between these diseases.
162–164
 The excess risk of HCC attributable 
to obesity or diabetes also occurs in people with CHB infection. A cohort study in Taiwan, the 
relative risk (RR) for joint exposures of obesity (body mass index: BMI ≥30 kg/m2) and CHB 
infection on HCC (22.0, 95% CI; 10.3-46.9) was almost equal to the sum of the RRs for CHB 
infection (19.9, 95% CI; 14.3-27.6) and for obesity alone (2.50, 95% CI; 0.99-6.32), whilst the 
RR for combined effect of diabetes and CHB infection on HCC (43.5, 95% CI; 20.5-92.3) was 
more than the sum of the RRs for CHB infection (18.7, 95% CI; 13.6-25.9) and for diabetes 
alone (3.49, 95% CI; 1.08-11.3).
165
 In The Gambia, very low prevalence of obesity (BMI ≥30 
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kg/m
2, 2.3%, 140/6024) and diabetes (fasting glucose ≥6.7 mMol/L, 0.2%, 14/5898) were 
reported in the general population aged over 15 years.
166
 However, these estimates are from a 
nationwide survey conducted in 1995 and the figures might have changed since then.  
 
1.6.7. Co-infection with hepatitis C virus 
Two meta-analyses have examined the effect of dual infection with HBV and hepatitis C virus 
(HCV) on HCC. Both have shown that the combined effect on HCC are between additive and 
multiplicative. The first meta-analysis of 32 case-controls studies reported that the summary OR 
for HBsAg positivity and anti-HCV/HCV RNA negativity was 20.4 (95% CI; 18.0-23.2), the 
OR for HBsAg negativity and anti-HCV/HCV RNA positivity was 23.6 (95% CI; 20.0-28.1) 
and the OR for both markers of positivity was 135 (95% CI; 79.7-242).
167
 The second 
meta-analysis was restricted to studies in China and reported that the summary OR for HBsAg 
positivity and anti-HCV/HCV RNA negativity was 15.6 (95% CI; 11.5-21.3), the OR for 
HBsAg negativity and anti-HCV/HCV RNA positivity was 8.1 (95% CI; 5.0-13.0) and the OR 
for both markers positivity was 35.7 (95% CI; 26.2-48.5).
168
 
 
In The Gambia, the Gambia Liver Cancer Study (GLCS), a case-control study of HCC between 
1997 and 2001, reported that the OR for joint exposures of dual infection on HCC (35.3, 95% 
CI; 3.9-323) was slightly greater than the sum of the ORs for HBsAg positivity (16.7, 95% CI; 
9.7-28.7), and for anti-HCV/HCV RNA positivity alone (16.7, 95% CI; 6.9-40.1).
169
 In this 
study, the prevalence of HCV infection differed between generations: the prevalence was <1% 
in controls younger than 50 years of age and 5.7% in controls aged over 50 years. An earlier 
case-control study of HCC conducted in The Gambia in 1988 found that the prevalence of HCV 
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infection in controls was 3.3% in those less than 50 and 6.3% in those over 50 years old.
169
 The 
decrease in HCV prevalence after 10 years in the younger controls (from 3.3% to <1%) was 
thought to be related to a cohort effect of HCV infection in The Gambia due to historical unsafe 
injections,
169
 as has been observed in other African countries.
170,171
 Subsequent studies 
supported this hypothesis. In a sero-survey of blood donors (mean age 30.6 years) in The 
Gambia in 2002, the prevalence of anti-HCV was 1.1% (5/460).
172
 In a population-based 
sero-survey in 2008 recruiting young adults (18 to 22 years old) estimated the prevalence of 
anti-HCV (3
rd
 generation ELISA) to be 0.5% (13/2598).
173
  
 
1.6.8. Co-infection with hepatitis delta virus 
Hepatitis delta virus (HDV) is a defective RNA virus which needs the presence of HBV for its 
own life cycle, and therefore can only infect the people infected with HBV.
174
 Routes of 
transmission include parenteral or sexual through exposure to contaminated blood or body 
fluid.
175
 There are two patterns of HDV infection: acute co-infection where uninfected 
individuals are simultaneously infected with HDV and HBV, and superinfection with HDV in 
people with established CHB infection. In the concomitant infection, the clinical course of acute 
hepatitis is more severe but the risk of progression to chronic HBV infection seems to be similar 
to acute HBV mono-infection.
174
 The risk of liver cirrhosis and HCC are higher after 
superinfection with HDV than in HBV mono-infected individuals.
72
 In The Gambia, HDV is 
rare. In the villages of Keneba and Manduar no one under 20 years was positive for anti-HDV.
60
 
 
1.6.9. Co-infection with HIV 
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The epidemiology of HBV and HIV co-infection differs considerably between high-income 
countries (Europe and North America) where the HBV prevalence is low and low-income 
countries (Asia and sSA) where the HBV prevalence is high. In high-income countries, the 
prevalence of CHB infection is higher in HIV-infected than non-infected people, because HBV 
and HIV share common routes of transmission (i.e., sexual or contaminated needles and 
syringes). In low-income countries, the prevalence of CHB infection is usually similar in 
HIV-infected and non-infected people because HBV infection mainly occurred before 
adolescence in the pre-hepatitis B vaccination era.
176
 In The Gambia, where HIV prevalence is 
1.5%,
177
 12.2% of individuals infected with HIV are HBsAg-positive (95% CI; 9.0-15.0%),
178
 
which is similar to the prevalence in Gambian adults in the general population (14-16%).
55,169
   
 
HIV co-infection modifies the natural history of CHB infection and vice versa. Compared to 
people without HIV infection, HIV-infected people are more likely to progress to chronic 
infection after exposure to HBV.
179
 Once HIV-infected people become chronic HBV carriers, 
they have a slower rate of HBeAg seroconversion,
180
 higher HBV DNA levels,
181
 and higher 
risk of liver cirrhosis
181
 than HBV mono-infected people. In a cohort of 5,293 men who have 
sex with men in the USA the combined effect of HBV and HIV on liver diseases was more than 
additive. The rate of liver-related mortality (per 1,000 person-years) was 0.0 in both HBsAg and 
HIV negative men, 0.8 in HBsAg-positive and HIV-negative men, 1.7 in HBsAg-negative and 
HIV-positive men and 14.2 in dually infected men.
182
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1.7. The effect of early age at hepatitis B virus infection on the 
risk of hepatocellular carcinoma and its predictors 
1.7.1. Evans’s hypothesis 
As presented earlier (section 1.1.), the prevalence of CHB infection varies considerably by 
geographical region, as does the incidence of HCC. And highly endemic areas of HBV infection 
have a high HCC incidence.
1
 However, the risk of HCC amongst people with CHB infection 
also varies markedly by geographical areas. Population-based cohort studies in HBsAg-positive 
men have estimated age-standardized HCC incidence rates of 34/100,000 carrier-years in 
Europe
99,100
 to 68/100,000 in Senegal, 
97
 230/100,000 in Alaska
81
 and 530-1,030/100,000 in East 
Asia
98,101
 (table 1.3-c). This variation in the incidence of HCC appears to be due to variation in 
the natural history of CHB infection as is discussed below. 
 
The persistence of high HBV viral load,
101
 or e antigenemia,
183
 plays an important role in 
increasing the risk of HCC, and variations in the prevalence of e antigenaemia may explain the 
observed geographical difference in HCC incidence. In Taiwan, about half of HBsAg-positive 
children remain HBeAg-positive into their twenties,
184
 while in sub-Saharan Africa, where HBV 
endemicity is similar, the prevalence of HBeAg among HBsAg-positive people declines to 10% 
in the second decade of life.
185
 Evans et al. identified factors responsible for the persistence of 
high viral replication in an ecological study comparing Chinese and African populations. They 
suggest that earlier age at HBV infection and prolonged maintenance of viral replication in 
Asians with CHB infection is the cause of the higher HCC incidence in Asia.
97
 In the 
pre-vaccination era, the average age at which persistent infection is established should have 
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been earlier in Asia where perinatal transmission was common than in sSA where child-to-child 
transmission predominated. 
 
It is well established that early age at HBV infection increases the risk of chronic infection after 
exposure to HBV.
68,69
 Early infection is therefore associated with a higher risk of HCC through 
the increased risk of chronic infection.
186
 The hypothesis proposed by Evans et al. implies that 
early HBV infection should further increase the risk of HCC through the persistence of high 
viral replication, beyond its effect of increasing the chance of becoming a chronic carrier.
83
 This 
thesis examines whether early age at HBV infection is associated with higher risk of HCC and 
its predictors amongst chronic carriers of HBV in The Gambia, West Africa. 
 
1.7.2. Outline of the thesis 
In Chapter 2, the use of birth order as a proxy indicator for the age at HBV infection is 
discussed. In Chapter 3, a systematic review of observational studies examining the association 
between early age at HBV infection and HCC and its predictors is presented. In Chapter 4, a 
historical dataset collected in The Gambia is analysed to determine the association between 
familial HBV sero-marker and the risk of hepatitis B e antigenaemia. An historical case-control 
study of HCC in The Gambia is analysed in Chapter 5 to determine the effect of birth order on 
HCC. Results from the long-term follow-up of chronic HBV carriers in three rural villages in 
The Gambia are described in Chapter 6. In particular this chapter examines the effect of having 
an HBsAg-positive mother on the predictors of HCC (HBeAg/HBsAg seroclearance, mean 
HBV DNA levels over time, and significant liver fibrosis). In Chapter 7, the association 
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between birth order and HCC is again examined in a new HCC case-control study within the 
PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) project in The Gambia.  
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Chapter 2. The use of birth order in the 
epidemiology 
 
 
2.1. Introduction 
This thesis examines the relationship between age at hepatitis B virus (HBV) infection and risk 
of hepatocellular carcinoma (HCC) in individuals with chronic HBV infection. Ideally the age at 
the time of HBV infection should be estimated by repeatedly testing a cohort of uninfected 
people for hepatitis B surface antigen (HBsAg). However, this study design requires a long 
period of follow-up and is therefore difficult to conduct.
187
 Alternatively, proxy markers for 
different modes of HBV transmission can be used to estimate the age at infection. Maternal 
HBV sero-status is an indicator for perinatal maternal transmission: a chronic HBV carrier 
whose mother is HBsAg-positive or hepatitis B e antigen (HBeAg)-positive is more likely to 
have been perinatally infected by their mother than a chronically infected individual with a 
seronegative mother. The serological profile of older siblings may also serve as a proxy for 
early childhood transmission, since a chronic HBV carrier who has older siblings with positive 
HBV sero-marker is more likely to have been infected by their siblings during early childhood 
than a chronic HBV carrier without any seropositive older siblings. Finally, some studies have 
used birth order as a proxy for age at infection by assuming that in the absence of immunisation, 
children with low birth order are exposed to HBV after they start schooling, whilst children with 
high birth order are infected much earlier by their older siblings who got the infection outside 
the household.
187
 
 
Birth order has been used as surrogate for biological and social risk factors in a number of 
studies, including diabetes,
188
 cancer,
189
 allergic conditions,
190
 and all-cause mortality.
191
 In this 
chapter, the definition of birth order, methods to examine the effect of birth order, potential 
confounding factors for the effect of birth order on diseases, and previous epidemiological 
studies applying this are discussed. 
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2.2. Definition of birth order 
The definition must specify how miscarriages, multiple pregnancies and half-siblings are 
handled, and should reflect the period when the postulated aetiological factor such as infection 
plays its role.
192
 When the risk factor is thought to affect an individual before their birth (e.g. 
intrauterine environment), miscarriages and stillbirths should be included in birth, whereas 
twins or triplets should be counted as one and half-siblings should not be included (table 2.1). In 
contrast, when the exposure to the risk agent is postulated to occur postnatally (e.g. childhood 
environment), birth order should be obtained by enumerating the number of older siblings who 
were alive during the risk period.
192
 Table 2.1 shows wide variation in what the birth order 
indicates in birth order studies of different cancer sites.  
 
Table 2.1 Definition of birth order 
Hypothesised factor Miscarriages / 
stillbirths 
Multiple 
pregnancies 
Half-siblings living 
with an affected 
individual 
Prenatal 
environmental factor 
Counted Counted as one Not counted 
Postnatal 
environmental factor 
Not counted Counted as 
independent births 
Counted 
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Table 2.2. Sources and definitions of birth order in previous epidemiological studies assessing the effect of birth order on the risk of cancer 
Author, year  Country Study 
design 
Population 
studied 
 
Source of birth 
order 
Definition of birth order 
Basis for 
definition 
Miscarriages 
and stillbirths 
Twins Half siblings  
HCC         
Ryder, 1992
193
 Gambia CC Adults Self-reported N/R N/R N/R N/R 
Hsieh, 1992
187
 Greece CC 
 
Adults Self-reported Children in the 
family 
Not counted Counted as 
independent birth 
N/R 
Kuper, 2000
194
 Greece CC Adults Self-reported Children in the 
family 
Not counted Counted as 
independent birth 
N/R 
Swedish 
Family-Cancer 
Database 
        
Hemminki, 
2001
195
; Altieri, 
2007
196
; Bevier, 
2011
189
 
Sweden Co Children & 
adults 
Second-Generation 
Register 
Maternal parity N/R N/R In the case of 
divorce, assumption 
that all children 
lived with the 
mother 
Breast cancer         
Hsieh, 1991
197
 USA, Wales, 
Japan 
CC Adults Self-reported Children in the 
parental family 
who lived to 40 
years 
N/R Counted as single 
pregnancy 
N/R 
Hodgson, 2004
198
 USA CC Adults Self-reported N/R N/R N/R N/R 
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Sorensen, 2005
199
 Denmark CC Adults Midwife record N/R N/R N/R N/R 
Testicular cancer         
Prener, 1992
200
 Denmark Nested 
CC 
Children Parental 
information 
Children in the 
family 
N/R N/R N/R 
Midwife record Maternal parity Counted 
(miscarriages) 
N/R N/R 
Westergaard, 
1998
201
 
Denmark Co Children Danish Civil 
Registration 
System 
Maternal parity Not counted N/R N/R 
Richiardi, 2004
202
 Sweden Nested 
CC 
Adults Swedish 
Multi-Generation 
Register 
N/R N/R Counted as 
singleton birth 
N/R 
Gastric cancer         
Blaser, 1995
203
, 
2007
204
 
USA Co Adults Self-reported Children in the 
family 
Not counted Counted as 
independent birth 
N/R 
Acute leukaemia         
MacMahon, 
1962
205
 
USA CC Children National Office of 
Vital Statistics 
Maternal parity Not counted N/R N/R 
Dockerty, 2001
206
 UK CC Children Birth record Maternal parity Counted 
(stillborns) 
N/R Excluding children 
born outside 
marriage 
Non-Hodgkin 
lymphoma 
        
Mensah, 2007
207
 UK CC, Adults Self-reported N/R N/R N/R N/R 
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GY 
Grulich, 2010
208
 Multi-national CC Adults Self-reported N/R N/R N/R N/R 
Crump, 2012
209
 Sweden Co Children & 
adults 
Birth registry & 
national census 
N/R N/R N/R N/R 
Hodgkin 
lymphoma 
        
Gutensohn, 
1981
210
 
USA CC Adults Self-reported N/R N/R N/R N/R 
Westergaard, 
1997
211
 
Denmark Co Children & 
adults 
Danish Civil 
Registration 
System 
Maternal parity Not counted N/R N/R 
Abbreviations: N/R, not reported; Co, cohort study; CC, case-control study; GY, Greenwood-Yule methods. 
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2.3. Design of birth order study 
There are two methods for investigating birth order associations. One is the case-control 
approach, the other is the Greenwood-Yule method.
192
 The latter assumes a random distribution 
of individuals by birth order in the population and studies whether the observed distribution of 
birth rank among affected individuals is different from what would be expected by chance.
212
 
The expected distribution of birth order is derived from a total sibship size of affected 
individuals, and the ratios of observed/expected in each birth order are examined. Haldane and 
Smith developed a statistical test which compares the sum of the birth orders of all affected 
cases with the expected value. If the observed sum is significantly higher than the expected sum, 
it can be concluded that higher birth order is associated with the disease.
213
  
 
These classical methods have advantages over the case-control method since it can be applied to 
a study without having a control group; the analysis of birth order is made within sibships and is 
therefore less prone to confounding by socioeconomic status and demographic factors.
214
 
However, the method is susceptible to bias when there are incomplete sibships or changes in 
population dynamics.
215–217
 Sibships are often incomplete in studies of children or younger 
adults because mothers of cases may have further children after the data were collected. 
Incomplete sibships violate the assumption that individuals are randomly distributed by birth 
order because there is an excess of later-born children.
216
 Changes in population dynamics may 
also result in bias in the Greenwood-Yule method. First, a change in the annual birth rate will 
influence the distribution of birth order in the population;
216,217
 increased birth rate will lead to 
an excess of early-born children. Second, migration causes the birth order distribution to depart 
from being random, because population movement generally is related with birth order.
216
 
Because of these potential biases in the Greenwood-Yule method, modern cancer epidemiology 
generally employs either case-control or cohort study to examine for birth order associations 
(table 2.2).  
 
 
2.4. Potential confounding factors for the association of birth 
order with a disease 
Studies of the effect of birth order on cancer are inconsistent in whether they adjust for total 
sibship size or number of younger siblings (Table 2.3). Out of 21 studies examined, 4 adjusted 
for sibship size, 2 adjusted for number of younger siblings, while 15 did not adjust for either 
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factor. The arguments for and against adjusting for total sibship size and the number of younger 
siblings are presented below. 
 
2.4.1. Total sibship size 
The importance of adjusting for total sibship size in birth order studies has been advocated by 
several investigators to obtain an accurate estimate of the effect of the birth order.
187,218
 This is 
because a disease which tends to occur in large sibships may provide a false impression that the 
disease is more common in higher birth orders,
214
 and that large sibship size is often related to 
lower socioeconomic status,
207
 which is a known risk factor for many of the diseases. In contrast, 
others claim that total sibship size should not be introduced in the same model with birth order 
because the two variables are substantially correlated. Spearman’s correlation coefficient for 
birth order and total sibship size was 0.41 in a study of gastric cancer,
203
 0.69 in a study of 
testicular cancer,
202
 and 0.50 in the study of HCC;
194
 and thus, collinearity was suspected.
202
 In 
addition, Richiardi et al.
202
 argued that empty cells in the regression models created by 
impossible combinations (e.g., a fifth-born child in a family with sibship of three) hamper 
inclusion of total sibship size in the model. Instead of total sibship size, several investigators 
controlled for the number of younger siblings.
202,211
  
 
It is important to consider the direction of causation between birth order and total sibship size in 
order to judge whether total sibship size confounds the association of birth order with disease 
incidence. Birth order is always determined at birth and temporally precedes total sibship size, 
which depends on the number of children subsequently born into the family. Consequently, total 
sibship size is affected by birth order and the number of younger siblings (figure 2.1), and thus 
should not be regarded as a confounding factor in birth order studies, unless the objective is to 
examine the effect of birth order which is not mediated through total sibship size. 
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Figure 2.1 A causal diagram of birth order, number of younger siblings and total sibship size 
 
 
2.4.2. Number of younger siblings 
Birth order is equal to the number of elder siblings plus one, in the absence of miscarriage, 
stillbirth or child death. The number of younger siblings is determined after birth order has been 
established, and the birth order might affect the number of younger siblings because parental 
behavior pertaining to conception is at least partly influenced by the number of children they 
already have. Consequently, the number of younger siblings cannot be considered as a 
confounding variable in studies examining the birth order effect, unless the objective is to 
estimate the effect of birth order which is not mediated by the number of younger siblings 
(figure 2.1). 
 
Due to the controversy, two distinct models are used throughout this thesis to assess the effect 
of birth order on liver disease. First model includes parental education levels or index cases’ 
education levels as proxy measures for socioeconomic status. The second model includes total 
sibship size as a surrogate for the socioeconomic status.  
Birth order Disease 
Number of 
younger siblings 
Total sibship 
size 
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Table 2.3 Confounding factors in previous observational studies assessing the effect of birth order on the risk of cancer 
Author, year Birth order as 
a proxy for 
Confounding factors 
Sex Age Birth 
year 
Race Region SES Family 
history 
of 
cancer 
Maternal 
age at 
birth 
Paternal 
age at 
birth 
Total 
sibship 
size 
No. 
younger 
siblings 
Others 
HCC              
Ryder, 1992
193
 Age at HBV 
infection 
M M M - M - - - - - - - 
Hsieh, 1992
187
 A A A R  - - - - - A - Cigarettes, HCV 
Kuper, 2000
194
 M/A M/A M/A - - A - - - A - Cigarette, alcohol 
Swedish 
Family-Cancer 
Database 
             
Hemminki, 2001
195
 N/A Str A A - A A R - - - - Participant’s  
parity and age at 
first childbirth 
(only for breast 
cancer) 
Altieri, 2007
196
 N/A A A A - A A A - - - - - 
Bevier, 2011
189
 N/A A A A - A A R - - - - - 
Breast cancer              
Hsieh, 1991
197
 Intrauterine 
oestrogen 
levels 
R A - - A - - A - - - Participant’s own 
parity, menopause, 
age at first 
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childbirth, age at 
menarche, height, 
and Quetelet’s 
index 
Hodgson, 2004
198
 R A R A - A - A - - - Current BMI, 
sampling fraction 
Sorensen, 2005
199
 R A M - - - - - - - - Birth weight, 
marital status of the 
mother 
Testicular cancer              
Prener, 1992
200
 Intrauterine 
oestrogen 
levels 
R M A - - A - - - - - Cryptorchidism, 
birth weight 
Westergaard, 
1998
201
 
R A/Str A/Str - - - - A/Str - - - Maternal age at 
first birth, interval 
to previous 
delivery, sex of the 
first-born child 
Richiardi, 2004
202
 R A A - A A R A A - A - 
Gastric cancer              
Blaser, 1995
203
, 
2007
204
 
Age at H. 
pylori 
infection 
R M/A M/A R R - - - - - - Cigarettes (2007 
study only) 
Acute leukaemia              
MacMahon, Age at - M/St M/St Str - - - Sta - - - - 
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1962
205
 common 
infection 
a a 
Dockerty, 2001
206
 M Str M - M A - A - - - - 
Non-Hodgkin 
lymphoma 
             
Mensah, 2007
207
 Age at 
common 
infection, EB 
virus 
M/A M/A M - A - - - - - - - 
Grulich, 2010
208
 M/A M/A - R  M/A Str - - - Str - - 
Crump, 2012
209
 A - A - - A A A - - - Fetal growth, 
gestational age, 
multiple birth,  
Hodgkin 
lymphoma 
             
Gutensohn, 1981
210
 Age at 
common 
infection 
M M - - - A - - - A - Religion, 
playmates, 
infectious 
mononucleosis 
Westergaard, 
1997
211
 
A A A - - - - A - - A - 
Abbreviations: M, variable matched on; A, variable adjusted for; Str, variable stratified by; R, variable restricted for; Sta, variable standardised by; SES, 
socioeconomic status. 
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2.5. Association between higher birth order and lower age at 
infection with common pathogens 
Age of infection is often assumed to be negatively correlated with birth order. For example,  
Stallybrass states that “the child attending the day school is much more likely to introduce the 
disease to the younger members of his own family than is the boarder. And so the attendance of 
the first-born at a day school often involves the repeated introduction of infection into his 
family”.219 Similarly, Fox, Hall and Elveback suggest that “the aspect of birth order is the 
influence it has upon the age and the overall probability of acquiring infections that are 
transmitted by contact. Contact between family members is particularly close so that, when one 
member becomes infected, he typically shares it with those not already immune. As a corollary, 
the larger the family, the greater is the probability that one member will bring an infection 
home. Also, the higher the birth order (i.e., the younger the child), the greater is the probability 
of contracting an infection at an early age from an older sibling”.35 The evidence for the 
association between birth order and age at infection is outlined below. 
 
2.5.1. Acute childhood infection 
Badger et al.
220
 identified the characteristics of family members at risk of introducing 
respiratory infection into the home in a cohort study in Cleveland. An index case was defined as 
a person who developed acute respiratory symptoms at least 10 days after the onset of any 
respiratory illness within a family. School children were more likely to become index cases than 
preschool children. In addition, amongst preschool children with one sibling, the incidence of 
  
84 
 
respiratory diseases was higher when the sibling was a school child than when the sibling was a 
preschool child. These findings suggest that school children serve as the most frequent source of 
respiratory infections within the family. 
 
In Houston a cohort of children was followed for influenza infection over the first year of life.
221
 
The incidence increased with increasing birth order from 18 per 100 infant-years in first-born 
children to 44 in third-born children. 
 
A UK birth cohort was used to determine the effect of birth order on the risk of childhood 
infections by age seven.
222
 After controlling for socioeconomic status, higher birth order was 
associated with an increased risk of pertussis. However, birth order had no effect on the risk of 
measles, rubella, varicella and mumps. The lack of association was explained by: 1) birth order 
having a limited effect after children start school, and 2) episodes of infection were 
retrospectively elicited from parents leading to potential recall bias.
223
  
 
In Guinea-Bissau, West Africa, the attack rate of measles in children aged 6-35 months was 
greater with increasing number of children aged <6 years in the same house (26.4%, 32.0%, and 
40.5% in households with 1-2, 3-4 and ≥5 children, respectively).224 A positive association 
between measles and the number of children <6 years old in the house was also observed in 
infants aged 0-5 months. Unfortunately the study did not examine the relationship between birth 
order and measles.  
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2.5.2. Helicobacter pylori infection 
About half the global population is infected with Helicobacter pylori, and in some areas the 
majority of adults show evidence of the infection. Having an infected sibling is a risk factor for 
H. pylori infection in children, illustrating the importance of sibling-to-sibling transmission 
during childhood.
225
 Other studies have found a positive association between birth order and 
prevalence of H. pylori infection.
226,227
 <sup>226</sup>For example in Columbia, the odds of 
infection in children increased with increasing birth order; adjusted ORs compared with 
first-born children were 1.8 (95% CI: 1.0-3.3), 2.1 (1.0-4.4) and 2.2 (0.9-5.2) in children born 
2
nd
, 3
rd
 and ≥4th, respectively.228 These findings support the role of birth order as a marker of 
early exposure to H. pylori. 
 
 
2.6. Use of birth order in cancer epidemiology  
Birth order has been used in cancer epidemiology as a surrogate for the intrauterine hormonal 
environment (breast and testicular cancer) or age at infection (liver, stomach and haematologic 
malignancy including childhood leukaemia, non-Hogdkin’s lymphoma, and Hodgkin’s disease). 
 
2.6.1. Breast cancer 
Trichopoulos
229
 proposed that an intrauterine environment with high oestrogen levels would 
lead to increased risk of breast cancer decades later. Birth order can be used as a proxy for 
oestrogen levels since the first pregnancy has higher oestrogen levels than subsequent 
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pregnancies.
198,230,231 
The hypothesis has been confirmed in some studies
197,199
 but other studies 
have not found an association.
189,195,196,198
 
 
2.6.2. Testicular cancer 
A high level of maternal oestrogen is thought to increase the risk of cryptorchidism and 
testicular cancer.
200,201
 Thus an inverse association between birth order and risk of testicular 
cancer is predicted, and this has generally been observed.
189,200–202
 However, a cohort study in 
Sweden found no association.
195
  
 
2.6.3. Gastric cancer 
A positive association between birth order and risk of Helicobacter pylori-associated stomach 
cancer has been reported in Japanese-American men infected with H. pylori.
203,204
 The 
hypothesis is that children with a high birth order (i.e., a birth order greater than two) acquire H. 
pylori infection at a younger age than first- or second-born children, and early exposure to H. 
pylori infection is associated with: 1) a longer duration of the infection, 2) immaturity of host 
immune system, and 3) interaction with other childhood infections, which may further enhance 
the gastric cancer risk associated with H. pylori infection.
203,204
 
 
2.6.4. Haematologic malignancy 
Birth order has been used as a surrogate for the timing of exposure to infections in the 
epidemiology of haematologic malignancy. An increased risk of childhood leukaemia for 
first-born children has been observed in many studies.
205,206,232–235
 Greaves has proposed that 
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delayed or diminished exposure to common infections in infancy is associated with an increased 
risk of the precursor B-cell subtype of acute lymphoblastic leukaemia.
236
  
 
There is inconsistent evidence regarding the association between birth order and risk of 
non-Hodgkin lymphoma (NHL). Some case-control studies have demonstrated a positive 
association, however, these could be attributable to a selection bias due to differential study 
participation between cases and controls according to socioeconomic status and birth order (see 
further discussion in Chapter 5 & 7).
207,208
 A recent large-scale Swedish national cohort study 
found an inverse association between birth order and NHL in children and young adults. The 
study supports the hypothesis that delayed exposure to Epstein-Barr virus and other infectious 
agents impedes the maturation of the immune system, and this may predispose individuals to 
NHL.
209
 Studies have yielded conflicting results for the association of birth order with Hodgkin 
lymphoma.
210,211,237
  
 
 
2.7. Birth order and the epidemiology of hepatitis B virus 
infection in The Gambia 
The definition of birth order used to estimate the timing of HBV infection in chronic HBV 
carriers should differ according to local epidemiology of the infection. Where perinatal 
mother-to-infant transmission of HBV is common, low birth order is a proxy for perinatal 
transmission; this is because low birth order children have younger mothers who were more 
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viraemic than older mothers at the birth of the children (viraemia decreases with age). Indeed, a 
study in Taiwan demonstrated that low maternal age was associated with higher risk of perinatal 
transmission.
125
 To reflect maternal age, birth order should count miscarriages and stillbirths but 
not twins and half-siblings.  
 
In contrast, where horizontal transmission during early childhood is common, high birth order 
may indicate earlier age at HBV infection through sibling-to-sibling transmission.
187
 
Consequently, birth order should reflect the number of older children that lived in the same 
household during the childhood.
187,194 
Therefore when birth order is a proxy for horizontal 
transmission in early childhood it should include half-siblings and count twins independently. 
 
In the pre-HBV vaccine era in The Gambia, most HBV infection occurred during early 
childhood.
42,60
 Therefore, a positive association between birth order and risk of liver diseases is 
expected, and  birth order should exclude miscarriages and stillbirths, whilst twins or triplets 
need to be enumerated independently. Half-siblings who grew up together with the participants 
also need to be included. It is particularly important to include half-siblings because The 
Gambia is a polygamous society. Perinatal maternal transmission is less common in The 
Gambia than in Asia,
63
 but it certainly exists in The Gambia.
238
 Therefore, the positive 
association of birth order with liver diseases might be J- or U-shape rather than linear (i.e., a 
moderate risk for low birth order, the lowest risk for intermediate birth orders and the highest 
risk in high birth orders).  
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2.8. Summary 
It is difficult to estimate the age at HBV infection in epidemiological studies. Birth order may 
be a useful proxy for the age at infection. Definition of birth order depends on the study 
hypothesis. Where postnatal child-to-child transmission of HBV is common, higher birth order 
predicts earlier age at HBV infection during childhood, and birth order should count twins 
independently and include half-siblings. There is evidence for an inverse association between 
birth order and age at infection in common acute childhood infection and H. pylori. In contrast, 
where mother-to-infant transmission of HBV is common, lower birth order predicts earlier age 
at HBV infection because high viral replication that determines the risk of perinatal 
transmission is more frequent in younger mothers. To reflect maternal age, birth order should be 
defined to include miscarriages and still births. In this thesis, confounding due to 
socio-economic status is accounted for using education or total sibship size as a proxy measure.
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Chapter 3. Association of early age at 
establishment of chronic hepatitis B infection 
with persistent viral replication, liver cirrhosis 
and hepatocellular carcinoma: a systematic 
review 
 
 
3.1. Abstract 
Background 
Age at infection with hepatitis B virus (HBV) is a known risk factor for chronic HBV infection. 
In addition, there is evidence that early age at infection further increases the risk of primary 
liver cancer beyond its association with increased risk of chronic infection. This systematic 
review of observational studies assesses the association between age at initiation of chronic 
HBV infection and liver cirrhosis, hepatocellular carcinoma, and their predictors including 
indicators of ongoing viral replication and hepatic damage.  
Methods 
The review includes birth order and maternal HBV serology as proxies for age at infection. 
Electronic searches in two English-language (Medline and Embase, until Jan 2012) and two 
Chinese-language (CNKI and SinoMed, until Sep 2012) databases without language restriction 
and manual search through reference lists were conducted. 
Results 
Of 7,077 papers identified, 19 studies of 21 outcomes (8 primary liver cancer, 1 liver cirrhosis, 
10 viral replication and 2 liver inflammation) are included. No African study was identified. 
One study directly examined the age at infection in a longitudinal cohort, 12 assessed maternal 
sero-status and 6 investigated birth order. The direction of associations in all studies was in 
accordance with the hypothesis that earlier age at infection is associated with worse outcomes in 
addition to its effect of increasing the probability of chronic HBV infection, although there was 
evidence of publication bias.  
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Conclusion 
Early age at HBV infection increases the risk of liver cancer and its predictors in chronic 
carriers of HBV. This has implications for the control of hepatitis B. 
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3.2. Introduction 
Age at infection is known to influence the establishment of HBV infection. Infection persists in 
80-90%, 20-30%, <10%, and <5% of people infected perinatally, in early childhood, 
adolescence, and adulthood, respectively.
68
 However, it is unclear whether early HBV infection 
also increases the risk of liver cirrhosis and/or HCC through the persistence of high viral 
replication, in addition to increasing the risk of chronic infection.
239
 I therefore undertook a 
systematic review of observational studies where the association between age at establishment 
of chronic HBV infection and risk of cirrhosis and/or HCC has been investigated among people 
chronically infected with HBV. 
 
In addition to liver cirrhosis and HCC as endpoints, two indicators of ongoing viral replication 
(serum HBV DNA level and presence or persistence of hepatitis B e antigen (HBeAg)) and two 
of hepatic damage (elevated serum alanine transaminase (ALT) and degree of hepatic fibrosis) 
were included. These are important predictive factors for cirrhosis and HCC, and often used as 
indicators for antiviral treatment of CHB infection.
6
 Our hypothesis is that earlier age at 
infection is associated with worse outcomes in addition to its effect of increasing the probability 
of chronic HBV infection. 
 
 
3.3. Methods 
3.3.1. Inclusion criteria 
3.3.1.1. Types of participants 
CHB infection was defined as serum HBsAg positivity on two occasions at least 6 months apart. 
However, because new HBV infections in adults are uncommon in highly endemic areas where 
the vast majority of HBsAg-positive people acquire the infection perinatally or during 
childhood, HBsAg positivity on only one occasion in adults living in highly prevalent 
communities was assumed to reflect chronic carriage of HBsAg.
97
 
 
3.3.1.2. Exposures of interest 
The age at the time of infection with HBV was estimated by one of the following: 1) direct 
measurement through frequent serological examination of an uninfected cohort to determine the 
time point at which a person sero-converted from negative- to positive-HBsAg; 2) the HBV 
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serological profile (HBsAg and/or HBeAg) of the mother of the participant; or 3) the person’s 
birth order. Maternal history of HBV infection was not considered in the review because it is 
frequently unknown, and absence of a history does not necessarily indicate that the mother is 
negative for HBV marker. 
 
3.3.1.3. Outcomes of interest  
Quantitative/qualitative serum HBV DNA, presence of serum HBeAg, levels of serum ALT, 
degree of liver fibrosis, cirrhosis, and HCC. 
 
3.3.1.4. Types of studies 
Any observational studies (i.e., cross-sectional, case-control or cohort) published in any 
language which met all of the following criteria were included: the study examined the 
association between any of the exposures of interest and any of the outcomes of interest 
described above; individuals without CHB infection were excluded from the analyses (because 
the primary focus of this review is the link between age at infection and the risk of HCC beyond 
its effect of increasing risk of CHB infection); in studies of maternal HBV sero-status, the 
subjects with unknown maternal sero-status were excluded from the analyses to avoid 
misclassification of exposure status; case series, i.e. studies without a control group, were 
included if the Greenwood-Yule method, or a related approach, was used to examine the birth 
order distribution.
212
 
 
3.3.2. Search strategy 
We conducted a systematic search using two English-language databases (Medline, 1946 to Jan 
2012 and Embase, 1974 to Jan 2012) and two Chinese-language databases (CNKI, 1979 to Sep 
2012 and SinoMed, 1979 to Sep 2012). Subject headings used in Medline search included 
“hepatitis B”, “alanine transaminase”, “hepatitis B e antigens”, “DNA, viral”, “virus 
replication”, “liver cirrhosis”, “hepatocellular carcinoma”, “age factors”, “infectious disease 
transmission, vertical”, and “birth order”. Manual search through reference lists was also 
conducted. Gray literature was not searched. The full search strategy is reported in Appendix 1. 
 
3.3.3. Study selection  
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Eligibility criteria were specified in advance and documented in a protocol (Appendix 2). The 
title and abstract of all papers identified by the electronic searches in English databases were 
screened by two independent reviewers (Yusuke Shimakawa and Naho Tsuchiya). Those 
identified in Chinese databases were screened by another reviewer (Hong-Jing Yan). Papers 
detected through the screening process were retrieved and reviewed to assess their eligibility. 
Disagreements were resolved by discussion with a fourth author (Andrew Hall). Twenty-seven 
authors of the articles were contacted for clarification of the study design or results. Seventeen 
responded and nine provided numerical data that were not presented in the published papers. 
Data extraction was independently carried out by two reviewers for articles from the English 
databases and by one reviewer for those from the Chinese databases. A standardized pre-piloted 
data extraction sheet was used (Appendix 3). The included studies were evaluated for the risk of 
bias (Appendix 4). The aim of assessing the risk of bias was to summarize limitations identified 
in each study, rather than to exclude additional studies on the basis of low methodological 
quality. 
 
3.3.4. Statistical analysis 
For the cross-sectional and case-control studies, odds ratios (OR) were estimated. In 
longitudinal studies, the risk ratio, rather than the rate ratio, was computed because person years 
at risk were not available for many of the published papers. The chi-squared test (or Fisher’s 
exact test for small samples) was used to test the statistical significance of the crude associations. 
The chi-squared test for trend was presented for the association between birth order and liver 
disease. For studies where no events were reported in one of the comparison groups, odds ratios 
were estimated by adding 0.5 to each cell of the contingency table. The Greenwood-Yule 
method was used to estimate the expected distribution of birth order among cases in studies 
without a control group, and a statistical test introduced by Haldane and Smith that compares 
the sum of the observed birth ranks with the sum of expected birth ranks was applied.
213
 We 
present adjusted effect estimates for studies where these were reported in the original analysis. 
A meta-analysis was not performed because of differences in outcomes and exposures between 
studies. Potential for publication bias was visually assessed using funnel plots and statistically 
with Egger’s test.240 This review was reported in accordance with checklists presented in the 
PRISMA guidelines.
241
 All analyses were conducted using STATA 11.0 (Stata Corporation, 
College Station, Texas). 
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3.4. Results 
The search of databases identified 7,077 potential articles (2,250 in Medline, 3,288 in Embase, 
136 in CNKI and 1,403 in SinoMed) of which 1,593 were excluded due to duplication. Review 
of the titles and abstracts excluded 5,086. Forty-three papers were manually identified from 
reference lists. The full text of the 441 articles was examined in detail, and of these 422 was 
discarded leaving 19 papers eligible for the systematic review. No African study was identified. 
Criteria of exclusion are described in figure 3.1.  
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Figure 3.1 Flow diagram of study selection 
 
Articles identified (n=7077) through; 
 Medline (2250) 
 Embase (3288) 
 CNKI (136) 
 SinoMed (1403) 
Articles screened on the basis of title and abstract 
(n=5484) 
Full-text articles assessed for eligibility (n=441);
 English (275), Chinese (144), 
 Japanese (6), German (3),  
 Russian (3), Polish (2), 
 French (2), Italian (2), 
 Spanish (2), Portuguese (1), 
 Greek (1) 
Included articles (n=19); 
- Direct measurement of age at infection (1) 
- Maternal HBV marker (12) 
- Birth order study (6) 
Duplicates removed (n=1593) 
Excluded by screening (n=5086) 
Manually added (n=43) 
Excluded articles (n=422); 
- No exposure of interest (n=208) 
- No outcome of interest (n=37) 
- Association between exposure and 
outcome not reported (n=21) 
- No reference group (n=75) 
- Analysis including subjects 
without CHB infection (n=11) 
- Analysis including subjects with 
unknown maternal sero-status 
(n=7) 
- No details (n=1) 
- Not epidemiological study (n=2) 
- Same studies (n=5) 
- Review articles (n=55)  
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Abbreviations: CHB, chronic hepatitis B; HBV, hepatitis B virus. 
 
 
 
There was only one longitudinal study that examined the association between age at first 
HBsAg-positive result and persistence of HBeAg.
81
 This study used an historical cohort of 
HBsAg-negative children in Alaska who were later identified to have a CHB infection through 
semi-annual serological follow-up. The cohort was followed up for greater than ten years to 
assess the timing of HBeAg loss (table 3.1).  
 
A total of 12 studies assessed the association of maternal HBV sero-status with various 
outcomes (table 3.2 and 3.3); HCC (2 case-control studies),
242,243
 cirrhosis by liver 
histopathology (1 cross-sectional study),
244
 persistence of HBeAg (4 cohort studies),
78,83,245,246
 
and presence of HBeAg at one time point (5 cross-sectional studies).
247–251
 The two cohort 
studies that evaluated HBeAg loss also examined ALT levels.
83,245
 Except for four studies,
246,248–
250
 the studies exclusively enrolled children. In all the cohort studies, treatment was not given 
during follow-up except one study of steroid withdrawal therapy.
246
 All studies examined 
HBsAg as the only maternal HBV marker, and three also considered maternal HBeAg.
83,247,251
 
The proportion of participants with available maternal sero-status varied markedly between 
studies. In two studies having a mother alive
248
 or maternal serology available
245
 was one of the 
eligibility criteria while among the remaining studies the percentage of subjects with known 
maternal sero-status varied from 49%
250
 to 95%.
78,83
 The timing of when maternal sero-status 
was defined in relation to the child’s age also varied. One study in England247 assessed prenatal 
maternal HBeAg whereas 6 studies examined mothers’ HBV markers when their children were 
enrolled in the study (table 3.2 and 3.3). In the remaining 5 studies, the timing was unclear. 
 
For birth order, one cross-sectional study
252
 and two case-control studies
187,194
 compared the 
frequency distribution of birth order by the presence of HBeAg-positivity and HCC, 
respectively (table 3.4). Three Chinese case series of HBV-related HCC used the 
Greenwood-Yule method (table 3.5).
253–255
 All birth order studies were conducted in adults. 
Except for one study,
83
 all longitudinal studies compared proportions rather than incidence rates. 
Results of multivariable analyses were only reported in three studies
83,187,194
 although some 
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studies presented results stratified by age group.
78,248
 The author of a New Zealand study
250
 
provided additional data which enabled me to control for age. The risk of bias in the included 
studies is summarized in Appendix 5. 
 
3.4.1. Time of HBV infection study  
In the Alaskan study children who remained HBeAg-positive were infected younger (median 
4.6 years) than children who lost HBeAg with subsequent reversion to HBeAg positive (median 
12.5 years) or without reversion (median 7.8 years, table 3.1).
81
  
  
3.4.2. Maternal HBV serology studies 
Three paediatric studies from Taiwan, two with HCC
242,243
 and one with cirrhotic changes in 
liver histopathology as outcome,
244
 revealed a similar magnitude of association with having an 
infected mother (ORs range from 11.3 to 16.0, table 3.2 and figure 3.2). One longitudinal study 
of treatment-induced HBeAg loss in adults
246
 and three studies of spontaneous HBeAg loss in 
children
78,83,245
 found good evidence for an association of HBeAg persistence with having an 
HBsAg-positive mother (table 3.3 and figure 3.2). However, in one of these
83
 the association 
was no longer statistically significant after adjusting for maternal HBeAg, peak ALT and HBV 
genotype (hazard ratio 1.2, 95% CI: 0.8-1.8). Another study
78
 stratified the analysis by age at 
study entry and observed heterogeneity (test of homogeneity P<0.0001) in the risk ratios; 0.87 
(95% CI: 0.79-0.95), 1.1 (0.8-1.4) and 1.3 (1.0-1.7) in age group of <1, 1-6 and >6 years old, 
respectively. Tseng et al.
83
 evaluated maternal HBeAg in addition to maternal HBsAg and found 
a good evidence for the association with children’s HBeAg persistence in univariable analysis 
(risk ratio 2.3, 95% CI: 1.5-3.6) and after controlling for maternal HBsAg, peak ALT and HBV 
genotype (hazard ratio 1.8, 95% CI: 1.1-2.8). 
 
Of five cross-sectional studies of HBeAg prevalence (table 3.3 and figure 3.2), one from New 
Zealand
250
 showed strong evidence for an association with positive maternal HBsAg and this 
remained after controlling for age (OR 1.8, 95% CI: 1.3-2.4). The paediatric study of 
immigrants in Sweden found weak evidence (OR 8.2, 95% CI: 0.8-400.8, P=0.09) for an 
association with having an HBsAg-positive mother.
251
 Although the other studies did not 
demonstrate a statistically significant difference in HBeAg prevalence between those born to 
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seropositive and seronegative mothers, the direction of the association was positive. Habu et 
al.
248
 found no evidence of an association after adjusting for age (OR 1.6, 95% CI: 0.9-2.9). 
Two longitudinal cohort studies of children positive for HBeAg assessed peak ALT levels 
during follow-up (table 3.2 and figure 3.2).
83,245
 In both studies, there was good evidence that 
the proportion that experienced abnormally high ALT levels was smaller in children born to 
HBsAg-positive mothers than in those born to negative mothers. 
 
3.4.3. Birth order studies with a control group  
Both Greek studies found that later birth order is associated with a higher risk of HCC (table 
3.4). This association did not change after adjusting for other prognostic factors.
187,194
 A 
Taiwanese cross-sectional study of HBeAg prevalence showed weak evidence for the 
association between earlier birth order and higher risk of positive HBeAg.
252
 
 
3.4.4. Birth order studies without control group 
A study from Haimen, China demonstrated that there was a higher than expected frequency of 
HCC patients in birth orders 1-3, and a lower than expected frequency in birth orders higher 
than 4 (table 3.5). The Haldane-Smith method confirmed statistical evidence (P=0.03) of this.
253
 
A study from Shunde district was consistent with these findings.
255
 And the association was in 
the same direction but not statistically significant in a study from Luoyang (P=0.4).
254
 
 
3.4.5. Publication bias 
A funnel plot is presented for the studies examining the association between the maternal HBV 
marker and the persistence/prevalence of HBeAg (figure 3.3). The plot appears asymmetric 
(which is indicative of publication bias) and this is confirmed by Egger’s test (P=0.04). There 
were too few studies to assess publication bias for other associations. 
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Table 3.1 Study of the association between time of HBV infection and the risk of HBeAg persistence in a systematic review, up to 2012 
First Author, Year 
(Reference No.) 
Region Study 
Design 
Serological Course No. of 
Subjects 
Median Age at 1
st
 
HBsAg-positive 
Result 
Median 
Duration of 
Follow-up 
Median No. 
of 
Serological 
Tests 
McMahon, 2001
81
 Alaska, 
USA 
Cohort 
study 
Remained HBeAg-positive throughout the 
follow-up period 
9 4.6 years old 11.1 years 12 
Lost HBeAg during the course without reversion 47 7.8 years old 16.6 years 17 
Lost HBeAg during the course with reversion to 
positive HBeAg 
11 12.5 years old 14.8 years 20 
 
 
 
Table 3.2 Studies Assessing the Effect of Maternal HBV Sero-status on HCC, Liver Cirrhosis and Peak ALT Levels in a Systematic Review, up to 2012 
First Author, Year, 
Region (Reference No.) 
Study 
Design 
Age 
Range, 
Years
a 
Type of 
Maternal HBV 
Sero-marker 
Frequency in 
Cases or 
Exposed 
Group
b
  
Frequency in 
Controls or 
Non-exposed 
Group
c
 
Crude Adjusted 
OR 
or 
RR
d 
95% CI P value OR 
or 
RR
 
95% 
CI 
P 
value 
1. HCC            
Beasley, 1982, Taiwan
242e
 CC Children
 
HBsAg
f
 12/14 (86%) 17/49 (35%) 11.3
 
1.9, 67.8
 
0.0008 N/R   
Chang, 1989, Taiwan
243
 CC 3-16 HBsAg at 
entry 
29/31 (94%) 22/44 (50%) 14.5
g 
2.5, 84.0
 
0.0001 N/R   
2. Cirrhosis            
Hsu, 1988, Taiwan
244
 CS Children HBsAg
f 
6/23 (23%) 0/21 (0%) 16.0
h 
0.8, 303.6
 
0.02
i 
N/R   
3. Peak ALT level            
Kojima, 1985, Japan
245
 Co 2-12 HBsAg
f 
3/9 (33%) 22/28 (79%) 0.42
 
0.17, 1.09 0.04
 
N/R   
Tseng, 2011, Taiwan
83
 Co 0-16 HBsAg at 63/137 (46%) 29/48 (60%) 0.76 0.57, 1.02 0.09
 
N/R   
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entry 
HBeAg at 
entry 
33/80 (41%) 59/105 (56%) 0.73 0.54, 1.00 0.04
 
N/R   
Abbreviations: ALT, alanine transaminase; CC, case-control study; CI, confidence interval; Co, cohort study; CS, cross-sectional study; HBeAg, 
hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HR, hazard ratio; N/R, not reported; OR, odds ratio; RR, risk 
ratio. 
a 
When age range was not available, study was categorized as children (<20 years old), adults (≥20 years old) or both children and adults. 
b 
Prevalence of exposure in cases presented in case-control design and prevalence of outcome in exposed group presented in cross-sectional and cohort 
study  
c 
Prevalence of exposure in controls presented in case-control design and prevalence of outcome in non-exposed group presented in cross-sectional and 
cohort study  
d 
Odds ratios for case-control or cross-sectional studies and risk ratios for cohort studies are presented.  
e
 Communication with the author confirmed that all the HCC cases were positive for HBsAg. 
f 
When the measurement of maternal sero-status was performed is not known. 
g 
Matched design without matched analysis 
h 
As a contingency table contains a zero cell, 0.5 was added to each cell. 
i 
Although the 95% CI does not exceed the unity, P value is <0.05 due to the small sample size.
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Table 3.3 Studies Assessing the Effect of Maternal HBV Sero-status on Persistence/Prevalence of HBeAg in a Systematic Review, up to 2012 
First Author, Year, 
Region (Reference No.) 
Study 
Design 
Age 
Range, 
Years
a 
Type of 
Maternal HBV 
Sero-marker 
Frequency in 
Exposed 
Group 
Frequency in 
Non-exposed 
Group 
Crude Adjusted 
OR 
or 
RR
b 
95% CI P value OR 
or 
HR
c 
95% 
CI 
P 
value 
1. Persistence of HBeAg            
Kojima, 1985, Japan
245
 Co 2-12 HBsAg at 
entry
 
7/9 (78%) 9/28 (32%) 2.4
 
1.3, 4.6
 
0.02 N/R   
Kojima, 1985, Japan
246
 Co 19-48 HBsAg at 
entry 
4/4 (100%) 2/9 (22%) 4.5 1.3, 15.3
 
0.02 N/R   
Chang, 1989, Taiwan
78
 Co 0-15 HBsAg
d
 121/142 (85%) 52/75 (69%) 1.2
 
1.0, 1.5
 
0.006 N/R   
Tseng, 2011, Taiwan
83
 Co 0-16 HBsAg at 
entry 
56/137 (41%) 8/48 (17%) 2.5 1.3, 4.8 0.002 1.2
e 
0.8, 
1.8 
0.5 
HBeAg at 
entry 
41/80 (51%) 23/105 (22%) 2.3 1.5, 3.6 <0.0001 1.8
e 
1.1, 
2.8 
0.01 
2. Prevalence of HBeAg            
Wheeley, 1989, UK
247
 CS 0-16 Prenatal 
HBeAg 
32/42 (76%) 0/1 (0%) 9.3
f 
0.4, 245.6 0.1
 
N/R   
Habu, 1991, Japan
248
 CS Children 
& adults 
HBsAg at 
entry 
71/101 (70%) 96/152 (63%) 1.4
 
0.8, 2.4 0.2
 
1.6
g 
0.9, 
2.9 
0.1 
Tai, 1999, Taiwan
249
 CS >15 HBsAg at 
entry 
67/221 (30%) 35/131 (27%) 1.2
 
0.7, 1.9 0.5
 
N/R   
Hopkirk, 2000, New 
Zealand
250h 
CS Children 
& adults 
HBsAg
d 
160/281 (57%) 214/530 (40%) 2.0 1.5, 2.6
 
<0.0001
 
1.8
g 
1.3, 
2.4 
0.0005 
Soderstrom, 2002, 
Sweden
251
 
CS 2-18 HBeAg
d 
15/16 (94%) 11/17 (65%) 8.2
 
0.8, 400.8 0.09
 
N/R   
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Abbreviations: ALT, alanine transaminase; CC, case-control study; CI, confidence interval; Co, cohort study; CS, cross-sectional study; HBeAg, 
hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HR, hazard ratio; N/R, not reported; OR, odds ratio; RR, risk 
ratio. 
a 
When age range was not available, study was categorized as children (<20 years old), adults (≥20 years old) or both children and adults. 
b 
Odds ratios for case-control or cross-sectional studies and risk ratios for cohort studies are presented.  
c
 Except for the study of Tseng et al.
83
 which presented hazard ratios, odds ratios are presented. 
d 
When the measurement of maternal sero-status was performed is not known. 
e
 Multivariable model included maternal HBsAg, maternal HBeAg, peak ALT and HBV genotype. 
f 
As a contingency table contains a zero cell, 0.5 was added to each cell. 
g
 Adjusted for age. 
h
 The author provided the raw data to compute odds ratio. 
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Table 3.4 Studies of Birth Order With Control Group in a Systematic Review, up to 2012 
First Author, 
Year (Reference 
No.) 
Region Study 
Design 
Age 
Range, 
Years
a 
Outcom
e 
Birth 
Order 
No. of 
Cases (%) 
No. of 
Controls 
(%) 
Crude Adjusted 
OR 95% CI P for 
trend 
OR 95% CI P for 
trend 
Hsieh, 1992
187
 Greece CC Adults HCC 1
st
 17 (20%) 9 (27%) 1.0 Reference 0.04
 
1.0
b
 Reference 0.02 
2
nd
 11 (13%) 11 (33%) 0.5 0.2, 1.7  0.9 0.2, 4.2  
3
rd
 17 (20%) 3 (9%) 3.0 0.7, 13.8  7.8 1.4, 42.4  
4
th
 15 (18%) 4 (12%) 2.0 0.5, 8.0  4.0 0.8, 20.7  
≥5th 25 (29%) 6 (18%) 2.2 0.6, 7.6  3.8 0.9, 16.5  
Kuper, 2000
194
 Greece CC Adults HCC 1
st
 42 (20%) 13 (43%) 1.0 Reference 0.0008
 
1
st
 1.0
c 
Reference N/R 
2
nd
 59 (28%) 9 (30%) 2.0 0.8, 5.2  2
nd
 2.0 0.8, 5.3  
3
rd
 49 (24%) 7 (23%) 2.2 0.8, 6.0  ≥3rd 4.1 1.3, 12.7  
≥4th 58 (28%) 1 (4%) 18.0 2.0, 163.4     
Tai, 2002
252
 Taiwan CS Adults HBeAg 1
st
 29 (29%) 65 (23%) 1.00 Reference 0.09
 
N/R
d 
  
2
nd
 29 (29%) 68 (25%) 0.96 0.51, 1.77     
3
rd
 24 (24%) 78 (28%) 0.69 0.36, 1.30     
4
th
 11 (11%) 40 (14%) 0.62 0.28, 1.38     
≥5th 7 (7%) 27 (10%) 0.58 0.23, 1.50     
Abbreviations: CC, case-control study; CI, confidence interval; CS, cross-sectional study; HBeAg, hepatitis B e antigen; HCC, hepatocellular 
carcinoma; N/R, not reported; OR, odds ratio. 
a 
When age range was not available, study was categorized as children (<20 years old), adults (≥20 years old) or both children and adults. 
b 
Adjusted for age, sex, smoking and anti-HCV. 
c 
Adjusted for age, sex, smoking, alcohol, schooling, anti-HCV and sibship size. 
d 
Stratification by relationship with index case (i.e., children and siblings) was reported. 
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Table 3.5 Studies of Birth Order Without Control Group in a Systematic Review, up to 2012 
First Author, 
Year 
(Reference 
No.) 
Region Study 
Design 
Age 
Range, 
Years
a 
Outcome Birth 
Order 
Observed 
Distribution 
Expected 
Distribution 
Greenwood-Yule 
Method  
Haldane-Smith Method 
Cai, 2003
253
 Haimen, 
China 
Case 
series 
>36 HCC 1
st
  29 26.27 1.10 Observed < Expected, t = 
2.17, df = 121, P = 0.03 2
nd
  28 22.27 1.26 
3
rd
  18 17.27 1.04 
4
th
  9 12.94 0.70 
≥5th 10 15.30 0.65 
Cao, 2005
254
 Luoyang, 
China 
Case 
series 
Adults HCC 1
st
  19 16.75 1.13 Observed < Expected, t = 
0.95, df = 62, P = 0.4 2
nd
  15 13.75 1.09 
3
rd
  11 12.25 0.90 
4
th
  10 9.25 1.08 
≥5th 8 11.00 0.73 
Song, 2009
255
 Shunde, 
China 
Case 
series 
Adults HCC 1
st
  17 13.92 1.22 Observed < Expected, t = 
2.20, df = 46, P = 0.03 2
nd
  15 10.92 1.37 
3
rd
  5 7.42 0.67 
4
th
  4 5.75 0.70 
≥5th 6 8.98 0.67 
Abbreviations: df, degree of freedom; HCC, hepatocellular carcinoma. 
a 
When age range was not available, study was categorized as children (<20 years old), adults (≥20 years old) or both children and adults. 
a
 Ratio of observed/expected number is presented.
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Figure 3.2 Effect measures and 95% CIs for the association between maternal HBV sero-status 
and HBV-related outcomes 
 
 
 
Odds ratios for case-control or cross-sectional studies
242–244,247–251
 and risk ratios for cohort 
studies
78,83,245,246
 are presented. Except the study by Wheeley
247
 which assessed maternal HBeAg, 
all studies examined maternal HBsAg. 
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Figure 3.3 Funnel plot for studies investigating the relation between maternal sero-marker and 
the persistence/presence of HBeAg 
 
Dashed line represents pseudo 95% confidence limits. 
 108 
 
 
3.5. Discussion 
Of 21 outcomes examined in 19 studies, univariable analysis of 14 outcomes supported our 
hypothesis with P≤0.05 and two with weak evidence (0.05<P<0.1). Although the other studies 
did not reach statistical significance, the direction of the associations was consistent with our 
hypothesis.  
 
3.5.1. Time of HBV infection study 
McMahon et al. directly assessed the age at HBV infection and its association with HBeAg 
persistence in Alaskan natives whose approximate date of infection was known because of 
consecutive serological tests.
81
 They showed that the median age at first HBsAg-positive result 
was lower in those who did not clear HBeAg during the follow-up period than those who 
HBeAg sero-converted, suggesting that the early age at infection is associated with delayed 
HBeAg loss. However, the length of follow up is different for the two groups, which is a crucial 
determinant of the chance of HBeAg loss.  
 
3.5.2. Maternal HBV serology studies 
Studies of maternal HBV serology showed that having a mother with a positive HBV marker is 
associated with worse outcomes (HCC, cirrhotic changes, persistence of HBeAg or possession 
of HBeAg at one particular time) although three of these were not supported by statistical 
evidence. Two longitudinal studies from East Asia which evaluated both HBeAg loss and peak 
ALT levels during follow-up demonstrated good evidence that children with HBsAg-positive 
mothers experienced elevated levels of hepatic enzymes less frequently and fewer episodes of 
 109 
 
HBeAg loss than those whose mothers are negative. It is well established that having a highly 
elevated serum ALT level during the immune-tolerant phase of CHB infection is a factor 
leading to early HBeAg seroconversion.
256
 
 
The only maternal serological study which reported the results of a multivariable analysis
83
 
showed that the association with maternal HBsAg observed in the univariable analysis was no 
longer significant after controlling for maternal HBeAg. This reflects the fact that maternal 
HBeAg is a stronger predictor of perinatal transmission than maternal HBsAg. In fact, the risk 
of perinatal transmission ranges from 10-20% in HBsAg-positive mothers without HBeAg to 
90% in mothers with positive HBeAg.
30
 Nevertheless, because HBeAg sero-clearance (loss of 
the maker) occurs faster than HBsAg sero-clearance in chronically infected persons (3-14% 
versus 0.5-2% per year, Chapter 1), misclassification of maternal HBeAg status between when 
the index child was born and when he/she entered the study is greater than misclassification of 
maternal HBsAg status. Apart from 5 studies not reporting when mothers were bled, all but one 
examined maternal sero-status at the child’s study entry, which might have led to 
non-differential misclassification of the exposure, resulting in underestimation of its association. 
The only study which investigated prenatal maternal HBeAg,
247
 the best proxy for perinatal 
transmission, was inconclusive because of a small sample size. 
 
Recent evidence suggests that viral genotypes modify the natural history of CHB infection. 
Certain genotypes are associated with delayed HBeAg seroconversion
143
 and also HCC risk.
146
 
Moreover, associations between certain viral genotypes and mother-to-infant transmission have 
been reported.
141,142
 For example, Tseng et al.
83
 found that genotype C was associated with 
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delayed HBeAg seroconversion after accounting for maternal HBsAg and HBeAg status. The 
study also showed that maternal HBeAg was associated with persistence of HBeAg after 
adjusting for viral genotype. 
 
3.5.3. Birth order studies 
Two Greek case-control studies of birth order demonstrated that HCC cases are concentrated in 
higher birth orders, suggesting that later-born children who might have been exposed to HBV at 
a young age through their older siblings have a higher risk of developing HCC than early-born 
children.
187,194
 In contrast, one Taiwanese study showed that HBeAg was more prevalent in 
earlier birth orders although the evidence was weak.
252
 Furthermore, three subsequent Chinese 
birth order studies which applied the Greenwood-Yule methods also suggested that HCC cases 
are associated with lower birth order. As discussed in Chapter 2, these heterogeneities can be 
understood in terms of geographic differences in the main mode of transmission. In Taiwan and 
China, perinatal mother-to-infant transmission is relatively important compared to other parts of 
the world.
63
 In such places, first-born children have a higher chance of having been born to a 
HBeAg-positive mother than later-born children, because young mothers with positive-HBeAg 
will clear it with older age.
6
 Consequently, early-born children have a higher chance of having 
been infected earlier from their mother than later-born children. In contrast, in Mediterranean 
countries where children are infected during childhood through other children with 
positive-HBeAg,
71
 birth order acts as an indicator for number of older siblings, and later-born 
children have an increased chance of being exposed to HBV at an early age through infectious 
older siblings than early-born children. Perinatal transmission also occurs in Greece but is much 
less common than in China. This could explain the results of the first Greek study where people 
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born as the second child have lower odds of HCC than the first birth rank (OR 0.5), with the 
odds increased for higher birth orders. 
 
3.5.4. Limitations of the study 
The funnel plot and Egger’s test suggest the presence of funnel plot asymmetry in the studies 
assessing the association between maternal sero-marker and persistence/presence of HBeAg. 
Publication bias is one of a number of reasons for the asymmetry in the funnel plot, and other 
explanations include: poor methodological design of small studies which lead to larger 
effects,
257
 systematic differences in the study population between smaller and larger studies, and 
shorter duration of follow-up in smaller cohort studies.
258
 It is difficult to prove that the 
asymmetry was due to the publication bias in the absence of prospective registries of 
epidemiological studies which include the information on unpublished studies.
259
 Nevertheless, 
observational studies are more vulnerable to publication bias than randomized trials, because 
epidemiological studies are often conducted retrospectively by analysing existing databases, and 
unless published, this kind of study is hard to trace and thus it is difficult to have the prospective 
registries of such studies.
240
 Although we were unable to assess the publication bias in the birth 
order studies due to the small number of studies included, these studies are prone to selective 
reporting bias because birth order is easily obtained by interview without additional cost. 
 
The study was also limited because no African study was included in the review. Sub-Saharan 
Africa (sSA) has high prevalence of HBV infection and high HCC incidence (Chapter 1). 
However, the epidemiology of HBV infection in sSA differs from East Asia, and therefore it is 
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questionable whether the findings observed in this review (which are mainly from East Asia) 
are applicable to the African context. 
 
3.5.5. Public health implications 
Although a robust conclusion cannot be drawn due to the potential role of publication bias and 
the heterogeneity of studies included in the review, this systematic review supports the 
hypothesis that earlier age at HBV infection is associated with an increased risk of HCC through 
persistence of viral replication. The implications of the effect of early age at infection on the 
prevention of cirrhosis and primary liver cancer are twofold. First it means that the impact of 
hepatitis B vaccination on raising the average age at infection will not simply be in reducing the 
prevalence of chronic infection but also in reducing the adverse effects of that chronic infection 
in those acquiring it at an older age. Second it adds emphasis to the critical importance of 
interrupting perinatal transmission – as reflected in the WHO recommendation for a timely birth 
dose within 24 hours of birth in all countries.
260
  
 
 
3.6. Summary 
A systematic review of the effect of age at HBV infection on HCC and its predictors amongst 
chronic HBV carriers was conducted. As the direct estimation of the age at HBV infection is 
difficult, the review included studies that used maternal HBV status and birth order as proxy 
measures for age at infection. The associations in all studies were in agreement with the 
hypothesis that earlier age at infection is associated with worse outcomes in chronic carriers. 
The review was potentially limited by publication bias and the absence of studies from Africa . 
 113 
 
Chapter 4. Association between perinatal 
mother-to-infant transmission of hepatitis B virus 
and the risk of hepatitis B e antigenaemia in 
children: a cross-sectional study in The Gambia, 
West Africa 
 
 
4.1. Abstract 
Background 
Early age at infection with hepatitis B virus (HBV) increases the risk of chronic HBV infection. 
In addition early age at infection may further increase the risk of persistent viral replication 
beyond its effect on chronicity. The effects of perinatal and early postnatal transmission on the 
risk of prolonged hepatitis B e antigenaemia in children with chronic HBV infection are not 
well documented in Africa. We examine these associations using maternal HBV sero-status and 
the number of HBV-positive older siblings as proxy measures for perinatal and early postnatal 
transmission. 
Methods  
Hepatitis B e antigen (HBeAg)-positive mothers were identified in six population-based HBV 
sero-surveys conducted in The Gambia in 1986-1990. For every HBeAg-positive mother a 
positive (hepatitis B surface antigen (HBsAg)-positive but HBeAg-negative) and negative 
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(HBsAg-negative) control mother was selected. These mothers and their family members were 
tested for HBV sero-markers in a subsequent survey in 1991-1993.  
Results 
Thirty-eight HBeAg positive mothers and the same number of positive and negative controls 
participated in the study. Sixty-nine percent of their children and 67% of their mothers also 
participated. There was a non-significant positive association between HBeAg prevalence in 
children and the number of HBeAg-positive older siblings (64.1%, 69.2% and 83.3% in children 
with 0, 1 and ≥2 HBeAg-positive older siblings, respectively). After adjusting for confounders, 
having an HBeAg-positive mother was a risk factor for HBeAg positivity in children carrying 
HBsAg (adjusted OR 4.5, 95% CI: 1.0-19.5, p=0.04), whilst the number of HBeAg-positive 
older siblings was not.  
Conclusions 
Maternal HBeAg was associated with positive HBeAg in children with chronic HBV infection. 
This suggests that interrupting mother-to-infant transmission in sub-Saharan Africa might help 
reduce the burden of liver disease. A timely dose of HBV vaccine within 24 hours of birth, as 
recommended by WHO, needs to be implemented in sub-Saharan Africa. 
 
 
 115 
 
4.2. Introduction 
Chronic infection with the hepatitis B virus (HBV) is a cause of hepatocellular carcinoma 
(HCC).
8
 The risk of chronic infection after exposure to HBV depends on the age at infection; 
infection becomes chronic in 80-90%, 20-30%, <10%, and <5% of individuals who are infected 
during perinatal period, early childhood, adolescence and adulthood, respectively .
68
 Early HBV 
infection is therefore associated with a higher risk of HCC through the increased risk of chronic 
infection.
186
 However, beyond its effect of increasing the chance of becoming a chronic carrier, 
early age at HBV infection may further increase the risk of persistent viral replication, which 
ultimately leads to HCC.
83
 The immaturity of the host immune system in neonates and toddlers 
has been suggested as a mechanism of prolonged e antigenaemia.
71
 
 
A systematic review of observational studies (Chapter 3)
261
 found a positive association 
between having a mother positive for HBV sero-marker (a proxy for perinatal mother-to-infant 
transmission) and prolonged hepatitis B e antigenaemia (an indicator of high viral replication) 
amongst children with chronic HBV infection. There was also a positive association between 
maternal sero-status and paediatric cases of HCC. 
 
However, the scope of the review was limited since: 1) most of the studies included were from 
East Asia where mother-to-infant transmission is frequent,
63
 and 2) none of the studies assessing 
the effect of maternal sero-marker examined the infectious status of older siblings, who are 
known to be a major source of HBV infection in many parts of the world including sub-Saharan 
Africa (sSA).
42,60,71
 Thus, the contribution of sibling-to-sibling HBV transmission during early 
childhood to the prolonged viral replication remains to be determined. 
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In this chapter the association between age at HBV infection and the presence of hepatitis B e 
antigen (HBeAg) is examined in The Gambia, West Africa, using maternal HBV sero-status and 
number of HBV-positive older siblings as a proxy for perinatal and early postnatal transmission, 
respectively. The analysis was restricted to study participants with positive hepatitis B surface 
antigen (HBsAg), because the aim of the analysis was to identify the effect of age at infection 
on the risk of hepatitis B e antigenaemia, beyond its effect of increasing the risk of chronic 
HBV infection.
261
  
 
 
4.3. Methods 
4.3.1. Setting 
A nation-wide hepatitis B vaccination trial was initiated in The Gambia in 1986 and by 1990 
countrywide coverage was achieved.
262
 In parallel, six population-based sero-surveys for HBV 
infection were conducted in The Gambia between 1986 and 1990 to assess immunological 
response to the vaccine and to determine risk factors for HBV transmission.
55,60,262
 These 
surveys obtained sera from both children and their mothers and tested for the presence of 
HBsAg in all the samples, and those that tested positive for HBsAg were further tested for 
HBeAg. In total, 53 HBeAg-positive mothers were identified from these studies (figure 4.1). 
 
On the basis of the HBV sero-status determined at these surveys, all HBeAg-positive mothers 
were invited to participate in “HBeAg Study”. The same numbers of positive (HBsAg-positive 
but HBeAg-negative) and negative (HBsAg-negative) control mothers was randomly selected 
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from the databases used in these surveys. Between 1991 and 1993, these mothers (i.e., index 
women) and their family members were bled for HBV markers to determine the effect of 
familial HBV sero-markers on presence of HBeAg.  
 
After consent was obtained, the women were bled and interviewed to collect demographic 
information on dead and living family members. Index women were bled twice, the first 
bleeding occurred between 1986 and 1990 and the second at the time of the HBeAg Study 
(1991-1993). We used the serological status recorded in the first survey as a proxy for 
serological status at birth of their children.  
 
Family members of the index woman (excluding half siblings), were contacted and if they 
agreed to participate in the study, were bled for HBV serology. All sera were assayed for 
HBsAg by reverse passive haemagglutination (Wellcotest, Murex Diagnostics, UK). HBeAg 
was tested by radioimmunoassay (Sorin, Biomedica, Italy) only when sera were 
HBsAg-positive. The study was approved by the Gambia Government/MRC (Medical Research 
Council) Joint Ethical Committee and the ethics committee at IARC (International Agency for 
Research on Cancer), France.  
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Figure 4.1 Flow chart of study participants in the HBeAg Study, The Gambia, 1991-93 
 
Total number of HBeAg 
positive mothers (n = 53)
1
 
Number of HBeAg 
positive mothers who 
participated in the HBeAg 
Study (1991-1993, n = 38) 
Case family 
Index women (n=38)
 
Mothers (n=38) 
Participated (24, 63%) 
Died (3, 8%) 
Untraced (11, 28%) 
Older siblings (n=53) 
 Participated (17, 32%) 
 Died (17, 32%) 
 Untraced (19, 36%) 
Children (n=137) 
 Participated (96, 70%) 
 Died (17, 12%) 
 Untraced (24, 18%) 
 
Positive control family 
Index women (n=38) 
Mothers (n=38) 
Participated (26, 68%) 
Died (7, 18%) 
Untraced (5, 13%) 
Older siblings (n=64) 
Participated (25, 39%) 
Died (13, 20%) 
Untraced (26, 41%) 
Children (n=153) 
Participated (102, 67%) 
Died (23, 15%) 
Untraced (28, 18%) 
Negative control family
 
Index women (n=38) 
Mothers (n=38) 
Participated (26, 68%) 
Died (7, 18%) 
Untraced (5, 13%) 
Older siblings (n=89) 
Participated (36, 40%) 
Died (31, 35%) 
Untraced (22, 25%) 
Children (n=144) 
Participated (101, 70%) 
Died (16, 11%) 
Untraced (27, 19%) 
HBsAg (+) children 
n=38/96 (40%) 
HBsAg (+) children 
n=14/102 (15%) 
HBsAg (+) children 
n=6/101 (6%) 
Population-based sero-surveys in 
The Gambia (1986-1990) 
The same number as cases 
(38) was randomly selected 
and participated as positive- 
and negative-control. 
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1
 Origins of HBeAg positive mothers are the following: GHIS group 1 (n=18), GHIS group 3 
(n=17), Arthropod study (n=6), Manduar sero-survey (n=4), Farafenni sero-survey (n=6), and 
Banjul sero-survey (n=2). 
 
 
4.3.2. Data analysis 
The association between maternal HBV markers (HBsAg, HBeAg) and e antigenaemia was 
examined in successive generations: mothers of index women (1
st
 generation) and index women 
(2
nd
 generation); and index women (2
nd
 generation) and their children (3
rd
 generation). The 
effect of the number of older siblings positive for HBsAg or HBeAg was evaluated in index 
women (2
nd
 generation) and their children (3
rd
 generation).  
 
Logistic regression was used to estimate adjusted odds ratios for the associations between 
familial HBV sero-status (maternal sero-status and number of elder siblings positive for HBV 
markers) and e antigenaemia in index women. In the children of index women, adjusted odds 
ratios for the same associations were estimated using generalised estimating equations with an 
exchangeable correlation structure to account for household clustering. 
 
4.3.2.1. Potential confounding factors 
In order to determine a minimally sufficient set of a priori confounders of the association 
between each of the familial sero-markers and e antigenaemia, the backdoor test was applied to 
a causal diagram.
263
 First, using external knowledge a causal diagram was constructed (figure 
4.2), in which each variable (exposures, outcome and potential confounding factors) was 
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assigned a fixed location and each direct causal effect of one variable on another was presented 
using an arrow starting from the cause with its tail to the effect with its head. Unmeasured but 
important variables are also presented and surrounded by dashed lines. A “path” is any 
unbroken route traced out along arrows connecting variables, irrespective of the direction of 
arrowheads. A “backdoor path from X to Y” is defined to be a path connecting X to Y with an 
arrowhead pointing to X. A “Collider” is a variable on the path where two arrowheads meet, and 
a path with one or more colliders is “blocked”; otherwise it is “unblocked” or “open”. 
 
Based on the theory of the directed acyclic graphs (DAGs), i) the diagram only included 
directed arrows (in which all direct associations are causal) and thus did not include any 
non-directed arrow which represents a direct non-causal association; and ii) there was no 
feedback loop in which a directed path forms a closed loop. In this diagram (figure 4.2), the 
exposures of interest are familial HBV sero-status (maternal HBV sero-status at the birth of the 
affected child (e and f) and number of older siblings with positive sero-marker (g and h)) and 
the outcome is persistent viral replication (l). Year of birth (a) and parental socioeconomic 
status (b) determine maternal HBV sero-status when the affected child was born (e and f) and 
number of older siblings with positive HBV sero-markers (g and h) through intermediate 
variables of maternal HBV sero-status when the mother delivered older siblings (c and d). 
Maternal HBV sero-markers at birth of the affected child (e and f) determine the risk of 
perinatal HBV transmission (i) whereas the number of older siblings with positive HBV 
markers (g and h) determines the risk of horizontal HBV transmission during early childhood (j). 
Early age at HBV infection through perinatal maternal transmission (i) or early horizontal 
transmission (j) indirectly increases the risk of persistent HBV viral replication (l), by 
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increasing the risk of chronic carriage (k). The hypothesis of this analysis is that early age at 
infection (i and j) increases the risk of persistent viral replication (l), beyond its effect of 
increasing the chronic HBV infection (k). This effect is represented by dashed arrows. Other 
potential risk factors for prolonged viral replication (m: current age, alcohol, hepatitis C, obesity 
and aflatoxin exposure) are affected by year of birth and parental socioeconomic status (a and b). 
Provision of hepatitis B vaccine (n) started in 1986 (a) and the likelihood of receiving vaccine 
was probably related to parental socioeconomic status (b). Vaccination is effective in preventing 
chronic HBV carriage (k).  
 
Conditioning on a variable X can generate a non-directed arrow between the ancestors of X (i.e., 
variables which give directed path to the conditioned variable X). In this diagram, the analysis 
was restricted to study participants with positive HBsAg (i.e., conditioning on “chronic HBV 
infection (k)”). Consequently, additional non-directed arrows are generated between HBV 
vaccination (n) and each of the following variables: perinatal (i) and early horizontal 
transmission (j), maternal HBsAg (e) and HBeAg (f) at birth and number of older siblings with 
HBsAg (g) and HBeAg (h). This is not illustrated in the Figure 4.2, but has been accounted for 
in the selection of confounders (see below). 
 
The causal effect of an exposure on an outcome can be estimated by eliminating all open 
backdoor paths between the two variables. This can be achieved by using a regression model to 
adjust for at least one variable from each open backdoor path. A set of variables S is minimally 
sufficient to identify the effect of exposure on the outcome, when removing any subset of 
variables from S results in an insufficient set. For the effect of maternal HBsAg at birth of 
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affected individual (e) on e antigenaemia (l), a minimally sufficient set of potential confounders 
that were measured is {year of birth (a), parental socioeconomic status (b), maternal HBeAg at 
birth of affected child (f), number of older siblings with positive HBsAg (g) and positive 
HBeAg (h)}. Similarly, for the effect of maternal HBeAg at birth of affected individual, a 
minimally sufficient set of potential confounders is {(a), (b), (e), (g) and (h)}. For the effect of 
number of older siblings with positive HBsAg (g), a minimally sufficient set is {(a), (b), (e), (f) 
and (h)}. Finally, for the effect of number of older siblings with positive HBeAg (h), a 
minimally sufficient set is {(a), (b), (e), (f) and (g)}. The mothers of index women were all 
negative for HBeAg and only one index woman had an HBeAg-positive older sibling. These 
variables were therefore omitted from multivariable models of e-antigenaemia in index women. 
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Figure 4.2 Causal diagram for the effect of familial HBV marker on hepatitis B e antigenaemia in the HBeAg Study, The Gambia, 1991-1993 
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The effect of maternal HBV sero-marker and number of older siblings with HBV sero-marker as proxies for age at establishment of chronic HBV infection on the 
risk for e antigenaemia was determined. The variables which were not measured are surrounded by dashed lines, and the exposure/outcome variables of interest are 
surrounded by lines in bold-type. SES denotes socio-economic stat 
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4.4. Results 
4.4.1. Participation  
Out of 53 HBeAg-positive mothers in the database, 38 (71.7%) were traced and agreed to 
participate in the study. The rate of refusal among controls was not recorded. More than 65% of 
the mothers and children of index women participated in the study, but participation was less 
than 35% among older siblings (figure 4.1). 
 
4.4.2. Index women (2
nd
 generation) 
The characteristics of 38 HBeAg-positive cases and 38 HBeAg-negative controls with positive 
HBsAg are presented in table 4.1. The median age in index women was 25.0 years (interquartile 
range: 23-30) for cases and 26.5 years (interquartile range: 22-30) for controls (Wilcoxon 
rank-sum test: p=0.8). The associations between familial HBV sero-status and HBeAg positivity 
in HBsAg-positive women are presented in table 4.2. The proportion of index women with 
HBsAg-positive mothers was higher in cases (16.7%, 4/24) than in controls (7.7%, 2/26), 
although the difference was not statistically significant (p=0.3). None of the HBsAg-positive 
mothers were HBeAg-positive. The proportion of index women with HBsAg-positive older 
siblings was similar in cases (15.4%, 4/26) and controls (17.2%, 5/29). After adjusting for 
confounding factors, there was no evidence for an association between HBeAg positivity in 
index women and either maternal HBsAg (OR 1.2, 95% CI: 0.1-23.2, p=0.9) or having an 
HBsAg-positive older sibling (OR 0.9, 95% CI: 0.2-5.5, p=0.9). 
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Table 4.1 Characteristics of HBeAg-positive index women (cases) and HBsAg-positive 
HBeAg-negative women (controls) 
Variables HBsAg (+) HBeAg (+) 
index women (n=38) 
HBsAg (+) HBeAg (-) 
index women (n=38) 
p-value (test 
for trend) 
No % No %  
Age group 17-20 6 15.8 7 18.4 0.9 
21-30 25 65.8 22 57.9  
31-45 7 18.4 9 23.7  
Year of 
birth 
1948-1960 6 15.8 8 21.0 0.8 
1961-1970 27 71.0 24 63.2  
1971-1974 5 13.2 6 15.8  
Total 
sibship size 
1-4 16 42.1 8 21.0 0.07 
5-6 12 31.6 15 39.5  
≥7 10 26.3 15 39.5  
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Table 4.2 Risk factors for HBeAg positivity in HBsAg-positive women 
Variables HBsAg (+) 
HBeAg (+) 
index 
women 
(n=38) 
HBsAg (+) 
HBeAg (-) 
index 
women 
(n=38) 
Crude odds ratios Adjusted odds ratios
1
 
No % No % OR 95% CI P OR 95% CI P 
Maternal HBsAg           
Negative 20 83.3 24 92.3 1.0  0.3 1.0  0.9
 
Positive 4 16.7 2 7.7 2.4 0.4-14.5  1.2
 
0.1-23.2 
 
Maternal HBeAg           
Negative 24 100 26 100 1.0   1.0   
Positive 0 0 0 0 N/A   N/A   
No. of older siblings 
with positive HBsAg 
          
0 22 84.6 24  82.8 1.0  0.9 1.0  0.9
 
1-2 4 15.4 5 17.2 0.9 0.2-3.7  0.9
 
0.2-5.5 
 
No. of older siblings 
with positive HBeAg 
          
0 25 96.2 29 100 1.0   1.0   
1 1 3.8 0 0 N/A   N/A   
1 
Model included maternal HBsAg, number of older siblings with HBsAg, year of birth, and 
total sibship size. 
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4.4.3. Children of index women (3
rd
 generation) 
In total, 96, 102 and 101 children with HBeAg-positive, HBsAg-positive and HBeAg-negative, 
and HBsAg-negative mothers participated, respectively. Of whom, 38 (39.6%), 14 (13.7%) and 
6 (5.9%) tested positive for HBsAg, respectively (p<0.001, figure 4.1). The characteristics of 
these HBsAg-positive children (n=58) by maternal HBV marker are presented in table 4.3. The 
median age was similar in the three groups. However, HBsAg-positive children with HBeAg 
positive mothers were more likely to be female, HBV vaccinated and to have three or fewer 
siblings than HBsAg-positive children born to HBeAg negative mothers.  
 
The associations between familial HBV sero-status and HBeAg positivity in HBsAg-positive 
children are presented in table 4.3. There was a non-significant trend that HBeAg prevalence in 
children increased with increasing number of HBeAg-positive older siblings (64.1%, 69.2% and 
83.3% in children with 0, 1, and ≥2 HBeAg-positive older siblings, respectively), but there was 
no trend after adjusting for confounding (table 4.4). In contrast, the presence of maternal 
HBeAg was a risk factor for HBeAg positivity after adjusting for confounding (adjusted OR 4.5, 
95% CI: 1.0-19.5, p=0.04). In a bivariable model with only maternal HBeAg and number of 
HBeAg-positive older siblings, OR for the association between maternal HBeAg and e 
antigenaemia in children did not differ from the crude OR (adjusted OR 1.6, 95% CI: 0.4-5.6, 
p=0.5) whilst the ORs for the number of HBeAg-positive older siblings decreased; using no 
HBeAg-positive older siblings as the reference, the ORs were 1.1 (95% CI: 0.2-5.6) and 1.5 
(0.5-4.8) for having one and two or more HBeAg-positive older siblings, respectively (p=0.7). 
The prevalence of e antigenaemia was similar between vaccinated (70.0%, 7/10) and 
unvaccinated (66.7%, 32/48, p=0.8) children. 
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Table 4.3. Characteristics of HBsAg-positive children according to maternal HBV sero-status 
Variables HBsAg(+) 
HBeAg(+) 
mother (n=38) 
HBsAg(+) 
HBeAg(-) 
mother (n=14) 
HBsAg(-) 
mother (n=6) 
p-value
 
No. % No. % No. % 
Sex Male 12 31.6 8 57.1 5 83.3 0.03 
Female 26 68.4 6 42.9 1 16.7  
Age group 0-5 15 39.5 2 14.3 3 50.0 0.4 
6-10 16 42.1 9 64.3 2 33.3  
≥11 7 18.4 3 21.4 1 16.7  
Year of birth 1973-1980 5 13.2 3 21.4 1 16.7 0.6 
1981-1985 18 47.4 9 64.3 3 50.0  
1986-1991 15 39.4 2 14.3 2 33.3  
Total sibship 
size 
1-3 10 26.3 1 7.1 1 16.7 0.03 
4-5 9 23.7 7 50.0 5 83.3  
6-7 19 50.0 6 42.9 0 0.0  
HBV 
vaccination 
No 28 73.7 14 100 6 100 0.04 
Yes 10 26.3 0 0.0 0 0.0  
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Table 4.4. Risk factors for HBeAg positivity in HBsAg-positive children 
Variables Prevalence of 
HBeAg (+) 
Crude odds ratios Adjusted odds ratios
2,3
 
OR 95% CI P OR 95% CI P 
Maternal HBsAg        
Negative 83.3% (5/6) 1.0  0.5 1.0  0.5
 
Positive 65.4% (34/52) 0.4 0.1-4.2  0.4 0.1-5.3 
 
Maternal HBeAg        
Negative 60.0% (12/20) 1.0  0.5 1.0  0.04
 
Positive 71.1% (27/38) 1.6 0.4-6.1  4.5 1.0-19.5 
 
No of older siblings with 
positive HBsAg 
       
0 65.6% (21/32) 1.0  0.7
1 
1.0  0.9
1 
1 66.7% (10/15) 1.0 0.3-3.8  1.1 0.2-7.2 
 
≥2 72.7% (8/11) 1.4 0.3-6.4  1.2 0.0-47.5  
No. of older siblings with 
positive HBeAg 
       
0 64.1% (25/39) 1.0  0.4
1 
1.0  0.8
1 
1 69.2% (9/13) 1.3 0.3-4.9  1.1 0.3-4.9  
≥2 83.3% (5/6) 2.8 0.3-27.7  2.0 0.1-42.7  
1
 Linear test for trend 
2 
Model included maternal HBsAg, maternal HBeAg, number of older siblings with HBsAg, 
number of older siblings with HBeAg, year of birth, and total sibship size. 
3
 Wald test from generalised estimating equations. 
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4.5. Discussion 
The effect of HBV sero-markers in mothers and older siblings on hepatitis B e antigenaemia in 
children carrying HBsAg (3
rd
 generation) was examined. Positive association was found 
between e antigenaemia in children and maternal HBeAg but not with maternal HBsAg. 
Likewise, the prevalence of e antigenaemia in children was higher if older siblings were HBeAg 
positive, although this result was not statistically significant. These relationships imply that the 
early establishment of chronic HBV infection through perinatal transmission from infectious 
mothers, as well as early postnatal transmission from infectious older siblings is associated with 
persistence of HBeAg. In addition, this is consistent with the observation that positive HBeAg 
confers greater infectivity than HBsAg positivity alone. For example, the risk of perinatal 
transmission is 10-17% in HBsAg-positive mothers without HBeAg and 63-67% in HBeAg 
positive mothers in sSA.
14,17 
Indeed, in the current study, I observed that prevalence of HBsAg 
in children with HBeAg-positive mothers was significantly higher than that in children with 
HBsAg-positive but HBeAg-negative mothers (40% versus 15%). 
 
The associations of familial HBeAg with e antigenaemia in index women (2
nd
 generation) could 
not be confirmed because all of the mothers of index women tested negative for HBeAg and 
only one older sibling tested positive for HBeAg. The low prevalence of HBeAg in the mothers 
and older siblings of index women was expected since HBeAg is lost over time. In The Gambia, 
85% of children who established chronic HBV infection during early childhood had lost HBeAg 
by the second decade of life.
185
 This makes it difficult to investigate the effect of familial 
HBeAg status in adults. 
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A strength of this study was that I could assess the effect of familial HBV sero-status, rather 
than a family history of HBV infection. The latter is inaccurate because the absence of such a 
history does not necessarily indicate that the family member was sero-negative for HBsAg.
261
 
Second, I could control for the HBV markers of older siblings when assessing the association of 
maternal HBV sero-status with HBeAg positivity. And similarly the association between 
siblings’ sero-status and HBeAg positivity was adjusted for maternal HBV markers. In other 
studies this has not been possible.
78,83,242,245,247,250,251
 The mutual adjustment with siblings’ 
sero-markers was particularly relevant in The Gambia, where sibling-to-sibling transmission 
during early childhood is the most frequent route.
42,60
 After the mutual adjustment the OR for 
the association between maternal HBeAg and e antigenaemia in children did not change whilst 
the ORs for the number of HBeAg-positive older siblings decreased. This suggests that perinatal 
maternal transmission might be a more important in determining the risk of persistent viral 
replication than early horizontal transmission from older siblings in The Gambia. This is 
consistent with the hypothesis that earlier age at HBV infection is associated with higher risk of 
e antigenaemia. 
 
Two African case-control studies have investigated the association between age at HBV 
infection and HCC, ultimate sequelae of chronic HBV infection. Larouze et al., found that the 
prevalence of maternal HBsAg was higher in HCC cases (71.4%, 20/28) than in healthy 
controls (14.3%, 4/28, P<0.0001) while the prevalence of HBsAg in siblings was similar in 
cases (9.6%, 7/73) and controls (14%, 8/58).
186
 Ryder et al., studied the association between 
birth order and HCC, and found strong evidence that higher birth order, and hence earlier age at 
infection, is associated with higher HCC risk (P<0.005).
193
 In the absence of immunisation, 
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children with low birth order are exposed to HBV after they start schooling, whilst children with 
high birth order are infected much earlier by their older siblings who got the infection outside 
the household.
187
 However, because individuals negative for HBsAg were included in both 
studies, the associations might be due to an increased risk of chronic HBV infection related with 
early age at infection. The results of these studies are therefore not directly comparable to the 
findings from the HBeAg Study. 
 
The study has several limitations. First, the sample size was small, and the associations were 
therefore poorly estimated. Second, many family members of the index women did not 
participate in the HBeAg study, and this might have led to selection bias. Third, important 
confounding variables might have been omitted, in particular viral genotype.  
 
HBV vaccination programmes in Africa and Asia have been successful in preventing postnatal 
horizontal transmission of HBV, thereby reducing the prevalence of chronic HBV 
infection.
238,264
 However, they have had a limited impact on perinatal mother-to-infant 
transmission, especially when the mothers are HBeAg-positive or highly viraemic.
126,238
 In East 
Asia, where perinatal maternal transmission is common, HBV vaccine is frequently given 
within 24 hours of delivery (i.e. timely birth dose).
265,266
 By contrast a timely birth dose of HBV 
vaccine is rarely administered in Africa because logistical challenges seem to outweigh its 
potential impact due to the relatively low frequency of mother-to-infant transmission.
267
 Despite 
a high coverage of hepatitis B vaccine, only six countries in sSA are undertaking the birth dose 
by the end of 2012 and The Gambia is one of them.
117
 However, in two villages in rural Gambia 
where HBV vaccine efficacy was evaluated,
238
 only 2.8% (63/2173) of children who were 
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vaccinated against HBV between 1984 and 2007 were given a dose within 24 hours of birth 
(unpublished data). This might be because in The Gambia, most children are born at home, and 
are usually not taken away from home in the first week.
113
 
 
This study suggests that the risk of prolonged e antigenaemia, an important predictor of HCC,
268
 
may be higher in individuals who perinatally established chronic infection through infectious 
mothers than in those infected with HBV by horizontal transmission. This implies that 
interrupting mother-to-infant transmission in sub-Saharan Africa might help reduce the burden 
of liver disease. A timely dose of HBV vaccine within 24 hours of birth, as recommended by 
WHO,
116
 needs to be considered in sub-Saharan Africa. 
 
 
4.6. Summary 
The effect of early age at infection with HBV on prolonged hepatitis B e antigenaemia was 
examined using maternal HBsAg and HBeAg as proxies for perinatal maternal transmission and 
number of older siblings with positive HBsAg and HBeAg as proxies for early postnatal 
transmission. Between 1986 and 1990, six cross-sectional HBV sero-surveys targeting mothers 
and children were conducted in The Gambia. All the mothers identified as being positive for 
HBeAg were invited to participate in the current study, as well as the same numbers of 
HBsAg-positive HBeAg-negative mothers and HBsAg-negative mothers who were randomly 
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selected from the databases. In addition, all the family members of these mothers (i.e. index 
women) were also asked to take part in the study. The associations of familial HBV markers 
with HBeAg positivity were examined in two successive generations: in index women and their 
children. 
 
In index women, the effect of maternal HBeAg could not be examined because none of mothers 
of index women (i.e. grandmothers) were positive for HBeAg. In contrast, there was a positive 
association between maternal HBeAg and e antigenaemia in children. The increasing HBeAg 
prevalence was also observed with increasing number of HBeAg-positive older siblings 
although this association did not reach the statistical significance. After maternal sero-status and 
older siblings’ sero-status were mutually adjusted, the effect of maternal HBeAg was stronger 
than the effect of older siblings’ HBeAg, suggesting that perinatal maternal transmission might 
be a more important determinant of persistent viral replication than early horizontal 
transmission from older siblings in The Gambia. Although it was difficult to draw a robust 
conclusion due to small sample size, these findings emphasise the importance of interrupting the 
mother-to-infant transmission in sub-Saharan Africa. 
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Chapter 5. The association of birth order with 
hepatocellular carcinoma and liver cirrhosis in 
people with chronic hepatitis B infection: a 
secondary data analysis of the Gambia Liver 
Cancer Study (GLCS), a case-control study in the 
Gambia, West Africa 
 
 
5.1. Abstract 
Background 
Early age at hepatitis B virus (HBV) infection is a potential risk factor for liver cirrhosis and 
hepatocellular carcinoma (HCC) in individuals with chronic hepatitis B infection. However, this 
has never been studied in Africa. A historical dataset from the Gambia Liver Cancer Study 
(GLCS) was further exploited focusing on the effect of age at infection on HCC and liver 
cirrhosis using birth order as a proxy for age at infection, a question not originally answered. 
Because the major mode of HBV transmission in The Gambia is sibling-to-sibling during 
childhood, it is hypothesised that the risk of HCC increases with increasing birth order. 
Methods 
HCC cases and liver cirrhosis cases were recruited from three referral hospitals in The Gambia 
between 1997 and 2001. In the original analysis, for each HCC case, two control participants 
without clinical liver disease, frequency matched by age, gender and study site, were recruited. 
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Because this current analysis was restricted to participants with positive hepatitis B surface 
antigen (HBsAg), the original sampling scheme and thus matching were disrupted.  
Results 
The analysis included 129 HBV-related HCC, 67 HBV-related liver cirrhosis, and 64 
HBsAg-positive controls. Compared to the first-born, the odds ratios for HCC were 0.62 (95% 
CI: 0.25-1.55), 0.99 (0.32-3.08), 0.87 (0.27-2.79) and 0.55 (0.18-1.67) in second-, third-, fourth- 
and fifth- or later-born participant, respectively, when the birth order excluded half-siblings 
(p=0.5). When the birth order counted both full- and half-siblings, the odds ratio for HCC was 
0.37 (95% CI: 0.11-1.16), 1.03 (0.33-3.18), 0.37 (0.11-1.20) and 0.64 (0.18-2.29), in 2
nd
-, 3
rd
- 
and 4
th
-, 5
th
- and 6
th
-, and 7
th
- or later-born participant, respectively (p=0.5). A similar 
non-significant trend was observed for liver cirrhosis. 
Conclusion 
Although the association was not statistically significant, 1
st
 birth order was associated with the 
highest risk for cirrhosis and HCC, while the risk was lower for 2
nd
, 3
rd
, 4
th
 and ≥5th birth order. 
This suggests, contrary to the original hypothesis, that mother-to-infant transmission of HBV 
might be an important determinant of liver cirrhosis and HCC in chronic HBV carriers in The 
Gambia. 
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5.2. Introduction 
The systematic review of observational studies in Chapter 3 suggests that there is an association 
between early age at hepatitis B virus (HBV) infection and increased risk of liver cirrhosis and 
hepatocellular carcinoma (HCC) amongst chronic carriers of HBV. However, the review did not 
include any African study. In this chapter, an old dataset of the Gambia Liver Cancer Study 
(GLCS) was further exploited focusing on the effect of early age at infection on liver cirrhosis 
and HCC, an association that was not examined in the original study. The GLCS is a 
case-control study of liver cirrhosis and HCC conducted by Kirk et al. in The Gambia in 
1997-2001.
169
 In the analysis, birth order is used as a proxy for early exposure to HBV through 
sibling-to-sibling transmission as discussed in Chapter 2.
187,194
  
 
 
5.3. Methods 
5.3.1. The Gambia Liver Cancer Study (GLCS) 
The GLCS is a case-control study which was conducted in The Gambia from 1997 to 2001. 
Cases had been diagnosed with either cirrhosis or liver cancer. The study was designed to 
estimate the population attributable fraction associated with HBV, hepatitis C virus (HCV), or 
aflatoxin.
156,169
 Study participants were recruited from three tertiary care hospitals in The 
Gambia, namely: Royal Victoria Teaching Hospital (RVTH), the sole tertiary care hospital in 
The Gambia located at capital Banjul; Medical Research Council (MRC) Clinic, within the 
Greater Banjul Area; and Bansang General Hospital (BSG) in the upcountry. First, patients with 
suspected liver disease were identified by local physicians or through active surveillance of the 
outpatient clinics and inpatient wards by field staff. After informed consent, the patients 
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underwent a structured interview with a standardised questionnaire, clinical and ultrasound 
examination and collection of a blood sample. For each case, two control participants without 
clinical liver disease were recruited from the outpatient clinics of the same hospitals. They were 
frequency matched to patients with liver disease by age (using 10-year age bands), gender and 
study site. The same questionnaire, examination and blood collection was administered to the 
controls. The study was approved by the Gambia Government/MRC joint ethics committee. 
 
5.3.2. Case and Control Definition 
HCC cases were defined as patients with suspected liver disease who had either 1) pathological 
confirmation or 2) a serum alpha-fetoprotein (AFP) levels >100 ng/mL with space-occupying 
hepatic lesions (SOL) on ultrasound. Liver cirrhosis cases were defined as patients with 
suspected liver disease who had 1) no evidence of SOL by ultrasound; 2) no evidence of 
alternative diagnoses such as cardiac or renal disorder; and 3) a score of ≥7 in the cirrhosis 
diagnostic scale using ultrasound.
269
 Control participants were defined as patients who had 1) no 
clinical evidence of liver disease and 2) AFP levels <20 ng/ml. 
 
5.3.3. Birth order 
The number of full-siblings (siblings who share both biological parents) and half-siblings who 
lived with the study participant when he or she was old enough to go to school was obtained by 
administering a standardised questionnaire. Twins and triplets were counted as independent 
births. Miscarriages and stillbirths were not counted. The number of siblings who were older 
than the participant at this time was used to derive birth order. Two different birth ranks were 
 140 
 
assessed: birth order in full-siblings and birth order in all siblings (counting both full- and 
half-siblings). 
  
5.3.4. Statistical analyses 
Analyses were restricted to study participants with positive HBsAg, because the objective was 
to examine the effect of early age at HBV infection on liver diseases beyond its effect of 
increasing the chance of chronic HBV infection. The restriction to HBsAg-positive individuals 
disrupted the original sampling scheme and thus matching. The prevalence of risk factors was 
compared between cirrhosis cases and controls, and between HCC cases and controls using the 
chi-squared test (sex, ethnic group, recruitment site, education level, family history of liver 
cancer, alcohol consumption, cigarettes smoking, HBeAg, anti-HCV and 249
ser
 TP 53 mutation), 
chi-squared test for trend (age group and number of siblings), or Wilcoxon rank-sum test (age). 
Logistic regression was used to estimate odds ratios for the association of birth order with liver 
cirrhosis and HCC adjusted for a priori confounders.  
 
As discussed in details in Chapter 4, a minimally sufficient set of a priori confounders for the 
association between birth order and liver diseases was identified by applying the backdoor test 
in a causal diagram (figure 5.1).
263
 The confounders identified from the causal diagram were: 
year of birth, birthplace, ethnic group and parental socioeconomic status (SES). Data for 
birthplace were unavailable and thus could not be included in the model. As discussed in 
Chapter 2, it is unclear whether to include the number of siblings (sibship size) as a confounder 
in the analysis of birth order.
202,218
 Therefore, two different models were used to account for 
confounding due to SES: in model 1 schooling (of the study participant) was used as a proxy for 
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SES and in model 2 sibship size was used as the proxy. Because participants were recruited over 
a relatively short period (5 years), year of birth and age at study entry were approximately 
equivalent. Both models included age, sex and study site, as cases and controls were frequency 
matched on these variables. Recruitment date was included in the multivariable model in the 
original paper,
165 
however this was excluded in the current analysis because it is unlikely that 
the recruitment date varies according to the exposure (i.e., birth order). 
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Figure 5.1. Causal diagram for the effect of birth order on the risk of liver cirrhosis and HCC in the Gambia Liver Cancer Study, 1997-2001 
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Early birth order is a proxy for perinatal mother-to-infant HBV transmission whilst late birth order is a proxy for early horizontal transmission. Early age at HBV 
infection is known to be associated with liver cirrhosis and HCC through increasing the risk of chronic HBV infection. The hypothesis of this analysis is that in 
addition to this effect, early age at infection further increases the risk of liver cirrhosis and HCC (presented as a dashed arrow). The exposure and outcome variables 
of interest are surrounded by lines in bold-type. Abbreviations: SES, socioeconomic status; HCV, hepatitis C virus.
 144 
 
5.4. Results 
5.4.1. Characteristics of the study participants 
Two-hundred sixteen HCC cases, 121 liver cirrhosis cases and 408 controls were recruited into 
the study, among which 129 (61.1%), 67 (56.3%), and 64 (15.9%) were HBsAg-positive, 
respectively (table 5.1). Characteristics of HBV-related HCC cases, HBV-related liver cirrhosis 
and HBsAg-positive controls are presented in table 5.2. The gender ratio was similar in each 
group. HCC cases tended to be older than cirrhosis or controls, but the difference was not 
significant. For ethnic group, cirrhosis and HCC cases were less likely to be Mandinka than 
controls and more likely to be Fula and Wollof. HCC cases were less educated than controls. 
Alcohol consumption, smoking cigarettes, anti-HCV and family history of liver cancer were 
similar in cases and controls. The prevalence of HBeAg was higher in cases than controls, as 
was the TP53 mutation.  
 
 
Table 5.1 Prevalence of HBsAg in controls, liver cirrhosis and HCC cases in the Gambia Liver 
Cancer Study, 1997-2001 
HBsAg Controls (N=408) Liver cirrhosis (N=121) HCC (N=216) 
Negative 338 (84.1%) 52 (43.7%) 82 (38.9%) 
Positive 64 (15.9%) 67 (56.3%) 129 (61.1%) 
Missing 6 2 5 
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Table 5.2 Characteristics of HBsAg-positive controls, HBV-related liver cirrhosis and 
HBV-related HCC in the Gambia Liver Cancer Study, 1997-2001 
 HBsAg (+) 
controls 
(N=64) 
HBV-related liver 
cirrhosis (N=67) 
HBV-related HCC 
(N=129) 
n % n % P n % P 
Male sex 52 81.3 51 76.1 0.5 108 83.7 0.7 
Age (yrs), median (IQR) 38.5 (27-50) 38 (29-48) 0.8
1
 42 (32-48) 0.3
1
 
Age group     0.6
2 
  0.5
2 
<30 21 32.8 17 25.4  24 18.6  
30 – 39 12 18.8 19 28.4  30 23.3  
40 – 49 11 17.2 17 25.4  44 34.1  
50 – 59 11 17.2 10 14.9  16 12.4  
≥60 9 14.1 4 6.0  15 11.6  
Ethnic group     0.1   0.05 
  Mandinka 21 34.4 16 24.2  29 23.0  
  Fula 11 18.0 22 33.3  37 29.4  
  Wollof 9 14.8 18 27.3  28 22.2  
  Other 20 32.8 10 15.2  32 25.4  
Number of full-siblings         
  1-2 5 8.3 12 18.5 0.4
2
 22 17.5 0.7
2
 
  3-4 20 33.3 16 24.6  32 25.4  
  5-6 17 28.3 20 30.8  29 23.0  
  ≥7 18 30.0 17 26.1  43 34.1  
Number of siblings (full + 
half)
 
 
        
  0-5 15 25.9 19 30.7 0.2
2
 37 29.6 0.4
2
 
  6-8 13 22.4 22 35.5  39 31.2  
  9-11 17 29.3 10 16.1  18 14.4  
  ≥12 13 22.4 11 17.7  31 24.8  
Recruitment site     0.07   0.2 
  RVTH 19 29.7 33 49.3  54 41.9  
  MRC 22 34.4 16 23.9  40 31.0  
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  BSG 23 35.9 18 26.9  35 27.1  
Education     0.07   0.03 
  Ever attended school 58 93.5 55 83.3  103 81.8  
  None 4 6.5 11 16.7  23 18.2  
Family history of liver 
cancer 
    0.3   0.1 
  Yes 2 3.3 5 7.6  13 10.3  
  No 59 96.7 61 92.4  113 89.7  
Ever drunk alcohol     0.9   0.3 
  Yes 6 9.7 7 10.6  19 15.3  
  No 56 90.3 59 89.4  10 84.7  
Ever smoked cigarettes     0.4   0.4 
  Yes 32 51.6 29 43.9  72 58.1  
  No 30 48.4 37 56.1  52 41.9  
HBeAg     0.001   0.006 
  Positive 2 3.5 16 25.0  23 81.6  
  Negative 56 96.5 48 75.0  102 18.4  
HCV infection
 
    0.3   0.2 
  Yes 1 1.7 0 0  7 6.0  
  No 59 98.3 57 100  110 94.0  
249
ser
 TP53 mutation     0.02   <0.001 
  Yes 2 4.0 10 18.2  41 40.6  
  No 48 96.0 45 81.8  60 59.4  
P-value was obtained using chi-squared test unless indicated. 
1
 Wilcoxon rank-sum test 
2
 Test for trend 
 
 
 147 
 
5.4.2. Characteristics of HBsAg-positive controls by birth order in full siblings 
The association between birth order in full siblings and risk factors for liver cirrhosis and HCC 
in HBsAg-positive controls is presented in table 5.3. The number of full siblings was lower in 
low birth order than in high birth order. Otherwise, there were no substantial imbalances in the 
distribution of risk factors according to birth order. Although none of a priori confounders (age, 
ethnic group, parental socioeconomic status, sex and study site) were associated with the 
exposure of interest (birth order in full-siblings), these factors were included in the 
multivariable analyses that assess the effect of birth order on liver cirrhosis and HCC. This is 
because small differences in the distribution of confounders between the exposed and 
unexposed group can still bias estimates even if the differences are not statistically significant.  
 
5.4.3. Birth order and risk of liver cirrhosis and HCC 
The results of univariable and multivariable analysis for the association of birth order with HCC 
and cirrhosis are presented in table 5.4 and 5.5, respectively. Although the association was not 
statistically significant, the risk of cirrhosis and HCC was generally greater for 1
st
 birth order 
than 2
nd
, 3
rd
, 4
th
 and ≥5th birth order, that had a similar lower degree of risk. The exceptions are 
multivariable model 2 for the effect of birth order in full-siblings on HCC and model 1 and 2 for 
the effect of birth order in all (full- and half-) siblings on HCC; these found the highest risk in 
the 3
rd
 birth rank.  
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Table 5.3 Characteristics of HBsAg-positive controls by birth order in full-siblings in the 
Gambia Liver Cancer Study, 1997-2001 
 Birth order in full-siblings P 
1
st
 (16) 2
nd
 (18) 3
rd
 (9) 4
th
 (7) 5
th
 (9) 
Male sex 14 (88%) 15 (83%) 6 (67%) 5 (71%) 7 (78%) 0.7 
Median age (range) 37 (19, 
75) 
48 (25, 
70) 
33 (22, 
40) 
30 (21, 
70) 
30 (21, 
80) 
0.2 
Ethnic group      0.6 
  Mandinka 5 (31%) 5 (28%) 3 (37%) 2 (29%) 4 (45%)  
  Fula 3 (19%) 4 (22%) 2 (25%) 0 2 (22%)  
  Wolof 1 (6%) 5 (28%) 1 (13%) 1 (14%) 0  
  Others 7 (44%) 4 (22%) 2 (25%) 4 (47%) 3 (33%)  
Number of full-siblings      0.09 
  1-2 1 (6%) 4 (22%) 0 0 0  
  3-4 7 (44%) 7 (39%) 4 (44%) 1 (14%) 0  
  5-6 2 (12%) 5 (28%) 3 (33%) 3 (43%) 4 (44%)  
  ≥7 6 (38%) 2 (11%) 2 (22%) 3 (43%) 5 (56%)  
Recruitment site      0.8 
  RVTH 6 (38%) 4 (22%) 2 (22%) 2 (29%) 2 (22%)  
  MRC 6 (38%) 5 (28%) 3 (33%) 2 (29%) 5 (56%)  
  BSG 4 (25%) 9 (50%) 4 (45%) 3 (43%) 2 (22%)  
Never attended school 0 1 (6%) 2 (22%) 0 1 (11%) 0.3 
Family history of HCC 5 (5%) 5 (11%) 1 (2%) 0 5 (10%) 0.3 
Ever drunk alcohol 3 (19%) 1 (6%) 1 (11%) 0 1 (11%) 0.6 
Ever smoked cigarettes 8 (50%) 11 (61%) 3 (33%) 3 (43%) 5 (56%) 0.7 
Obesity (BMI≥30) 0 0 0 0  0 1.0 
HBeAg positive 0 1 (6%) 1 (17%) 0 0 0.4 
HCV positive 0 0 0 0 1 (11%) 0.3 
249
ser
 TP53 mutation 0 0 0 1 (20%) 1 (13%) 0.2 
P-value was obtained using chi-squared test unless indicated.
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1
 Kruskal-Wallis one-way analysis of variance
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Table 5.4 Univariable and multivariable analysis for the association between birth order and HCC among HBsAg-positive individuals in the Gambia Liver Cancer 
Study, 1997-2001 
Variables HBsAg (+) 
controls 
(N=64) 
HBV-related 
HCC 
(N=129) 
Univariable analysis Model 1 (education level as 
proxy for parental SES) 
Model 2 (total sibship size 
as proxy for parental SES) 
n % n % OR (95% CI) P
 
OR (95% CI) P
 
OR (95% CI) P
 
Birth order 
in full- 
siblings
2 
1
st
  16 27.1 43 34.4 1.00 0.5
1 
1.00 0.5
1 
1.00 0.6
1 
2
nd
  18 30.5 32 25.6 0.66 (0.29-1.49)  0.62 (0.25-1.55)  0.71 (0.29-1.74)  
3
rd
  9 15.3 20 16.0 0.83 (0.31-2.19)  0.99 (0.32-3.08)  1.05 (0.34-3.20)  
4
th
  7 11.9 15 12.0 0.80 (0.27-2.31)  0.87 (0.27-2.79)  0.93 (0.29-3.02)  
≥5th 9 15.3 15 12.0 0.62 (0.22-1.70)  0.55 (0.18-1.67)  0.58 (0.18-1.91)  
Not reported 5  4        
Birth order 
in siblings 
(full + 
half)
3 
1
st
  8 14.3 27 22.1 1.00 0.4
1 
1.00 0.5
1 
1.00 0.7
1 
2
nd
  15 26.8 22 18.0 0.43 (0.16-1.21)  0.37 (0.11-1.16)  0.39 (0.12-1.24)  
3
rd
 & 4
th
 13 23.2 41 33.6 0.93 (0.34-2.55)  1.03 (0.33-3.18)  1.16 (0.38-3.61)  
5
th
 & 6
th
  11 19.6 16 13.1 0.43 (0.14-1.30)  0.37 (0.11-1.20)  0.39 (0.11-1.31)  
≥7th 9 16.1 16 13.1 0.53 (0.17-1.64)  0.64 (0.18-2.29)  0.69 (0.18-2.67)  
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Not reported 8  7        
1 
Test for trend 
2 
Multivariable model included age, sex, ethnicity, recruitment site, birth order in full-siblings and education level (model 1) or number of full-siblings (model 2). 
3 
Multivariable model included age, sex, ethnicity, recruitment site, birth order in siblings (full + half) and education level (model 1) or number of siblings (full + 
half) (model 2). 
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Table 5.5 Univariable and multivariable analysis for the association between birth order and liver cirrhosis among HBsAg-positive individuals in the Gambia Liver 
Cancer Study, 1997-2001 
Variables HBsAg (+) 
controls 
(N=64) 
HBV-related 
liver 
cirrhosis 
(N=67) 
Univariable analysis Model 1 (education level as 
proxy for parental SES) 
Model 2 (total sibship size 
as proxy for parental SES) 
n % n % OR (95% CI) P
 
OR (95% CI) P
 
OR (95% CI) P
 
Birth order 
in full- 
siblings
2 
1
st
  16 27.1 27 41.5 1.00 0.4
1 
1.00 0.6
1 
1.00 0.7
1 
2
nd
  18 30.5 14 21.5 0.46 (0.18-1.17)  0.39 (0.13-1.13)  0.33 (0.11-0.99)  
3
rd
  9 15.3 7 10.8 0.46 (0.14-1.48)  0.50 (0.13-1.95)  0.52 (0.13-2.00)  
4
th
  7 11.9 8 12.3 0.68 (0.21-2.22)  0.81 (0.19-3.38)  0.85 (0.20-3.69)  
≥5th 9 15.3 9 13.9 0.59 (0.20-1.80)  0.63 (0.18-2.15)  0.80 (0.21-3.00)  
Not reported 5  2        
Birth order 
in siblings 
(full + 
half)
3 
1
st
  8 14.3 17 27.4 1.0 0.3
1 
1.0 0.4
1 
1.0 0.6
2 
2
nd
  15 26.8 12 19.4 0.38 (0.12-1.17)  0.40 (0.11-1.44)  0.36 (0.10-1.26)  
3
rd
 & 4
th
 13 23.2 15 24.2 0.54 (0.18-1.67)  0.71 (0.19-2.72)  0.62 (0.17-2.32)  
5
th
 & 6
th
  11 19.6 7 11.3 0.30 (0.08-1.06)  0.24 (0.05-1.09)  0.26 (0.06-1.20)  
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≥7th 9 16.1 11 17.7 0.58 (0.17-1.94)  0.69 (0.16-3.02)  0.83 (0.18-3.91)  
Not reported 8  5        
1 
Test for trend 
2 
Multivariable model included age, sex, ethnicity, recruitment site, birth order in full-siblings and education level (model 1) or number of full-siblings (model 2). 
3 
Multivariable model included age, sex, ethnicity, recruitment site, birth order in siblings (full + half) and education level (model 1) or number of siblings (full + 
half) (model 2). 
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5.5. Discussion 
There was no statistically significant association between birth order and risk of HCC and 
cirrhosis in people with chronic HBV infection. However, the study found that first child in the 
family tended to have the highest risk of developing cirrhosis or HCC whilst later-born children 
had a lower degree of risk. 
 
Of six studies of birth order that were included in the systematic review (Chapter 3), two from 
Greece
187,194
 found that HBV-related HCC cases have higher birth orders than HBsAg-positive 
non-HCC controls while four from China and Taiwan found that lower birth order was 
associated with HCC
253–255
 or positive HBeAg.
252
 This heterogeneity in the direction of 
association was explained by the geographical difference in the main mode of HBV 
transmission between East Asia and Southern Europe (Chapter 2 & 3). In SSA, the major mode 
of HBV transmission and subsequent natural history of chronic HBV infection is similar to 
Mediterranean countries.
71
 However, the current study did not reproduce the association 
observed in Greece.  
 
There are several explanations for such a discrepancy. First, mother-to-infant transmission 
might be more common in SSA than in Greece. Indeed, the prevalence of HBeAg among 
HBsAg-positive women of child-bearing age was slightly higher in The Gambia 
(6.8-13.7%)
55,60,114
 than in Greece (2.7%).
270
 Second, the positive association observed in the 
Greek data might be due to differential study participation, as demonstrated by Grulich et al. in 
their pooled analysis of data from 14 case-control studies of birth order and risk of non-Hodgkin 
lymphoma (NHL).
208
 The analysis revealed that statistically significant positive associations 
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between birth order and NHL were confined to studies which have lower response rates.
208
 
Because higher SES is related with smaller family size and thus lower birth order,
207
 and people 
in higher SES are more likely to participate in a study,
271
 there would be a significant excess of 
individuals with low birth order among participants than non-participants. Since response rates 
are generally higher in cases than in controls,
208
 the differential participation between cases and 
controls according to SES and birth order would eventually lead to a false conclusion that 
having more elder siblings is a risk of the disease. Unfortunately there is no information on the 
participation rate in the current study or the Greek studies.  
 
The study has several limitations. First, the sample size was small. Second, the birth order 
question in the current study was designed to quantify the probability of early horizontal 
transmission from older siblings rather than the probability of perinatal maternal transmission. 
Exclusion of miscarriages and stillbirths and counting twins and triplets independently might 
have contributed to the lack of significant association between birth order and HCC. Third, 
using hospital-controls may not be ideal,
208
 as birth order has been suggested to be associated 
with many other morbidity and mortality,
191
 such as other cancers,
189
 allergic conditions,
190
 and 
cardiovascular risk factors.
188
  
 
Although the association was not statistically significant, the direction of the association is 
consistent with the findings from the HBeAg Study (Chapter 4). Together these studies suggest 
that mother-to-infant transmission might play a role in the persistence of viral replication and 
liver diseases in The Gambia. This needs to be further confirmed with a population-based 
case-control study of HCC or a longitudinal cohort study of people with chronic HBV infection. 
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5.6. Summary 
The association between early age at HBV infection and liver cirrhosis and HCC was assessed 
using birth order as a proxy for the age at infection. Before the analysis a positive association 
between birth order and liver diseases was hypothesised, because most transmission in The 
Gambia occurs between siblings during childhood. Contrary to the hypothesis, the analysis 
showed that first birth order had the highest risk for HCC and liver cirrhosis, although the 
association was not statistically significant. This suggests that birth order might be a surrogate 
for maternal age at delivery. 
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Chapter 6. The natural history of chronic 
hepatitis B infection in The Gambia, West Africa: 
a longitudinal population-based study of chronic 
carriers in three rural villages 
 
 
6.1. Abstract 
Background 
The natural history of chronic hepatitis B (CHB) infection in sub-Saharan Africa (sSA) is 
poorly documented. In particular the effect of perinatal maternal transmission of hepatitis B 
virus (HBV) on progression of liver disease after establishing the chronic infection is unknown. 
An open cohort study of treatment-naïve people with CHB infection in The Gambia, was used 
to estimate the rates of hepatitis B e (HBeAg) and surface antigen (HBsAg) clearance, incidence 
of hepatocellular carcinoma (HCC), overall mortality and prevalence of active CHB disease, 
significant liver fibrosis and condition meeting the international treatment criteria for CHB 
infection. The association of maternal HBsAg, a proxy for perinatal mother-to-infant 
transmission with these outcomes was also examined. 
Methods 
Since 1973, HBV sero-surveys have been conducted every 4-5 years in three villages in the 
West Kiang District in The Gambia. In 2012-2013, as part of the PROLIFICA (Prevention of 
Liver Fibrosis and Cancer in Africa) project, we invited the cohort of chronic HBV carriers for a 
comprehensive liver assessment. CHB infection was defined as a serum HBsAg positivity on 
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two occasions at least 6 months apart for the people aged less than 10 years and HBsAg 
positivity at least once for those over 10 years old. 
Results 
414 chronic carriers were recruited. The median length of follow-up was 28 years (range: 4-39) 
and the median number of sero-surveys participated in was six (range: 2-10). The HBeAg and 
HBsAg seroclerance rate was 7.3% (95%CI: 6.1-8.7%) and 1.3% (1.1-1.6%) per annum, 
respectively. Six subjects died of HCC, which implies an HCC incidence of 54.9/100,000 
carrier-years. In 2012-13, 264 individuals with CHB infection were assessed (41% male, 
median age 37 years, range 11-78 years). The prevalence of significant liver fibrosis (≥7.5 kPa 
by transient elastography) was 10% (95%CI: 6-14%), and 5% (95%CI: 2-8%) met the EASL 
(European Association for the Study of the Liver) treatment criteria. Having an HBsAg-positive 
mother was significantly associated with delayed HBeAg sero-clearance, higher viral load and 
ALT levels over time, active CHB disease, advanced liver fibrosis and meeting the EASL 
criteria. It was estimated that 71.4% (95% CI: 6.3-91.3%) of chronic carriers requiring antiviral 
therapy were attributable to perinatal mother-to-infant transmission. 
Conclusion 
Positive maternal HBsAg was associated with an increased risk of liver fibrosis through 
persistent viral replication and frequent hepatitis flare. Interventions to prevent perinatal 
maternal transmission, such as a dose of hepatitis B vaccination within 24 hours of birth, could 
have a substantial impact on the burden of complications associated with CHB infection in 
sub-Saharan Africa.  
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6.2. Introduction 
In sub-Saharan Africa (sSA), prevalence of hepatitis B virus (HBV) infection in adults is still 
high and exceeds 8% in many countries.
2
 Hepatocellular carcinoma (HCC) is ranked the second 
and third most common malignancy in African men and women, respectively, 
5
 and more than 
half of HCC cases are attributable to chronic HBV (CHB) infection.
169
 Hepatitis B vaccine is 
highly effective in preventing CHB infection. It has been included in the national immunisation 
programmes in all African countries, with vaccine coverage ranging between 58% and 99%.
272
 
However, the vaccine is limited as a control measure. First, a large number of people who 
acquired the infection prior to the implementation of the vaccination programme are left with 
CHB infection.
273
 Theses individuals will continue to be at high risk of developing cirrhosis and 
HCC.
274
   
 
Second, hepatitis B vaccine does not always prevent mother-to-infant transmission,
238,126
 
especially when the vaccine was not given at birth.
121
 In Asia where mother-to-infant 
transmission is common, HBV vaccine is frequently given within 24 hours of delivery to 
interrupt perinatal transmission.
265,266
 In sSA, however, HBV vaccination usually occurs later 
because logistical challenges outweigh the potential impact on chronic HBV infection due to the 
relatively low frequency of mother-to-infant transmission.
267
 It is well known that early age at 
HBV infection increases the risk of chronic infection.
69
 Moreover, a systematic review (Chapter 
3) suggests that mother-to-infant transmission, or early age at HBV infection, may further 
increase the risk of HCC and its predictors beyond its effect of increasing the risk of CHB 
infection.
261
 However, this association has not been studied in Africa. 
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The Gambia is a small country in West Africa. The prevalence of HBV infection in adults is 
high (>8%),
275
 with horizontal transmission during childhood being the major mode of spread,
60
 
and HCC is the most frequent cancer.
276
 Community-based surveys of HBV sero-markers have 
been regularly conducted in Keneba and Manduar, two villages in rural Gambia, since 1973. A 
pilot hepatitis B vaccination programme started in 1984, and sero-surveys were undertaken 
between 1984 and 2008, primarily to measure vaccine efficacy. A cohort of chronic carriers was 
followed in parallel during this period. The PROLIFICA (Prevention of Liver Fibrosis and 
Cancer in Africa) project started in The Gambia in 2011; it is the first community-based HBV 
treatment programme in sSA. As part of this project, we invited the chronic carriers in the 
Keneba and Manduar cohort for a comprehensive liver assessment between 2012 and 2013.  
 
The objectives of this study are to determine: i) the sero-clearance rate of HBeAg and HBsAg, ii) 
the incidence of HCC and end-stage liver disease (ESLD), iii) the overall mortality rate, iv) the 
prevalence of active CHB disease, significant liver fibrosis and conditions that meet the 
international antiviral treatment criteria, and v) whether these outcomes are associated with 
maternal HBsAg, a proxy marker for perinatal mother-to-infant transmission. The hypothesis is 
that in addition to increasing the risk of chronic infection (which is already well known), 
perinatal maternal transmission increases the risk of active CHB disease, progression of liver 
fibrosis and the risk of requiring antiviral treatment, through persistence of HBeAg, prolonged 
HBV viraemia and high frequency of alanine transaminase (ALT) flares (figure 6.1). The 
analyses were restricted to a comparison of chronic HBV carriers believed to be due to perinatal 
infection (i.e., those with HBsAg-positive mother) to chronic carriers believed to be due to 
horizontal infection (i.e., those with HBsAg-negative mother), in order to remove the effect of 
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perinatal transmission on chronic infection. To demonstrate that changes in HBeAg, HBV DNA 
and ALT mediate the effect of perinatal transmission on disease outcomes (i.e., active CHB 
disease, degree of liver fibrosis and condition requiring the antiviral therapy), the association of 
maternal HBsAg with these intermediate variables and the associations between the 
intermediate variables and the disease outcomes were evaluated. The proportion of chronic 
carriers requiring antiviral therapy due to perinatal transmission was estimated to quantify the 
impact of this mode of transmission on disease outcome. 
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Figure 6.1 Hypothetical causal pathway between perinatal maternal transmission of HBV and increased risk of advanced liver fibrosis and condition meeting the 
international antiviral treatment criteria 
 
Exposure of interest:  
- Maternal HBsAg 
(proxy marker for 
perinatal mother-to-infant 
transmission of HBV) 
Intermediate variables 
measured at baseline: 
- Presence of HBeAg 
- HBV DNA levels 
- ALT levels 
Longitudinal changes in 
intermediate variables: 
- HBeAg (seroclerance rate) 
- HBV DNA levels 
- ALT levels 
Outcomes measured at the 
2012-13 liver assessment: 
- Active chronic hepatitis B 
disease 
- Degree of liver fibrosis 
- Condition meeting the 
EASL treatment criteria 
Confounding factors: 
- Sex 
- Current age 
- Calendar year 
- Hepatitis B vaccination 
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6.3. Methods 
6.3.1. Study participants in historical open cohort  
Keneba and Manduar are small villages located 8 km apart in the West Kiang District (figure 
6.2). The combined population of the villages has increased from 1,099 in 1973 to 2,421 in 
2013 (Tony Fulford, unpublished data). The inhabitants predominantly belong to the Madinka 
tribe and about half were under the age of 15 years in 1980.
42
 The first sero-survey was 
undertaken in 1973 and 174 (13.2%) of 1,317 villagers had HBsAg.
277
 Since 1980, the 
community-based HBV sero-surveys were conducted every 4-5 years (1980, 1984-1985, 1989, 
1992-1993, 1998, 2003, and 2008).
42,60,115,238,278–280 
In 1980, all children under the age of 15 
years in the study villages and their mothers were asked to participate in the second 
sero-survey.
42
 This included 67 of the 174 HBsAg-positive individuals in 1973 survey, and 109 
persons who were newly identified as HBsAg positive (table 6.1). In 1984, all children aged 
<20 years in these villages were invited to participate in the third sero-survey; 191/936 (20.4%) 
were found to carry the virus and 147 were newly identified as HBsAg positive.
60
 This survey 
was immediately followed by a vaccine trial. All non-immune children under 5 years in these 
villages were randomly allocated to one of the following three regimens of plasma derived 
hepatitis B vaccine: three intradermal doses of 2 μg at two-month intervals; 20 μg intramuscular 
dose followed by two intradermal doses of 2 μg at two-month intervals; and three intramuscular 
doses of 20 μg at 2-month intervals.115 Subsequently, routine infant vaccination began. Since 
this vaccine trial, sero-surveys were undertaken primarily to measure the vaccine efficacy. In 
parallel, the serological markers (HBsAg and HBeAg) of people with positive HBsAg in 
Keneba and Manduar were also regularly assessed every 4-5 years (table 6.1 and figure 6.3). 
Since 2003, the study expanded to include Kantong Kunda, another village adjacent to Keneba. 
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Participation in the surveys was generally high, especially in small children. Between 1980 and 
1998, attendance ranged from 92-94% in children aged 0-4 years, to 50-73% in those aged 
10-14 and 81-85% in those aged 15-19. 
 
 
Figure 6.2. Map of The Gambia showing Keneba and Manduar 
 
 
 
 
  
 
 
  
 
 
  
 
  
   
  
   
 
 
 
 
 
  
   
 
 
 
 
  
 
 
Western Region 
Lower River Region 
North Bank Region 
Central River Region 
Upper River Region 
Kanifing 
Keneba 
Manduar 
Fajar
a 
Banjul 
 165 
 
Table 6.1 Number of participants, number who tested HBsAg-positive (number of newly identified HBsAg-positive and number who were already found 
HBsAg-positive and who were followed-up) and type of laboratory tests at each sero-survey 
Year Villages Target 
populatio
n 
Total 
teste
d 
HBsAg(+) 
(a) 
Tested HBsAg-positive at least once Laboratory tests performed 
Newly 
identified 
(b) 
Already in 
cohort who 
tested 
positive (c) 
Already in 
cohort who 
tested 
HBsAg 
negative (d) 
Number of 
HBsAg(+) 
who did not 
return to a 
current 
survey (%) 
(e) 
Total 
cumulati
ve 
number 
(f) 
HBsAg HBeAg HBV 
DNA 
ALT 
1973 K & M All 1317 174 
(13.2%) 
136
1 
- - - 136 RIA - - - 
1980 K & M Children 
<15 yo & 
mothers 
790 144 
(18.2%) 
109 35 32 69 (28.2%) 245 RPHA RIA - - 
1984 K & M Children 936 191 147 44 55 146 392 RPHA RIA q-PCR Cobas 
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<20 yo (20.4%) (37.2%) Mira 
1985 K & M Vaccinate
d children 
221 5 (2.3%) 3 2 5 385 
(97.5%) 
395 RPHA RIA - - 
1989 K & M Children 
<20 yo & 
mothers 
1356 217 
(16.0%) 
49 168 98 129 
(29.1%) 
444 RPHA RIA q-PCR - 
1992 K & M Carriers 271 187 
(69.0%) 
1 186 84 174 
(39.1%) 
445 RPHA RIA Dot-blot 
Hybridis
ation 
Cobas 
Mira 
1993 K & M Children 
<20 yo & 
mothers 
1478 132 (8.9%) 27 105 71 269 
(57.0%) 
472 RPHA RIA q-PCR - 
1998 K & M Carriers 
& 
vaccinees 
1343 126 (9.3%) 11 115 56 301 
(62.3%) 
483 RPHA RIA - - 
2003 K, M & All 1637 251 63 188 103 192 546 IC EIA q-PCR - 
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KK (15.3%) (35.2%) 
2008 K, M & 
KK 
Carriers 
& 
vaccinees 
2056 213 
(10.4%) 
3 210 110 226 
(41.2%) 
549 IC EIA q-PCR Vitros 
DT60-II 
2012
-13 
K, M & 
KK 
Carriers 284 247 
(87.0%) 
0 247 37 265 
(48.3%) 
549 IC EIA q-PCR Vitros 
350 
Abbreviations: K, Keneba; M, Manduar; KK, Kantong Kunda; RIA, radioimmunoassay; RPHA, reverse passive haemagglutination assay; PCR, polymerase chain 
reaction; IC, immunochromatography; EIA, enzyme immunoassay. 
Total number of participants tested positive for HBsAg (a) is a sum of newly identified HBsAg-positive (b) and participants who were already in the cohort and who 
tested positive (c). Total cumulative number of people ever tested positive (f) in a previous survey equals to a sum of people already in the cohort and tested positive 
in the current survey (c), people in the cohort and tested negative in the current survey (d), and people in the cohort but lost in the current survey (e). Total 
cumulative number of people ever tested positive (f) in the current survey equals to a sum of (b), (c), (d) and (e) in the corresponding survey. 
1
 Thirty-eight records are missing. 
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Figure 6.3 Flow diagram of study participants 
Tested positive for HBsAg at least once 
between 1973 and 2008 (n=549) 
Serological follow-up after the first test 
(n=515) 
Follow-up was never made (n=34) 
Chronic HBV carriers (n=414), number 
of follow-up visits was as follows: 
 2 (37, 9%) 
 3 (73, 18%) 
 4 (46, 11%) 
 5 (49, 12%) 
 6 (59, 14%) 
 7 (48, 12%) 
 8 (59, 14%) 
 9 (31, 7%) 
 10 (12, 3%) 
Of whom, 258 (62.3%) individuals have 
maternal HBV results. 
Not chronic HBV infection (children <10 
years old who tested positive only once and 
subsequently lost HBsAg, n=101) 
Participated in the liver assessment in 
2012-2013 (n=264, 63.8%) 
Of whom, 169 (64.0%) individuals have 
maternal HBV results. 
Died (n=44) 
Migrated to other countries (n=19) 
Untraceable (n=4) 
Refusal (n=83) 
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6.3.2. Follow-up liver assessment in 2012-13 
CHB infection was defined as serum HBsAg positivity on two occasions at least 6 months apart. 
However, in the pre-vaccination era, more than 80% of children in Keneba and Manduar 
acquired the infection (indicated by positive anti-HBc) by the age of 10 years, suggesting that 
new HBV infections in adults were uncommon.
60
 Thus, for those over 10 years old, HBsAg 
positivity on only one occasion was considered sufficient to reflect chronic infection.  
 
Between 1973 and 2008, 549 people tested positive for HBsAg at least once. There were no 
cases of HCC at enrolment into the cohort. After excluding 34 people who did not participate in 
further follow-up sero-surveys, and 101 children <10 years who only tested positive once and 
who were negative in their subsequent surveys, there were 414 people with CHB infection 
(figure 6.3). The chronic carriers were invited for a liver assessment as part of the PROLIFICA 
project in 2012-2013. A team of fieldworkers and I met the head of each village (Keneba, 
Manduar and Kantong Kunda) and explained the purpose of the follow-up study in April 2012. 
This was followed by a meeting with villagers. After community approval, trained fieldworkers 
identified eligible persons by verifying their name, date of birth, birth place and the names of 
their parents. Eligible individuals were asked to participate in a liver assessment at the clinic. 
The study was conducted in two phases. In May 2012, a team of fieldworkers, nurses, 
laboratory technicians and hepatologists organised a specialist liver clinic at Medical Research 
Council (MRC) Keneba Field Station to assess the severity of the liver disease for persons with 
CHB infection resident in the study villages (phase 1). Those who had migrated from the study 
villages to another part of The Gambia were invited to the liver clinic at MRC Fajara, close to 
the capital Banjul, from June 2012 to December 2013 (phase 2). After written consent, the 
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participants underwent a structured interview, and a standardised clinical examination which 
included abdominal ultrasound and collection of a blood and urine sample. Liver stiffness 
measurement (LSM) was performed using transient elastography (Fibroscan FS402, Echosens, 
France) following the manufacturer’s instructions.104 As food intake increases the frequency of 
unreliable measurements by transient elastography and overestimates the liver stiffness, 
participants were asked not to have breakfast on the day of liver assessment.
281
 After the first 
liver assessment, those who met any of the study criteria: HBV DNA levels ≥2,000 IU/ml, LSM 
≥6.5 kPa or serum alanine transaminase (ALT) ≥40 IU/L, were invited for ultrasound-guided 
percutaneous liver biopsy. Liver fibrosis was scored according to the Metavir system
282
 by one 
liver pathologist in The Gambia and another in UK. The study was approved by the Gambia 
Government/MRC Joint Ethics Committee. 
 
6.3.3. Laboratory assays 
HBsAg was detected by radioimmunoassay (RIA) (Ausria I, Abbott, USA) in 1973 survey,
42
 
reverse passive haemagglutination assay (RPHA) (Wellcotest, Wellcome Diagnostics, UK) 
from 1980 to 1998,
278
 and immunochromatography (IC) (Determine, Abbott, USA) from 2003 
to 2013.
185
 When the samples were positive using RPHA, the test was repeated after 
neutralisation with rabbit anti-HBs. The manufacturer of Determine HBsAg changed to 
Inverness, UK (currently Alere) in 2005. Samples positive for HBsAg were tested for HBeAg 
by RIA (Sorin Biochemica, Italy) from 1980 to 1998
278
 and later by enzyme immunoassay (EIA) 
(Diasorin, Biomedica, Italy).
185
 A good correlation was observed among the IC, RIA and RPHA 
for HBsAg detection, and between the EIA and RIA for HBeAg.
185
 HBV DNA levels were 
measured by dot-blot hybridisation with a phosphorus-32 label (detection limit of 3 x 10
6 
IU/ml) 
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for samples collected in 1992
283
 and quantitative real-time polymerase chain reaction (q-PCR) 
(detection limit of 5 x 10 IU/ml)
284
 for those collected in 1984, 1989, 1993, 2003 and 2008. In 
2013, we used another in-house q-PCR. These assays for viral load measurement were 
calibrated against an international HBV DNA standard
284
 and thus should be correlated with 
each other. Serum transaminases were measured by Cobas Mira Autoanalyser (Roche, 
Switzerland) in 1984 and 1992, by Vitros DT60-II analyser (Johnson & Johnson, USA) in 2008 
and by Vitros 350 analyser in 2013. The tests used are summarised in table 6.1. In addition, we 
tested samples collected in 2012 and 2013 for alpha-fetoprotein and other co-infection 
(anti-HCV (hepatitis C virus), anti-HDV (hepatitis D virus) and anti-HIV (human 
immunodeficiency virus)) (see details in Chapter 7). 
 
6.3.4. Ascertainment of hepatocellular carcinoma (HCC), end-stage liver disease (ESLD) and 
death 
New cases of HCC were identified either through a follow-up examination, by reviewing the 
medical records in the Keneba MRC Clinic, or by data linkage with the Gambia National 
Cancer Registry. The diagnosis was based on the identification of a focal hepatic lesion 
consistent with HCC on the ultrasound and elevated serum alpha-fetoprotein. ESLD includes 
HCC and non-malignant ESLD; the latter was defined as a clinical diagnosis of liver cirrhosis 
without HCC and the presence of one of the following: ascites, hepatic encephalopathy, or 
haematemesis. Non-malignant ESLD was ascertained through a follow-up examination or a 
review of the medical records in Keneba Clinic. The vital status of study participants was 
determined by fieldworkers, and the date of death was ascertained through a review of medical 
 172 
 
chart in Keneba or data linkage with the West Kiang Demographic Surveillance System (DSS). 
When the linkage was unsuccessful, the date reported by a family member was used. 
 
6.3.5. Statistical analyses 
6.3.5.1. HBeAg and HBsAg Sero-clearance 
The person-years of follow-up for HBeAg or HBsAg loss were calculated from the date they 
were identified as HBsAg-positive test to the date of sero-clearance or the date of last follow-up 
sero-survey, whichever came first. Some individuals were initially HBsAg-negative. For these 
individuals the date they became HBsAg-positive was assumed to be the midpoint between their 
last HBsAg-negative and their first HBsAg-positive sample. The date of sero-clearance was 
defined as the midpoint between the last positive HBsAg test and the first negative result. 
Incidence rates were calculated by dividing the number of events by person-years, and are 
presented stratified by sex. The cumulative incidence was estimated as a function of age using 
the Kaplan-Meier Method. Age was used rather than time since entry into the study because 
most infections occur perinatally, or during early childhood, and therefore age approximates the 
duration of HBV infection.
83
 Poisson regression models were used to estimate the effect of 
having an HBsAg-positive mother on sero-clearance. The analysis used maternal HBsAg status 
as recorded at the survey in which a child entered the study. The association of maternal HBsAg 
was adjusted for current age, calendar year, sex and HBV vaccine (figure 6.1). To account for 
clustering in children that share the same mother, p-values and confidence intervals were based 
on robust standard errors. The association of HBeAg, HBV DNA (<2,000, 2,000-10
8
 and ≥108 
IU/ml) and ALT levels (<40 or ≥40 IU/L) measured at baseline with subsequent sero-clearance 
was also assessed; the multivariable models included current age, calendar year, sex, HBV 
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vaccine and maternal HBsAg in addition to HBeAg, HBV DNA and ALT levels at baseline. 
Baseline refers to when a participant had the first positive result for HBsAg. When HBV DNA 
or ALT was unavailable at the baseline survey, the value recorded in the subsequent survey was 
taken. Baseline HBeAg was not included in the analysis when the outcome was HBeAg 
sero-clearance. 
 
6.3.5.2. Incidence of HCC, ESLD and death 
The person-years for HCC, ESLD or death were calculated from the date when individuals were 
identified as HBsAg-positive to the date of endpoint (HCC or ESLD diagnosis or death) or the 
date of last contact, whichever was earliest. The incidence of HCC and mortality are 
approximately equivalent because all HCC patients died within one year after the diagnosis. As 
the number of the event was small, the association between maternal HBsAg and HCC, ESLD 
and death was examined using Fisher’s exact test and results from multivariate models are not 
presented. 
 
6.3.5.3. Longitudinal change in viral load and ALT 
HBV viral load and ALT levels were treated as continuous variables, and the former was log10 
transformed. The detection limit of the quantitative HBV DNA assay was assigned to samples 
with undetectable viral load. Locally weighted regression (LOWESS) was used to present the 
trajectories of HBV DNA levels and ALT levels over time by maternal sero-status. The 
association of maternal HBsAg status with HBV DNA and ALT was quantified using 
generalised estimating equations, with an autoregressive correlation structure to account for the 
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multiple measurements made on the same individuals over time. The associations were adjusted 
for current age, calendar year, sex and HBV vaccine.  
 
6.3.5.4. Liver fibrosis and condition meeting the international treatment criteria 
The 2012-2013 liver assessment was used to determine the phase of the natural history of CHB 
infection, degree of liver fibrosis and whether individuals required antiviral therapy according to 
the EASL (European Association of the Study of the Liver) criteria.
70
 The proportion of 
participants in each phase of the natural history was described based on the definitions presented 
in table 6.2. Significant liver fibrosis was defined as a LSM ≥7.5 kPa by transient elastography 
based on a recent validation study in The Gambia which demonstrated that this cut-off 
distinguished significant liver fibrosis (≥F2 with Metavir) from no or mild fibrosis (sensitivity 
88.1% and specificity 80.3% ) (Lemoine et al., unpublished data). The EASL criteria for 
antiviral therapy are: i) HBV viral load ≥2,000 IU/ml and significant liver fibrosis (LSM ≥7.5 
kPa or ≥F2 by Metavir fibrosis score), or ii) viral load ≥2,000 IU/ml and moderate/severe active 
necroinflammation (≥A2 by Metavir activity grade), or iii) viral load ≥20,000 IU/ml and serum 
ALT ≥80 IU/L or iv) detectable serum viral load and cirrhosis (LSM ≥9.0 kPa or F4 by Metavir 
fibrosis score). The effect of maternal HBsAg on diseases (active CHB diseases including both 
HBeAg-positive and –negative CHB disease, significant liver fibrosis, and requiring antiviral 
therapy) was estimated using logistic regression to control for age, sex and HBV vaccination. 
The effect of persistent HBeAg, frequent high HBV DNA and ALT levels on diseases was also 
assessed controlling for current age, sex, HBV vaccination and maternal HBsAg. The categories 
for “persistence of HBeAg” were: 1) negative HBeAg at baseline, 2) HBeAg sero-clearance 
during the follow-up, and 3) HBeAg positive at the last follow-up. High viral load (≥2,000 
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IU/ml) and elevated ALT (≥40 IU/L) were only examined in participants who had at least two 
results available, and they were categorised as: 1) never, 2) <50% of visits, and 3) ≥50% of 
visits.
139
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Table 6.2 Phases of the natural history of CHB infection (adapted from EASL/AASLD 
guidelines)
70,7  
Phase HBsAg HBeAg HBV DNA 
(IU/ml) 
ALT (U/L) 
Immune tolerant phase Positive Positive ≥20,000 <40 
Chronic 
hepatitis B 
disease 
HBeAg-positive 
chronic hepatitis B 
Positive Positive Any ≥40 
HBeAg-negative 
chronic hepatitis B 
Positive Negative ≥2,000 ≥40 
Inactive HBV carrier state Positive Negative <2,000 <40 
Occult HBV infection Negative Negative Detectable Any 
Resolved hepatitis B Negative Negative Undetectable <40 
Unclassified HBeAg-positive Positive Positive <20,000 <40 
HBeAg-negative Positive Negative ≥2,000 <40 
<2,000 ≥40 
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6.3.5.5. Population attributable fraction for perinatal maternal transmission 
As discussed in the Chapter 1, in The Gambia preventive measures that may eliminate the risk 
of perinatal maternal HBV transmission (e.g., timely birth dose of hepatitis B vaccine within 24 
hours of birth, provision of hepatitis B immunoglobulin, or treating pregnant women with 
antiviral therapy) have not been well implemented. Therefore, it is important to estimate the 
proportion of high-risk chronic HBV carriers in the total population that would be avoided if the 
risk of perinatal maternal transmission was removed. Here, the proportion of chronic carriers 
requiring antiviral treatment (based on EASL criteria) due to mother-to-infant transmission was 
estimated using the formula for the population attributable fraction (PAF):
285
  
 
PAF = pc (OR – 1) / OR, 
 
where pc is the proportion of cases whose mothers were HBsAg-positive, and OR is the odds 
ratio for the effect of maternal HBsAg status on liver disease (needing treatment based on the 
EASL criteria) adjusted for current age and sex. This analysis included all the survey 
participants in Keneba and Manduar between 1973 and 2008 with available maternal HBsAg 
status. It was not restricted to chronic carriers in order to consider the whole effect of perinatal 
transmission: both the increased risk of chronic infection and the increased risk of liver disease 
progression in those who have established chronic infection. Ideally, the PAF should be derived 
from people who received hepatitis B vaccine as most of children are now immunised against 
HBV in The Gambia. However, the analysis included both vaccinees and non-vaccinees because 
there were few cases that required antiviral treatment in the vaccinated group. All analyses were 
conducted using STATA 11.0 (Stata Corporation, College Station, Texas). 
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6.4. Results 
6.4.1. Baseline characteristics 
Table 6.3 shows the baseline characteristics of 414 individuals with CHB infection. Half were 
men and 261 (63%) were children <15 years at baseline. Most were residents of Keneba or 
Manduar. Thirty chronic HBV carriers had been vaccinated for hepatitis B: four were 
vaccinated after HBsAg-positivity was confirmed, six were HBsAg-negative when the vaccine 
was given but subsequently became positive for HBsAg (vaccine failure), and the timing of 
infection in relation to vaccination was unknown in 20. About half of the participants were 
HBeAg-positive at baseline and viral load exceeded 2,000 IU/ml in 43%. Abnormal ALT was 
seen only in 6%. There were no data for maternal HBV sero-status in 156 participants, and the 
exact reasons for this are unknown. However, because the participants without maternal 
sero-status tend to be older at the study entry than those with maternal sero-status (table 6.3), it 
is possible that their mothers have already died before these children’s study entry. This might 
be a source of bias as mortality may be higher in HBV-positive than HBV-negative mothers. Of 
258 participants with available maternal HBV sero-status, mothers of 175 (68%) were 
HBsAg-negative, 63 (24%) were HBsAg-positive and HBeAg-negative, and 20 (8%) were 
HBsAg-positive and HBeAg-positive at enrolment. There was no difference in the distribution 
of sex and age between those with HBsAg-positive and –negative mothers. However, children 
of HBsAg-positive mothers were more likely to live in Manduar or Kantong Kunda (p=0.05). 
The proportion of carrier children who had received vaccine was significantly higher in those 
with HBsAg-positive mothers (17% vs. 5%, p=0.005). Children of positive mothers tended to 
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carry HBeAg more often (69% vs. 60%) and were more likely to have a viral load exceeding 
2,000 IU/ml (68% vs. 54%), but neither of these differences was statistically significant. The 
proportion with abnormal ALT levels was higher in children with carrier mothers (10% vs. 3%, 
p=0.04). The amount of follow-up was similar in the two groups. 
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Table 6.3 Baseline characteristics of people with chronic HBV infection by maternal HBsAg 
status (N=414) 
 All 
(N=414) 
Unknown 
maternal 
sero-status 
(n=156) 
With 
HBsAg(+) 
mother 
(n=83) 
With 
HBsAg(-) 
mother 
(n=175) 
p-value
1 
 
 
 
Sex     1.0 
  Male 205 (50%) 62 (40%) 46 (55%) 97 (55%)  
  Female 209 (50%) 94 (60%) 37 (45%) 78 (45%)  
Age group     0.9
2 
  <5 108 (26%) 4 (3%) 39 (47%) 65 (37%)  
  5 – 9 82 (20%) 8 (5%) 20 (24%) 54 (31%)  
  10 – 14 71 (17%) 24 (15%) 9 (11%) 38 (22%)  
  15 – 19 38 (9%) 22 (14%) 5 (6%) 11 (6%)  
  ≥20 115 (28%) 98 (63%) 10 (12%) 7 (4%)  
Birth place     0.05 
  Keneba 199 (48%) 75 (48%) 33 (40%) 91 (52%)  
  Manduar 177 (43%) 50 (32%) 44 (53%) 83 (47%)  
  Kantong Kunda 38 (9%) 31 (20%) 6 (7%) 1 (1%)  
Maternal sero-status      
  HBsAg(-) 175 (68%)     
  HBsAg(+) 
HBeAg(-) 
63 (24%)     
  HBsAg(+) 
HBeAg(+) 
20 (8%)     
HBV vaccine     0.005 
  No vaccination 384 (93%) 149 (95%) 69 (83%) 166 (95%)  
  Infected before 
vaccination 
4 (1%) 1 (1%) 0 (0%) 3 (2%)  
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  Infected after 
vaccination 
6 (2%) 0 (0%) 2 (2%) 4 (2%)  
Time of infection 
relative to vaccination 
unknown 
20 (5%) 6 (4%) 12 (15%) 2 (1%)  
HBeAg
 
    0.2 
  Positive 165 (47%) 15 (14%) 51 (69%) 99 (60%)  
  Negative 183 (53%) 93 (86%) 23 (31%) 67 (40%)  
HBV DNA (IU/ml)
 
    0.1
2 
  Undetectable 151 (40%) 93 (66%) 16 (21%) 42 (26%)  
  50-2,000 68 (18%) 26 (18%) 9 (12%) 33 (20%)  
  2,000-10
5 
30 (8%) 9 (6%) 7 (9%) 14 (9%)  
  10
5
-10
8 
58 (15%) 10 (7%) 13 (17%) 35 (21%)  
  ≥108 75 (20%) 4 (3%) 32 (42%) 39 (24%)  
ALT (IU/L)
 
    0.04 
  <40 369 (94%) 137 (93%) 70 (90%) 162 (97%)  
  ≥40 24 (6%) 11 (7%) 8 (10%) 5 (3%)  
Median no. of 
follow-up 
sero-surveys (range) 
6 (2, 10) 4 (2, 8) 6 (2, 10) 7 (2, 10) 0.1
2
  
Median years of 
follow-up (range) 
28.1 (3.9, 
38.9) 
19.0 (3.9, 
38.9) 
28.1 (3.9, 
38.3) 
28.2 (3.9, 
38.9) 
0.1
2 
1
 Comparison was made between participants with HBsAg-positive mothers and 
HBsAg-negative mothers. P-value and 95% CI were obtained by Wald test with robust standard 
error to take account of clustering among individuals who share the same mother. 
2
 Linear test for trend 
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6.4.2. HBeAg sero-clearance 
One hundred and sixty-five individuals were positive for HBeAg at baseline and the mean 
duration of their follow-up was 10.0 years. HBeAg was cleared in 120, and the annual rate of 
clearance was 7.3% (95% CI: 6.1-8.7, table 6.4). Half had cleared HBeAg by 14 years of age 
(figure 6.4). Table 6.5 presents factors associated with HBeAg sero-clearance obtained by 
Poisson regression models. The rate of loss was slowest in children between 0-9 years and 
during the period 1973-92. Having an HBsAg-positive mother was associated with a delayed 
HBeAg loss (figure 6.5 and table 6.5). Higher viral load at baseline was also associated with a 
slower rate of loss, but this was not statistically significant (p=0.09).  
 
6.4.3. HBsAg sero-clearance 
There were 7,880 person-years of follow-up, and the annual rate of HBsAg sero-clearance was 
1.3% (95% CI: 1.1-1.6, table 6.4). Half had cleared HBsAg by 53 years of age (figure 6.4). 
Male sex, younger age and recent period (1993-2013) were associated with delayed HBsAg 
sero-clearance (table 6.6). The rate of sero-clearance was slower in individuals with an 
HBsAg-positive mother, but this was not statistically significant (figure 6.5 and table 6.6). 
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Table 6.4 Rate of HBeAg and HBsAg sero-clearance, incidence of HCC and ESLD and 
all-cause mortality in people with chronic HBV infection by gender 
Event No. of 
subjects 
Person-years 
at risk 
No. of 
events 
Rate 95% CI 
HBeAg clearance 165 1653 120 7.3 / 100  6.1 – 8.7 
  Male 106 1046 74 7.1   5.6 – 8.9 
  Female 59 607 46 7.6   5.7 – 10.1 
HBsAg clearance 414 7880 103 1.3 / 100  1.1 – 1.6 
  Male   205   3687   35   0.9   0.7 – 1.3 
  Female   209   4193   68   1.6   1.3 – 2.1 
HCC 414 10925 6 54.9 / 100,000  24.7 – 122.3 
  Male 205 5141 6 116.7 52.4 – 259.8 
  Female 209 5784 0 0.0 N/A 
ESLD (including HCC) 414 10925 8 73.2 / 100,000 36.6 – 146.4 
  Male 205 5141   7   136.2   64.9 – 285.6 
  Female 209 5784   1   17.3   2.4 – 122.7 
All-cause mortality 414 10925 44 402.8 / 100,000  299.7 – 541.2 
  Male 205 5141   25   486.3   328.6 – 719.7 
  Female 209 5784   19   328.5   209.5 – 515.0 
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Figure 6.4 Proportion of participants with CHB infection who cleared HBeAg and HBsAg as a 
function of age 
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Figure 6.5 Proportion of participants with CHB infection who cleared HBeAg and HBsAg as a 
function of age according to maternal HBsAg positivity 
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Table 6.5 Factors associated with HBeAg sero-clearance (n=165) 
Variables Person-years at risk No. of subjects 
cleared HBeAg 
Rate (% per 
annum) 
Crude RR (95% CI) p-value
1 
Adjusted RR (95% 
CI)
 
p-value
1 
Sex Male 1046 74 7.1 1.0 (ref) 0.7  
 
Female 607 46 7.6 1.1 (0.8 – 1.5)    
Current age 0-9 628 32 5.1 1.0 (ref) 0.03
2 
 
 
10-19 687 59 8.6 1.7 (1.1 – 2.6)    
≥20 337 29 8.6 1.7 (1.0 – 2.8)    
Calendar year 1973-92 1140 69 6.1 1.0 (ref) 0.01  
 
1993-2013 513 51 9.9 1.6 (1.1 – 2.4)    
Maternal 
HBsAg 
Negative 922 79 8.6 1.0 (ref) 0.03
 
1.0 (ref) 0.04
3 
Positive 566 34 6.0 0.7 (0.5 – 0.9)  0.7 (0.4 – 0.9)  
Hepatitis B 
vaccination 
None 1545 114 7.3 1.0 (ref) 0.6 1.0 (ref) 0.4
3 
Yes 108 7 6.5 0.9 (0.5 – 1.5)  0.8 (0.4 – 1.4)  
HBV DNA 
(IU/ml) at 
-2,000
 
258 22 8.5 1.0 (ref) 0.1
2 
1.0 (ref) 0.09
2,4 
2000-10
8 
546 44 8.1 0.9 (0.6 – 1.4)  0.9 (0.5 – 1.4)  
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baseline ≥108 785 51 6.5 0.8 (0.5 – 1.1)  0.7 (0.4 – 1.1)  
ALT (IU/L) at 
baseline 
<40 1536 115 7.5 1.0 (ref) 0.1 1.0 (ref) 0.3
4 
≥40 79 3 3.8 0.5 (0.2 – 1.2)  0.6 (0.2 – 1.6)  
1
 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same mother. 
2
 Test for linear trend. 
3
 Model included sex, current age, calendar year, maternal HBV status and hepatitis B vaccination. 
4
 Model included sex, current age, calendar year, maternal HBV status, hepatitis B vaccination, HBV DNA and ALT. 
 
 
Table 6.6 Factors associated with HBsAg sero-clearance (n=414) 
Variables Person-years at risk No. of subjects 
cleared HBsAg 
Rate (% per 
annum) 
Crude RR (95% CI) p-value
1 
Adjusted RR (95% 
CI)
 
p-value
1 
Sex Male 3686 35 0.95 1.0 (ref) 0.008  
 
Female 4193 68 1.62 1.7 (1.1 – 2.5)    
Current age 0-9 948 1 0.11 1.0 (ref) <0.0001
3 
 
 
10-19 2188 21 0.96 9.1 (1.3 – 61.8)    
20-29 2153 27 1.25 11.9 (1.6 – 87.0)    
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30-39 1306 16 1.22 11.6 (1.5 – 88.0)    
40-49 750 19 2.53 24.0 (3.2 – 179.4)    
50-70 535 19 3.55 33.7 (4.5 – 252.7)    
Calendar year 1973-92 3457 61 1.76 1.0 (ref) 0.004  
 
1993-2013 4423 42 0.95 0.5 (0.4 – 0.8)    
Maternal 
HBsAg 
Negative 3773 32 0.85 1.0 (ref) 0.3
 
1.0 (ref) 0.1
3 
Positive 1745 9 0.52 0.6 (0.3 – 1.4)  0.5 (0.2 – 1.2)  
Hepatitis B 
vaccination 
None 7493 100 1.33 1.0 (ref) 0.6 1.0 (ref) 0.4
3 
Yes 387 3 0.78 0.6 (0.2 – 1.8)  2.0 (0.4 – 9.5)  
HBeAg at 
baseline 
Negative 3699 40 1.08 1.0 (ref) 0.0004 1.0 0.8
4 
Positive 3742 13 0.35 0.3 (0.2 – 0.6)  0.9 (0.3 – 2.5)  
HBV DNA 
(IU/ml) at 
baseline 
-2,000
 
4105 79 1.92 1.0 (ref) <0.0001
2 
1.0 (ref) 0.4
2,4 
2000-10
8 
1904 10 0.53 0.3 (0.1 – 0.5)  0.9 (0.3 – 3.2)  
≥108 1660 3 0.18 0.1 (0.0 – 0.3)  0.5 (0.1 – 2.6)  
ALT (IU/L) at 
baseline 
<40 7421 95 1.28 1.0 (ref) 0.6 1.0 (ref) 0.5
4 
≥40 303 5 1.65 1.3 (0.5 – 3.4)  2.0 (0.2 – 20.1)  
1
 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same mother. 
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2
 Test for linear trend. 
3
 Model included sex, current age, calendar year, maternal HBV status and hepatitis B vaccination. 
4
 Model included sex, current age, calendar year, maternal HBV status, hepatitis B vaccination, HBeAg, HBV DNA and ALT. 
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6.4.4. HCC, ESLD and death of any cause 
Forty-four people died and the all-cause mortality rate was 402.8/100,000 person-years (95% CI: 
299.7-541.2) (table 6.4). In 25 men who died, HCC was the most common cause (24%), 
followed by bacterial infection (12%) and neurological diseases (12%). In the 19 women who 
died, bacterial infection was the most frequent cause (21%) followed by cardiac diseases (16%) 
(table 6.7). There were two patients with non-malignant ESLD - one male and one female. The 
cause of death was unknown in 32% of the patients. 
 
All patients with HCC and non-malignant ESLD died within one year of diagnosis, and none 
survived to the end of follow-up. Incidence rates (per 100,000 person-years) of HCC and ESLD 
(including HCC and non-malignant ESLD) were 54.9 (95% CI: 24.7-122.3) and 73.2 (95% CI: 
36.6-146.4), respectively (table 6.4). All HCC patients were men aged between 38 and 67 years 
old at diagnosis (table 6.8). One patient with a non-malignant ESLD was a woman who died at 
the age of 19 years. Maternal HBV status was known in three ESLD patients, and all had 
HBsAg-positive mothers. Crude mortality rate according to maternal HBsAg status was as 
follows; all-cause mortality rate (288.9/100,000 person-years (95% CI: 129.8-642.9) in 
individuals with an HBsAg-positive mother versus 203.4/100,000 person-years (109.4-378.0) in 
individuals with an HBsAg-negative mother, p=0.5) and ESLD mortality rate (144.4/100,000 
person-years (95% CI: 46.6-447.8) in those with an HBsAg-positive mother versus 0/100,000 
person-years in those with an HBsAg-negative mother, p<0.001). Two (25%) of ESLD patients 
were HBeAg-negative at baseline. Amongst six ESLD patients who participated in the 1992 
survey, HBV DNA measured by dot-blot hybridisation was undetectable in five and ALT was 
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normal in five patients. HBsAg sero-clearance was confirmed in one patient before the 
diagnosis of ESLD. 
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Table 6.7 Causes of death (n=44) 
 Males (n=25) Females (n=19) Total (n=44) 
HCC 6 (24%) 0 6 (14%) 
Non-malignant ESLD 1 (4%) 1 (5%) 2 (5%) 
Bacterial infection 3 (12%) 4 (21%) 7 (16%) 
Tuberculosis 1 (4%) 2 (11%) 3 (7%) 
AIDS 1 (4%) 1 (5%) 2 (5%) 
Cardiac diseases 2 (8%) 3 (16%) 5 (11%) 
Neurological diseases 3 (12%) 0 3 (7%) 
Other neoplasms 0 2 (11%) 2 (5%) 
Unknown 8 (32%) 6 (32%) 14 (32%) 
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Table 6.8 Characteristics of individuals who died of ESLD (includes HCC and non-malignant ESLD) 
Cause of death Age at 
enrolment 
Age at 
diagnosis 
Sex Birth 
place 
Maternal 
HBsAg 
HBeAg 
at 
baseline 
HBV DNA 
in 1992 
(IU/ml) 
ALT in 
1992 
(IU/L) 
HBsAg loss 
during F/U 
Source of 
diagnosis 
HCC 43 45 M Keneba N/A (-) N/A N/A No KMN & NCR 
HCC 29 67 M Manduar N/A (-) <3 x 10
6 
43 No KMN & NCR 
HCC 23 57 M Manduar N/A (-) <3 x 10
6 
13 No KMN & NCR 
HCC 20 50 M Manduar (+) (-) <3 x 10
6 
10 No KMN 
HCC 21 42 M Manduar (+) (+) 3 x 10
6 
15 No KMN 
HCC 21 38 M Manduar N/A (-) N/A N/A Yes NCR 
Non-malignant ESLD 21 57 M Keneba N/A (-) <3 x 10
6 
6 No KMN 
Non-malignant ESLD 7 19 F Keneba (+) (+) <3 x 10
6 
5 No KMN 
Abbreviations: KMN, Keneba medical notes; NCR, National Cancer Registry. 
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6.4.5. Mean HBV DNA and ALT levels over time 
Table 6.9 and 6.10 present factors associated with elevated HBV DNA levels and ALT levels 
respectively. Both were derived from generalised estimating equations to account for the repeat 
measurements made on the same individuals over time. High viral load was associated with 
male sex, younger age group, recent years (1993-2013), and having an HBsAg-positive mother 
(table 6.9). Mean ALT level was positively associated with older age, recent calendar years 
(1993-2013), and having an HBsAg-positive mother (table 6.10). The trajectories of HBV DNA 
levels and ALT levels over time are presented in figures 6.6 and 6.7. HBVDNA declined with 
increasing age whilst ALT levels increased. The positive maternal HBsAg group was 
consistently higher for both HBV DNA and ALT levels.  
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Table 6.9 Predictors of geometric mean HBV DNA (IU/ml) (n=414) 
Variables Geometric 
mean viral 
load (IU/ml) 
Ratio of geometric mean 
viral load (95% CI)
1 
p-value
1
 
Sex Male 6,310 1.0 (ref) <0.001 
Female 631 0.08 (0.04 – 0.2)  
Current age 0-9 2,511,886 1.0 (ref) <0.001
2 
10-19 6.310 2x10
-3
 (6x10
-4
 – 6x10-3)  
20-29 794 3x10
-4
 (9x10
-5
 – 8x10-4)  
30-39 251 1x10
-4
 (3x10
-5
 – 3x10-4)  
40-49 158 7x10
-5
 (2x10
-5
 – 2x10-4)  
50-70 126 6x10
-5
 (2x10
-5
 – 2x10-4)  
Calendar year 1973-92 7.943 1.0 (ref) <0.001
 
1993-2013 794 0.11 (0.06 – 0.192)  
Maternal HBsAg Negative 2,511 1.0 (ref) 0.005
3
 
Positive 10,000 3.8 (1.5 – 9.9)  
Hepatitis B 
vaccination 
None 1,585 1.0 (ref) 0.3
3 
Yes 10,000 0.3 (0.1 – 2.3)  
1
 Ratio of geometric means, p-value and 95% CI estimated using generalised estimating 
equations with an autoregressive correlation structure to account for dependence of repeated 
measurements within participants 
2
 Test for linear trend. 
3
 Model included sex, current age, calendar year, maternal HBV status and hepatitis B 
vaccination. 
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Table 6.10 Predictors of mean ALT levels (IU/L) (n=414) 
Variables Mean ALT 
(IU/ml) 
Difference (95% CI)
1
 p-value
1
 
Sex Male 20.6  0.2 
Female 18.9 -2.2 (-5.4 – 0.9)  
Current age 0-9 10.8  <0.001
2 
10-19 15.0 3.2 (0.1 – 6.3)  
20-29 24.9 13.2 (7.6 – 18.8)  
30-39 23.5 12.9 (9.4 – 16.4)  
40-49 21.1 9.6 (6.8 – 12.5)  
50-70 21.6 12.9 (5.9 – 19.9)  
Calendar year 1973-92 12.3  <0.001 
1993-2013 25.9 12.9 (9.7 – 16.1)  
Maternal HBsAg Negative 17.4  0.02
3 
Positive 22.9 4.4 (0.7 – 8.1)  
Hepatitis B 
vaccination 
None 19.1  0.2
3 
Yes 28.3 3.2 (-1.3 – 7.8)  
1
 Mean difference, p-value and 95% CI estimated using generalised estimating equations with 
an autoregressive correlation structure to account for dependence of repeated measurements 
within participants 
2
 Test for linear trend. 
3
 Model included sex, current age, calendar year, maternal HBV status and hepatitis B 
vaccination. 
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Figure 6.6 Changes with age in serum HBV DNA levels by maternal HBsAg status using 
samples tested between 1984 and 2013 (n=414), the best fit line was obtained using locally 
weighted regression (LOWESS)  
 
  
2
4
6
8
1
0
0 20 40 60 0 20 40 60
Negative maternal HBsAg Positive maternal HBsAg
H
B
V
 D
N
A
 (
lo
g
1
0
 I
U
/m
l)
age
Changes with age in serum HBV DNA levels by maternal HBsAg
 198 
 
Figure 6.7 Changes with age in serum ALT levels by maternal HBsAg status using samples 
tested between 1984 and 2013 (n=414), line was generated using locally weighted regression 
(LOWESS)
1 
 
 
1 
Two outliers (ALT: 166 and 351 IU/L) in positive maternal HBsAg group are not presented 
in the figure.   
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6.4.6. Liver assessment (2012-13) 
Of 414 people with CHB infection who were identified between 1973 and 2008, 44 died, 19 
migrated to other countries, four were untraceable and 83 refused to participate in the liver 
assessment (figure 6.3). The remaining 264 (63.8%) people were enrolled in the PROLIFICA 
study and had a comprehensive liver assessment in 2012-13. Table 6.11 shows the baseline 
characteristics of attenders and non-attenders. Attenders were more likely to be women, 
originally from Kantong Kunda and HBeAg negative at baseline. 
  
Of 264 chronic carriers who participated in the PROLIFICA, 107 (41%) were male, and the 
median age was 37 years (table 6.12). Twenty-three participants (8%) received hepatitis B 
vaccine. The median duration of follow-up was 32 years (range: 4-39). Only five (2%) have 
ever drunk alcohol, three (1%) were co-infected with HIV and none were positive for anti-HCV 
or anti-HDV. Twenty-three (10%) had ALT ≥40 IU/L and 32 (15%) had a platelet count 
<150,000/microL. Fifty-five (21%) had lost HBsAg by 2012-13. Twenty-eight individuals (12%) 
had viral load ≥2,000 IU/ml. More than half were negative for HBeAg at the baseline survey. 
Amongst 102 participants who were HBeAg-positive at the baseline, 79 (78%) lost HBeAg 
during the follow-up, and 23 (22%) remained HBeAg-positive in 2012-13. Of 217 participants 
whose HBV DNA levels were measured at least twice during the follow-up (median number of 
assays: 3, range: 2-7), 96 (44%) had persistently low viral load (<2,000 IU/ml), 71 (33%) 
exceeded 2,000 IU/ml on less than 50% of visits and 50 (23%) had high viral load at ≥50% of 
visits. Of 235 participants whose ALT was measured at least twice (median: 3, range: 2-4), 197 
(83%) had persistently normal ALT, 13 (6%) had abnormal ALT but on less than <50% of visits 
and 25 (11%) had abnormal ALT at ≥50% of visits. 
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Table 6.12 shows the characteristics of participants in the liver assessment 2012-13 by maternal 
HBsAg. The distributions of age and sex were similar in the two groups. Vaccination was more 
common in people with carrier mothers. Viral load measured in 2012-13 as well as the 
frequency of high viral load measurements and abnormal ALT were significantly higher in 
carriers whose mothers were also HBV carriers.  
 201 
 
Table 6.11 Baseline characteristics of those who attended and those who did not attend the liver 
assessment 2012-13 (n=414) 
 Attenders (n=264) Non-attenders 
(n=150) 
p-value
1 
Sex   <0.001 
  Male 107 (41%) 98 (65%)  
  Female 157 (59%) 52 (35%)  
Age group   0.8
2 
  <5 74 (28%) 34 (23%)  
  5 – 9 52 (20%) 30 (20%)  
  10 – 14 38 (14%) 33 (22%)  
  15 – 19 24 (9%) 11 (9%)  
  ≥20 76 (29%) 39 (26%)  
Birth place   0.003 
  Keneba 123 (46%) 76 (51%)  
  Manduar 105 (40%) 72 (48%)  
  Kantong Kunda 36 (14%) 2 (1%)  
Maternal sero-status   0.1
2
 
  HBsAg(-) 111 (66%) 64 (72%)  
  HBsAg(+) HBeAg(-) 42 (25%) 21 (24%)  
  HBsAg(+) HBeAg(+) 16 (9%) 4 (4%)  
HBV vaccine   0.1 
  None 241 (91%) 143 (95%)  
  Yes 23 (9%) 7 (5%)  
HBeAg
 
  0.02 
  Positive 102 (43%) 63 (56%)  
  Negative 134 (57%) 49 (44%)  
HBV DNA (IU/ml)
 
  0.7
2
 
  Undetectable 96 (38%) 55 (43%)  
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  50-2,000 55 (22%) 13 (10%)  
  2,000-10
5 
19 (7%) 11 (9%)  
  10
5
-10
8 
37 (14%) 21 (17%)  
  ≥108 48 (19%) 27 (21%)  
ALT (IU/L)
 
  0.1 
  <40 239 (92%) 130 (97%)  
  ≥40 20 (8%) 4 (3%)  
1
 p-value from Wald test with robust standard error to take account of clustering among 
individuals who share the same mother. 
2
 Linear test for trend 
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Table 6.12 Characteristics of people with chronic HBV infection who participated in the liver 
assessment 2012-13 by maternal HBsAg status (n=264) 
 All (n=264) With 
HBsAg(+) 
mother (n=58) 
With HBsAg(-) 
mother (n=111) 
p-value
1 
Sex    0.9 
  Male 107 (41%) 28 (48%) 52 (47%)  
  Female 157 (59%) 30 (52%) 59 (53%)  
Age group    0.9
2 
  11 – 29 41 (17%) 14 (25%) 18 (17%)  
  30 – 39 101 (43%) 26 (47%) 56 (53%)  
  40 – 49 45 (19%) 7 (13%) 24 (23%)  
  50 – 78 48 (20%) 8 (15%) 7 (7%)  
Birth place    0.1 
  Keneba 123 (46%) 21 (36%) 58 (52%)  
  Manduar 105 (40%) 32 (55%) 52 (47%)  
  Kantong Kunda 36 (14%) 5 (9%) 1 (1%)  
HBV vaccine    0.005 
  No vaccination 241 (91%) 48 (83%) 103 (93%)  
  Infected before 
vaccination 
4 (1%) 0 (0%) 3 (3%)  
  Infected after vaccination 4 (1%) 0 (0%) 4 (4%)  
Time of infection relative 
to vaccination unknown 
15 (6%) 10 (17%) 1 (1%)  
Median no. of follow-up 
sero-surveys (range) 
6 (2, 10) 7 (2, 10) 7 (2, 10) 0.1 
Median years of follow-up 
(range) 
32 (4, 39) 32 (4, 38) 32 (10, 39) 0.1 
ALT in 2012/13    0.07 
 204 
 
  <40 IU/L 201 (90%) 43 (81%) 92 (92%)  
  ≥40 IU/L 23 (10%) 10 (19%) 8 (8%)  
Platelet count in 2012/13    0.4 
  <150,000/microL 32 (15%) 5 (10%) 15 (16%)  
  ≥150,000/microL 180 (85%) 43 (90%) 80 (84%)  
HBV marker in 2012/13    0.3
2 
  HBsAg(+), HBeAg(+) 23 (9%) 9 (16%) 10 (9%)  
  HBsAg(+), HBeAg(-) 186 (70%) 42 (72%) 84 (76%)  
  HBsAg(-) 55 (21%) 7 (12%) 17 (15%)  
HBV DNA (IU/ml) in 
2012/13 
   0.002
2 
  Undetectable 81 (39%) 16 (30%) 48 (49%)  
  50-200 61 (27%) 13 (25%) 26 (26%)  
  200-2,000 48 (21%) 11 (21%) 17 (17%)  
  2,000-100,000 14 (6%) 5 (9%) 4 (4%)  
  ≥100,000 14 (6%) 8 (15%) 4 (4%)  
Persistence of HBeAg    0.1
2 
  Negative at baseline 134 (57%) 17 (33%) 48 (44%)  
  Cleared during follow-up 79 (33%) 26 (50%) 50 (46%)  
  Still carrier of HBeAg 23 (10%) 9 (17%) 10 (9%)  
Frequency of having high 
HBV DNA levels (≥2,000 
IU/ml)
3 
   0.001
2 
  Never 96 (44%) 10 (20%) 44 (39%)  
  <50% of visits 71 (33%) 18 (36%) 48 (43%)  
  ≥50% of visits 50 (23%) 22 (44%) 20 (18%)  
Frequency of having ALT 
elevation (≥40 IU/L)3 
   0.002
2 
  Never 197 (83%) 36 (71%) 94 (90%)  
  <50% of visits 13 (6%) 4 (8%) 7 (7%)  
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  ≥50% of visits 25 (11%) 11 (21%) 4 (4%)  
1
 p-value from Wald test with robust standard error to take account of clustering among 
individuals who share the same mother. 
2
 Linear test for trend 
3 
This only includes subjects who had at least two measurements during the follow-up. 
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6.4.7. Phase of natural history of CHB infection 
Table 6.13 presents the characteristics of the participants by phase of the natural history of CHB 
infection. Five (2%) were immunotolerant, three (1%) were HBeAg-positive CHB disease, 15 
(6%) were HBeAg-positive unclassified, six (2%) were HBeAg-negative CHB disease, 153 
(58%) were inactive carriers, 27 (10%) were HBeAg-negative unclassified, 14 (5%) were occult 
HBV and 41 (16%) were resolved hepatitis B. Although most people in the inactive phase did 
not meet the EASL criteria for requiring antiviral treatment (99%, 206/208), significant liver 
fibrosis was observed in 8% (13/162) in this group. Chronic carriers with active CHB disease 
were more likely to have an HBsAg-positive mother, persistent HBeAg, high viral replication 
and abnormal ALT than in carriers in other phases (table 6.14).  
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Table 6.13 Characteristics of participants in the liver assessment 2012-13 by phase of natural history (n=264) 
Variables HBsAg(+) and HBeAg(+) HBsAg(+) and HBeAg(-) HBsAg(-) 
Immune 
tolerant 
N=5 
Unclassified 
 
N=15 
HBeAg(+) 
CHB disease 
N=3 
HBeAg(-) 
CHB disease 
N=6 
Unclassified 
 
N=27 
Inactive carrier 
 
N=153 
Occult HBV 
 
N=14 
Resolved 
hepatitis B 
N=41 
Male sex 4 (80%) 9 (60%) 3 (100%) 2 (33%) 16 (59%) 63 (41%) 0 (0%) 10 (24%) 
Median age 
(range) 
32 (26-46) 28 (11-44) 28 (18-30) 38 (29-61) 35 (12-58) 37 (16-78) 51 (30-67) 42 (31-73) 
Positive 
maternal 
HBsAg 
2/4 (50%) 4/12 (33%) 3/3 (100%) 3/4 (75%) 8/20 (40%) 31/102 (30%) 4/8 (50%) 3/16 (19%) 
Significant 
fibrosis by TE 
1/5 (20%) 0/10 (0%) 1/3 (33%) 1/6 (17%) 4/21 (19%) 10/132 (8%) 1/11 (9%) 2/19 (11%) 
Meeting EASL 
criteria 
1/5 (20%) 0/15 (0%) 1/3 (33%) 5/6 (83%) 4/27 (15%) 2/153 (1%) 0/14 (0%) 0/41 (0%) 
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Table 6.14 Factors associated with active CHB disease (HBeAg-positive and –negative CHB disease) among 264 people with CHB infection who participated in the 
liver assessment 2012-13 
Variables Proportion with outcome Crude OR (95% CI) P
1 
Adjusted OR (95% CI)
 
P
1 
Sex Male 5/107 (5%) 1.0 (ref) 0.4  
 
Female 4/157 (3%) 0.5 (0.1-2.0)    
Current age 11 – 29 3/41 (7%) 1.0 (ref) 0.23   
30 – 39 4/101 (4%) 0.5 (0.1-2.4)    
40 – 80 2/93 (2%) 0.3 (0.1-1.7)    
Maternal HBsAg Negative 1/111 (1%) 1.0 (ref) 0.02 1.0 (ref) 0.03
4 
Positive 6/58 (10%) 12.7 (1.5-107.1)  18.5 (1.3-249.9)  
Hepatitis B vaccination None 8/241 (3%) 1.0 (ref) 0.8 1.0 (ref) 0.2
4 
Yes 1/23 (4%) 1.3 (0.2-10.2)  0.2 (0.0-1.9)  
Persistence of HBeAg Negative at baseline 2/134 (1%) 1.0 (ref) 0.01
3 
1.0 (ref) 0.02
3,4 
Cleared during follow-up 4/79 (5%) 3.5 (0.6-19.5)  7 x 10
6
 (1 x 10
6
-5 x 10
7
)  
Still carrier 3/23 (13%) 9.9 (1.5-63.4)  2 x 10
7
 (3 x 10
6
-2 x 10
8
)  
Percent samples with viral Never 0/96 (0%) N/A 0.003
3 
N/A 0.001
3,5 
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load  ≥2,000 IU/ml2 <50% 1/71 (1%) 0.08 (0.0 – 0.6)  0.07 (0.0 – 0.5)  
≥50% 8/50 (16%) 1.0 (ref)  1.0 (ref)  
Percent samples with ALT 
elevation ≥40 IU/L2 
Never 0/197 (0%) N/A <0.001
3 
N/A <0.001
3,4 
<50% 4/13 (31%) 1.8 (0.3 – 9.3)  4.5 (0.4 – 47.8)  
≥50% 5/25 (20%) 1.0 (ref)  1.0 (ref)  
1
 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same mother. 
2 
This only includes subjects who had at least two measurements during the follow-up. 
3
 Test for linear trend. 
4
 OR adjusted for sex, current age, maternal HBV status and hepatitis B vaccination. 
5
 OR adjusted for sex and current age.
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6.4.8. Significant liver fibrosis 
Measurements of liver fibrosis based on transient elastography were classified as a failure or 
unreliable in 1% (3/227) and 8% (17/227), respectively. Of the remaining 207 (91%) with a 
successful measurement, 20 (9.7%, 95% CI: 5.6-13.7%) were found to have significant liver 
fibrosis (≥7.5 kPa), and five (2.4%, 95% CI: 0.3-4.5%) were over 9.0 kPa which are in cirrhotic 
range. Male sex, having HBsAg-positive mothers, having ever had high viral load (≥ 2,000 
IU/ml), and abnormal ALT measurements were associated with significant liver fibrosis (table 
6.15).  
 
A liver biopsy was performed in 30 of the 65 patients who were eligible for the procedure. Six 
(25%) had moderate or severe necroinflammation (≥A2) and four (15%) had significant or 
severe liver fibrosis (≥F2). The prevalence of Metavir ≥A2 was similar in carriers with 
HBsAg-positive mothers (29%, 2/7) and –negative mothers (22%, 2/9, p=0.8). However, the 
prevalence of Metavir ≥F2 was higher in those with carrier mothers (43%, 3/7 versus 9%, 1/11, 
p=0.1). 
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Table 6.15 Factors associated with significant liver fibrosis (≥7.5 kPa by TE) among 207 people with CHB infection with a successful liver stiffness measurement 
(excluding participants with failure or unreliable measurements) 
Variables Proportion with outcome Crude OR (95% CI) P
1 
Adjusted OR (95% CI)
 
P
1 
Sex Male 16/91 (18%) 1.0 (ref) 0.002  
 
Female 4/116 (3%) 0.2 (0.1-0.5)    
Current age 11 – 29 4/37 (11%) 1.0 (ref) 1.03   
30 – 39 7/92 (8%) 0.7 (0.2-2.2)    
40 – 49 6/37 (16%) 1.6 (0.4-6.7)    
50 – 80 3/41 (7%) 0.7 (0.1-3.1)    
Maternal HBsAg Negative 7/94 (7%) 1.0 (ref) 0.08 1.0 (ref) 0.01
4 
Positive 9/49 (18%) 2.8 (0.9-9.0)  4.8 (1.4-17.1)  
Hepatitis B vaccination None 19/190 (10%) 1.0 (ref) 0.6 1.0 (ref) 0.3
4 
Yes 1/17 (6%) 0.6 (0.1-4.6)  0.3 (0.1-4.1)  
Persistence of HBeAg Negative at baseline 5/108 (5%) 1.0 (ref) 0.02
3 
1.0 (ref) 0.6
3,4 
Cleared during follow-up 11/73 (15%) 3.7 (1.2-10.7)  2.6 (0.5-13.3)  
Still carrier 2/18 (11%) 2.6 (0.5-14.5)  0.9 (0.1-7.8)  
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Percent samples with viral 
load  ≥2,000 IU/ml2 
Never 3/81 (4%) 1.0 (ref) 0.03
3 
1.0 (ref) 0.05
3,4 
<50% 10/65 (15%) 4.7 (1.2-18.7)  1 x 10
7
 (4 x 10
6
-4 x 10
7
)  
≥50% 6/43 (14%) 4.2 (0.9-19.1)  1 x 107 (2 x 106-4 x 107)  
Percent samples with ALT 
elevation ≥40 IU/L2 
Never 12/159 (8%) 1.0 (ref) 0.02
3 
1.0 (ref) 0.05
3,4 
<50% 2/12 (17%) 2.5 (0.5-12.8)  0.9 (0.1-8.7)  
≥50% 5/21 (24%) 3.8 (1.2-12.3)  4.7 (1.0-21.4)  
1
 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same mother. 
2 
This only includes subjects who had at least two measurements during the follow-up. 
3
 Test for linear trend. 
4
 OR adjusted for sex, current age, maternal HBV status and hepatitis B vaccination. 
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6.4.9. EASL treatment criteria 
Thirteen participants (4.9%, 95% CI: 2.3-7.6%) met the EASL treatment criteria. Participants 
with HBsAg-positive mother and higher frequency of high viral load and abnormal ALT levels 
were more likely to require the antiviral therapy (table 6.16).  
 
PAF for meeting the EASL criteria was calculated from the data including all the survey 
participants in Keneba and Manduar (1973-2008) with available maternal sero-status (n=2,760). 
The proportion of chronic carriers meeting the criteria with an HBsAg-positive mother (pc) was 
77.8% (7/9) and the adjusted OR for the effect of maternal HBsAg status was 12.7 (table 6.17). 
Therefore 71.4% (95% CI: 6.3-91.3%) of the chronic carriers requiring treatment are 
attributable to maternal transmission. Using the same data, the proportion of chronic carriers 
attributable to maternal perinatal transmission was 13.9% (95% CI: 5.5-21.5%). 
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Table 6.16 Factors associated with condition fulfilling the EASL treatment criteria among 264 people with CHB infection who participated in the liver assessment 
2012-13 
Variables Proportion with outcome Crude OR (95% CI) P
1 
Adjusted OR (95% CI)
 
P
1 
Sex Male 6/107 (6%) 1.0 (ref) 0.7  
 
Female 7/157 (4%) 0.8 (0.2-2.4)    
Current age 11 – 29 3/41 (7%) 1.0 (ref) 0.33   
30 – 39 7/101 (7%) 0.9 (0.2-4.0)    
40 – 49 1/45 (2%) 0.3 (0.1-2.9)    
50 – 80 2/48 (4%) 0.6 (0.1-3.4)    
Maternal HBsAg Negative 2/111 (2%) 1.0 (ref) 0.01 1.0 (ref) 0.01
4 
Positive 7/58 (12%) 7.5 (1.5-37.5)  8.9 (1.5-52.1)  
Hepatitis B vaccination None 12/241 (5%) 1.0 (ref) 0.9 1.0 (ref) 0.3
4 
Yes 1/23 (4%) 0.9 (0.1-7.1)  0.2 (0.0-3.4)  
Persistence of HBeAg Negative at baseline 4/134 (3%) 1.0 (ref) 0.1
3 
1.0 (ref) 0.2
3,4 
Cleared during follow-up 5/79 (6%) 2.2 (0.6-8.4)  3.2 (0.2-53.0)  
Still carrier 2/23 (9%) 3.1 (0.5-18.1)  6.9 (0.2-238,4)  
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Percent samples with viral 
load  ≥2,000 IU/ml2 
Never 2/96 (2%) 1.0 (ref) 0.007
3 
1.0 (ref) 0.03
3,4 
<50% 2/71 (3%) 1.4 (0.2-9.9)  7 x 10
6
 (1 x 10
6
-5 x 10
7
)  
≥50% 9/50 (18%) 10.3 (2.1-51.9)  4 x 107 (3 x 106-4 x 108)  
Percent samples with ALT 
elevation ≥40 IU/L2 
Never 4/197 (2%) 1.0 (ref) <0.001
3 
1.0 (ref) 0.005
3,4 
<50% 2/13 (15%) 8.8 (1.4-53.7)  10.1 (0.8-122.0)  
≥50% 6/25 (24%) 15.2 (3.9-59.2)  12.8 (2.0-83.1)  
1
 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same mother. 
2 
This only includes subjects who had at least two measurements during the follow-up. 
3
 Test for linear trend. 
4
 OR adjusted for sex, current age, maternal HBV status and hepatitis B vaccination. 
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Table 6.17 Factors associated with condition fulfilling the EASL treatment criteria among 2,760 sero-survey participants (1973-2008) with available maternal 
sero-status 
Variables Proportion with outcome Crude OR (95% CI) P
1 
Adjusted OR (95% CI)
 
P
1 
Sex Male 6/1,387 (0.36%) 1.0 (ref) 0.8  
 
Female 4/1,367 (0.29%) 0.8 (0.2-3.0)    
Current age 11 – 29 3/1,771 (0.17%) 1.0 (ref) 0.032   
30 – 39 4/683 (0.59%) 3.5 (0.8-15.6)    
40 – 49 1/223 (0.45%) 2.7 (0.3-25.8)    
50 – 80 1/75 (1.33%) 8.0 (0.8-74.8)    
Maternal HBsAg Negative 2/2,146 (0.09%) 1.0 (ref) 0.002 1.0 (ref) 0.001
3 
Positive 7/614 (1.14%) 12.4 (2.6-59.1)  12.7 (2.8-57.3)  
Hepatitis B vaccination None 8/975 (0.81%) 1.0 (ref) 0.01 1.0 (ref) 0.01
3 
Yes 1/1,777 (0.06%) 0.07 (0.01-0.55)  0.06 (0.01-0.53)  
1
 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same mother. 
2
 Test for linear trend. 
3
 Model included sex, current age, maternal HBV status and hepatitis B vaccination. 
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6.5. Discussion 
This study used data from an open cohort to estimate incidence rates of major endpoints in the 
natural history of CHB infection: HBeAg and HBsAg sero-clearance, HCC, and death. These 
parameters have been poorly described in sSA.
73,71
 In addition, a comprehensive liver 
assessment, including transient elastography and liver biopsy, was used to estimate the 
prevalence of significant liver fibrosis and the requirement for antiviral treatment according to 
international guidelines. 
 
6.5.1. Incidence of HCC 
The risk of HCC among people with CHB infection differs considerably by geographical 
location. HCC incidences estimated from population-based cohort studies of HBsAg-positive 
men vary from 34/100,000 carrier-years in Europe
99,100
 to 230/100,000 in Alaska
81
 and 
530-1,030/100,000 in East Asia.
98,101
 In sSA, the incidence was 68.3/100,000 carrier-years in a 
cohort of men in the Senegalese army.
97
 In the current study the incidence of HCC in 
HBsAg-positive men was 116.7/100,000 carrier-years. This figure might be an underestimate 
because the HCC cases were ascertained through linkage with the Gambia National Cancer 
Registry database, which is estimated to contain only 50% of cases.
286
 However, it is unlikely to 
be a substantial underestimate because we also reviewed the medical records at the primary care 
clinic in Keneba to improve the ascertainment of HCC cases. 
 
6.5.2. Risk factors for HCC and its predictors 
The geographical variation in HCC risk amongst HBsAg-positive persons suggests that factors 
other than HBsAg affect HCC risk. Certain HBV genotypes,
146
 alcohol consumption,
157
 diabetes 
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mellitus
165
 or co-infection with other viruses (HCV,
167
 HDV,
72
 and HIV
182
) have been shown to 
increase the risk of HCC among chronic HBV carriers in other parts of the world. In The 
Gambia, the majority of people are Muslim and alcohol consumption is rare (2%). The 
prevalence of diabetes in adults was 0.2% in a nationwide survey.
166
 And in our cohort, 
co-infection with HIV, HCV and HDV was almost zero. The distribution of HBV genotypes 
was studied in this cohort using the sample from 2003 sero-survey and almost all (96.0%, 95/99) 
were genotype E.
148
   
 
Having an HBsAg-positive mother was associated with known predictors of HCC (delayed 
HBeAg sero-clearance, persistence of high viral replication and high ALT levels over time, 
higher prevalence of active CHB disease, significant liver fibrosis, and condition meeting the 
EASL treatment criteria). Moreover, all the patients who died of ESLD (including HCC) and 
whose maternal sero-status was known had HBsAg-positive mothers, although the numbers 
were small. These findings suggest that mother-to-infant transmission may increase the risk of 
HCC beyond its effect of increasing the risk of CHB infection. The findings are also consistent 
with previous reports from East Asia suggesting the effect of positive maternal HBV 
sero-markers on delayed HBeAg and HBsAg sero-clearance,
78,83,245,246
 high ALT levels after 
HBeAg loss,
76
 and paediatric HCC.
242,243
 The chance of perinatal transmission from an 
HBsAg-positive mother to her infant is especially high when the mother is also 
HBeAg-positive.
30
 The transplacental passage of HBeAg or HBeAg-derived peptides from 
mother to foetus is thought to induce a tolerance in newborns against the virus.
75
 Such a 
mechanism may lead to CHB infection, and prolong the persistence of high viral replication, 
which can cause HCC.
101,139
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The current study found an association between high viral load and abnormal ALT during the 
follow-up and the disease outcomes (active CHB disease, significant liver fibrosis and condition 
requiring antiviral therapy). Similar findings were reported in a study conducted in Hong 
Kong.
111
 This is consistent with our hypothesis that it is through prolonged viral replication and 
frequent hepatitis flare that perinatal mother-to-infant transmission leads to liver fibrosis. 
 
6.5.3. Limitations of the study 
There are several limitations to this study. First, the date of the HBeAg and HBsAg loss was not 
known and was estimated as the midpoint between the last positive result and the first negative 
result. The estimated date is less accurate than in other studies because the interval between 
follow-up sero-surveys (4-5 years) was longer than in other studies of the natural history of 
CHB infection (6 months to 1 year).
81,83,88
 Nonetheless, the results obtained in this study are 
within a range that has been reported from other parts of the world (HBeAg loss per year: 
3-9%,
80,81,83
 and HBsAg loss per year: 0.5-2.3%).
81,88,89
 Second, the effect of maternal HBsAg 
was examined rather than maternal HBeAg. Maternal HBeAg positivity is a stronger predictor 
of perinatal transmission than HBsAg positivity. However, maternal sero-status in this study 
was determined when the child entered the cohort, and by this time HBeAg is likely to have 
been lost.
261
 Third, the associations between maternal HBsAg and factors predictive for HCC 
may have been confounded by factors that were not measured in this study. For example, an 
environmental risk factor for HCC such as aflatoxin exposure
156
 could confound the association 
because the amount of dietary consumption of crops contaminated by this fungal toxin could 
vary between households. Moreover, aflatoxin can transfer from mother to child in utero
287
 and 
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through the breast milk.
288
 However, cross-sectional studies that examined the samples from the 
current cohort failed to identify the association of indicators for aflatoxin exposure (i.e. 
aflatoxin-albumin adducts levels in plasma and tumour protein 53 (TP53) mutation at codon 249 
in circulating cell-free DNA in plasma) with hepatitis B viraemia.
148,153,156 
 
6.5.4. Population impact of perinatal maternal transmission 
In the pre-vaccine era, mothers in sSA had similar seroplevalence of HBsAg (10%) to mothers 
in East Asia. However, the prevalence of HBeAg among HBsAg-positive mothers was lower in 
sSA (10% versus 40%),
63,289
 and consequently the chance of mother-to-infant transmission was 
smaller in sSA than in East Asia. Previous mathematical modelling estimated that 40% of 
chronic HBV carriers in East Asia acquired the infection through the perinatal route while this 
was only 10% in sSA.
63
 Indeed, the current study estimated that 13.9% of chronic HBV carriers 
were attributable to this mode of transmission. However, in people with established CHB 
infection, only few (5%) develop liver disease requiring antiviral therapy, and having an 
HBsAg-positive mother is a strong predictor of requiring antiviral therapy. Consequently, 71.4% 
of chronic carriers requiring antiviral therapy were estimated to be attributable to perinatal 
maternal HBV transmission (assuming that the estimated association reflects a causal relation). 
This figure may be conservative where there is high hepatitis B vaccine coverage (e.g. >95% in 
The Gambia), for the following reasons. First, the majority (50-90%) of children with vaccine 
failure resulting in CHB infection have HBV-positive mothers.
238,173
 Second, as this study has 
shown, the vaccine does not seem to prevent progression of liver disease amongst people 
established the CHB infection. Nevertheless, there is considerable uncertainty in the estimate 
presented given the wide confidence interval and possibility of residual confounding. 
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The high PAF emphasises the potential importance of interrupting perinatal maternal 
transmission in sSA. The WHO recommends that the first dose of hepatitis B vaccine should be 
administered as soon as possible after the birth, ideally within 24 hours.
116
 Despite a relatively 
high coverage of hepatitis B vaccine worldwide, the timely birth dose (<24 hours) is not always 
given. By the end of 2012, only half of the countries with national hepatitis B vaccine 
programmes recommended the first dose within 24 hours.
117
 In sSA, only six countries are 
undertaking the birth dose and The Gambia is one of them. However, in Keneba and Manduar, 
of 2,173 persons who were vaccinated against HBV between 1984 and 2007, only 2.8% 
(63/2173) were given the first dose within 24 hours (unpublished data). This might be because 
in The Gambia, only half of births are in a health facility,
290
 and the children are usually not 
taken away from home for at least seven days.
113
 Currently there is no community-based 
delivery of hepatitis B vaccination in the country. A cost-effective analysis of birth dose in sSA 
that takes account of the additional risk of maternal transmission on disease progression is 
needed. 
 
 
6.6. Summary 
Sero-surveys of HBV markers have been conducted regularly in small villages in the West 
Kiang District of The Gambia since 1973. By the latest survey in 2008, 414 chronic HBV 
carriers have been identified and they were invited for the comprehensive liver assessment as 
part of the PROLIFICA project in 2012-13. This open cohort study allowed me to assess the 
effect of maternal HBV sero-marker when child entered the study. Positive maternal HBsAg (a 
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proxy for the presence of perinatal maternal transmission) was associated with predictors of 
HCC (delayed HBeAg seroclearance, high HBV DNA and high ALT levels over time, active 
CHB disease, significant liver fibrosis and requirement of antiviral treatment) in chronic HBV 
carriers. Moreover, all of the three individuals who died of ESLD and whose maternal 
sero-status was known had mothers carrying HBsAg. These results suggest that the effect of 
mother-to-infant transmission is two-fold: 1) it increases the risk of CHB infection (which is 
already established) and 2) it increases the risk of HCC in people with CHB infection. The 
proportion of chronic HBV carriers attributable to perinatal maternal transmission is small (13%) 
in The Gambia as the frequency of this mode of transmission is low. However, the proportion of 
chronic carriers requiring antiviral treatment that are attributable to perinatal maternal 
transmission is high (71%). Although there is much uncertainty in these estimates due to small 
number of cases requiring antiviral therapy and potential residual confounding, the study 
suggests that a timely birth dose of hepatitis B vaccine in sSA might help to reduce the burden 
of disease associated with CHB infection more efficiently than postponing hepatitis B vaccine. 
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Chapter 7. The association between birth order 
and hepatocellular carcinoma in people with 
chronic hepatitis B infection: a case-control study 
in the Gambia, West Africa 
 
 
7.1. Abstract 
Background 
In Chapter 5, the effect of age at hepatitis B virus (HBV) infection on hepatocellular carcinoma 
(HCC) amongst chronic carriers of HBV was assessed using a historical case-control study in 
The Gambia. However, the association was not significant and the study was limited by a small 
sample size, unknown participation rate, and having hospital-based controls. In this chapter data 
from PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) project in The Gambia 
are used to examine the association between age at infection and HCC using birth order as a 
proxy measure for the age at infection (or mode of transmission). 
Methods 
PROLIFICA consists of two main studies: WATCH (West African Treatment Cohort for 
Hepatitis B) which aims to reduce HCC incidence through community-based screening for 
HBV infection, clinical assessment and antiviral therapy; and HC4 (Hepato-Celllular Carcinoma 
Case-Control study) which is a hospital-based HCC case-control study. The screening targeted 
all individuals ≥30 years old in 27 urban and 27 rural areas randomly selected within the 
Western Gambia. The distribution of birth order in hepatitis B surface antigen (HBsAg)-positive 
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HCC cases recruited from the HC4 study was compared with two different control groups. The 
first group comprised of people identified as HBsAg-positive without HCC in a 
community-based HBV screening of the WATCH. The second group was HBsAg-positive 
patients without HCC recruited from the HC4 study. The analysis was weighted for 
non-attendance in the first case-control comparison to better represent the distribution of birth 
order in the population. 
Results 
Between December 2011 and January 2014, 5,980 of 8,170 eligible people (68.9%, 95% CI: 
65.1-72.6%) participated in the screening. HBsAg prevalence was 8.8% (495/5980, 95% CI: 
7.9-9.7%). The first control group consisted of 392 HBsAg-positive subjects without HCC. 
From June 2012 to November 2013, 242 patients referred for suspected liver disease were 
enrolled in the HC4 study from which 72 HBsAg-positive HCC cases and 63 HBsAg-positive 
controls (second control group) were identified. After adjusting for age, ethnicity, birthplace and 
parental education levels, odds ratios decreased with increasing birth order in full-siblings in the 
first case-control analysis: 1.00 (reference), 0.55 (95% CI: 0.23-1.30), 0.61 (0.21-1.73), 0.55 
(0.17-1.86) and 0.18 (0.05-0.68) in 1
st
, 2
nd
, 3
rd
, 4
th, and ≥5th birth order, respectively (p = 0.01). 
There was a similar inverse association between birth order in full-siblings and HCC in the 
second case-control comparison (p = 0.05). 
Conclusion 
HCC cases had lower birth order than controls. Low birth order is associated with perinatal 
transmission because low birth order children have young mothers who are more likely to have 
high viral replication. This is consistent with the findings described in the previous chapters that 
perinatal mother-to-infant transmission might increase the risk of HCC and its predictors 
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beyond its effect of increasing the risk of chronic HBV infection. The incidence of HBV-related 
HCC in The Gambia might be reduced by interrupting this mode of transmission. 
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7.2. Introduction 
The studies of maternal hepatitis B virus (HBV) markers in The Gambia (Chapters 4 and 6) 
found associations between having an HBV-positive mother and predictors of hepatocellular 
carcinoma (HCC) in people chronically infected with HBV. In Chapter 5 (historical case-control 
study of HCC), the first birth order was associated with higher risk of liver cirrhosis and HCC 
than higher birth order, although the association did not reach statistical significance. These 
results are consistent with the hypothesis that perinatal mother-to-infant transmission of HBV is 
an important determinant of progression of liver diseases in The Gambia.
42,60
 However, the 
study linking birth order with HCC (Chapter 5) was limited by a small sample size, unknown 
participation rate, and particularly by having hospital-based controls. In this chapter the same 
association was examined by using data from a new case control study of HCC in The Gambia. 
I attempted to improve the study design by comparing with population-based controls who may 
better represent the distribution of birth order of the population which derived the cases than 
hospital-based controls whose birth order may be biased because birth order is often associated 
with other diseases.
188–191
  
 
The PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) Programme, funded by 
European Union FP 7 grant and lead by Prof. Mark Thursz, started in 2011 in The Gambia, 
Senegal and Nigeria. In The Gambia, the principle investigator is Dr. Ramou Njie. PROLIFICA 
consists of two main studies: a cohort study of people with chronic hepatitis B (CHB) infection 
(WATCH: West African Treatment Cohort for Hepatitis B) and a case-control study of HCC 
(HC4: Hepato-Celllular Carcinoma Case-Control study). The former aims to reduce HCC 
incidence through screening for HBV infection, clinical assessment and antiviral therapy using 
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tenofovir (nucleotide analogue). Because people aged <30 years are likely to have been 
vaccinated against HBV in The Gambia, screening targeted people over 30 years old. The HC4 
study was designed to develop a research platform for scientific studies of proteomics, 
metabonomics, molecular diagnostics, host genetics, HBV viral genetics of HCC in West Africa. 
HCC cases are recruited from the referral hospitals in The Gambia. 
 
The primary objective of this chapter is to assess the association between birth order and HCC 
using data from the WATCH and HC4 studies. HCC cases recruited in the referral hospitals are 
compared with two different sets of HBsAg-positive controls; namely, population-based 
controls from the community screening, and hospital-based controls. The hypothesis is that 
HCC cases are associated with lower birth order, which is correlated with perinatal transmission 
because low birth order children have young mothers with high viral replication. The secondary 
objectives of this analysis are to determine: i) the attendance rate for community-based 
screening and factors associated with non-attendance, ii) the prevalence of HBsAg in adults 
over 30 years old in the Western part of The Gambia and factors associated with positive 
HBsAg, iii) the attendance rate at the liver clinic in people who tested positive for HBsAg and 
factors associated with non-attendance at the clinic, iv) the association between birth order and 
HBsAg positivity, and v) the associations between birth order and predictors of HCC (active 
CHB diseases, significant liver fibrosis and condition requiring antiviral treatment according to 
the international guidelines). 
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7.3. Methods  
7.3.1. WATCH study 
The WATCH study uses two methods of screening people for HBV infection: community-based 
screening and blood donor screening at blood donation centre of the Edward Francis Small 
Teaching Hospital (EFSTH). Data from the blood donor screening were not used for this 
analysis, as the recruitment of the study participants is still ongoing. 
 
7.3.1.1. Stratification 
The WATCH study aimed to screen 5,500 people in The Gambia and 8,000 in Senegal. In The 
Gambia, the study was conducted in the Western part of the country (figure 7.1), which includes 
Banjul (capital), Kanifing and nine districts of the Western Region. Foni Kansala was excluded 
from the sample for political reasons. Because the natural history of CHB infection and risk 
factors for HCC are likely to differ between urban and rural populations due to environmental 
factors such as aflatoxin exposure,
153
 the sample was stratified by urban and rural districts and 
the study aimed to screen equal numbers of participants (2,750) in each. Banjul, Kanifing, and 
two districts in the Western Region (Kombo North and Kombo Central) were classified as urban, 
and the others were classified as rural (figure 7.1, table 7.1).
286
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Figure 7.1 Districts of the Western Gambia (area surrounded by blue boundary indicates urban 
area. Foni Kansala was excluded.) 
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Table 7.1 Number of people aged over 30 years in each district of the Western Gambia (data 
from the national census in 2003) 
Region District Number of 
enumeration 
areas (EAs) 
Total population 
size 
Population size 
(≥30 years)1 
Urban 1,197 608,633 164,331 
Banjul  92 35,061 9,467 
Kanifing  634 322,735 87,138 
Western Region Kombo North 316 166,715 45,013 
Kombo Central 155 84,122 22,713 
Rural 253 138,437 37,378 
Western Region Kombo South 112 61,247 16,537 
Kombo East 52 27,944 7,545 
Foni Brefet 22 10,822 2,922 
Foni Bintang 
Karanai 
25 15,136 4,087 
Foni Kansala 
(excluded) 
20 11,353 3,065 
Foni Bondali 11 6,080 1,641 
Foni Jarrol 11 5,855 1,581 
Total 1,450 747,070 201,709 
1
 Estimates were obtained by multiplying the total population size by 0.27, which is the 
proportion of people aged ≥30 years in the whole country in 2003. 
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7.3.1.2. Two-stage sampling 
The Western Gambia is divided into 1,450 enumeration areas (EAs) defined by Gambia Bureau 
of Statistics (table 7.1). One EA could be an entire village, or part of large village, or a cluster of 
small villages. According to the previous national census in 2003, 747,070 people reside in the 
Western Gambia, which is 55% of the total population. The population size per EA varies from 
16 to 1,246 in the Western Gambia, and the mean is 516. The proportion of people aged ≥30 
years in the whole country in 2003 was 27%, therefore the average population ≥30 years old in 
one EA is estimated to be 140. Twenty-seven EAs were randomly selected from each of the list 
of urban EAs and rural EAs. All inhabitants in the selected EAs were assessed for eligibility 
(eligibility criteria listed below). 
 
7.3.1.3. Sensitisation of the population 
The selected communities were informed about the study before the survey. A team of 
fieldworkers and I visited the head of the village (alkalo) with kola nuts as a gift. We explained 
the study purpose, delineated the study area by referring to a map from the Gambia Bureau of 
Statistics, and asked the alkalo to invite the community for a meeting. We visited the village 
again for the community meeting, at which point the study was described to the community. We 
used a poster and leaflet to help explain the study (Appendix 6). 
 
7.3.1.4. Pre-screening registration 
Following community approval, a team of fieldworkers registered people in the EA. Because 
there are no lists of village residents in The Gambia, the team conducted a rapid census by 
visiting each compound and registering everyone eligible for screening. Eligibility criteria were: 
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1) age ≥30 years, and 2) having spent the previous night in the compound. A number was 
assigned to each compound, and names, sex, age or year of birth, and phone numbers of eligible 
persons were recorded. Information was obtained from the head of the compound on people not 
present at the time of registration. We obtained year of birth from the national identity card. 
Eligible persons were invited to participate in the screening.  
 
7.3.1.5. Screening 
While some of the team registered eligible individuals, the rest set up a screening site at the 
centre of the EA. This could be at a health centre, school, mosque, bantaba (community 
gathering space under a large tree) or someone’s compound depending on what was agreed with 
the community. At the screening site, the team confirmed the eligibility of the person who came 
by checking against the list of registered people. After obtaining written consent for the 
screening, a point-of-care test for HBsAg using immunochromatography (Determine, Alere, 
USA) and a standardised questionnaire (Appendix 7) were administered. The diagnostic 
accuracy of Determine was studied in The Gambia; sensitivity was 88.5% (95% CI: 80.7-93.9%) 
and specificity was 100% (95% CI: 99.5-100%) using a reference standard of enzyme-linked 
immunosorbent assay (ELISA) for HBsAg using AxSYM (Abbott, USA) (unpublished data). 
Responses to the questionnaire and test results were recorded using a Tablet PC (a small laptop 
with touch screen, Samsong Galaxy, Samsong, Korea). The electronic questionnaire included 
functions to reduce errors (automated range, consistency checks and skip patterns).
291
  
 
The result of the rapid test was available within 15 minutes and post-test counselling was 
provided on site. All individuals who tested positive were given an appointment at the liver 
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clinic at the Medical Research Council (MRC), Fajara, for further investigations. This usually 
occurred 1-2 weeks after the survey. Once the screening in an EA was complete, the same 
number of HBsAg-negative people was randomly selected from the EA and invited to the liver 
clinic. 
 
From August to November 2013, we conducted an add-on field validation study of point-of-care 
tests within the community screening programme. During this period, we used an additional 
point-of-care test (Vikia, Biomerieux, France) to compare diagnostic accuracy of Determine and 
Vikia against the AxSYM ELISA for HBsAg as the gold standard test which was performed on 
dried-blood spots collected at the field. The survey participants during this period were also 
asked whether they had been ever tested for HBV infection.  
 
7.3.1.6. Reminder and reason for non-attendance 
People who were registered but who did not come to the screening were reminded by 
fieldworkers by a phone call or visiting the compound. Up to three attempts either by phone or 
visit were made to follow the person up. The reason for non-attendance was selected from a list 
of possible choices; multiple choices were not allowed. The reasons were categorised as absence 
or refusal. The reasons for absence included: absence due to work, travelling or social gathering. 
The reasons for refusal included: being afraid of bleeding, too busy to participate, feeling ill, no 
benefit, already tested before for HBsAg, no trust in MRC, or husband refusal (women only). 
When the answer did not fit any of these a specific reason was recorded. 
 
7.3.1.7. Team of fieldworkers 
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The team of fieldworkers consisted of one field supervisor, one nurse and six field assistants. 
All had had previous experience of fieldwork, but the length of experience before joining the 
project ranged from 2 to 29 years. A one-week workshop for fieldworkers was held before 
starting the project. This included an introduction to the epidemiological and clinical aspects of 
HBV infection, and training for administering a finger prick, use of the point-of-care test, for 
HBsAg, administering the questionnaires using the Tablet PC, and pre- and post-test 
counselling of HBsAg test.  
 
In all the screening sessions, a field supervisor was available to lead the team. The availability 
of a nurse and field assistants for the fieldwork was determined by the amount of clinical 
activity at the liver clinic at the MRC, Fajara. However, at least four of the field workers 
including the supervisor were involved in screening at all times. Whenever possible, a village 
health worker (under the Regional Public Health Office) was asked to help the screening. In 
addition, the community often allocated a few volunteers to help with the project. 
 
7.3.1.8. Clinical assessment at the liver clinic at MRC, Fajara 
People identified to be positive for HBsAg and randomly selected HBsAg-negative people were 
invited for a comprehensive liver assessment at the liver clinic at the MRC, Fajara. After written 
consent for the study participation, urine and blood sample were collected. An interview using 
standardised epidemiological questionnaire and standardised clinical examination including 
abdominal ultrasound and liver stiffness measurement (LSM) with transient elastography 
(Fibroscan FS402, Echosens, France)
104
 were performed. Participants fasted overnight as the 
ingestion of food hampers reliable measurements by transient elastography.
281
 After the first 
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liver assessment, those who met any of the study criteria: HBV DNA levels ≥2,000 IU/ml, LSM 
≥6.5 kPa or serum alanine transaminase (ALT) ≥40 IU/L, were invited for a liver biopsy. Liver 
fibrosis was scored according to the Metavir system
282
 by one liver pathologist in The Gambia 
and another in the UK. The study was approved by the Gambia Government/MRC Joint Ethics 
Committee. 
 
7.3.2. HC4 study 
7.3.2.1. Setting 
The study started in June 2012, and the current analysis included the patients recruited until 
November 2013. Participants were recruited from referral hospitals in The Gambia, namely: 
Edward Francis Small Teaching Hospital (EFSTH, formally known as Royal Victoria Teaching 
Hospital), the sole tertiary care hospital in The Gambia located at capital Banjul; MRC Clinic, 
in Fajara, Kanifing; Bwiam Hospital located in a rural part of the Western Gambia, Farafenni 
Hospital and Bansang General Hospital in the upcountry. Patients with suspected liver disease 
were identified by local physicians or through active surveillance of the outpatient clinics and 
inpatient wards by research nurses. All the patients referred for clinically suspected liver disease 
were eligible for the study. Consequently, the study included not only HCC or liver cirrhosis 
patients, but also patients with other diseases of non-hepatic origin such as metastatic liver 
cancer or tuberculous peritonitis, which are difficult to distinguish from liver diseases on a 
clinical basis alone. After informed consent, all the patients underwent a structured interview 
with a standardised questionnaire and a clinical examination which included ultrasound and 
transient elastography. Blood and urine samples were also collected. The questionnaires and 
case report forms used in the HC4 study were identical to those used in the WATCH study. 
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Unless contraindicated (e.g. because of coagulopathy), a liver biopsy was performed in all the 
study participants with a hepatic nodule on ultrasound who agreed to have the procedure. Those 
without a hepatic nodule were invited for the liver biopsy when they met one or more of the 
study criteria (which are the same as the one used in the WATCH study).  
 
7.3.2.2. Case Definition 
To estimate the effect of early age at HBV infection on HCC and its predictors beyond its effect 
of increasing the risk of CHB infection (figure 7.2), both cases and controls were restricted to 
people with positive HBsAg. Three different definitions for HCC were used for this analysis: 1) 
histopathologically confirmed; 2) clinically confirmed; and 3) clinically probable HCC cases. 
Clinically confirmed cases of HCC met all of the criteria: i) focal liver lesion ≥2 cm consistent 
with HCC by ultrasound; ii) alpha-fetoprotein levels ≥200 ng/ml; and iii) liver cirrhosis.292 
Clinically probable HCC cases met two of the criteria above. As the distribution of birth order 
and potential confounding factors for the association of birth order with HCC was similar 
between the three groups (table 7.2), confirmed and probable cases were combined.  
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Figure 7.2 Causal diagram for the effect of birth order on the risk of HCC and its predictors 
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Early birth order is a proxy for perinatal mother-to-infant HBV transmission whilst late birth order is a proxy for early horizontal transmission. Early 
age at HBV infection is known to be associated with liver cirrhosis and HCC through increasing the risk of chronic HBV infection. The hypothesis of 
this analysis is in addition to this effect, early age at infection further increases the risk of HCC and its predictors (presented as a dashed arrow). The 
exposure and outcome variables of interest are surrounded by lines in bold-type. SES denotes socio-economic status
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Table 7.2. Distribution of birth order and a priori confounders for the association between birth 
order and HCC in HBV-related HCC according to the basis of diagnosis (histopathologically 
confirmed HCC cases, clinically confirmed HCC cases and clinically suspected HCC cases) 
 Histo- 
pathologically 
confirmed HCC 
(n=16) 
Clinically 
confirmed 
HCC (n=17) 
Clinically 
suspected 
HCC (n=39) 
P 
Male sex  14 88% 13 77% 27  71% 0.4 
Median age 
(range) 
 36 (21, 
60) 
 39 (23, 
60) 
 40 (24, 
78) 
 0.5 
Ethnic group
 
Mandinka 4 25% 3 19% 10 27% 0.3 
Jola 0 0 3 19% 2 5%  
Others 12 75% 10 63% 25 68%  
Birth place
 
Urban 2 13% 0 0 6 16% 0.4 
Rural  13 81% 13 81% 28 76%  
Foreigners 1 6% 3 19% 3 8%  
Parental 
schooling
 
None 6 37% 11 65% 23 59% 0.4 
One parent 
only 
4 25% 4 23% 6 15%  
Both parents 6 37% 2 12% 10 26%  
Number of full 
siblings
 
1-2 3 19% 1 7% 5 14% 0.5 
3-4 3 19% 3 20% 8 22%  
5-6 6 37% 6 40% 6 16%  
7-8 3 19% 4 27% 9 24%  
≥9 1 6% 1 6% 9 24%  
Number of 
siblings (full + 
half)
 
0-5 1 7% 1 7% 6 18% 0.1 
6-8 9 64% 3 20% 7 21%  
9-11 1 7% 5 33% 9 26%  
12-14 0 0 1 7% 4 12%  
≥15 3 21% 5 33% 8 23%  
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Birth order in 
full siblings 
1
st
  5 31% 7 47% 13 35% 0.9 
2
nd
  4 25% 2 13% 6 16%  
3
rd
  1 6% 3 20% 5 14%  
4
th
  3 19% 1 7% 7 19%  
≥5th 3 19% 2 13% 6 16%  
Birth order in 
siblings (full + 
half) 
1
st
  2 13% 2 13% 11 30% 0.7 
2
nd
  4 27% 3 20% 3 8%  
3
rd
 & 4
th
 2 13% 4 27% 7 19%  
5
th
 & 6
th
  4 27% 3 20% 7 19%  
≥7th 3 20% 3 20% 9 24%  
P-value was obtained using chi-squared test unless indicated. 
1
 Kruskal-Wallis test 
 
 
7.3.2.3. First control group: population-based controls  
Two HBsAg-positive control groups were considered for the comparison with the HBV-related 
HCC cases. The first control group was HBsAg-positive people identified at the 
community-based screening who did not meet the HCC criteria listed above at the first clinical 
assessment at the liver clinic. One HBsAg-positive participant in the control group without 
evidence of HCC at the enrolment developed HCC during the course of follow-up. This control 
group consisted of people over 30 years old from the Western part of The Gambia. 
Consequently, HBV-related HCC cases less than 30 years old and those recruited at the 
hospitals outside the Western Gambia (i.e. Farafenni and Bansang Hospital) were excluded 
from this case-control analysis.  
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The strength of this population-based control group is that they represent the birth order in the  
general population; by contrast the distribution of birth order in hospital controls might be 
affected by other diseases.
188–191
  
 
A possible disadvantage of the population-based is that the ascertainment of HCC cases in the 
Western Gambia is unlikely to be complete because not everyone can afford medical care when 
they develop HCC.
286
 For this reason, hospital controls might better represent the population 
that generated the cases and another case-control analysis using hospital controls was 
performed.  
 
7.3.2.4. Second control group: hospital-based controls 
The second control group consisted of patients enrolled in the HC4 study who were referred to 
the liver clinics for suspected liver disease. The patients were HBsAg positive and without HCC 
at enrolment. In addition they were selected to be over 20 years old, because the youngest 
HBV-related HCC case was 21 years old.  
 
7.3.3. Definition of birth order 
When the questionnaire was designed it was assumed that birth order is a proxy for the number 
of infectious older siblings which might determine the probability of early childhood HBV 
infection. However, during the course of my PhD, I found that mother-to-infant transmission 
might determine the risk of liver diseases (Chapter 4, 5 and 6). The role of birth order has 
therefore changed from a proxy for early horizontal HBV transmission to a proxy for perinatal 
mother-to-infant transmission. Accordingly an inverse association between birth order and HCC 
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is predicted. To reflect perinatal transmission, birth order should include miscarriages and 
stillbirths, and multiple pregnancies should be counted as one (Chapter 2). Unfortunately in the 
WATCH and HC4 study we did not count miscarriages and stillbirths and did not record 
whether the siblings included twins or triplets. Although the current primary interest is the effect 
of birth order in full siblings, the effect of birth order counted in all siblings (full and half 
siblings) is also presented. 
 
7.3.4. Blinding 
The study hypothesis was not disclosed to fieldworkers who administered the birth order 
questions to avoid information bias. In addition, laboratory technicians were blinded to the 
demographic information of participants, including their birth order. In the WATCH study, birth 
order was determined at the community screening before clinical assessment occurred. 
Therefore, study clinicians were blinded to the birth order of the participants. Consistency check 
programmed in the electronic questionnaire avoided entering of implausible values (e.g. 
fifth-born in a family with sibship of three). 
 
7.3.5. Laboratory assays  
HBsAg status was determined using the point-of-care test (Determine, Alere, USA) in the field 
for the WATCH study and in the laboratory for the HC4 study. HBsAg-positive samples were 
tested for hepatitis B e antigen (HBeAg) using ELISA (ETI-EBK Plus, Diasorin, Italy), and 
quantified for HBV DNA using in-house real time quantitative polymerase chain reaction 
(qPCR). Alanine transaminase (ALT) was measured using VITROS 350 analyser (Ortho, USA). 
Alpha-fetoprtein level was quantified using Microparticle Enzyme Immunoassay (MEIA, 
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AxSYM AFP, Abbott, USA). Antibodies to Hepatitis C virus (anti-HCV) and Hepatitis D Virus 
(anti-HDV) were detected using MEIA (AxSYM, anti-HCV, Abbott, USA) and ELISA 
(ETI-AB-DELTAK-2, Diasorin, Italy). Antibodies to HIV-1 and HIV-2 and HIV p24 antigen 
were detected using enzyme immunoassay (EIA, Genscreen ULTRA HIV Ag-Ab, Bio-Rad, 
USA). 
 
7.3.6. Statistical analyses 
7.3.6.1. Attendance at screening 
The attendance rate at screening was estimated by dividing the number of screening participants 
by the number registered as eligible. The estimates and confidence intervals accounted for 
survey design (stratification and clustering). The stratification weight for people from rural EAs 
was obtained by dividing the population in whole rural Western Gambia in 2003 census by the 
total number of eligible people in 27 rural EAs that were selected. Similarly, the urban weight 
was the population of urban Western Gambia in 2003 divided by the total number of eligible 
people in 27 urban EAs that were selected. The effect of each individual-level variable (sex and 
age) and each area-level variables (variables defined at each EA level: urban or rural area, 
average household size, major ethnic group, time elapsed since the start of the screening project, 
season, length of screening, screening during weekend and involvement of village health worker) 
on screening attendance was estimated using logistic regression, which allowed for clustering 
and stratification. A minimally sufficient set of a priori confounders of the association between 
each of the area-level variables and attendance was identified from a causal diagram (figure 7.3) 
by applying the backdoor test.
263
 Based on the causal diagram the odds ratio (OR) for the 
association between each community factor (urban or rural area, average household size and 
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major ethnic group in the EA) and screening participation was adjusted for sex, age and the 
other community factors. ORs for time-related factors (whether the screening took place in the 
first year or second year of the project, and in the dry or rainy season) were adjusted for 
community factors and for the other time-related factors. Factors related to logistics (length of 
screening and number of days in weekend in the EA, and involvement of village health worker) 
were adjusted for community factors, time-related factors and other logistic factors. The major 
ethnic group in the EA was defined to be the one with more than 50% of participants. When no 
ethnic group constituted ≥50%, the EA was categorised as “mixture”. 
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Figure 7.3 Causal diagram for the factors associated with attendance at screening 
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7.3.6.2. HBsAg prevalence in the Western Gambia 
The prevalence of positive HBsAg in the Western Gambia was estimated by dividing the 
number of HBsAg-positive people by the number of screening participants. The estimates 
accounted for stratification and clustering in the survey design, and non-attendance at screening. 
The non-attendance weight was the reciprocal of the attendance probability obtained from 
logistic regression in which age group, sex and EA were predictors. A weighted logistic 
regression was used to estimate ORs for the associations between potential risk factors and 
presence of HBsAg. The weights were used to adjust for stratification and non-attendance, and 
confidence intervals were adjusted for clustering by EA. Potential confounders were identified 
using the causal diagram (figure 7.4). ORs for the association between determinants (age, 
birthplace, ethnic group and total number of siblings from the biological parents as proxy for 
parental socioeconomic status) and positive HBsAg were mutually adjusted for the other 
determinants. The OR for birth order was adjusted for age, birthplace, ethnic group and total 
number of siblings. And the OR for current address (urban or rural) was adjusted for age, 
birthplace, ethnic group, total number of siblings, sex and birth order.  
 
To explore whether a change in HBsAg prevalence with increasing age can be explained by a 
spontaneous HBsAg loss over time and death related with CHB infection, the age- and 
sex-specific HBsAg sero-clearance rate and sex-specific mortality rate with end-stage liver 
disease derived from the cohort study in three rural villages (Chapter 6) was applied to the 
HBsAg prevalence in the lowest age group (30-39 years). The prevalence, pn, in age group n 
was estimated from the prevalence in preceding age group n-1, separately for males and females 
using the equation: 
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pn = pn-1 * (1 – qn-1 – r) / (1 - pn-1 * r) 
 
where qn-1 is HBsAg sero-clearance rate (per one carrier in 10 years) in previous age group, and 
r is mortality rate with HBV-related end-stage liver disease (per one carrier in 10 years). 
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Figure 7.4 Causal diagram for the factors associated with positive HBsAg 
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7.3.6.3. Attendance at liver clinic at MRC 
The rate of attendance at the liver clinic in people who tested positive for HBsAg in the Western 
Gambia was estimated by dividing the number who consented to take part in the liver 
assessment by the number tested positive at the community-screening. The estimates of the 
attendance rate and ORs for the association between potential predictive factors and clinic 
attendance accounted for clustering and stratification in the survey design, and non-attendance 
at screening. Logistic regression was used to estimate ORs for the effect of individual-level 
variables (sex, age, ethnic group, birthplace and total number of siblings from the biological 
parents as proxy for parental socioeconomic status) on the clinic attendance, and was adjusted 
for other individual level variables. To estimate the effect of birth order on participation,
208
 the 
OR was adjusted for the other individual-level variables (sex, age, ethnic group, birthplace and 
total number of siblings) based on the causal diagram (figure 7.5). The OR for current residence 
(rural or urban) was adjusted for the individual-level variables including birth order. ORs for 
time-related factors (first or second year of the project, season of the screening) were adjusted 
for the current residence and for the other time-related factors. And the ORs for logistic factors 
(fieldwork experience of staff who provided the post-test counselling and involvement of 
village health worker in the screening) were adjusted for the current residence, time-related 
factors and for the other logistic factors.  
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Figure 7.5 Causal diagram for the factors associated with attendance to the liver clinic at the 
MRC, Fajara 
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7.3.6.4. Association of birth order with the predictors of HCC 
The association between birth order and predictors of HCC (active CHB disease, significant 
liver fibrosis defined as LSM ≥7.5 kPa with transient elastography and condition requiring 
antiviral therapy according to the EASL (European Association of the Study of the Liver) 
guidelines
70
) was estimated using logistic regression. The analysis was conducted in 
HBsAg-positive people from the community-based screening who had clinical assessment at the 
liver clinic. The survey design (cluster sampling and stratification) and non-attendance at 
screening (see above) were accounted for in the analysis. In addition, the non-attendance weight 
to the clinic, which was the reciprocal of the attendance probability obtained from logistic 
regression in which age group, sex and current residence were predictors, was taken account. 
The definitions of active CHB disease, significant liver fibrosis and antiviral treatment criteria 
were the same as those used in the cohort study (Chapter 6). 
 
The effect of birth order on the predictors of HCC was adjusted for a priori confounders by 
applying the backdoor test in a causal diagram (figure 7.2).
263
 {Year of birth, birthplace, ethnic 
group and parental socioeconomic status (SES)} was identified as a minimally sufficient set of a 
priori confounders for the association between birth order and liver diseases (causal diagram is 
the same as the one in Chapter 5). As in Chapter 5, two different proxy markers for parental 
SES were used: parental schooling in model 1 and total sibship size in model 2. Age was used in 
the analyses instead of their year of birth, but this is a good proxy measure as participants were 
recruited within two years (from December 2011 to January 2014). 
 
7.3.6.5. Association of birth order with HCC 
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The association between birth order and HCC was estimated using logistic regression to 
compare HBsAg-positive HCC cases with HBsAg-positive population-based controls (first 
control group), and HBsAg-positive hospital-based controls (second control group). As the first 
control group should represent HBsAg positive population in The Western Gambia, the analysis 
used weights to account for stratification and non-attendance to the screening and the clinic, and 
adjusted confidence intervals for clustering by EA (see above). The probability of being 
recruited in the study was assumed to be 99% in the HCC cases and they were weighted 
accordingly (there were only 2 refusals and one death during the consultation). The ORs for the 
effect of birth order on HCC were adjusted for the same set of a priori confounders used to 
estimate the effect of birth order on the predictors of HCC (see above). 
 
7.4. Results 
7.4.1. Attendance at screening 
From December 2011 to January 2014, 27 urban and 27 rural EAs were screened, and 3,785 and 
4,385 people ≥30 years old were registered as eligible for the screening, respectively (figure 
7.6). The number registered varied from 33 in Banjul North (urban EA) to 424 in Basori (rural 
EA), with a median of 123 people/EA. The median number of adults attending the community 
sensitisation meeting was 30, ranging from 5 in Jalanbang to 110 in Basori (both are rural EAs). 
The number of days that the team of fieldworkers spent for the screening in each EA ranged 
from 2 to 8 days (median 3 days), and 13 and 41 EAs were screened during the rainy (from June 
to September) and dry season (from October to May), respectively. 
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Of 8,170 eligible people, 5,980 (68.9%, 95% CI: 65.1-72.6%) agreed to take part in the 
screening. The response rate varied from 48.9% in Tallinding (urban EA) to 95.1% in 
N’demban Jola (rural EA). The response rate was higher in women (75.5%, 95% CI: 
71.9-79.0%) than in men (60.0%, 95% CI: 55.4-64.5%, p<0.001), and in the older age group 
(OR per 10-year increase in age: 1.2, 95% CI: 1.1-1.3, p<0.001) (table 7.3). There was evidence 
for an interaction between age and sex in relation to the screening attendance (p=0.04, test of 
homogeneity). In men, the response rate steadily increased from 63.0% (95% CI: 58.0-68.0%) 
in the age group 30-39 to 78.9% (95% CI: 75.0-82.9%) in ≥60 years old, respectively, whilst 
among women there was less of an increase (figure 7.7).  
 
Areas where average household size was larger (OR 2.1, 95% CI: 1.6-2.7, p<0.001), and areas 
where the screening took place on weekends (OR 1.4: 1.0-1.9, p=0.05) were associated with 
higher participation (table 7.3). There was weak evidence that people in Jola community 
participated more than those in Mandinka community (OR 1.6, 95% CI: 1.0-2.5). Although the 
rural population had higher attendance than in urban population in the crude analysis (79.1%, 95% 
CI: 75.1-83.1% versus 66.3%, 61.7-71.0%), the association disappeared in the multivariable 
analysis because the rural population was older than the urban population (mean age: 46.7 ± 
14.3 versus 44.1 ± 12.6 years, p=0.0001).  
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Figure 7.6 Flow chart of study participants in WATCH study and HC4 study 
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There are three case-control comparisons. First is between HBV-related HCC cases ≥30 years 
old recruited from the Western Gambia (n=51) and HBsAg-positive people from the 
community-based screening (n=392). Second is between all HBV-related HCC cases (n=72) 
and HBsAg-positive non-HCC patients ≥20 years old (n=63). Third is between HBsAg-negative 
HCC cases ≥30 years old recruited from the Western Gambia (n=43) and HBsAg-negative 
people from the community-based screening (n=301). Parenthesis presents the number of 
subjects who could report the number of full siblings/the number of half siblings. 
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Table 7.3 Attendance at screening, Western Gambia, 2011-2014 
 Total 
eligible 
(8,170)
 
Percent 
attended 
 
p-value
 
Odds ratio 
OR 95%CI p-value 
1. Individual-level variables
2 
      
Sex Male 3,523 60% <0.0001 1.0  <0.001 
Female 4,646 76%  2.1 1.8-2.4  
Age group 30-39 3,259 72% <0.0001
1 
1.0  <0.001
1
 
40-49 1,822 77%  1.3 1.1-1.5  
50-59 1,211 78%  1.4 1.2-1.7  
≥60 1,347 81%  1.7 1.5-2.0  
2. Area-level variables       
2-1. Community factors
3 
      
Area Urban 3,785 66% 0.0001 1.0  0.9 
Rural 4,385 79%  1.0 0.7-1.4  
Average household 
size 
<8.5 4,098 64% <0.0001 1.0  <0.001 
≥8.5 4,072 79%  2.1 1.6-2.7  
Major ethnic group Mandinka 3,169 71% 0.05 1.0  0.09 
Jola 1,789 81%  1.6 1.0-2.5  
Mixture 3,212 66%  1.2 0.9-1.6  
2-2. Time-related factors
4
       
Time since project 
started 
1
st
 year 4,162 68% 0.5 1.0  0.5 
2
nd
 year 4,008 70%  1.1 0.8-1.5  
Season Dry 6,095 68% 0.5 1.0  0.6 
Rainy 2,075 72%  1.1 0.8-1.6  
2.3. Logistic factors
5 
      
Number of days for 
screening in the area 
<4 days 4,169 68% 0.7 1.0  0.6 
≥4 days 4,001 70%  0.9 0.7-1.3  
Number of days in 
weekend in the area 
0-1 day 5,799 67% 0.02 1.0  0.05 
2 days 2,391 74%  1.4 1.0-1.9  
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Involvement of 
village health 
worker 
No 5,856 68% 0.005 1.0  0.6 
Yes 2,314 79%  1.2 0.7-2.2  
Point estimates (percentages and ORs) were weighted for stratification. p-values and 95% CIs 
accounted for survey design (cluster sampling and stratification). 
1 
Test for trend 
2 
Crude odds ratios are presented. 
3 
OR from multivariable model which included sex, age, rural/urban area, household size and 
major ethnic group.  
4 
OR from multivariable model which included rural/urban area, household size, major ethnic 
group, time since project started and season.  
5 
OR from multivariable model which included rural/urban area, household size, major ethnic 
group, time since project started, season, number of days spent in the area, number of days in 
weekend spent in the area, and village health worker involvement. 
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Figure 7.7Attendance rate to the screening by age and sex  
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7.4.2. Reasons for non-attendance 
A similar proportion of men could not attend due to absence (35.4%, 95% CI: 28.0-42.9%) or 
refusal (37.9%: 31.2-44.5%), but refusal (48.9%: 40.6-56.8%) was a more common reason for 
non attendance in women than absence (26.9%: 21.6-32.1%) (table 7.4). The most common 
reason for absence in men was work, and in women the most common reasons were travelling 
or social gathering. For both sexes, “no benefit” was the most common reason for refusal. 
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Table 7.4 Reasons for non-attendance by sex, Western Gambia, 2011-2014 
 Male (n=1,195) Female (n=994) 
Number Percentage 
adjusted for 
sample design 
Number  Percentage 
adjusted for 
sample design 
Absence 440 35% 274 27% 
  Work 215 52% 82 30% 
  Travelling/social gathering 165 37% 172 64% 
  Details unknown 60 11% 20 6% 
Refusal 443 38% 480 49% 
  No benefit 284 64% 283 60% 
  Too busy 35 10% 30 8% 
  Feeling ill 26 6% 29 6% 
  Husband refused N/A N/A 43 8% 
  Afraid of bleeding 12 2% 9 2% 
  No trust in MRC 4 1% 7 1% 
  Already tested before 3 1% 1 1% 
  Details unknown 79 16% 78 15% 
Unknown 312 27% 240 24% 
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7.4.3. HBsAg prevalence in the community-based screening 
Of 5,980 people screened for HBsAg in the Western Gambia, 495 (8.8%, 95% CI: 7.9-9.7%) 
tested positive. The prevalence varied according to the EA from 1.9% (1/52) in Bundung (urban 
EA) to 18.2% (12/66) in Gunjur (rural EA). The prevalence in men (10.5%, 239/2328, 95% CI: 
8.9-12.1%) was higher than that in women (7.6%, 256/3652, 95% CI: 6.5-8.7%, p=0.004) (table 
7.5). In both sexes, the prevalence decreased with age: 16.1% (95% CI: 13.0-19.1%), 9.1% 
(6.1-12.1%), 6.4% (3.4-9.5%) and 4.0% (1.9-6.2%) in men and 9.5% (7.9-11.1%), 7.6% 
(5.5-9.7%), 3.9% (1.5-6.3%) and 4.4% (1.5-7.2%) in women, in the age group of 30-39, 40-49, 
50-59 and ≥60 years old, respectively (figure 7.8). There was no evidence of an interaction 
between age and sex on HBsAg positivity (p=0.1). Figure 7.9 presents age- and sex-specific 
HBsAg prevalence derived from a model to which the age- and sex-specific HBsAg 
seroclearance rate and sex-specific mortality rate with end-stage liver disease in Keneba 
Manduar Cohort (Chapter 6) were applied. In women, except in the age group of 50-59 years, 
the reduction in prevalence is predicted by the model. In contrast, in men, the decay in HBsAg 
prevalence was much faster than the model prediction. 
 
HBsAg prevalence also varied by ethnicity (low in Jola and Fula and high in minor ethnic 
groups (e.g. Manjago, Serere, or Balanta)) and birthplace (low in rural Gambia, high in 
foreigners and middle in urban Gambia).  
 
There were positive associations between the number of full siblings and HBsAg (p=0.003), and 
between number of all siblings (full and half) and HBsAg (p=0.02). The prevalence of HBsAg 
increased with increasing birth order in full siblings: 6.7% (95% CI; 5.6-7.8%), 8.2% 
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(6.8-9.7%), 9.2% (6.8-11.7%), 9.6% (6.1-13.1%) and 12.0 % (8.3-15.7%) in 1
st
, 2
nd
, 3
rd
, 4
th
, and 
≥5th birth order. The positive association remained after adjusting for age, ethnicity, birthplace 
and number of full siblings (OR per unit increase in birth order in full siblings: 1.1, 95% CI: 
1.0-1.2, p=0.03). In contrast, there was no association when the number of siblings included 
both full- and half-siblings. HBsAg prevalence did not differ between urban and rural residence. 
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Table 7.5 Prevalence of hepatitis B surface antigen (HBsAg), Western Gambia, 2011-2014 
 Total 
screened 
(5,980)
 
% HBsAg 
positive  
 
p-value
 
Odds ratio 
OR 95%CI p-value 
Sex
2 
Male 2,328 10.5 0.004 1.0  0.004 
Female 3,652 7.6  0.7 0.6-0.9  
Age group
3 
30-39 2,397 11.9 <0.0001
1 
1.0  <0.001
1 
40-49 1,456 8.2  0.7 0.5-0.9  
50-59 988 5.1  0.4 0.3-0.6  
≥60 1,127 4.2  0.3 0.2-0.5  
Ethnicity
3 
Mandinka 2,455 8.5 0.2 1.0  0.04 
Jola 1,397 7.6  0.9 0.6-1.3  
Fula 763 7.7  0.9 0.5-1.4  
Wolof 469 9.7  1.2 0.8-1.7  
Others 891 11.3  1.4 1.0-1.8  
Birth 
place
3
 
Urban Gambia 1,250 10.0 0.006 1.0  0.03 
Rural Gambia 4,037 7.5  0.8 0.6-1.0  
Foreigners 686 11.6  1.3 0.9-1.7  
  Senegal 427 11.4     
  Bissau 97 14.6     
  Conakry 96 6.8     
  Others 68  16.2     
Number of 
full 
siblings
3 
1-2 886 5.9 <0.001
1 
1.0  0.003
1
 
3-4 1,333 8.3  1.5 1.0-2.3  
5-6 1,588 8.4  1.4 1.0-2.0  
7-8 1,223 10.0  1.6 1.1-2.4  
≥9 858 11.5  1.9 1.2-2.9  
Number of 
siblings 
0-5 1,022 5.3 0.002
1 
1.0  0.02
1
 
6-8 1,508 9.0  1.6 1.0-2.7  
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(full + 
half)
4
 
9-11 1,393 8.6  1.5 1.0-2.4  
12-14 866 10.4  1.8 1.2-2.9  
≥15 925 11.0  1.8 1.2-2.9  
Birth order 
in full 
siblings
5 
1
st
  1,935 6.7 0.001
1 
1.0  0.03
1
 
2
nd
  1,315 8.2  1.2 0.9-1.6  
3
rd
  951 9.2  1.2 0.9-1.8  
4
th
  630 9.6  1.3 0.9-2.1  
≥5th 1,048 12.0  1.6 1.0-2.5  
Birth order 
in siblings 
(full + 
half)
6
 
1
st
  1,136 7.3 0.04
1 
1.0  0.4
1 
2
nd
  965 7.8  1.1 0.8-1.5  
3
rd
 & 4
th
 1,477 8.4  1.1 0.8-1.5  
5
th
 & 6
th
  930 9.8  1.2 0.8-2.0  
≥7th 1,205 10.5  1.2 0.7-1.8  
Current 
residence
7 
Urban 2,511 8.9 0.4 1.0  0.5 
Rural 3,469 8.2  1.1 0.9-1.3  
Point estimates (percentages and ORs) were weighted for stratification and non-attendance to 
the screening. p-values and 95% CIs accounted for survey design (cluster sampling and 
stratification) and non-attendance to the screening.
 
1 
Test for trend 
2
 Crude odds ratio was presented. 
3 
OR from multivariable model which included age, ethnicity, birthplace and number of full 
siblings. 
4 
OR from multivariable model which included age, ethnicity, birthplace and number of siblings 
(full + half). 
5 
OR from multivariable model which included age, ethnicity, birthplace, number of full siblings 
and birth order in full siblings. 
6 
OR from multivariable model which included age, ethnicity, birthplace, number of siblings 
(full + half) and birth order in all siblings (full + half). 
7 
OR from multivariable model which included sex, age, ethnicity, birthplace, number of full 
siblings, birth order in full siblings and current residence. 
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Figure 7.8 Prevalence of positive-HBsAg by age and sex  
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Figure 7.9 Age- and sex-specific prevalence of positive-HBsAg in the WATCH study and from 
a model applying the age- and sex-specific HBsAg seroclearance rate and sex-specific mortality 
rate with end-stage liver disease in Keneba Manduar Cohort (Chapter 6) to the HBsAg 
prevalence in previous age group 
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7.4.4. Proportion previously tested for HBsAg 
From August to November 2013, as part of an ancillary study, residents in six enumeration 
areas (2 urban and 4 rural) were asked if they had previously been tested for HBV. Of 489 
individuals questioned, 2 (0.4%, 0.0-1.6%) men aged 37 and 41 years reported that they had 
been tested before for HBV infection. Both men were negative for HBsAg on both occasions.  
 
7.4.5. Attendance at liver clinic 
Of 495 HBsAg-positive people, 392 (78.3%, 95% CI: 72.1-84.5%) visited the liver clinic.  
Participation was highest in the age group 50-59 years in both sexes although this was not 
statistically significant (table 7.6 and figure 7.10). None of the other factors examined were 
associated with clinic attendance. 
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Table 7.6 Attendance at the liver clinic at the MRC, Western Gambia, 2011-2014 
 Total 
HBsAg 
positive 
(495)
 
Percent 
attended 
 
p-value
 
Adjusted odds ratio 
OR 95%CI p-value 
1. Individual-level variables
 
      
Sex
2
 Male 239 80% 0.6 1.0  0.8 
Female 256 77%  0.9 0.5-1.7  
Age group
2
 30-39 284 77% 0.8
1 
1.0  0.2
1 
40-49 117 78%  1.2 0.6-2.3  
50-59 47 92%  3.7 0.9-15  
≥60 45 78%  1.0 0.4-2.6  
Ethnicity
3
 Mandinka 207 82% 0.4 1.0  0.6 
Jola 100 83%  0.9 0.4-2.4  
Others 187 75%  0.7 0.4-1.4  
Birth place
2
 Urban Gambia 120 79% 0.1 1.0  0.2 
Rural Gambia 308 82%  1.2 0.5-2.8  
Foreigners 66 68%  0.6 0.2-1.3  
Number of 
full siblings
2 
1-2 55 81% 0.9
1 
1.0  0.6
1 
3-4 103 71%  0.5 0.2-1.4  
5-6 124 87%  1.3 0.5-3.4  
7-8 115 76%  0.7 0.3-1.9  
≥9 88 78%  0.9 0.3-2.6  
Number of 
siblings (full + 
half)
3
 
0-5 60 82% 0.5
1 
1.0  0.5
1 
6-8 121 74%  0.6 0.2-1.6  
9-11 114 78%  0.8 0.3-2.2  
12-14 83 86%  1.4 0.4-4.9  
≥15 96 78%  0.9 0.3-2.4  
Birth order in 1
st
  136 77% 0.8
1 
1.0  0.5
1 
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full siblings
4 
2
nd
  105 78%  1.1 0.5-2.2  
3
rd
  77 81%  1.4 0.6-3.2  
4
th
  64 83%  1.5 0.4-5.4  
≥5th 103 77%  1.0 0.5-2.2  
Birth order in 
siblings (full + 
half)
5
 
1
st
  91 79% 0.5
1 
1.0  0.6
1 
2
nd
  70 78%  1.0 0.4-3.0  
3
rd
 & 4
th
 120 79%  1.1 0.4-2.8  
5
th
 & 6
th
  83 88%  1.9 0.7-5.6  
≥7th 110 72%  0.6 0.3-1.5  
2. Community factors
6
       
Current 
residence
 
Urban 218 78% 0.6 1.0  0.9 
Rural 277 80%  1.0 0.5-1.8  
3. Time factors
7
       
Time since 
project started 
1
st
 year 250 80% 0.5 1.0  0.7 
2
nd
 year 245 77%  0.9 0.4-1.7  
Season Dry 358 77% 0.4 1.0  0.5 
Rainy 137 83%  1.5 0.5-4.0  
4. Logistic factors
8 
      
Staff experience 
(years) 
<5 145 74% 0.2
1 
1.0  0.1
1 
5-14 183 80%  1.5 0.9-2.4  
≥15 167 82%  1.6 0.8-3.0  
Involvement of village 
health worker 
No 347 78% 0.2 1.0  0.1 
Yes 148 85%  1.8 0.8-4.1  
Point estimates (percentages and ORs) were weighted for stratification and non-attendance to 
the screening. p-values and 95% CIs accounted for survey design (cluster sampling and 
stratification) and non-attendance to the screening.
 
1 
Test for trend 
2 
OR from multivariable model which included sex, age, ethnic group, birthplace and number of 
full siblings.  
3 
OR from multivariable model which included sex, age, ethnic group, birthplace and number of 
siblings (full + half).  
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4 
OR from multivariable model which included sex, age, ethnic group, birthplace, number of full 
siblings and birth order in full siblings..  
5 
OR from multivariable model which included sex, age, ethnic group, birthplace, number of 
siblings (full + half) and birth order in all siblings (full + half)..  
6 
OR from multivariable model which included sex, age, ethnic group, birthplace, number of full 
siblings, birth order in full siblings and rural/urban area.  
7 
OR from multivariable model which included rural/urban area, time since project started and 
season.  
8 
OR from multivariable model which included rural/urban area, time since project started, 
season, experience of fieldworkers who performed a post-test counselling, and village health 
worker involvement. 
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Figure 7.10 Attendance rate to the liver clinic in HBsAg-positive people by age and sex 
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7.4.6. Characteristics of population-based HBsAg-positive controls 
At the enrolment, none of the HBsAg-positive participants from the screening met the HCC 
criteria. Of 392 HBsAg-positive controls, seven did not report the number of siblings. The 
characteristics of 385 HBsAg-positive controls are presented by birth order (full-siblings) in 
table 7.7. The number of full-siblings was highly correlated with the birth order in the 
full-siblings (p<0.0001). The remaining characteristics did not differ by birth order. 
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Table 7.7 Characteristics of HBsAg-positive controls from the community-based screening by 
birth order in full siblings, Western Gambia, 2011-2014 
 Birth order in full siblings (n=385) P 
1
st
 (105) 2
nd
 (83) 3
rd
 (64) 4
th
 (53) 5
th
 (80) 
Male sex 52 (54%) 37 (45%) 36 (60%) 24 (43%) 33 (42%) 0.3 
Median age (range) 38 (30, 
75) 
39 (30, 
80) 
36 (30, 
80) 
37 (30, 
65) 
37 (30, 
88) 
0.8
1 
Age group      0.7 
  30 – 39 58 (62%) 44 (54%) 39 (66%) 32 (68%) 47 (60%)  
  40 – 49 24 (21%) 23 (25%) 14 (14%) 11 (17%) 19 (25%)  
  ≥50 23 (17%) 16 (21%) 11 (20%) 10 (15%) 14 (15%)  
Ethnic group      0.07 
  Mandinka 46 (49%) 37 (37%) 28 (41%) 22 (25%) 33 (38%)  
  Jola 32 (21%) 15 (11%) 12 (20%) 14 (33%) 12 (7%)  
  Others 27 (30%) 31 (52%) 24 (39%) 17 (42%) 35 (55%)  
Birth place      1.0 
  Urban 23 (37%) 19 (35%) 16 (41%) 11 (39%) 24 (43%)  
  Rural  70 (48%) 52 (55%) 40 (46%) 37 (47%) 50 (46%)  
  Foreigners 12 (15%) 12 (10%) 8 (13%) 5 (14%) 6 (11%)  
Parental schooling      0.1 
  None 44 (42%) 35 (41%) 27 (35%) 29 (62%) 38 (40%)  
  One parent only 27 (22%) 13 (9%) 15 (26%) 12 (25%) 17 (20%)  
  Both parents 34 (36%) 35 (50%) 22 (39%) 12 (13%) 25 (40%)  
Number of full 
siblings 
     <0.0001 
1-2 31 (29%) 15 (20%) 0 0 0  
3-4 26 (26%) 17 (23%) 21 (27%) 13 (21%) 0  
5-6 17 (17%) 24 (27%) 18 (34%) 27 (59%) 17 (23%)  
7-8 17 (14%) 20 (23%) 18 (31%) 3 (2%) 32 (39%)  
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≥9 14 (14%) 7 (7%) 7 (8%) 10 (18%) 31 (38%)  
Current address      0.3 
  Urban  38 (78%) 36 (82%) 30 (86%) 21 (81%) 40 (87%)  
  Rural  67 (22%) 47 (18%) 34 (14%) 32 (19%) 40 (13%)  
Education level      0.6 
  None 29 (24%) 22 (25%) 10 (14%) 15 (29%) 21 (23%)  
  Koranic only 21 (18%) 25 (29%) 20 (30%) 14 (21%) 25 (28%)  
  Primary school or 
above 
54 (58%) 34 (46%) 32 (56%) 24 (50%) 33 (50%)  
Family history of 
HCC 
5 (5%) 5 (11%) 1 (2%) 0 5 (10%) 0.2 
Ever drunk alcohol 7 (13%) 5 (7%) 6 (16%) 4 (8%) 4 (4%) 0.3 
Ever smoked 
cigarettes 
40 (36%) 24 (24%) 20 (29%) 17 (34%) 17 (23%) 0.6 
Obesity (BMI≥30) 4 (3%) 8 (13%) 4 (7%) 5 (10%) 11 (18%) 0.09 
Abnormal ALT (≥40 
IU/L) 
11 (15%) 10 (15%) 9 (13%) 4 (2%) 8 (12%) 0.3 
HBeAg positive 2 (1%) 1 (3%) 3 (5%) 2 (1%) 2 (3%) 0.5 
High HBV DNA 
(>2,000 IU/ml) 
10 (6%) 8 (20%) 3 (8%) 6 (15%) 7 (12%) 0.4 
HIV positive 1 (0.4%) 1 (0.7%) 0 1 (0.7%) 2 (0.9%) 0.9 
HCV positive 0 0 2 (1%) 0 0 0.7 
HDV positive 1 (7%) 1 (2%) 0 0 1 (1%) 0.4 
Successful LSM
2 
     0.3 
  Failure 0 3 (6%) 1 (2%) 2 (5%) 1 (2%)  
  Unreliable 12 (11%) 4 (2%) 6 (11%) 8 (7%) 9 (13%)  
  Successful 93 (89%) 75 (92%) 56 (87%) 42 (88%) 69 (85%)  
Point estimates (percentages) were weighted for stratification and non-attendance to the 
screening and clinic. p-values accounted for survey design (cluster sampling and stratification) 
and non-attendance to the screening and clinic. 
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1
 Kruskal-Wallis test 
2
 Unreliable measurement defined as success rate of <60% and/or ratio of IQR and LSM 
exceeding 30%. 
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7.4.7. Factors associated with active chronic hepatitis B diseases 
Four HBsAg-positive controls from the community screening (1.2%, 95% CI: 0.0-2.6%) were 
immunotolerant, four (0.3%: 0.0-0.6%) were HBeAg-positive CHB disease, two (0.5%: 
0.0-1.3%) were HBeAg-positive unclassified, nine (3.4%: 0.8-5.9%) were HBeAg-negative 
CHB disease, 324 (81.8%: 75.1-88.5%) were inactive carriers and 49 (12.8%: 7.1-18.5%) were 
HBeAg-negative unclassified. Factors associated with active chronic hepatitis B disease (13/392, 
3.7%, 95% CI: 1.2-6.2%) are presented in table 7.8. Younger age group, higher parental 
education levels, a family history of liver cancer, HBeAg positivity and higher viral load were 
all associated with active chronic hepatitis B disease. Active chronic hepatitis B disease was not 
associated with birth order based on full-siblings or all siblings (full + half) (table 7.9).  
 
7.4.8. Factors associated with significant liver fibrosis or above 
Of 392, transient elastography was unavailable for seven. The measurement with transient 
elastography was classified as a failure in seven individuals (2.7%, 95% CI: 0.7-4.8%) and 40 
(9.5%: 5.2-13.7%) had unreliable measurements. The prevalence of significant liver fibrosis 
(LSM ≥7.5 kPa) was 13.2% (36/338, 95% CI: 6.5-19.8%). Male sex, higher parental education 
levels, higher education levels of the participants, and positive anti-HDV were all associated 
with significant liver fibrosis (table 7.8). Fewer full siblings, positive HBeAg, higher viral load 
and early birth order were marginally (0.05 < p <0.1) associated with significant liver fibrosis 
(table 7.8 and 7.9). The prevalence of significant liver fibrosis was 17.4% (95% CI: 2.5-32.3%), 
16.6% (6.4-26.9%), 13.6% (0.6-26.6%), 9.5% (0.0-22.4%), and 7.8% (0.0-16.6%), in 1
st
, 2
nd
, 3
rd
, 
4
th, and ≥5th birth order in full-siblings respectively (p = 0.06) (table 7.9). After adjusting for age, 
ethnicity, birthplace and number of full-siblings, there was no association between birth order in 
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full-siblings and significant liver fibrosis, whereas there was a significant association after 
adjusting for age, ethnicity, birth place and parental education levels (p = 0.04). Birth order was 
not associated with degree of liver fibrosis when defined using all siblings (full + half). 
 
7.4.9. Factors associated with requiring antiviral treatment 
The proportion of individuals who required antiviral treatment was 4.1% (16/392, 95% CI: 
1.5-6.7%). This was more common for men, younger ages, higher parental education levels, 
family history of liver cancer, ever smoked cigarettes, positive HBeAg and high viral load (table 
7.8). There was no association with birth order (table 7.9). 
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Table 7.8 Prevalence of active CHB disease, condition requiring the antiviral therapy and 
significant liver fibrosis or above in HBsAg-positive people from the community-based 
screening, Western Gambia, 2011-2014 
 Total examined  Successful liver 
stiffness 
measurement
2 
Total 
(392) 
Active CHB 
disease  
Requiring 
antiviral 
therapy 
Total 
(338) 
Significant 
liver fibrosis 
or above
 
% P % P % P 
Sex Male 188 6 0.1 7 0.05 174 20 0.02 
Female 204 2  1  164 5  
Age group 30 – 39 221 6 0.031 6 0.021 194 17 0.21 
40 – 49 94 0  1  83 6  
≥50 77 1  1  61 10  
Ethnic group Mandinka 170 5 0.2 5 0.4 146 12 0.9 
Jola 86 1  1  75 13  
Others 136 3  4  117 14  
Birth place Urban 94 5 0.6 4 0.7 79 15 0.4 
Rural  254 2  3  220 10  
Foreigners 44 6  7  39 20  
Parental 
schooling 
None 177 1 <0.001
1 
1 <0.001
1 
144 8 0.04
1 
One parent only 86 1  1  78 15  
Both parents 129 9  10  116 18  
Number of 
full siblings 
1-2 46 7 0.5
1 
6 0.7
1 
40 24 0.06
1 
3-4 77 7  7  70 18  
5-6 103 1  2  88 13  
7-8 90 2  3  74 6  
≥9 69 5  5  60 10  
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Number of 
siblings (full 
+ half)
 
 
0-5 48 9 0.6
1 
8 0.3
1 
41 12 0.1
1 
6-8 91 2  7  78 24  
9-11 91 4  1  78 9  
12-14 70 4  4  61 5  
≥15 78 3  3  67 12  
Current 
address 
Urban  168 4 0.9 4 0.7 144 14 0.3 
Rural  224 4  5  194 10  
Education 
level 
None 100 1 0.2
1 
2 0.06
1 
82 4 0.01
1 
Koranic only 107 5  3  97 6  
Primary school 
or above 
179 4  6  156 21  
Family 
history of 
liver cancer 
No 376 3 0.006 3 0.008 323 13 0.7 
Yes 16 19  19  15 18  
Ever drunk 
alcohol 
No 359 3 0.6 4 0.5 309 12 0.2 
Yes 28 7  8  27 21  
Ever smoked 
cigarettes 
No 262 3 0.4 2 0.02 220 11 0.1 
Yes 125 5  9  116 19  
Obesity 
(BMI≥30) 
No 352 4 0.1 5 0.3 316 14 0.3 
Yes 32 1  0  17 0  
HBeAg Negative 286 3 0.03 4 0.0001 246 11 0.06 
Positive 10 16  36  7 44  
HBV DNA 
(IU/ml) 
Undetectable 126 1 <0.001
1 
0 <0.001
1 
100 9 0.09
1 
50-200 71 0  1  67 8  
200-2,000 82 0  1  74 10  
2,000-100,000 22 17  29  18 30  
>100,000 13 61  55  11 26  
HIV Negative 256 4 0.7 6 0.3 219 12 0.4 
Positive 5 0  18  3 28  
HCV Negative 355 4 0.8 4 0.8 307 13 0.7 
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Positive 2 0  0  1 0  
HDV Negative 151 8 0.7 9 0.7 126 8 <0.001 
Positive 3 0  0  2 87  
Point estimates (percentages) were weighted for stratification and non-attendance to the 
screening and clinic. p-values accounted for survey design (cluster sampling and stratification) 
and non-attendance to the screening and clinic.
 
1 
Test for trend 
2
 Excluding participants with failure or unreliable measurements with transient elastography. 
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Table 7.9 Birth order and predictors of HCC (active CHB disease, significant liver fibrosis or above, and condition requiring the antiviral therapy) in 
HBsAg-positive people from the community-based screening, Western Gambia, 2011-2014  
Variables Prevalence 
with outcome
 
Crude OR (95% 
CI)
 
P
1 
Model 1 (parental 
schooling as proxy for 
parental SES)
 
Model 2 (total sibship size 
as proxy for parental SES) 
Adjusted OR 
(95% CI) 
P
1 
Adjusted OR 
(95% CI)
 
P
1 
1. Active CHB disease (n=13)        
Birth order in 
full siblings
3 
1
st
  3/105 (1%) 1.0 1.0
 
1.0 0.8
 
1.0 0.3
 
2
nd
  4/83 (10%) 8.9 (1.8-43.2)  13.6 (1.4-135.7)  24.3 (2.8-212.1)  
3
rd
  1/64 (1%) 0.3 (0.0-3.5)  0.3 (0.0-7.2)  0.1 (0.0-5.9)  
4
th
  2/53 (1%) 1.0 (0.1-6.4)  3.5 (0.2-51.5)  0.9 (0.1-16.2)  
≥5th 2/80 (5%) 4.0 (0.6-26.4)  6.5 (0.5-92.3)  18.8 (0.7-478.6)  
Not reported 7       
Birth order in 
siblings (full + 
1
st
  2/70 (1%) 1.0 0.4
 
1.0 0.5
 
1.0 0.3
 
2
nd
  2/56 (6%) 4.9 (0.6-41.0)  8.6 (0.3-279.4)  28.8 (1.2-700.1)  
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half)
4 
3
rd
 & 4
th
 4/97 (4%) 3.1 (0.4-24.5)  6.0 (0.2-206.9)  12.5 (0.4-367.2)  
5
th
 & 6
th
  0/71 (0%) N/A  N/A  N/A  
≥7th 4/84 (8%) 6.7 (1.3-35.9)  8.3 (0.3-196.6)  49.7 (0.8-3229)  
Not reported 14       
2. Significant liver fibrosis or 
above (n=36)
2 
       
Birth order in 
full siblings
3 
1
st
  11/92 (17%) 1.0 0.06 1.0 0.04
 
1.0 0.4
 
2
nd
  7/74 (17%) 0.9 (0.2-3.9)  1.0 (0.3-3.9)  1.2 (0.3-4.6)  
3
rd
  7/56 (14%) 0.7 (0.2-2.5)  0.7 (0.2-2.5)  1.0 (0.3-3.9)  
4
th
  6/42 (10%) 0.5 (0.2-1.3)  0.5 (0.2-1.6)  0.5 (0.1-2.1)  
≥5th 4/68 (8%) 0.4 (0.1-1.5)  0.4 (0.1-1.4)  0.7 (0.2-2.6)  
Not reported 6       
Birth order in 
siblings (full + 
half)
4 
1
st
  7/61 (18%) 1.0 0.2
 
1.0 0.1
 
1.0 0.3
 
2
nd
  6/51 (19%) 1.1 (0.2-5.5)  1.2 (0.3-5.0)  1.3 (0.4-4.9)  
3
rd
 & 4
th
 9/80 (10%) 0.5 (0.1-2.0)  0.4 (0.1-1.8)  0.5 (0.1-1.7)  
5
th
 & 6
th
  7/59 (13%) 0.7 (0.2-2.6)  0.8 (0.2-2.9)  0.8 (0.2-3.0)  
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≥7th 5/74 (8%) 0.4 (0.1-2.4)  0.3 (0.1-1.9)  0.5 (0.1-3.6)  
Not reported 13       
3. Requiring antiviral therapy 
(n=16) 
       
Birth order in 
full siblings
3 
1
st
  6/105 (4%) 1.0 0.7
 
1.0 0.8
 
1.0 0.9
 
2
nd
  4/83 (9%) 2.4 (0.4-14.0)  2.2 (0.2-27.1)  3.9 (0.4-35.8)  
3
rd
  1/64 (1%) 0.1 (0.0-1.1)  0.1 (0.0-1.1)  0.1 (0.0-1.8)  
4
th
  2/53 (1%) 0.3 (0.0-2.0)  0.6 (0.1-6.2)  0.4 (0.0-5.8)  
≥5th 2/80 (5%) 1.2 (0.2-8.9)  1.5 (0.1-20.1)  2.3 (0.2-34.5)  
Not reported 7       
Birth order in 
siblings (full + 
half)
4 
1
st
  4/70 (2%) 1.0 0.3
 
1.0 0.4
 
1.0 0.1
 
2
nd
  2/56 (4%) 1.8 (0.2-16.4)  2.2 (0.1-39.0)  4.2 (0.3-58.4)  
3
rd
 & 4
th
 3/97 (3%) 1.5 (0.2-11.7)  1.7 (0.1-25.5)  2.6 (0.2-33.4)  
5
th
 & 6
th
  3/71 (3%) 1.5 (0.2-12.1)  3.2 (0.2-57.7)  5.4 (0.3-93.6)  
≥7th 3/84 (7%) 3.2 (0.6-16.5)  3.0 (0.3-25.7)  13.9 (0.8-243.0)  
Not reported 14       
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Point estimates (percentages and ORs) were weighted for stratification and non-attendance to the screening and clinic. p-values and 95% CIs accounted for survey 
design (cluster sampling and stratification) and non-attendance to the screening and clinic.
 
1 
Test for trend 
2
 Excluding participants with failure or unreliable measurements with transient elastography. 
3 
OR from multivariable model which included age, ethnicity, birthplace, birth order in full siblings and parental education (model 1) or number of full siblings 
(model 2). 
4 
OR from multivariable model which included age, ethnicity, birthplace, birth order in siblings (full + half) and parental education (model 1) or number of siblings 
(full + half) (model 2). 
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7.4.10. Characteristics of HBV-related HCC cases and hospital-based HBsAg-positive controls 
Two-hundred forty-two patients were enrolled in the HC4 study from June 2012 to November 
2013 (figure 7.6). There were 72 HBsAg-positive HCC cases. The basis of diagnosis was 
histopathological confirmation (n=16), clinically confirmed (17) and clinically suspected (39). 
There was no imbalance between the groups in either the distribution of birth order or the 
distribution of potential confounders (confounders of the association of birth order with HCC) 
(table 7.2). The three groups were therefore pooled for the subsequent analyses. The first 
case-control analysis which compared HCC cases with HBsAg-positive population-based 
controls from the community-screening excluded two cases who were recruited outside the 
Western Gambia (one in Farafenni and one in Bansang Hospital) and 19 who were <30 years 
old at recruitment. 
 
Of 119 patients who did not have HCC, 63 were HBsAg-positive and aged ≥20 years, and were 
used as hospital-based controls (figure 7.6). Their final diagnoses were: liver cirrhosis (39, 
61.9%), chronic HBsAg carriers without HCC and cirrhosis (21, 33.3%) and other malignancy 
(3, 4.8%: one metastatic liver cancer, one gastric cancer and one lymphoma, all were clinically 
diagnosed using ultrasound and/or CT scan).  
 
7.4.11. HCC cases compared to population-based controls 
In the first-case control analysis male sex, older age group, ethnic groups other than Mandinka 
and Jola, rural born, lower parental education levels, lower education levels of the study 
participants, positive HBeAg, high HBV DNA levels, positive HIV, positive HCV and lower 
birth order in full-siblings to be significantly associated with HCC (table 7.10 and 7.11). Odds 
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ratios decreased with increasing birth order in full-siblings in the crude analysis: 1.00 
(reference), 0.79 (95% CI: 0.36-1.74), 0.65 (0.27-1.58), 0.62 (0.23-1.72) and 0.23 (0.07-0.74) in 
1
st
, 2
nd
, 3
rd
, 4
th, and ≥5th birth order, respectively (p = 0.009). After taking account of age, sex, 
ethnic group, birthplace and parental schooling (model 1), there was good evidence for an 
inverse association between birth order (full-siblings) and HCC (OR per unit increase in birth 
order: 0.72. 95% CI: 0.55- 0.95). There was also an inverse association based on the model that 
used the number of full-siblings as a proxy for SES (OR per unit increase in birth order: 0.70, 
95% CI: 0.53-0.93). Although there was a similar inverse association when birth order was 
defined to include full and half siblings, this did not reach statistical significance. 
 
7.4.12. HCC cases compared to hospital-based controls 
In the analysis that used HBsAg-positive hospital-based controls older age group, rural born, 
lower education levels of the study participants, no family history of liver cancer, positive 
HBeAg and high viral load were all significantly associated with HBV-related HCC cases (table 
7.10). There was a non-significant inverse association between birth order (full-siblings) and 
HCC in the crude analysis (table 7.11). After adjusting for confounding factors, there was a 
statistically significant association between birth order (full-siblings) and HCC: the OR per unit 
increase in birth order was 0.77 (95% CI: 0.59-1.00) in model 1 and 0.73 (95% CI: 0.54-0.98) in 
model 2. 
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Table 7.10 A comparison of HBV-related hepatocellular carcinoma cases with HBsAg-positive population controls and HBsAg-positive hospital controls 
 First case-control comparison Second case-control comparison 
HBsAg(+) 
HCC cases 
(N=51)
1 
HBsAg(+) 
population 
controls 
(N=392)
2 
Crude OR (95% 
CI) 
P
3
 HBsAg(+) 
HCC cases 
(N=72)
 
HBsAg(+) 
hospital 
controls 
(N=63)
4 
Crude OR (95% 
CI)
 
P
5
 
No. % No. % No. % No. % 
Sex Male 40 78 188 50 1.0 0.0002 54 76 50 81 1.0 0.6 
Female 11 22 204 50 0.3 (0.1-0.6)  17 24 12 19 1.3 (0.6-3.0)  
Median age (range)  43 (30, 
78) 
 38 (30, 
88) 
 
 
0.005
5
 40 (21, 
78) 
 35 (20, 
84) 
  0.1
5
 
Age group 20 – 29 0 0 0 0  0.0046 18 25 24 39 1.0 0.046 
30 – 39 16 31 221 61 1.0  17 24 16 26 1.4 (0.6-3.5)  
40 – 49 22 43 94 21 3.9 (1.9-8.2)  23 33 12 19 2.6 (1.0-6.5)  
50 – 59 8 16 40  10 3.0 (1.1-7.9)  8 11 6 10 1.8 (0.5-6.0)  
≥60 5 10 37  8 2.5 (0.8-7.6)  5 7 4 6 1.7 (0.4-7.1)  
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Ethnic group Mandinka 11 23 170  40 1.0 0.006 17 25 15 26 1.0 0.3 
Jola 4 8 86 17 0.9 (0.2-3.0)  5 7 9 15 0.5 (0.1-1.8)  
Others 34 69 136 44 2.8 (1.3-6.2)  47 68 35 59 1.2 (0.5-2.7)  
Birth place Urban 5 10 94 39 1.0 0.0003 8 12 20 34 1.0 0.01 
Rural  39 80 254 49 6.2 (2.3-16.8)  54 78 34 58 4.0 (1.6-10.0)  
Foreigners 5 10 44  12 3.1 (0.8-11.7)  7 10 5 8 3.5 (0.9-14.3)  
Parental schooling None 31 60 177 43 1.0 0.01
6
 40 56 24 38 1.0 0.2
6
 
One parent only 11 21 86  20 0.8 (0.4-1.6)  14 19 24 38 0.4 (0.2-0.8)  
Both parents 10 19 129 37 0.4 (0.2-0.8)  18 25 15 24 0.7 (0.3-1.7)  
Number of full siblings 1-2 7 14 46 11 1.0 0.7
6
 9 13 5 9 1.0 0.7
6
 
3-4 11 23 77 19 0.9 (0.3-2.7)  14 21 14 24 0.6 (0.1-2.1)  
5-6 10 20 103 29 0.5 (0.2-1.6)  18 26 23 39 0.4 (0.1-1.5)  
7-8 12 25 90 23 0.8 (0.3-2.3)  16 24 8 14 1.1 (0.3-4.4)  
≥9 9 18 69 18 0.8 (0.3-2.4)  11 16 8 14 0.8 (0.2-3.2)  
Number of siblings 
(full + half)
 
 
0-5 6 13 48 11 1.0 0.5
6
 8 13 10 19 1.0 0.4
6
 
6-8 16 35 91 25 1.2 (0.4-3.5)  19 30 15 28 1.6 (0.5-5.0)  
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9-11 8 17 91 23 0.7 (0.2-2.1)  15 24 13 25 1.4 (0.4-4.7)  
12-14 5 11 70 20 0.5 (0.1-1.7)  5 8 5 9 1.3 (0.3-5.9)  
≥15 11 24 78 21 1.0 (0.3-2.9)  16 25 10 19 2.0 (0.6-6.8)  
Current address Urban  39 80 168 83 1.0 0.7 53 77 49 83 1.0 0.4 
Rural  10 20 224  17 1.2 (0.5-3.2)  16 23 10 17 1.5 (0.6-3.6)  
Education level None 17 37 100  23 1.0 0.04
6
 24 36 11 18 1.0 0.04
6
 
Koranic only 12 26 107  25 0.7 (0.3-1.5)  16 24 18 30 0.4 (0.2-1.1)  
Primary school 
or above 
17 37 179  52 0.5 (0.2-1.0)  26 40 31 52 0.4 (0.2-0.9)  
Family history of liver 
cancer 
No 51 100 376 94 1.0 0.5 72 100 58 92 1.0 0.02 
Yes 0 0 16 6 N/A  0 0 5 8 N/A  
Ever drunk alcohol No 45 96 359 90 1.0 0.2 64 97 54 92 1.0 0.2 
Yes 2 4 28 10 0.4 (0.1-1.7)  2 3 5 8 0.3 (0.1-1.8)  
Ever smoked cigarettes No 26 55 262 69 1.0 0.07 40 61 35 59 1.0 0.9 
Yes 21 45 125 31 1.8 (0.9-3.6)  26 39 24 41 0.9 (0.5-1.9)  
HBeAg Negative 18 60 286 97 1.0 <0.001 20 50 22 79 1.0 0.02 
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Positive 12 40 10 3 25.8 (7.3-91.6)  20 50 6 21 3.7 (1.2-11.0)  
HBV DNA (IU/ml) Undetectable 2 5 126 43 1.0 <0.001
6
 2 4 7 23 1.0 0.03
6
 
50-200 4 11 71  20 4.3 (0.8-24.6)  5 11 4 13 4.4 (0.6-33.9)  
200-2,000 7 20 82  26 5.8 (1.1-30.1)  8 17 6 19 4.7 (0.7-31.0)  
2,000-100,000 7 20 22  6 23.4 (4.0-137.1)  10 22 3 10 11.7 (1.5-89.1)  
>100,000 15 43 13  5 60.7 
(12.0-307.8) 
 21 46 11 35 6.7 (1.2-37.8)  
HIV Negative 26 93 256 99 1.0 0.0001 33 94 24 92 1.0 0.8 
Positive 2 7 5  1 13.9 (2.5-76.7)  2 6 2 8 0.7 (0.1-5.5)  
HCV Negative 46 98 355 99 1.0 0.007 64 98 51 93 1.0 0.1 
Positive 1 2 2 1 13.5 (1.2-156.2)  1 2 4 7 0.2 (0.0-1.8)  
HDV Negative 26 96 151 97 1.0 0.8 30 94 22 92 1.0 0.8 
Positive 1 4 3 3 1.4 (0.1-16.2)  2 6 2 8 0.7 (0.1-5.6)  
P-value was obtained using chi-squared test unless indicated. 
1
 Excluding patients recruited outside the Western Gambia (n=2) and <30 years old (n=19). 
2
 Point estimates (percentages) were weighted for stratification and non-attendance to the screening and clinic.
 
3
 P-values accounted for survey design (cluster sampling and stratification) and non-attendance to the screening and clinic. 
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4
 Excluding patients <20 years old (n=6). 
5
 Wilcoxon rank-sum test 
6
 Test for trend 
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Table 7.11 Association between birth order and HCC in two case-control comparisons 
Variables HCC cases  Controls  Crude OR 
(95% CI)
 
P
1 
Model 1 (parental 
schooling as proxy for 
parental SES)
 
Model 2 (total sibship 
size as proxy for 
parental SES) 
Adjusted OR 
(95% CI) 
P
1 
Adjusted OR 
(95% CI)
 
P
1 
1. HBsAg(+) HCC cases vs. HBsAg(+) 
population controls
2 
        
Birth order in full 
siblings
3 
1
st
  18 (37%) 105 (24%) 1.0 0.009 1.0 0.02
 
1.0 0.01
 
2
nd
  12 (25%) 83 (20%) 0.8 (0.4-1.7)  0.6 (0.2-1.3)  0.5 (0.2-1.4)  
3
rd
  9 (18%) 64 (19%) 0.7 (0.3-1.6)  0.6 (0.2-1.7)  0.5 (0.2-1.6)  
4
th
  6 (12%) 53 (13%) 0.6 (0.2-1.7)  0.6 (0.2-1.9)  0.6 (0.2-2.1)  
≥5th  4 (8%) 80 (24%) 0.2 (0.1-0.7)  0.2 (0.1-0.7)  0.1 (0.0-0.6)  
Not reported 2 7       
Birth order in siblings 
(full + half)
4 
1
st
  12 (25%) 70 (16%) 1.0 0.2
 
1.0 0.3
 
1.0 0.6
 
2
nd
  7 (14%) 56 (15%) 0.7 (0.2-1.8)  0.4 (0.1-1.4)  0.6 (0.1-2.4)  
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3
rd
 & 4
th
 13 (27%) 97 (25%) 0.7 (0.3-1.6)  0.5 (0.2-1.4)  0.8 (0.2-2.9)  
5
th
 & 6
th
  8 (16%) 71 (20%) 0.5 (0.2-1.5)  0.3 (0.1-1.1)  0.5 (0.1-1.9)  
≥7th 9 (18%) 84 (24%) 0.5 (0.2-1.3)  0.7 (0.2-2.1)  1.0 (0.3-3.4)  
Not reported 2 14       
2. HBsAg(+) HCC cases vs. HBsAg(+) 
hospital controls
 
        
Birth order in full 
siblings
3 
1
st
  25 (37%) 12 (21%) 1.0 0.1 1.0 0.05
 
1.0 0.04
 
2
nd
  12 (18%) 10 (17%) 0.6 (0.2-1.7)  0.3 (0.1-1.0)  0.4 (0.1-1.3)  
3
rd
  9 (13%) 15 (26%) 0.3 (0.1-0.8)  0.2 (0.1-0.7)  0.2 (0.1-0.7)  
4
th
  11 (16%) 8 (14%) 0.7 (0.2-2.1)  0.6 (0.2-2.2)  0.7 (0.2-3.0)  
≥5th 11 (16%) 13 (22%) 0.4 (0.1-1.2)  0.3 (0.1-0.9)  0.2 (0.1-0.9)  
Not reported 4 5       
Birth order in siblings 
(full + half)
4 
1
st
  15 (22%) 5 (9%) 1.0 0.1
 
1.0 0.2
 
1.0 0.1
 
2
nd
  10 (15%) 7 (13%) 0.5 (0.1-1.9)  0.3 (0.1-1.5)  0.3 (0.1-1.8)  
3
rd
 & 4
th
 13 (19%) 15 (28%) 0.3 (0.1-1.0)  0.3 (0.1-1.0)  0.2 (0.0-0.8)  
5
th
 & 6
th
  14 (21%) 13 (24%) 0.4 (0.1-1.3)  0.3 (0.1-1.2)  0.2 (0.1-1.2)  
 294 
 
≥7th 15 (22%) 14 (26%) 0.4 (0.1-1.2)  0.3 (0.1-1.4)  0.2 (0.0-1.0)  
Not reported 5 9       
1 
Test for trend 
2 
Point estimates (percentages and ORs) were weighted for stratification and non-attendance to the screening and clinic. P-values and 95% CIs accounted for survey 
design (cluster sampling and stratification) and non-attendance to the screening and clinic. 
3 
OR from multivariable model which included age, ethnicity, birthplace, birth order in full siblings and parental education (model 1) or number of full siblings 
(model 2). 
4 
OR from multivariable model which included age, ethnicity, birthplace, birth order in siblings (full + half) and parental education (model 1) or number of siblings 
(full + half) (model 2). 
 295 
 
7.5. Discussion 
7.5.1. Attendance at screening and liver clinic 
The WATCH study is the first community-based screening programme for HBV infection in 
Africa, it aimed to identify chronic carriers who might benefit from antiviral therapy. The 
proportion who attended the screening was significantly higher in women than men. This is not 
surprising because women generally seek medical attention more frequently than men and are 
more likely to participate in screening programmes.
293–295
 For example, among the African 
Americans uptake of colorectal cancer screening (endoscopy or faecal occult blood test) is 
higher in women than in men.
296,297
 A qualitative study found: i) distrust in health care system, ii) 
fear of being seen by a doctor, and iii) the sexual connotation of having a colonoscopy, to be 
related with negative perceptions towards the colorectal cancer screening in African American 
men.
298
 In PROLIFICA, extensive qualitative work has not been undertaken. Therefore, it is 
difficult to understand the reasons for non-attendance. Nevertheless, lower attendance in men, 
particularly young men, can be partly explained by work-related absence during the screening 
campaign. This was also reflected in the finding that areas being screened during weekends had 
higher attendance rate although there was no evidence for an interaction between sex and 
weekend screening in relation to the screening attendance (p=0.4, test of homogeneity).  
 
The positive relationship between the areas with larger household size and higher uptake might 
be explained by better sharing of information in villages where people live in large traditional 
extended families. In this programme, information was disseminated by the alkalo (head of 
village, often from a founding family of the settlement), who invited inhabitants to a community 
sensitisation meeting. Although all members of the community were supposed to be invited to 
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the meeting, it was usually only village elders close to the alkalo and their family who attended. 
The alkalo and village elders themselves are also the head of large compound. This mode of 
communication might have favoured the areas with extended families. Moreover, a sense of 
collectivism within large family and within traditional communities might also have a 
favourable effect on screening participation, as demonstrated in a study of colorectal cancer 
screening in African Americans.
299
  
 
The most common reason for non participation in the screening was “no benefit”, which may be 
related with the lack of knowledge on HBV infection. A recent questionnaire survey in Nigeria 
found that only 10% of pregnant women attending an antenatal care at primary care facility had 
certain level of knowledge on HBV infection.
300
 Despite a prevailing belief in The Gambia that 
MRC steals the blood of study participants and sells it in Europe,
301
 only 1% said they did not 
trust the MRC. Attendance at the liver clinic in people notified to be infected with HBV was 
relatively good, and was similar in men and women and in different age groups. This suggests 
that pre- and post-test counselling at the screening site was effective. 
 
There are two lessons to be learn from this study. First attendance can be improved by opening 
the screening site during weekend. Second, alternative methods of communication, such as 
using the radio, should be considered in settlements where family sizes are small. 
 
7.5.2. HBsAg prevalence in the community-based screening 
There was a clear trend of decreasing HBsAg prevalence with age, and the prevalence was 
lower in women. These findings are not unique to The Gambia.
2,302
 Higher prevalence in men 
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can be explained by: i) higher risk of CHB infection in men than women despite similar risk of 
HBV exposure in both sexes,
62,303
 and ii) lower rate of spontaneous HBsAg seroclearance in 
men
77,90
 (Chapter 6). Possible explanations for the reduction with age are: i) spontaneous 
HBsAg loss over time, ii) higher mortality rate in people who continue to carry HBsAg, iii) low 
sensitivity of point-of-care test to identify chronic HBV carriers with low viral replication 
and/or low HBsAg levels, and iv) birth cohort effects. A birth cohort effect is unlikely, as the 
HBsAg prevalence in adults in The Gambia reported in previous studies is higher than the 
prevalence observed in this study (table 7.12). Nevertheless, most of the previous studies 
targeted people outside the Western Gambia or people recruited in hospitals, and thus care 
should be taken for this comparison. 
 
As shown in Figure 7.9, spontaneous HBsAg loss and death related with CHB infection alone 
could not explain the reduction in HBsAg-positivity with increasing age, especially amongst 
men. Another explanation could be the low sensitivity of point-of-care tests (Determine) in 
people with low level of HBsAg or viral replication.
304
 Older people are more likely to be 
inactive carrier state than in the immune tolerant phase (Chapter 6), and the former is associated 
with relatively low HBsAg levels and low HBV DNA levels.  
 
It was not surprising to observe differences in HBsAg prevalence by ethnic group and 
birthplace.
305
 For example, Keneba and Manduar, two adjacent villages situated 8km apart, have 
very different HBsAg prevalence in adults (9.9-13.9% versus 26.6-34.5%, respectively).
42,280
 
Although the exact mechanism of such a difference is unknown, it might be explained by the 
replication-infection cycle in a community;
160
 the number of infectious inhabitants (especially 
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mothers and children) determines the average age at HBV infection in a community, and the 
latter defines the persistence of the infection in individuals who later become a source of the 
infection in the community. The cycle is maintained because there is limited mixing between 
villages and might explain the regional or ethnic variation in HBsAg prevalence in The Gambia.  
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Table 7.12 Prevalence of HBsAg in Gambian adults (aged 15 year or more) without hepatitis B vaccination in previous studies 
Author, 
year 
Year 
of 
survey 
Area Target No 
tested 
% Anti-HBc(+) Test 
used 
% HBsAg(+) Test 
used 
% HBeAg(+) 
in HBsAg(+) 
people 
Test 
used 
1. Keneba Manduar         
Whittle, 
1983 
1980 Keneba Mothers 111 N/R  11 (9.9%) RPHA 0 (0%) RIA 
Manduar 58 20 (34.5%) 4 (20.0%) 
Whittle, 
1990 
1984 Keneba 15-19 years 
old 
47 N/R  8 (17.0%) RPHA 1 (12.5%) EIA 
Manduar 30 10 (33.3%) 5 (50.0%) 
Van der 
Sande, 
2006 
2003 Keneba ≥15 years old 632 N/R  88 (13.9%) IC 6 (6.8%) EIA 
Manduar 372 99 (26.6%) 9 (9.1%) 
Keneba & 
Manduar 
15-24 200 73 (36.5%) N/R 
25-34 207 50 (24.2%) 
35-49 146 22 (15.1%) 
50-69 194 33 (17.0%) 
≥70 115 9 (7.8%) 
2. GHIS         
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Vall 
Mayans, 
1990 
1988 Villages (LRR) Parents 839 94.3% (mothers) 
89.9% (fathers) 
RIA 115 (13.7%) RPHA 7/103 (6.8%) RIA 
Inskip, 
1991 
1986 Essau (NBR) 
and Brikama 
(WR) 
Fathers 242 226 (93.4%) RIA 25 (10.3%) RPHA 2 (8.0%) RIA 
Mothers 290 250 (86.2%) 39 (13.4%) 4 (10.3%) 
Chotard, 
1992 
1986 Essau (NBR), 
Brikama,(WR), 
Dankunku & 
Kudang (CRR), 
and Badjakunda 
& Yorobawal 
(URR) 
Mothers 1,000 N/R RIA 131 (13%, overall) 
Ranging from 8% in 
Essau to 18% in 
Dankunku & Kudan 
RPHA 18 (13.7%, 
overall) 
RIA 
Van der 
Sande, 
2007 
2004 N/R 15 years old 424 226 (53.3%) EIA 56 (13.2%) IC N/R  
Peto, 
2014 
2007-8 Villages in CRR 
& URR 
17-22 years 
old 
475 267 (56.2%) EIA 59 (12.4%) IC 17/65 
(26.2%)
 
EIA 
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3. Case-control study of HCC         
Ryder, 
1992 
1981-2 Neighbourhood 
controls 
15-49 38 N/R  9 (24%) RPHA 0 (0%) RIA 
50-72 29 4 (14%)  0 (0%)  
Kirk, 
2004 
1997- 
2001 
Hospital 
controls from 
RVTH, MRC 
and Bansang 
Hospital 
Overall 402 N/R  64 (15.9%) RPHA 2 (3.1%) RIA 
Men 286 52 (18.2%) 2 (3.8%) 
Women 116 12 (10.3%) 0 (0%) 
17-29, male 55 17 (30.9%) 0 (0%) 
30-39, male 49 9 (18.4%) 2 (22.2%) 
40-49, male 54 9 (16.7%) 0 (0%) 
50-59, male 59 10 (17.0%) 0 (0%) 
60-80, male 69 7 (10.1%) 0 (0%) 
19-29, female 27 4 (14.8%) 0 (0%) 
30-39, female 27 3 (11.1%) 0 (0%) 
40-49, female 24 2 (8.3%) 0 (0%) 
50-59, female 19 1 (5.3%) 0 (0%) 
60-75, female 19 2 (10.5%) 0 (0%) 
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Abbreviations: GHIS, Gambia Hepatitis Intervention Study; RPHA, reverse passive haemagglutination; IC, immunochromatography; EIA, enzyme 
immunoassay; WR, Western Region; LRR, Lower River Region; NBR, North Bank Region; CRR, Central River Region; URR, Upper River Region; 
N/R, not reported.
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7.5.3. Effect of birth order on HBsAg prevalence 
The prevalence of HBsAg increased with increasing birth order when the latter was defined by 
the number of full-siblings. This suggests that birth order is acting as a proxy for number of 
infectious older siblings and reflects the probability of early horizontal transmission, because 
early age at HBV infection increases the risk of chronic HBV infection,
68,69
 and in The Gambia 
infectious older siblings were the main source of HBV infection during childhood before the 
widespread use of HBV vaccines.
42,60,65
 The association between birth order and HBsAg 
positivity was linear, and not J- or U-shape that would have been observed if the perinatal 
mother-to-infant transmission also played a substantial role. This supports two previous 
observations which suggested that mother-to-infant transmission might not be important in 
maintaining the prevalence of CHB infection in The Gambia: the prevalence of HBeAg among 
HBsAg-positive mothers in The Gambia (6.8-13.7%)
55,114
 is lower than that in Asia (40%);
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and in Keneba and Manduar the risk of the youngest child in each household being sero-positive 
for HBsAg was strongly associated with the number of HBsAg-positive older siblings after 
adjusting for maternal HBsAg status in the pre-vaccination era.
60
 The latter is in contrast with a 
cohort study in Taiwan, which demonstrated that the association between having an 
HBeAg-positive mother and the incidence of postnatal HBV infection in the second and third 
year of life remained significant after adjusting for number of HBsAg-positive older siblings, 
whilst the association between the number of positive older siblings and the incidence of 
infection disappeared after controlling for maternal sero-status.
9
 
 
When birth order was defined to include half-siblings, the association between birth order and 
HBsAg was not statistically significant. The Gambia is patrilineal and polygamous society. 
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Co-wives may live in the same compound, but usually in separate dwellings within the 
compound, and children sleep in the mother’s room.42 This implies that children spend more 
time with full-siblings sharing the biological mother than half-siblings, and thus birth order 
counting half-siblings might have been less accurate to predict the probability of early 
horizontal transmission than birth order in full-siblings. This is in line with a study in Ghana 
which revealed that the number of HBsAg-positive individuals in the same household, rather 
than within the large domestic compound, were the main source of HBV infection for 
children.
52
 
 
7.5.4. Effect of birth order on HCC and its predictors 
Both case-control comparisons found an inverse association between birth order in full-siblings 
and HBV-related HCC. The results are in agreement with the findings from other studies in this 
thesis that perinatal mother-to-infant transmission might increase the risk of HCC and its 
predictors beyond its effect of increasing the risk of CHB infection (Chapter4-6). The direction 
of the association was opposite to the one observed between birth order and HBsAg prevalence. 
This agrees with the results in the Keneba and Manduar cohort study (Chapter 6); while the 
proportion of chronic carriers attributable to the mother-to-infant transmission is low (13.9%), 
the proportion of high-risk chronic carriers (who require the antiviral therapy) due to this mode 
of transmission is high (71.4%). The risk of CHB infection, historically a common event in The 
Gambia, is largely determined by the age at infection during childhood as indicated by the linear 
positive association with birth order. Of course, the risk of CHB infection should be even higher 
with perinatal maternal transmission,
68,69
 however, this mode is uncommon in The Gambia and 
therefore birth order mainly affects the probability of early horizontal transmission. In contrast, 
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the risk of HBV-related HCC, a rare event compared to CHB infection, is largely determined by 
the mode of transmission (perinatal maternal versus postnatal horizontal) rather than the timing 
of postnatal transmission (early versus late childhood) since the lowest risk of HBV-related 
HCC was observed in individuals with high birth order (≥5th birth order). 
 
The inverse associations between birth order and HCC in both case-control comparisons did not 
show a clear dose response. First and ≥5th birth order were associated with the highest and 
lowest risk of HCC respectively, however, the birth order between these (i.e., from 2
nd
 to 4
th
) 
had a similar risk. This could be explained by a maternal age at first birth and rate of 
spontaneous HBeAg loss in Gambian women. In The Gambia, average age at first birth is 
estimated at 21.4 years old (taken from a data in Senegal in 2010).
307
 According to the 
observation in Keneba and Manduar Cohort (Chapter 6), about half of HBsAg-positive women 
still have HBeAg at the age of 13, a beginning of reproductive age in The Gambia. Then, there 
is a steep decrease in proportion of HBeAg-positive women until the age of 20, by that time 
only 30% of carrier women are also positive for HBeAg (Figure 7.11). The rate of HBeAg loss 
becomes slower after the age of 20, and after the age of 30, more than 90% of women had 
already cleared HBeAg. This may explain the limited change in HCC risk between 2
nd
 and 4
th
 
birth order.  
 
The results are not consistent with the previous case-control studies in Greece where a positive 
association between birth order and HBV-related HCC was demonstrated in people with CHB 
infection.
187,194
 The discrepancy might be related to: i) a higher frequency of mother-to-infant 
transmission in The Gambia than in Greece, as suggested by higher HBeAg prevalence in 
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HBsAg-positive women of child-bearing age in The Gambia (6.8-13.7%)
55,114
 than in Greece 
(2.7%);
270
 ii) most of Greek mothers might have already lost HBeAg when they start having 
children (median age of first birth is 21.4 years in The Gambia and 31.2 years in Greece)
307
 and 
iii) selection bias due to differential participation between cases and controls according to their 
birth order. The latter was virtually eliminated for the current hospital-based case-control 
comparison, as the participation rate for the study was 98.8%. In addition, although the 
participation was low in the population-based controls (68.9% attended the screening and 78.0% 
of screening positive came for the liver assessment), attendance to the liver clinic was 
independent of birth order (table 7.6) and non-attendance weights were applied to each of the 
participants in the analysis such that their birth order distribution would be representative of the 
general population. 
 
Birth order was not associated with HCC when its definition included half siblings. For HCC 
risk, birth order acts as a proxy for maternal age at birth and therefore reflects the probability of 
perinatal maternal transmission. Including half-siblings in the definition of birth order is likely 
to have reduced the reliability of birth order as a proxy for maternal age.  
 
Amongst the predictors of HCC, only significant liver fibrosis was positively related with 
full-sibling birth order. Birth order was not associated with active CHB diseases or antiviral 
therapy. This may have been because of a lack of statistical power. 
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The risk factors for HCC and its predictors identified in this study (male sex, older age, ethnic 
group, birthplace, SES, positive HBeAg, high HBV DNA levels, and co-infection with HIV) 
have previously been reported.
308
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Figure 7.11 Proportion of women with CHB infection in Keneba and Manduar Cohort who 
cleared HBeAg as a function of age
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7.5.5. Study limitations 
Birth order was self-reported and participants who answered “I don’t remember” were excluded 
from the analysis. This might be a source of bias because those who cannot recall are more 
likely to be from larger families and have higher birth rank.
216
 However, the numbers excluded 
were small for both cases and controls; 3.9% (2/51) and 1.8% (7/391) in the first case-control 
comparison using population-based controls and 5.6% (4/72) and 7.9% (5/63) in the second 
case-control comparison using hospital controls, respectively.  
 
Maternal age at birth would be a closer proxy marker than birth order for the probability of 
perinatal maternal transmission. Indeed, an attempt was made to estimate the maternal age at 
birth by including a series of questions in the questionnaire (Appendix 7). Unfortunately 
maternal age at birth could only be estimated in 40.3% (158/392) of the population-based 
controls and in 28.1% (68/242) of hospital-based participants, because of recall error. Even in 
those who could answer the question, the accuracy of the information was questionable. 
Consequently, the effect of maternal age at birth was not evaluated. 
 
Although most of variables associated with HCC in the analysis using population-based controls 
were also found to be associated with HCC in another analysis using hospital-based controls, 
there were few exceptions. For example, male sex was a risk factor in the former analysis but 
not in the latter. Concern related with the use of the community control is that not all of them 
may afford to come to a hospital when they develop HCC. Thus, it is unclear whether gender is 
a genuine risk factor for HCC or the factor influencing one’s affordability to end up in a tertiary 
care hospital in The Gambia. 
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7.5.6. Public health implications 
The study confirmed that the major route of HBV infection in The Gambia is a postnatal 
sibling-to-sibling transmission. Therefore, even delayed administration of the first dose of 
hepatitis B vaccine (i.e. 1-2 weeks after the birth) should reduce the prevalence of CHB 
infection in The Gambia, as has been shown in vaccine trials.
173,238
 However, the study also 
implied that perinatal maternal transmission might be a risk factor for HCC. Consequently, the 
proportion of HBV-related HCC prevented by the delayed provision of the first vaccine would 
be smaller than the proportion of CHB infection prevented. In Taiwan, the reduction in 
incidence of paediatric HCC (64%) was not as dramatic as the reduction in the prevalence of 
CHB infection in children (93%) after the introduction of HBV vaccination programme in 
which the first dose was given within the first week of the birth.
309
 Interruption of perinatal 
mother-to-infant transmission of HBV needs to be considered in The Gambia. 
 
 
7.6. Summary 
A comparison of birth order in HBsAg-positive and –negative people from the 
community-based screening demonstrated that higher birth order is associated with higher risk 
of HBsAg-positivity. This is consistent with previous data from The Gambia which suggest that 
postnatal sibling-to-sibling transmission is the major mode of HBV transmission and early age 
at infection through infectious older siblings is an important risk factor for chronic HBV 
infection. In this context, the role of perinatal maternal transmission seems to be small in The 
Gambia. 
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In contrast, there was a significant inverse association between birth order and HCC in people 
with chronic HBV infection. This was confirmed in two different case-control comparisons, 
which suggest that early birth order - a proxy for young maternal age and high viral replication 
in mothers - may increase the risk of HCC. Provision of birth dose of HBV vaccine within 24 
hours of birth needs to be considered in sub-Saharan Africa where the perinatal mother-to-infant 
transmission might increase the risk of HCC.
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Chapter 8. Discussion 
 
 
8.1. Key results 
The hypothesis of this thesis is that early age at hepatitis B virus (HBV) infection increases the 
risk of hepatocellular carcinoma (HCC) and its predictors in The Gambia. In order to separate 
the effect of the early age at infection on the risk of chronic HBV (CHB) infection, which is 
already established,
68,69
 the analyses have been restricted to HBsAg positive individuals. The 
systematic review of Chapter 3 showed that early age at infection may increases the sequelae of 
CHB infection, but it did not include any studies from Africa. 
 
Data are presented from four studies in The Gambia, including two historical studies. The 
hepatitis B e antigeaemia study (Chapter 4) showed that having an hepatitis B e antigen 
(HBeAg)-positive mother was a risk factor for HBeAg positivity in children after adjusting for 
number of HBeAg-positive older siblings.  In a  historical sero-survey in Gambian children,  
the risk of the youngest child being sero-positive for hepatitis B surface antigen (HBsAg) was 
strongly associated with the number of HBsAg-positive older siblings after taking account for 
maternal HBsAg status.
60
 Together these findings suggest that the chance of CHB infection is 
largely determined by sibling-to-sibling transmission during early childhood whilst the risk of 
persistent viral replication (hepatitis B e antigenaemia) in those who already established chronic 
carrier state might be influenced by perinatal maternal transmission. 
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In Chapter 6, a community-based open cohort in rural villages in The Gambia was used to 
assess the effect of maternal HBsAg on HCC and its predictors. Having an HBsAg-positive 
mother was significantly associated with delayed HBeAg sero-clearance, higher viral load and 
alanine transaminase (ALT) levels over time, active CHB disease, advanced liver fibrosis and 
requiring antiviral therapy. Three end-stage liver disease cases had mothers with known HBV 
sero-status, and in all of them the mother was HBsAg-positive. The proportion of chronic HBV 
carriers attributable to maternal transmission was only 14%, whilst 71% of carriers requiring 
antiviral therapy according to the international treatment guidelines were due to maternal 
transmission. 
 
The association between birth order and HBV-related HCC was examined using data from a 
historical case-control study (Chapter 5) and data from the ongoing PROLIFICA project 
(Chapter 7). In both studies the risk of HCC was highest for first birth order, although the 
association was not statistically significant in the historic case control study. Data from the 
community-based screening in PROLIFICA suggested a positive association between birth 
order and HBsAg positivity in general population in the Western Gambia. 
 
These findings are consistent with the hypothesis that early age at HBV infection through 
perinatal maternal transmission increases the risk of HCC and its predictors in people with CHB 
infection. 
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8.2. Replication-infection cycle 
There were striking differences in the epidemiology of CHB infection between Asia and 
sub-Saharan Africa (sSA) in the pre-vaccination era, particularly with regard to the frequency of 
perinatal mother-to-infant transmission, the patterns of viral replication decay and the HCC 
incidence (Chapter 1). These differences probably reflect different “HBV replication-infection 
cycles”.160 In Asia, the persistence of viral replication is often observed beyond reproductive 
ages, leading to a higher prevalence of HBeAg-positive mothers. The infants born to these 
mothers have a markedly increased risk of developing chronic infection, and tend to suffer from 
a prolonged period of viral replication, which may lead to a higher incidence of cirrhosis and 
HCC. On the other hand, most African mothers with CHB infection do not have active viral 
replication, and transmission of HBV is therefore usually postponed until early childhood. 
Delayed age at HBV infection is associated with a lower chance of developing CHB infection, 
and may also reduce the duration of active viral replication. In this infection cycle loop, the 
critical time period for the epidemiology of CHB infection is the age at HBV infection (or the 
mode of transmission). This thesis provided the evidence to support this hypothesis at individual 
levels in The Gambia. 
 
 
8.3. Limitations in the interpretation 
There are several limitations related to the use of proxy measures for age at HBV infection (or 
mode of transmission). First, it is unclear whether the risk of HCC and its predictors differs 
between people who established the CHB infection during early childhood (1-3 years old) and 
those established during late childhood at school entry (6-8 years old). In the HBeAg study 
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(Chapter 4), risk of hepatitis B e antigenaemia in children still tended to increase with 
increasing number of HBeAg-positive older siblings after adjusting for maternal HBV status. 
Although the association was not statistically significant, this suggests that the timing of 
postnatal infection during childhood might affect the persistence of HBeAg. However, the 
results of birth order studies (Chapter 5 and 7) did not support this; no increment in HCC risk 
was observed in people with higher birth order (≥5), who should have higher chance of having 
had early postnatal transmission, compared to those with intermediate birth order (3 or 4).  
 
Second, having an HBeAg-positive (and particularly HBsAg-positive) mother does not always 
indicate in sSA that the chronic infection was perinatally established. As discussed in Chapter 1, 
the risk of perinatal transmission from an HBeAg-positive mother is low in sSA;
10
 accordingly 
without immunoprophylaxis the prevalence of HBsAg by the age of 9 months in children born 
to HBeAg-positive mother is 20-25% in sSA,
13,58,59
 compared with >90% in Taiwan.
37,38
 The 
incidence of HBV infection increases after 9 months in sSA, and being born to an HBsAg (or 
HBeAg) positive mother is an important risk factor for postnatal HBV infection.
13,17,61
 Many 
chronic carriers with an HBsAg (or HBeAg)-positive mother in sSA might therefore have been 
infected postnatally rather than perinatally. The thesis could not determine whether the higher 
risk of HCC and its predictors is specifically associated with perinatal maternal transmission or 
generally associated with maternal transmission irrespective of the timing of the infection.  
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8.4. Public health implications 
The results presented in this thesis suggest that the burden of HBV-related chronic liver disease 
in The Gambia might be reduced by interrupting maternal transmission. This can be achieved by 
providing the first dose of HBV vaccine as soon as after the birth.
116
 There is also good 
evidence that the use of hepatitis B immunoglobulin (HBIG) as an adjunct to hepatitis B vaccine 
further reduces the HBV infection in children born to HBeAg-positive mothers.
112
 However, the 
supply, safety and cost of HBIG prohibit its use in many areas including sSA.
116
  
 
Despite the WHO recommendation of a timely birth dose within 24 hours,
116
 only a few African 
countries provide monovalent HBV vaccine at birth.
117
 It is important to explore the 
cost-effectiveness of a timely birth dose in light of the findings from this thesis since previous 
modelling studies
103,310
 have assumed that the risk of HCC is not affected by age at infection 
once a CHB infection has become established. In addition, it needs to be determined what 
would be the most effective way to deliver the timely birth dose: universal timely birth dose or 
maternal HBV screening and subsequent selective birth dose to those born to infected mothers. 
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Appendix 1. Search strategy 
 
(1) Electronic Searches 
 
Following electronic databases were searched using the OvidSP search platform: 
 
 MEDLINE (1946 to January (week 2) 2012); 
 EMBASE (1974 to January (week 2) 2012); 
 CNKI (1979 to September (week 2) 2012); 
 SinoMed ( 1979 to September (week 2) 2012). 
 
(1-1) MEDLINE 
#1 explode “Hepatitis B”/ all subheadings or explode “Hepatitis B virus”/ all 
subheadings 
#2 hepatitis b or hepatitis-b or (type b adj1 hepatitis) or hbv or hep b or hbsag or 
hbs-ag or hbs antigen* or hbs-antigen* or hepatitis b surface antigen* or 
hepatitis-b surface antigen* 
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#3 “Alanine Transaminase”/ all subheadings 
#4 alanine transaminase* or alanine aminotransferase* or glutamic pyruvate 
transaminase* or ALT or ALAT or GPT or SGPT 
 
#5 “Hepatitis B e Antigens”/ all subheadings 
#6 hbeag or hbe-ag or hbe antigen* or hbe-antigen* or (hepatitis b adj3 e antigen*) 
or (hepatitis-b adj3 e antigen*) or ((type b adj1 hepatitis) adj3 e antigen*) or 
(hbv adj3 e antigen*) 
 
#7 “DNA, viral”/ all subheadings or “Virus replication”/ all subheadings 
#8 dna or replication* or viral titre or viral titer or viral load 
 
#9 “Liver Cirrhosis”/ all subheadings 
#10 cirrho* or ((liver or hepat*) adj3 fibro*) 
 
#11 “Carcinoma, Hepatocellular”/ all subheadings 
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#12 ((liver or hepat*) adj3 (cancer* or carcinom* or neoplasm* or malign* or 
tumo?r*)) or hcc or hepatoma 
 
#13 “Age Factors”/ all subheadings 
#14 age adj5 infect* 
 
#15 “Infectious Disease Transmission, Vertical”/ all subheadings 
#16 perinatal or peri-natal or vertical or MTCT or mother-to-child or mother to 
child or mother-child or mother child or mother-to-infant or mother to infant or 
mother-infant or mother infant or maternal-to-child or maternal to child or 
maternal-child or maternal child or maternal-to-infant or maternal to infant or 
maternal-infant or maternal infant or adult-to-child or adult to child or 
adult-child or adult child or adult-to-infant or adult to infant or adult-infant or 
adult infant or maternal-f?etal or maternal f?etal or f?etomaternal 
#17 postnatal or post-natal or horizontal or child-to-child or child to child or 
child-child or child child or sibling-to-sibling or sibling to sibling or 
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sibling-sibling or sibling sibling or between children or between siblings or 
between family or within household 
 
#18 “Birth Order”/ all subheadings 
#19 birth adj3 (order* or link*) 
 
#20 (serolog* or seropositiv* or serostatus) adj5 (famil* or parent* or father* or 
paternal or mother* or maternal or sibling* or brother* or sister*) 
#21 (hepatitis b or hepatitis-b or (type b adj1 hepatitis) or hbv or hep b or hbsag or 
hbs-ag or hbs antigen* or hbs-antigen* or hepatitis b surface antigen* or 
hepatitis-b surface antigen*) adj5 (famil* or parent* or father* or paternal or 
mother* or maternal or sibling* or brother* or sister*) 
 
#22 #1 or #2 
#23 #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 
#24 #13 or #14 
#25 #15 or #16 or #17 
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#26 #18 or #19 
#27 #20 or #21 
#28 #22 and #23 and #24 
#29 #22 and #23 and #25 
#30 #22 and #23 and #26 
#31 #22 and #23 and #27 
#32 #28 or #29 or #30 or #31 
 
(1-2) EMBASE 
#1 “hepatitis B”/ all subheadings or “hepatitis b B virus”/ all subheadings 
#2 hepatitis b or hepatitis-b or (type b adj1 hepatitis) or hbv or hep b or hbsag or 
hbs-ag or hbs antigen* or hbs-antigen* or hepatitis b surface antigen* or 
hepatitis-b surface antigen* 
 
#3 “alanine aminotransferase”/ all subheadings 
#4 alanine transaminase* or alanine aminotransferase* or glutamic pyruvate 
transaminase* or ALT or ALAT or GPT or SGPT 
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#5 “hepatitis B(e) antigen”/ all subheadings 
#6 hbeag or hbe-ag or hbe antigen* or hbe-antigen* or (hepatitis b adj3 e antigen*) 
or (hepatitis-b adj3 e antigen*) or ((type b adj1 hepatitis) adj3 e antigen*) or 
(hbv adj3 e antigen*) 
 
#7 “virus DNA”/ all subheadings or “virus replication”/ all subheadings 
#8 dna or replication* or viral titre or viral titer or viral load 
 
#9 “liver cirrhosis”/ or “decompensated liver cirrhosis”/ all subheadings 
#10 cirrho* or ((liver or hepat*) adj3 fibro*) 
 
#11 “liver cancer”/ or “ascites hepatoma”/ or “liver carcinoma”/ or “liver cell 
carcinoma”/ all subheadings 
#12 (liver or hepat*) adj3 (cancer* or carcinom* or neoplasm* or malign* or 
tumo?r*) or hcc or hepatoma 
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#13 “age”/ all subheadings 
#14 age adj5 infect* 
 
#15 “vertical transmission”/ all subheadings 
#16 perinatal or peri-natal or vertical or MTCT or mother-to-child or mother to 
child or mother-child or mother child or mother-to-infant or mother to infant or 
mother-infant or mother infant or maternal-to-child or maternal to child or 
maternal-child or maternal child or maternal-to-infant or maternal to infant or 
maternal-infant or maternal infant or adult-to-child or adult to child or 
adult-child or adult child or adult-to-infant or adult to infant or adult-infant or 
adult infant or maternal-f?etal or maternal f?etal or f?etomaternal 
 
#17 postnatal or post-natal or horizontal or child-to-child or child to child or 
child-child or child child or sibling-to-sibling or sibling to sibling or 
sibling-sibling or sibling sibling or between children or between siblings or 
between family or within household 
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#18 “birth order”/ all subheadings 
#19 birth adj3 (order* or link*) 
 
#20 (serolog* or seropositiv* or serostatus) adj5 (famil* or parent* or father* or 
paternal or mother* or maternal or sibling* or brother* or sister*) 
#21 (hepatitis b or hepatitis-b or (type b adj1 hepatitis) or hbv or hep b or hbsag or 
hbs-ag or hbs antigen* or hbs-antigen* or hepatitis b surface antigen* or 
hepatitis-b surface antigen*) adj5 (famil* or parent* or father* or paternal or 
mother* or maternal or sibling* or brother* or sister*) 
 
#22 #1 or #2 
#23 #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 
#24 #13 or #14 
#25 #15 or #16 or #17 
#26 #18 or #19 
#27 #20 or #21 
#28 #22 and #23 and #24 
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#29 #22 and #23 and #25 
#30 #22 and #23 and #26 
#31 #22 and #23 and #27 
#32 #28 or #29 or #30 or #31 
  
(1-3) CNKI 
(关键词=乙肝 or乙型肝炎 or HBV or HBsAgor 乙肝表面抗原) AND (关键词=ALT or 丙
氨酸氨基转移酶 or HBeAg or 乙肝核心抗原 or 肝癌 or 肝细胞癌 or肝硬化 or 肝纤维
化 or HBVDNAor HBV-DNA) AND (关键词=年龄 or 出生顺序分析 or垂直传播 or水平传
播 or家庭) 
 
(1-4) SinoMed 
1.主题词:肝炎, 乙型, 慢性/全部树/全部副主题词 -限定:- 
2.全部字段:乙肝 -限定:- 
3.全部字段:乙型肝炎 -限定:- 
4.全部字段:HBV -限定:- 
5.全部字段:hbsag -限定:- 
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6.主题词:丙氨酸转氨酶/全部树/全部副主题词 -限定:- 
7.全部字段:ALT -限定:- 
8.全部字段:丙氨酸氨基转移酶 -限定:- 
9.主题词:肝炎 e抗原, 乙型/全部树/全部副主题词 -限定:- 
10.全部字段:HBeAg -限定:- 
11.全部字段:乙肝 e抗原 -限定:- 
12.主题词:病毒复制/全部树/全部副主题词 -限定:- 
13.全部字段:DNA -限定:- 
14.全部字段:复制 -限定:- 
15.全部字段:病毒滴度 -限定:- 
16.全部字段:病毒载量 -限定:- 
17.主题词:肝硬化/全部树/全部副主题词 -限定:- 
18.全部字段:肝纤维化 -限定:- 
19.主题词:肝肿瘤/全部树/全部副主题词 -限定:- 
20.主题词:年龄因素/全部树/全部副主题词 -限定:- 
21.主题词:疾病传播, 垂直/全部树/全部副主题词 -限定:- 
22.全部字段:母婴传播 -限定:- 
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23.主题词:疾病传播, 水平/全部树/全部副主题词 -限定:- 
24.全部字段:水平传播 -限定:- 
25.主题词:出生顺序/全部树/全部副主题词 -限定:- 
26.全部字段:出生顺序分析 -限定:- 
27.主题词:家庭/全部树/全部副主题词 -限定:- 
28.#5 or #4 or #3 or #2 or #1 -限定:- 
29.#19 or #18 or #17 or #16 or #15 or #14 or #13 or #12 or #11 or #10 or #9 
or #8 or #7 or #6 -限定:- 
30.#24 or #23 or #22 or #21 -限定:- 
31.#29 and #28 and #20 -限定:- 
32.#26 or #25 -限定:- 
33.#30 and #29 and #28 -限定:- 
34.#32 and #29 and #28 -限定:- 
35.#29 and #28 and #27 -限定:- 
36.#35 or #34 or #33 or #31 -限定:- 
 
(2) Additional Searches 
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Additional studies were sought manually by checking reference lists of all included 
papers. None of the searches were restricted by date, language or publication status 
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Appendix 2. Protocol for the systematic review 
 
1. Objectives 
To review the association between the age at HBV infection and risk of high HBV DNA level, 
persistent viral replication, elevation of serum alanine transaminase level, advanced fribrosis 
and/or HCC in persons with chronic hepatitis B infection 
 
2. Criteria for Considering Studies for this Review 
2-1. Types of Studies 
Any studies whether interventional or observational, reported in any language, irrespective of 
publication status. Studies must have a reference group to make a comparison. The only 
exception is a case series using the Greenwood-Yule method or its related approaches to 
examine the effect of birth order, because these methods compare the observed birth order 
distribution of affected individuals with the expected distribution and do not require control 
group.
192
 In a case-control design, a control group which only consists of people chronically 
infected with HBV must be reported. 
 
2-2. Types of Participants 
Participants of any age who were found to have CHB infection at some stage of study are 
considered. Chronic hepatitis B is defined as a condition proven by serum HBsAg positivity on 
two occasions at least 6 months apart. However, because new HBV infections in adults are not 
so common in highly endemic areas where the vast majority of HBsAg positive people acquire 
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the infection perinatally or during childhood, HBsAg positivity on only one occasion in an adult 
living in highly prevalent communities is assumed to reflect chronic carriage of HBsAg.
97
  
 
2-3. Exposure of interest 
The age at the time of infection with HBV is estimated either by: 
 
 Direct measurement through frequent follow-up examination of an uninfected cohort to 
determine the time point at which a person seroconverted to positive HBsAg 
 HBV serological profile of the mother of the participant 
 Person’s birth order 
 
2-4. Outcome of Interest 
 Levels of serum alanine transaminase (ALT) 
 Presence of serum hepatitis B e antigen (HBeAg) 
 Quantitative/qualitative serum HBV DNA 
 Liver fibrosis determined by either liver histology or non-invasive tests 
 Cirrhosis 
 HCC 
 
3. Data Collection 
3-1. Study Selection  
First, the title and abstract of all papers identified by the electronic searches will be screened by 
two independent reviewers, by applying the inclusion criteria. Second, papers detected through 
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screening process will be retrieved and reviewed to assess the eligibility. When there is any 
doubt whether a paper can be included, clarification will be sought from the author of the paper. 
Disagreements will be resolved by discussion with a third author. Only studies which fulfilled 
all inclusion criteria will be included in the review.  
 
3-2. Data Extraction 
Data extraction will be carried out, by using a standardised pre-piloted data extraction sheet. 
The information included in the sheet is summarised in Appendix 3. 
 
4. Assessment of Risk of Bias 
The included studies will be evaluated for the risk of bias by modified framework that was 
introduced by Altman
240
 (Appendix 4).  
 
5. Data Analysis 
For the study of maternal HBV serological profile, the odds ratio (OR) of having a worse 
outcome (high HBV DNA load (>2,000 IU/ml), positive HBeAg, elevated serum ALT (>40 
U/L), advanced liver fibrosis (Metavir F≥2, or equivalent value in non-invasive tests), cirrhosis 
or HCC) in participants who have seropositive mother compared with those with seronegative 
mother will be calculated. For the birth order study, the odds of outcomes in each rank of birth 
will be compared with the odds in the first-born child as the reference. Measure of effect, its 
95% confidence interval and p-value will be all reconstructed from the information reported in 
each included article. The results of multivariable analyses reported in the original paper will be 
presented without any modification in this review. STATA version 11 will be used for all 
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analyses. This protocol was made in accordance with checklists presented in the PRISMA 
guideline.
241
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Appendix 3. Information included in the 
Standardised Data Extraction Sheet 
 First author 
 Country or region of study 
 Year of study 
 Study design 
 Selection of participants 
 Characteristics of participants studied (age, sex, whether asymptomatic, whether cirrhotic, 
prevalence of HBsAg, definition of cases and controls in case-control study, participation rate, 
drop-out rate in cohort study) 
 Exposures of interest: 
o If age at infection was directly measured, the interval between each follow-up, test used for 
detect seroconversion 
o If serological profile of participant’s mother was assessed, what serological test was performed 
and when the sample was taken (before the birth of study participant or current serostatus) 
o If birth order was examined, how the information was collected and the definition that the 
authors used 
 Outcomes of interest: 
o Definition of high HBV DNA level, which method was used to measure this 
o Method used to measure HBeAg 
o Definition of elevated ALT level, which method was used to measure this 
o Definition of advanced fibrosis, which criteria was used when liver histology was performed, 
and which method was used when non-invasive test was carried out 
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o Case definition of cirrhosis 
o Case definition of HCC 
 Follow-up of participants (in a cohort study) 
 Univariable analyses 
 Multivariable analyses and confounding factors adjusted for 
 
 367 
 
Appendix 4. Framework for assessing the risk of 
bias in individual studies 
Adapted from the framework presented by Altman (Egger M, Smith GD, Altman D, eds. 
Systematic Reviews in Health Care: Meta-analysis in Context. Wiley-Blackwell; 2001). 
Study 
feature 
Qualities sought  
1. Sample of 
patients 
Eligibility criteria defined Good Poor N/R N/A 
Sample selection explained (setting, 
locations and periods of recruitment) 
Good Poor N/R N/A 
Clinical and demographic characteristics 
fully described 
Good Poor N/R N/A 
Representative (unbiased selection of 
controls) 
Good Poor N/R N/A 
Assembled at a common stage in the 
course of their disease 
Good Poor N/R N/A 
Completeness Good Poor N/R N/A 
2. Follow up 
of patients 
Sufficiently long Good Poor N/R N/A 
3. Outcome Fully defined Good Poor N/R N/A 
Known for all or a high proportion of 
patients 
>80% 60-79% <60% N/R 
Outcome assessor blinded to exposure Good Poor N/R N/A 
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status 
4. Prognostic 
variable 
Fully defined, including details of method 
of measurement (maternal HBsAg study: 
when maternal serology was investigated?) 
Good Poor N/R N/A 
Available for all or a high proportion of 
patients 
>80% 60-79% <60% N/R 
Exposure assessor blinded to outcome 
status 
Good Poor N/R N/A 
5. Analysis Continuous predictor variable analysed 
appropriately 
Good Poor N/R N/A 
Appropriate control for confounding 
factors 
Good Poor N/R N/A 
Appropriate statistical method Good Poor N/R N/A 
6. Treatment 
subsequent 
to inclusion 
in cohort 
Fully described Good Poor N/R N/A 
Treatment standardized or randomised Good Poor N/R N/A 
Abbreviations: N/A, not applicable; N/R, not reported. 
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Appendix 5. Description of risk of bias in included studies 
Appendix 5-1. Description of Risk of Bias in Case-Control Studies, Cross-Sectional Studies and Case Series  
First 
Author, 
Year, 
(Reference 
No.) 
1. Sample of Patients 2. Outcome 3. Exposure 4. Analysis 
Eligibilit
y 
Criteria 
Sample 
Selection 
Represen
tativeness 
in 
Controls 
Fully 
Define
d 
Blinded 
to 
Exposure 
Status 
Known 
for All 
Subject
s? 
Fully 
Define
d 
Blinded 
to 
Outcome 
Status 
Known 
for All 
Subject
s? 
Confounding Factors 
Adjusted for 
Appropri
ate 
Analysis 
Beasley, 
1982 
242
 
N/R N/R N/R N/R N/R N/R N/R N/R N/R None good 
Chang , 
1989 
243
 
good poor
b
 poor
d 
poor
e 
N/A 100% good N/R 65% matched on age poor
e 
Hsu, 1988 
244
 
poor
a 
poor
c
 N/A good N/R 100% poor
g
 N/R 67% None good 
Wheeley, 
1989 
247
 
poor
a 
poor
c
 N/A good N/R 100% good N/A 90% None poor
m 
Habu, 
1991 
248
 
poor
a 
poor
c
 N/A good N/R 100% poor
h
 N/R 100%
k
 stratified by age group good 
Tai, 1999 good good N/A good N/R 90% poor
i
 N/R 52% None poor
m 
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249
 
Hopkirk, 
2000 
250
 
N/R poor
c
 N/A poor
h 
N/R 89% poor
g
 N/R 49% adjusted for age good 
Soderstrom
,2002 
251
 
good poor
c
 N/A good N/R 100% poor
g
 N/R 75% None good 
Hsieh, 
1992 [16] 
good good good good Good 100% good N/R 100% adjusted for age, sex, 
smoking, anti-HCV, 
HBsAg and sibship size 
poor
n 
Kuper, 
2000 
194
 
good poor
b
 good poor
e 
N/A 100% good N/R 99% for 
cases 
and 97% 
for 
controls 
matched on age and sex, 
adjusted for age, sex, 
schooling, smoking, 
alcohol, anti-HCV, 
HBsAg and sibship size 
poor
l, n 
Tai, 2002 
252
 
good good N/A good N/R 95% good N/R 100% stratified by relationship 
with index case 
good 
Cai, 2003 
253
 
good poor
c
 N/A good N/R 100% poor
j
 N/A 100% None poor
o 
Cao, 2005 
254
 
good poor
c
 N/A poor
f 
N/R 100% poor
j
 N/A 100% None poor
o 
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Song, 2009 
255
 
good good N/A good N/R 96% poor
j
 N/A 100% None poor
o 
Abbreviations: HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; N/A, not applicable; N/R, not reported. 
a 
Definition of HBsAg carrier was not presented. 
b 
The way of selecting control subjects was unclear. 
c 
Setting of sample selection was unclear. 
d 
Hospital-based cases were compared with population-based controls. 
e 
Cut-off value of alpha fetoprotein (AFP) for hepatocellular carcinoma (HCC) diagnosis was not presented. 
f 
Diagnostic criteria for HCC were not presented. 
g 
When maternal sero-status was examined was unclear. 
h 
Method of testing hepatitis B virus (HBV) marker was not presented. 
i 
When maternal sero-status was examined was not presented in the original paper, however this was described in a subsequent paper of the same study 
252
. 
j 
Birth order was not defined. 
k 
Maternal sero-status was known in all the participants because having a mother alive was one of the eligibility criteria. 
l 
Matched design, but no matched analysis. 
m 
Clustering effect of being born to the same mother was not taken account. 
n 
Two different control groups were combined. 
o 
Both the Greenwood-Yule and Haldane-Smith method are prone to bias due to change in population dynamics. 
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Appendix S5-2. Description of Risk of Bias in Cohort Studies  
First 
Author, 
Year, 
(Referen
ce No.) 
1. Sample of Patients 2. Follow 
up 
3. Outcome 4. Exposure 5. Analysis 6. 
Treatment 
After 
Inclusion 
in Cohort 
Eligibili
ty 
Criteria 
Sample 
Selectio
n 
Assemble
d at a 
Common 
Stage 
Sufficientl
y Long 
Fully 
Define
d 
Blinde
d to 
Expos
ure 
Status 
Know
n for 
all 
Subje
cts? 
Fully 
Defined 
Blinded 
to 
Outcom
e Status 
Know
n for 
all 
Patien
ts? 
Confou
nding 
Factors 
Adjuste
d for 
Approp
riate 
Analysi
s 
Fully 
Described 
McMaho
n,2001 
81
 
good poor
b 
Good good Good N/R 100% poor
e
  N/A 100% N/R poor
i
 poor
j
 
Kojima, 
1985 
245
 
poor
a 
poor
b 
Good good poor
c 
N/R 100% poor
f
 N/R 100%
h 
N/R poor
i
 good (no 
treatment) 
Kojima, 
1985 
246
 
poor
a 
poor
b 
Good good poor
d
 N/R 100% poor
f
 N/R 72% N/R poor
i
 good 
(steroid)  
Chang, 
1989 
78
 
good poor
b 
Good good Good N/R 100% poor
g
 N/R 95% Stratifie
d by age 
poor
i
 good (no 
treatment) 
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group 
Tseng, 
2011 
83
 
good poor
b 
Good good good N/R 100% good  N/R 95% adjusted 
for HBV 
genotyp
e and 
maternal 
HBV 
marker 
Good good (no 
treatment) 
Abbreviations: HBV, hepatitis B virus; N/A, not applicable; N/R, not reported. 
a 
Definition of hepatitis B surface antigen (HBsAg) carrier was not presented. 
b 
Setting of sample selection was unclear. 
c 
Method of measuring serum alanine transaminase (ALT) was not presented. 
d 
Method of testing HBV marker was not presented. 
e 
How often blood sample was obtained to determine timing of HBV infection was not reported. 
f 
When maternal sero-status was examined was not presented in this paper, but this was confirmed by the communication with the author.  
g 
When maternal sero-status was examined was unclear. 
h 
Maternal sero-status was known in all the participants because having a mother tested was one of the eligibility criteria. 
i 
Person-years at risk were not taken account in the analysis. 
j 
For the sub-study of patients with known age at HBV infection, number of those who were treated was not reported. 
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Appendix 6. Poster used for the community 
sensitisation 
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Appendix 7. Questionnaire for birth order 
Community-Based Screening Questionnaire 
(Version 3.0., drafted on 19
th
 Feb 2012) 
 
(1) Registered Information 
1. Enter: Screening IDNO   [ S | G |   |   |   |   |   ] 
2. Enter: Compound number   [   |   |   ] 
3. Enter: Name of head of compound       
4. Enter: Year of birth   [ 1 | 9 |   |   ] 
5. Enter: Age     [   |   ] years old 
6. Enter: Phone numbers   [   |   |   |   |   |   |   ] 
  (If more than one phone number)  [   |   |   |   |   |   |   ] 
     [   |   |   |   |   |   |   ] 
7. Enter: Date of interview   Day [   |   ] Month [   |   ] Year 
[   |   ] 
8. Enter: Code of interviewer   [   |   ] 
9. Enter: Enumeration area code  [   |   |   ] 
10. Enter: First name         
11. Enter: Family name        
12. Enter: Sex    1. Male  2. Female 
 
(2) Demographic Questionnaire 
13. In which district were you born?       
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8. I don’t know 
14. To which ethnic group do you belong? 
 1. Mandinka 2. Fula  3. Wolof     
 4. Jola  5. Serahule 6. Aku     
 7. Bambara 8. Manjago 9. Serere     
 10. Others        
 88. I don’t know 
15. What is the name of your true father? 
(first name)    (family name)    
8. I don’t know. 
16. What is the name of your true mother? 
(first name)    (family name)    
8. I don’t know, 
17. Is your true mother still alive?   
1. Yes  2. No  8. I don’t know 
If yes or “I don’t know”, go to question 18. If no, skip to question 20. 
18. How old is your true mother? 
[   |   ] years old 
8. I don’t know 
19. Is she living in the same compound as you now?   
1. Yes  2. No  8. I don’t know 
If yes, enter Screening IDNO of the mother (if she was allocated).    
 [ S | G |   |   |   |   |   ] 
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Now, skip to question 22. 
20. When did your true mother die?   [   |   ] years ago 
8. I don’t know 
21. How old was your true mother, when she died?  [   |   ] years old 
8. I don’t know 
22. For the following questions please include both living and deceased sisters and brothers. 
Multiple pregnancies are counted as independent births (twins: 2; triplets: 3; etc). I will 
ask you the numbers of brothers and sisters from the same father and same mother, then 
I will ask you the numbers from the same father and different mother, and finally I will 
ask you the numbers from the same mother and different father. 
 
22-1. How many brothers do you have by the same mother and father? 
Number       [   |   ] 
88. I don’t know 
22-2. How many of these brothers are older than you?  
Number       [   |   ] 
88. I don’t know 
22-3. Are there any brothers by the same mother and father who are living in the same 
compound as you now?   
1. Yes  2. No  8. I don’t know 
If yes, what is the name of these brothers? (up to 10 persons) 
(first name)    (family name)    
8. I don’t know 
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22-4. How many sisters do you have by the same mother and father? 
Number       [   |   ] 
88. I don’t know 
22-5. How many of these sisters are older than you? 
Number       [   |   ] 
88. I don’t know 
22-6. Are there any sisters by the same mother and father who are living in the same 
compound as you now?   
1. Yes  2. No  8. I don’t know 
If yes, what is the name of these brothers? (up to 10 persons) 
(first name)    (family name)    
8. I don’t know 
22-7. How many brothers do you have by the same father but different mother? 
Number       [   |   ] 
88. I don’t know 
22-8. How many of these brothers are older than you? 
 Number       [   |   ] 
88. I don’t know 
22-9. Are there any brothers by the same father but different mother who are living in the 
same compound as you now?   
1. Yes  2. No  8. I don’t know 
If yes, what is the name of these brothers? (up to 10 persons) 
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(first name)    (family name)  
  
8. I don’t know 
22-10. How many sisters do you have by the same father but different mother? 
Number       [   |   ] 
88. I don’t know 
22-11. How many of these sisters are older than you? 
 Number       [   |   ] 
88. I don’t know 
22-12. Are there any sisters by the same father but different mother who are living in the same 
compound as you now?   
1. Yes  2. No  8. I don’t know 
If yes, what is the name of these brothers? (up to 10 persons) 
(first name)    (family name)  
  
8. I don’t know 
22-13. How many brothers do you have by the same mother but different father? 
Number       [   |   ] 
88. I don’t know 
22-14. How many of these brothers are older than you? 
 Number       [   |   ] 
88. I don’t know 
22-15. Are there any brothers by the same mother but different father who are living in the 
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same compound as you now?   
1. Yes  2. No  8. I don’t know 
If yes, what is the name of these brothers? (up to 10 persons) 
(first name)    (family name)  
  
8. I don’t know 
22-16. How many sisters do you have by the same mother but different father? 
Number       [   |   ] 
88. I don’t know 
22-17. How many of these sisters are older than you? 
 Number       [   |   ] 
88. I don’t know 
22-18. Are there any sisters by the same mother but different father who are living in the same 
compound as you now?   
1. Yes  2. No  8. I don’t know 
If yes, what is the name of these brothers? (up to 10 persons) 
(first name)    (family name)  
  
8. I don’t know 
 
 
(4) Point-of-care Test Result 
23. Enter: code of examiner        
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24. Enter: test result 
 1. Positive 
 2. Negative 
 
(5) Appointment at the Clinic for Enrolment 
All participants tested positive for the test have an appointment at the clinic for enrolment.  
Some participants tested negative will be later selected randomly as healthy controls and will 
have an appointment at the clinic. 
 
25. Are you pregnant now? (this question only applies to female participants aged <55 
years) 
1. Yes  2. No  8. I don’t know 
If yes, go to question 26. If no or “I don’t know”, skip to question 27. 
26. How many months pregnant are you? 
[   |   ] months 
Thank you, we will call you after your delivery to invite to the Liver Clinic. 
27. Enter: date of appointment  Day [   |   ] Month [   |   ] Year [   |   ] 
28. Enter: time of appointment  [   |   ] o’clock 
29. Enter: name of clinic  
1. The Liver Clinic in Medical Research Council (MRC), in Fajara 
2. The Liver Clinic in Royal Victoria Teaching Hospital (RVTH), in Banjul 
3. The Liver Clinic in Serrekunda Hospital, in Kanifing 
4. The Clinic in Sibanor 
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5. The MRC Clinic in Keneba 
 
 
 
 
